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Abstract 
 
 The concept of cellular senescence is based on the notion that proliferation 
of normal diploid cells can only occur for a limited period of time after which 
cells slowly cease to divide and die. This limitation of lifespan for in vitro cell 
cultures was first described by Leonard Hayflick in 1961, going against the theory 
formulated by Alexis Carrel claiming that cells kept in culture have an unlimited 
potential for division (Carrel and Ebeling, 1921).  
Evidence from cell senescence studies have been used to explain the basis 
of healthy ageing as well as develop food supplements promoting the delay of 
ageing. Since these discoveries, there has been marked expansion of anti-stress 
gene response research with relation to the role of the transcription factor NF-E2-
related factor-2 as well as healthy ageing with regards to dietary activators intake.
 This study examined the effects of sulforaphane (SFN) and hesperetin 
(HESP) on MRC-5 cell senescence in vitro as well as characterized gene 
expression and cell metabolism in cells escaping senescence by treatment with 
SFN and HESP and the mechanism of decrease glucose metabolism by SFN and 
HESP action linked to delay of fibroblast senescence. The effects of treatment of 
MRC-5 with the dietary bioactivators SFN and HESP was studied and shown to 
delay cellular senescence in these cells in vitro. Similar findings for SFN 
treatment of BJ cells were found previously by studies of the host team. Caloric 
restriction mimetic mechanisms by treatment with 1 µM SFN and 5 µM HESP 
was shown due to the decrease in culture glucose consumption increase with 
senescence in these treatment groups and this CR restriction mimetic effect and 
decrease in the flux of formation of D- and L-lactate in the SFN-treated group was 
consistent with previous studies done in CR and ageing in mice models 
(Hargopan, Ramsey and Weindruch, 2003). Moreover, in this study, SFN was 
shown to act as a CRM dietary bioactive through cellular contents of glycolytic 
intermediates with SFN-treatment (Bensaad et al., 2006).  
 Finally, the mechanism by which SFN induces delay of senescence 
through CR was shown to be due to the extraction of Mondo A from the cell 
nucleus to the cytoplasm.  
  
xviii 
 
Abbreviations and Symbols 
 
µg  Microgram 
µl  Microliter 
2-DG  Glucose analog 2-deoxyglucose  
2-DG6P 2-deoxyglucose-6-phosphate  
3 DG-H Hydroimidazolone of 3-dexyglucosone 
3-DG  3-deoxyglucosone  
3-NT  3-nitro tyrosine 
53BP1  Tumor suppressor p53-binding protein 1 
8-OxodG 8-oxo-7,8-dihydro-2’-deoxyguanosine  
A1 UDP Glucuronosyltransferase 1 
AASA  α-aminoadipic semialdehyde  
ACTB  Beta Actin 
AEBSF 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride  
AGEs  Advanced glycation endproducts  
AKR1C1 Aldoketo reductase 1C1 
AKRB1 Aldoketo-reductase B1  
AKRB2 Aldoketo-reductase B2  
AKRd  Aldoketo reductase 
AldDH Aldehyde dehydrogenase 
AMP  Adenosine monophosphate 
AMPK  AMP-activated kinase  
AREs   Anti-oxidant response elements  
ATF-2  Activating transcription factor 2 
ATM  Ataxia telangiectasia mutated kinase 
ATR  Rad3-related protein 
BEH   Bridged Ethane Hybrid column 
bHLHZ  Basic helix-loop-helix-leucine zipper  
BSA  Bovine serum albumin 
C/EBPb CCAAT/enhancer-binding proteins 
cAMP   3'-5'-cyclic adenosine monophosphate 
CAT   Catalase  
CBR1  Carbonyl reductase-1  
xix 
 
CCL2   Monocyte chemotactic protein-1/Chemokine (C-C motif) ligand 2 
CDKIs  Cyclin-dependent kinase inhibitors 
CDKN1A  Cyclin-dependent kinase inhibitor 1/p21 
CDKN2A  Cyclin-dependent kinase inhibitor 2A/P16INK4a 
cDNA   Complementary DNA 
CEL  Nε-(1-carboxyethyl)lysine 
CFD   Chromosome Frequency Distribution  
CHK1   Checkpoint kinase 1 
CHK2  Checkpoint kinase 2 
ChoREs  Carbohydrate response elements  
ChREBP  Carbohydrate-responsive element-binding protein 
CK2   Casein kinase-2  
ClO-   Hypochlorite  
CLS   Chronological Life Span  
CLTC   Clathrin, heavy chain 
CMA  Nω-carboxymethyl-arginine 
CML   Nε-carboxymethyl-lysine  
CO3
•¯   Carbonate radical anion  
COL1A1  Collagen 1-alpha 
cPDL   Cumulative PDL  
CR   Caloric restriction  
CRM   Caloric restriction mimetic  
CRM1  Chromosome region maintenance 1 
CSCs  Cancer stem cells  
CTP  Cytidine triphosphate 
CTSO   Cathepsin O 
Cu2+   Cupric ion  
Cul3   Cullin-3  
CXCL1 GRO-alpha oncogene/Chemokine (C-X-C motif) ligand 1 
d3-AAA  2,5,5[
2H3]DL-α-aminoadipic acid  
DAF-2  insulin-like growth factor 1 (IGF-1) receptor in C. elegans 
DALYs  Disability-adjusted life years  
DAPI   4’,6-diamidino-2-phenylindole  
DCD   Dimerization and cytoplasmic localization domain  
xx 
 
DCR2  Decoy receptor 2 
DDR  DNA damage response 
DETAPAC  Diethylenetriamine penta-acetic acid  
DILPs   Insulin-like peptides  
DMSO  Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid 
DNA-SCARS DNA segments with chromatin alterations reinforcing senescence 
dNTPs  Deoxynucleotide triphosphates 
DTT  Dithiothreitol 
EC  Endothelial cells 
ECACC  European Collection of Animal Cell Cultures  
ECL  Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid  
ELN   Elastin 
EmC  Embryonic cells 
ER   Endoplasmic reticulum  
F3PK   Fructosamine-3-phosphokinase  
FASN   Fatty acid synthase 
FBS   Fetal bovine serum  
Fe3+   Ferric ion  
FL    Nε-fructosyl-lysine  
FTH1   Ferritin 
FYN   Fyn kinase 
G6P   Glucose-6-phosphate  
G6PDH  Glucose-6-phosphate dehydrogenase 
GADD153  Growth-arrest and DNA-damage inducible protein 153  
Gas1   Growth-arrest-specific protein 1  
GC50   Median growth inhibitory concentration value 
GCLC  γ-glutamylcysteine ligase – catalytic subunit   
GCLM  γ-glutamylcysteine ligase – modulatory subunit  
GdG  3-(2’-deoxyribosyl)-6,7-dihydro-6,7-dihydroxyimidazo-[2,3-
b]purine-9(8)one 
 
GE  Gene expression 
GEEK  Nε(γ-glutamyl)lysine  
xxi 
 
G-H1  Hydroimidazolone of glyoxal 
g-H2AX  Histone variant H2AX  
GLB1   Senescence-associated beta-galactosidase 
Glo1   Glyoxalase 1  
GPx   Glutathione peroxidase  
GPX1   Glutathione peroxidase-1 
GRACE  Glucose-response activation conserved element  
GSA   Glutamic semialdehyde  
GSH   Reduced glutathione    
GSM   Glucose-sensing module   
GSM   Glucose-sensing module  
GSR   Glutathione reductase  
GSSG  Glutathione oxidised form 
GSTD1  Glutathione-S-transferase D1  
GSTP1  Glutathione transferase P1 
GSTs   Glutathione S-transferases  
GTP   Guanosine-5'-triphosphate  
GUSB  Beta-glucuronidase 
H2O2  Hydrogen peroxide  
HCl  Hydrochloric acid 
HDFs   Human diploid fibroblasts  
HEPES  4-(2-hydroxyethyl) piperazine-1-ethanesulfonice acid  
HepG2  Human hepatocellular liver carcinoma cell line 
HESP   Hesperetin 
HIF-1   Hypoxia-inducible factor 1 
HIF1-α Hypoxia-inducible factor 1 alpha 
HIRA  Histone repressor A 
HK   Hexokinase  
HK1   Hexokinase-1 
HL60   Human leukaemia 60 cells 
HMGA high mobility group A proteins 
HMOX1  Haem oxygenase-1 
HO•   Hydroxyl radical  
HOMA  Homeostatic model assessment   
xxii 
 
HP-1b  Heterochromatin protein 1b 
HPLC   High performance liquid chromatography 
HSA   Human serum albumin  
hTERT  Catalytic subunit of human telomerase  
ICAM-1  Toll-4 receptor and intercellular adhesion molecule-1  
IGF  Insulin-like growth factor  
IGF-1   Insulin-like growth factor 1 
IGF-BP2  Insulin-like growth factor binding proteins 2  
IGF-BP5 Insulin-like growth factor binding proteins 5 
IgG   Immunoglobulin G 
IL1  Interleukin-1 
IL15   Interleukin-15 
IL1B   Interleukin 1-beta 
IL3   Interleukin-3 
IL6  Interleukin-6 
IL8  Interleukin-8 
INR  Insulin receptor  
INS-1  Insulin type 1 protein 
KCl  Potassium chloride 
kDa   KiloDalton 
KEAP1 Kelch-like ECH-associated protein 1 
KH2PO4 Potassium dihydrogen phosphate 
L   Liter 
LC-MS/MS  Tandem mass spectrometric detection  
LDL  Low density lipoprotein 
LF   Lipofuscin  
LID   Low-glucose inhibitory domain 
MAFG  Maf protein-G 
MCP-1 Monocyte chemoattractant protein-1 
MCR  Mondo conserved regions 
MDC1  DNA damage checkpoint protein 1 
MDM2 Double minute 2 homolog protein 
ME1  Metallothionein 1 
MeCN  Acetonitrile 
xxiii 
 
MEM   Eagle’s Minimum Essential Medium 
MetSO  Methionine sulfoxide  
MG   Methylglyoxal  
MGdG  MG-derived imidazopurinone, 3-(2’-deoxyribosyl)-6,7-dihydro-
6,7-dihydroxy-6/7-methylimidazo-[2,3-b]purine-9(8)one isomers  
MG-H1  Methylglyoxal derived hydroimidazolone N-(5-hydro-5-methyl-4-
imidazolon-2-yl)ornithine  
ml   Milliliter 
MLX   Max-Like BHLHZip Protein2 
MLXIP  MondoA (MLX interacting protein) 
mM   Millimolar 
MMLV-RT Moloney Murine Leukemia Virus Reverse Transcriptase 
MMP1  Fibroblast collagenase/matrix metalloproteinase-1 
MMP13  Collagenase-3/matrix metalloproteinase-13 
MMP3  Stromelysin-1/matrix metalloproteinase-3 
MMPs  Matrix metalloproteinases 
MMTV  Mouse mammary tumor virus  
MOLD Methylglyoxal-derived lysine dimer 
MondoA  Anti-MLX-interacting protein  
MRM   Multiple reaction monitoring  
mRNA  Messenger ribonucleic acid 
Mrp2   Multidrug resistance-associated protein 2 
MSC  Mesenchymal stem cells 
mTOR  Rapamycin kinase  
mTORC1  mTOR complex 1 
mTORC2  mTOR complex 2  
Na2HPO4  Disodium hydrogen phosphate 
NaCl  Sodium chloride  
NAD   Nicotinamide adenine dinucleotide-oxidised form  
 NADH  Nicotinamide adenine dinucleotide, reduced form 
NADPH Nicotinamide adenine dinucleotide phosphate, reduced form  
NBS1  Nijmegen breakage syndrome protein 
NEAA  Non-essential amino acids  
xxiv 
 
NFE2L2  Nuclear factor (erythroid-derived 2)-like 2  
NFK  N-formylkynurenine 
NF-kB  Nuclear factor kappa light chain enhancer of activated B cells  
NFKB1  Nuclear factor NF-kappa-B p105 subunit/p50 
NFKB3  Transcription factor p65 
nM   Nanomolar 
nmol   Nanomol 
NOS  Nitric-oxide synthase 
NQO1  Quinone reductase 
Nrf2   Nuclear factor erythroid 2-related factor 2  
NT   Nitrotyrosine  
O2
•-   Superoxide  
OMM   Outer mitochondrial membrane  
p21  Cyclin-dependent kinase inhibitor 1  
PAI-1   Plasminogen activator inhibitor type-1  
PAM   Peptidyl-a amidating monooxygenase  
PBS  Phosphate buffered saline  
PCA   Perchloric acid  
PDEs   Phosphodiesterases 
PDL   Population Doubling Limit  
PEG  Polyethylene glycol 
PFKFB2  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2 
PFKFB4  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 
PGAM5 Protein threonine phosphatase 
PGC-1a Peroxisome proliferator-activated receptor-gamma coactivator 1a 
PML  Promyelotic Leukemia 
pmol   Picomol 
PRDX1  Peroxiredoxin-1 
PRDXs  Peroxiredosins 
PSMA1  Proteasome subunit A1 
PSMB5  Proteasome subunit B5 
PVDF   Polyvinyl difluoride  
QTN   Quercetin 
RB1   Retinoblastoma gene  
xxv 
 
RES   Resveratrol, 3, 4’,5-trihydroxy-trans-stilbene  
RHEB  Ras homolog protein enriched in brain  
RLS   Replicative Life Span 
ROOH  Hydroperoxides  
ROS   Reactive oxygen species  
RPMI   Roswell Park Memorial Institute 1640 medium  
RS   Replicative senescence 
RT-PCR Reverse Transcription polymerase chain reaction 
SA-B-GAL  Senescence-associated beta-galactosidase 
SAHF   Senescence-associated heterochromatic foci 
SASP   Senescence-associated secretory phenotype  
SAX SPE  Anion-exchange solid-phase extraction  
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SERPINB2  Plasminogen activator inhibitor-2 
SERPINE1  Plasminogen activator inhibitor-1 
SFN   R-sulforaphane  
SIPS   Stress induced premature senescence 
SIR2   Silent information regulator 2 
SIT1   Signaling threshold regulating transmembrane adaptor 1 
SOD   Superoxide dismutase  
SOD1   Superoxide dismutase-1 
SOD2   Mitochondrial superoxide dismutase 
SPSS   Statistical Package for the Social Sciences  
SQSTM1  Sequestosome 1 
SQSTM1  Sequestosome-1/p62 
SREBF1  Sterol response element binding protein-1 
T3   Triiodothyronine 
T4   Thyroxin 
TAF   Telomere-associated foci 
TALDO Transaldolase 
TALDO1  Transaldolase-1  
TBST  Tris-buffered saline with Tween 20 
TCA   Trichloroacetic acid  
TEMED  N,N,N’,N’-tetramethylethylene-1,2-diamine  
xxvi 
 
TFA  Trifluoroacetic acid  
TFs   Transcription factors  
THF   Tetrahydrofuran  
TIF   Telomere dysfunction-induced foci 
TKT   Transketolase 
TLR4   Toll-like receptor 4 
TNFRSF10D Tumor necrosis factor receptor superfamily, member 10d, decoy 
with truncated death domain 
 
TOR   Target of Rapamycin  
TSH   Thyroid stimulating hormone 
Tween-20 Polysorbate 20 
TXN   Thioredoxin 
TXNIP  Thioredoxin interacting protein  
TXNRD1  Thioredoxin reductase-1 
UDP   Glucoronyl transferase  
UGT1A1 Uridine diphosphate glucuronyltransferase A1 
UPLC   Ultra high performance liquid chromatography  
UV  Ultraviolet  
X-Gal   5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside  
 1 
 
1. Introduction - Ageing, senescence and the Nrf2 system 
 
1.1 Ageing 
Ageing is a multi-factorial and near universal process of multi-cellular 
organisms (Huges and Reynolds, 2005). This complex process was originally 
described by Benjamin Gompertz in 1825 as an exponential chance of death as 
age increases (Gompertz, 1825). Ageing has been defined at the population level 
as a “process of intrinsic deterioration that is reflected as an increase in the 
likelihood of death and a decline in the production of offspring” (Partridge and 
Gems, 2002) and at the organism level “decrease in physiological reserves which 
cannot adapt to any additional and even physiological stress, whilst still 
supporting acceptable functioning in the steady state” (Fulop et al., 2010). It is the 
primary risk factor for disease of major social impact: cancer, diabetes, 
cardiovascular disorders, and neurodegenerative diseases (Lopez-Otin et al., 
2013). In Western countries, the decline in mortality combined with the decrease 
in birth rates is leading to a stable increase in the ageing population number 
(Martin and Sheaff, 2007). Another aspect in determining life expectancy is the 
concept of genetic predispositions. Studies conducted on twins have demonstrated 
that only around 25% of variations on life expectancy can be associated with 
genetic predisposition (Skytthe et al., 2003), implying that environmental factors, 
which could be controlled, are mainly responsible for healthy ageing (Abbott, 
2004). Species-associated lifespan and association of genetic polymorphism 
within species in genome-wide association with longevity studies have 
demonstrated a genetic link to ageing (Kenyon, 2010). However, diversity in the 
lifespan of different populations based on their diet and geographic location can 
be observed. For example, the Okinawa prefecture in Japan shows an unusual 
extended life span of its population. The average life span for Americans and 
Okinawans is 79 and 84 years respectively, and the maximum lifespan is 101 
years in Americans compared to 105 years in the Okinawan population (Willcox 
et al., 2007). This increase in the lifespan of the Okinawans is thought to be due to 
their large intake of green vegetables, soy and sweet potatoes, as well as lower 
caloric intake and higher Vitamin E intake as a result of their diet (Suzuki et al., 
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2010). This reflects a complex interaction of genes, environment and nutrition in 
the ageing process – compounded in longevity studies by infection, inflammation 
and access to medicines (Harman, 2010).   
In studies of ageing and longevity it is instructive to also consider major 
causes of death – particularly when employing experimental models of ageing for 
comparison with human ageing where causes of mortality may be different. For 
experimental studies of longevity with laboratory animals - rats and mice, the 
major causes of death in ageing is tumourigenesis (Suzuki et al., 2010). This 
contrasts with ageing in the human population where the major cause of death is 
cardiovascular disease, followed by cancer, cerebrovascular disease and 
complications of diabetes (Fullop et al., 2010). Indeed ageing is a risk factor for a 
large number of health impairments and disease in the human population such as 
dementia, osteoporosis and frailty, which contribute to the major causes of death 
resulting from this condition. Given the large environmental influence on human 
longevity it is likely that appropriate lifestyle and dietary interventions may help 
provide for healthy ageing and decrease morbidity and improve lifespan. Dietary 
supplements for healthy ageing are likely to achieve high compliance; cf. high 
intake of vitamin supplements for putative improvement of health (Fusco et al., 
2007). Currently it is unclear and often controversial which dietary supplements 
are likely to be effective. 
 
1.1.1 Theories of ageing 
Several theories of ageing have been formulated. The most well-
established being the evolutionary theory, the rate-of living (“burn out”) theory, 
the aberrant gene regulation theory and the accumulation of cell damage theory. 
 
1.1.1.1 Evolutionary theory of ageing 
The evolutionary theory of ageing is based on the principle that ageing is a 
phenomenon that is seen universally in all animals (Partridge and Gems, 2002). 
However, each organism ages differently which leads to the assumption that 
evolution is the key element leading to ageing rather than wear and tear. The 
evolutionary theory was further approved after Haldane studies on Huntington’s 
disease (Haldane, 1941). This lethal genetic disease is only symptomatic once the 
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adult life of the patient is reached, by which time he may already have had 
progeny which could be affected by the disease. From these observations, ageing 
has been defined as an evolutionary genetic disease which strikes later on in life 
(Partridge and Gems, 2002). The contribution of genetics to diversity of human 
ageing was assessed in twin studies – see above. There are also many genes 
known to be influential on lifespan of animals in experimental studies of ageing – 
so-called “vitagenes”. Epigenetic influences on ageing may be explained, at least 
in part, by changes in expression of vitagenes induced by dietary factors (De 
Magalhaes and Church, 2005). 
 
1.1.1.2 Rate-of-living theory of ageing 
The rate-of-living theory of ageing was first suggested in 1928 by Pearl, 
and states that animals with a smaller energy expenditure or metabolic rate 
should, in theory, live longer (Pearl, 1928). Indeed, the rate at which calories are 
burned in the body is closely related to oxygen consumption and respiration 
(Walker et al., 2005). This later observation, along with the fact that damaging 
reactive metabolites are produced at increased rates as energy expenditure 
increases – reactive oxygen species (superoxide, hydrogen peroxide, hydroxyl 
radical; ROS), reactive nitrogen species (peroxynitrite and others; NOS) and 
dicarbonyls (glyoxal, methylglyoxal and others), lead to the theory that ageing 
occurs as a result of increased macromolecular damage. Initial theories focussed 
on oxidative damage (Harman, 1956). Others have highlighted possible roles of 
NOS (Lam et al., 2009) and reactive dicarbonyls in the contribution of glycation 
to ageing (Sejersen and Rattan, 2009). 
 
1.1.1.3 Gene regulation theory of ageing 
The gene regulation theory of ageing is based on the principle that, 
although expression of specific genes seems to be modified as age progresses 
(Weindruch et al., 2002), ageing occurs as a result of impaired expression of 
genes promoting longevity (Weinert and Timiras, 2003). The main observations 
made on this theory have been done in C. elegans and later on confirmed in 
Drosophila melanogaster (Tatar et al., 2003). Indeed, extension of life span has 
been shown to be regulated by expression of genes inhibiting insulin-like 
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signalling, hence demonstrating the role of gene regulation in ageing (Weinert and 
Timiras, 2003). This theory finds contemporary evidence and discussion on the 
effects of vitagenes – particularly in functional genomics studies utilising mutant 
gene deletion (knockout) and gene overexpressing transgenic organisms. 
 
1.1.1.4 Accumulation of cell damage theory of ageing 
The concept of accumulation of cell damage as a theory of ageing was 
originally formed from the disposable soma theory formulated by Kirkwood in 
1977, stating that energy must be used wisely to be able to perform cellular 
maintenance aimed at conserving longevity (Kirkwood, 1977). Accumulation of 
cell damage from extrinsic and intrinsic sources affect DNA repair, protein repair 
and the antioxidant response as well as other protective mechanisms responsible 
for maintenance of the aging status. Indeed, somatic mutations and damage to the 
DNA impair cell division (Kim et al., 2002), as well as protein damage in the 
form of damage to the proteasome and chaperone proteins (Soti and Csermely, 
2003) and increased steady-state concentrations of reactive oxygen species (ROS) 
due to impairment of the antioxidant cellular response (Huges and Reynolds, 
2005). These are all factors contributing to the accumulation of cell damage 
theory of ageing. 
 
Perspectives of theories of ageing tend towards a unified theory that embrace 
aspects of all of the above theories and reveal new features and emphasis of the 
contributory factors underlying the above theories (Partrige and Gems, 2005).   
 
1.1.2 Experimental models of ageing 
Models used experimentally to gain insight on the mechanisms of ageing 
range from yeast Saccharomyces cerevisiae, nematode Caenorhabditis elegans, 
fruit flies Drosophila melanogaster, laboratory rodents (mice, rats and others) to 
human subjects. 
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1.1.2.1 Yeast: Saccharomyces cerevisiae 
The single-cell yeast, such as Saccharomyces cerevisiae (Figure 1), is 
a very good candidate in order to establish genes involved in the ageing 
process (Fontana et al., 2010). 
 
 
Figure 1. Saccharomyces cerevisiae.  
(a) after 8 divisions and (b) showing morphological signs of ageing after 25 
divisions. Source: Barker and Smart, 1998. 
 
Indeed, yeast cells undergo characteristic changes as they age, such as: an 
increase in cell surface, a decrease in the ability to reproduce, accumulation of 
non-chromosomal DNA and dark stains on their surface (Powell et al., 2000) - 
Figure 2. 
 
     
 
Figure 2. Effect of age on Saccharomyce cerevisiae.  
As age progresses, mother cells produce smaller daughter cells which leads to 
formation of budding scars on the mother cell, as well as production of smaller 
daughter cells. Source: Sinclair et al., 1998.  
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Yeast cells are also useful in the understanding of the ageing process as 
the daughter cells produced from old mother cells inherit all the characteristics 
associated with ageing. Moreover, yeast has been extensively used for the study of 
Replicative Life Span (RLS) in the ageing process (Kennedy et al., 1994). Indeed, 
yeast replicative senescence studies have led to the identification of a battery of 
genes such as SIR2, a homologue of the mammalian sirtuin 2, which are thought 
to be involved in the regulation of life span (Steinkraus et al., 2008). The use of 
yeast to study the role of SIR2 in ageing has shown that SIR2 expression leads to 
an increase in RLS which then leads to a decrease in acetylation at the histone H4 
lysine 16, which in turn is responsible for induction of silencing at the telomere 
and sub-telomere regions (Dang et al., 2009). Moreover, yeast models have been 
used for the monitoring of Chronological Life Span (CLS) which allows for 
observing of survival of non-dividing cells (Fabrizio and Longo, 2003) as well as 
the effects of caloric restriction on life span. Indeed, studies have shown that yeast 
lifespan is modified depending not only on the total caloric intake but also the 
nature of the glucose content to which they are exposed (Wu et al., 2013). 
 
1.1.2.2 Nematode Caenorhabditis elegans 
Caenorhabditis elegans is a small soil nematode of around 1 mm in 
length which is found in compost and gardens. These small organisms have a 
short life span of 2 - 3 weeks as well as rapid reproductive cycle which makes 
them ideal candidates for the study of ageing (Kaletsky and Murphy, 2010). As 
well as displaying morphological signs of ageing seen in humans (Figure 3) such 
as a loss of motility and reproductive capacity (Hughes et al., 2007), gene 
mutations in this organism can change the C. elegans into the dauer worm. The 
dauer worms are thin and can move but they do not eat. Dauers can remain viable 
for 3 months and go through a dormant stage with limited ageing. 
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Figure 3. Morphological signs of ageing in Caenorhabditis elegans. 
(A) A 5 days old adult with good mobility and (B) a 16 days old adults 
with a wrinkly appearance and decreased mobility. Source: Partridge and 
Gems, 2002. 
 
Indeed, as seen in Figure 4, mutations in the daf-2 gene involved in the 
insulin/IGF signalling pathway has been shown to be responsible for the 
formation of dauer worms from C. elegans (Partridge and Gems, 2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Implications of the daf-2 gene in the lifespan of C. elegans. 
daf-2 is involved in development to adulthood via the insulin/IGF signalling 
pathway. (B) Mutations of the daf-2 gene leads to the formation of dauer larva 
from C. elegans which have a considerably longer lifespan. Source: Partridge and 
Gems, 2002. 
  
Moreover, in the 1980s, Johnson and Wood discovered that life span in C. 
elegans has the particularity of being strongly influenced by gene polymorphism 
(Johnson and Wood, 1982). Indeed, this short-lived multicellular organism has 
been used in order to study insulin/IGF signalling in ageing (Friedman and 
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Johnson, 1988; Kenyon et al., 1993; Kimura et al., 1997). This expression of IGF-
1 has been linked with life extension by sometimes three fold the normal lifespan 
as observed in wild type C. elegans (Partrige and Gems, 2002). Moreover, the 
study of C. elegans has provided insight on the involvement of the 
neuroendocrine system in the modulation of ageing. Indeed, insulin/IGF mutants 
also carry a mutation in the age-1 gene which in turns encodes for the lipid kinase 
enzyme (phosphatidylinositol-3 kinase) which is responsible for the transmission 
of information to trigger the Dauer-2 state in C. elegans (Kenyon et al., 1993). 
Another interesting observation is that the C. elegans genome contains 37 genes 
that encode insulin-like proteins, one of which INS-1, is very closely related to 
human insulin (Pierce et al., 2001). Indeed, INS-1 modulates the action of Daf-2 
by antagonising it rather than activating it. 
 
1.1.2.3 Fruit fly: Drosophila melanogaster 
The fruit fly Drosophila melanogaster is a very useful organism in the 
study of ageing as it can give indication on mechanisms of ageing in different 
tissues and sexes (Fontana et al., 2010). Depending on the strain, Drosophila can 
live up to 70 days and show an increase in lifespan with caloric restriction (CR). 
Indeed, when female Drosophila consume 60% and male consume 40% of their 
normal caloric intake, a 60% and 40% life extension, respectively, can be 
observed (Murphy and Partridge, 2008). As seen in Figure 5, this mechanism is 
thought to be regulated by insulin-like peptides (DILPs) which have a direct 
action on the ovaries and the isoprenoid hormone responsible for male fertility 
(Brogiolo et al., 2001). 
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Figure 5. Mechanism of life extension by caloric restriction in the Drosophila 
melanogaster. 
Upon binding of DILPs from food, the insulin receptor (Inr) is couples with the 
insulin receptor substrate (chico) which leads to regulation of male juvenile sex 
hormones production and female ovaries development. Upon mutation of lnr and 
chico, an increase of lifespan of up to 85% and 52% respectively can be seen. 
Caloric restriction also increases lifespan of up to 3 folds in wild type Drosophila. 
Source: Partridge and Gems, 2002. 
 
As described earlier in the C. elegans ageing models, the Drosophila 
equivalents of Daf-2 and age-1 (Inr-isulin-like receptor and Dp110 respectively) 
are responsible for determining organ and body size in these fruit flies (Weinkove 
and Leevers, 2000). Indeed, this mechanism is thought to be controlled by the 
neuroendocrine system as characterised in C. elegans models. Moreover, this 
phenomenon is somewhat faulty as only specific mutations in the insulin/IGF 
signalling pathway increases lifespan in the Drosophila and mainly had an effect 
on females (Partridge and Gems, 2002). 
 
1.1.2.4 Mice 
Studies of invertebrate experimental models of ageing give insight on the 
genes and mechanisms involved in longevity but mice are the closest model to 
human, which is important for the initiation of clinical trials (Fontana et al., 
2010). The effect of caloric restriction in mice on their lifespan was first 
observed in 1986 by Weindruch and colleagues. Their observations are shown in 
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Figure 6, where survival is increased as CR is increased (Weindruch et al., 
1986). 
                       
Figure 6. Survival rate of mice as a function of caloric intake. 
Mice show a 20 months life extension and an extended survival rate after a 
60% caloric restriction compared to an ad libitum feeding regime. Source: 
Weidruch et al., 1986. 
 
Moreover, genetic manipulation of mice is very useful in the study of the 
ageing process – with expectation that where beneficial effects are found it may 
provide insight into critical mechanisms of ageing and where to focus efforts into 
development of pharmacological agents for healthy ageing. Indeed, transgenic 
mice genetically modified to overexpress catalase have been shown to have an 
extension of lifespan of up to 30 months which raises the implications of this 
enzyme in the ageing process (Schriner et al., 2005). However, overexpression of 
plasminogen activators Plau genes in mice has been shown to lead to decrease in 
their development, accompanied by a self-imposed caloric restriction with a 20% 
increase in lifespan (Miskin and Masos, 1997).  
 
1.2 Cell senescence as a model of ageing 
The above experimental models of ageing have the fundamental weakness 
for application to human ageing that they do not involve human cells. To develop 
a model of aging based on human cells the phenomenon of human cell senescence 
in vitro has been explored. Ageing is studied experimentally as proliferative 
senescence. The term proliferative senescence or replicative senescence (RS) 
refers to the inability of cells to divide further after they have gone through 
several replicative cycles. Therefore, as most cells in the body are post-mitotic, 
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meaning that they are non-dividing, RS is only a “model” of ageing as opposed to 
an exact representation of the ageing process. 
 
Senescence as a model of ageing has raised controversy since its 
introduction by Leonard Hayflick (Hayflick, 1965). For example, the in vivo 
ageing mechanism is seen as a whole, whereas cell senescence differs in time 
course of events in different primary cell cultures where multiple mechanisms are 
involved, raising the issue of fidelity of the senescence model to the ageing 
process (Cristofalo and Pignolo, 1993). Moreover, it has been suggested that 
senescence is a process that can only occur in vitro. However, this argument was 
refuted by a study done on skin fibroblasts of older baboons where increased RS 
was seen as age increased (Jeyapalan et al., 2007). Pignolo et al. (1992) compared 
replicative life span in vitro of skin fibroblasts derived from Fischer 344 rats of 6, 
24, and 29 months of age and found there was decreasing replicative capacity and 
more rapid induction of senescence with age of donor, suggesting that skin 
fibroblasts in situ in rats lose their replicative capacity with age. For human skin 
fibroblast, initial studies suggested an inverse relationship between donor age and 
replicative lifespan but the health status of the donors was unknown. 
Determination of replicative lifespans of 124 skin fibroblast cell lines from donors 
of different ages in the Baltimore Longitudinal Study of Aging where donors were 
healthy found no correlation between the proliferative potential of the cell lines 
and donor age (Cristofalo et al., 1998). A subsequent study however revealed that 
replicative fibroblasts isolated from young, middle-age, and old-age humans and 
humans with progeria, a rare genetic disorder characterized by accelerated aging, 
had changes in gene expression associated with the ageing phenotype and 
progeria. This suggested increasing errors in the mitotic control of dividing cells 
in the post-reproductive stage of life is linked to the aging process (Ly et al., 
2000). Moreover, a study of cells from healthy donors and donors with the adult 
progeria, Werner’s syndrome, of the same age revealed that cells from donors 
with Werner’s syndrome had decrease proliferative capacity compared to normal 
donor cells (Martin et al., 1970). Despite the in vivo nature of senescence, this 
model is used in order to get insight on the ageing process. In fact, in vivo ageing 
markers are expressed in vitro and cell proliferation seems to be a key element in 
ageing as seen in senescence studies (Cristofalo and Pignolo, 1993). 
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1.2.1 The Hayflick Limit 
Ageing at the cellular level is often referred to as ‘cellular senescence’. 
The concept of cellular senescence lays on the idea that proliferation of normal 
diploid cells can only be achieved for a limited period of time after which, cells 
stop dividing (Cristofalo and Pignolo, 1993). This limitation of lifespan for in 
vitro cell cultures was first described by Leonard Hayflick in 1961, going 
against the theory formulated by Alexis Carrel claiming that cells kept in culture 
have an unlimited potential for division (Carrel and Ebeling, 1921). Indeed, 
Hayflick and Moorhead demonstrated that culture of normal human fibroblasts 
followed a pattern consisting of 3 phases (Figure 7). 
 
 
 
Figure 7. The 3 phases of cell culture as described by Hayflick and 
Moorhead. 
Phase I refers to the primary culture, Phase II is characterised by an abundant 
exponential cell growth and Phase III is defined as the time period during which 
cell growth decreases and ultimately comes to an arrest (Hayflick and Moorhead, 
1961; Wright and Shay, 2000). 
 
At the start of his research on human foetal fibroblasts culture, Hayflick 
defined Phase 1 as the primary culture. This phase is followed by Phase II which 
refers to the time at which cells divide exponentially and profusely. Finally, cells 
enter Phase III in which they divide much slowly and eventually stop dividing 
(Hayflick and Moorhead, 1961). This later phase is also referred to as the 
‘senescent’ phase. Moreover, the term replicative senescence (RS) was brought 
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about after the observation that senescence can be triggered by cell-intrinsic 
mechanisms after extensive proliferation (Ben-Porath and Weinberg, 2005). 
Having challenged the undisputed ideas of Alexis Carrel, and described 
the 3 phases of cellular culture, Hayflick’s onset of Phase III is now more 
commonly known as the Hayflick Limit. The Hayflick limit is defined as the 
number of times a normal cell population can divide before it comes to a point of 
cell growth arrest (Masaro, 2006). Indeed, Hayflick established that normal 
human foetal cells in culture can divide up to around 50 times after which they 
reach the Hayflick limit (Hayflick and Moorhead, 1961). 
It is now known that the protective termini of chromosomal DNA, telomeres, are 
progressively shortened with the propagation of human cells in culture which 
ultimately causes cells to reach their Hayflick limit. Attrition of telomeres occurs 
due to DNA polymerase failing to completely replicate the lagging strands 
(Watson, 1972). Telomere length reflects the replicative history of cells in 
primary culture (Harley et al., 1990).  
 
1.2.2 Markers of cell senescence 
Although markers of cell senescence are numerous, their specificity is 
yet to be exclusive and they need to be chosen with caution when used to 
determine cell senescence in cultures. These markers can be phenotypic or 
molecular and examples are shown in Table 1. 
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Table 1. Phenotypic and molecular markers of cellular senescence. 
Source: Salama et al., 2014. 
 
       
 
1.2.2.1 Exit from the cell cycle 
Long-term exit from the cell cycle is a necessary marker of cell senescence 
in vitro and in vivo. However, this is not a unique phenomenon as terminal 
differentiation of cells causes the same effect. Differentiation is triggered by 
physiological factors which does not involve the activation of tumor suppressor 
networks. To prevent or delay senescence – as attempted in this study – added 
compounds will need to delay or weaken engagement of cells in senescence 
pathways or block their mediators (Kuilman et al., 2010). 
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1.2.2.2 Changes in cell morphology 
It is long established that when cells reach senescence, an increase in cell 
size and heterogeneity can be observed (Greenberg et al., 1977). Alongside this 
cell expansion, the size of senescent human fibroblasts nucleolus and nucleus has 
been observed to increase as the ageing process progresses (Mitsuishi et al., 
2010). As shown in Figure 8, senescent human fibroblasts display prominent 
morphological alterations. Moreover, the lysosome and Golgi apparatus of 
senescent cells appear larger than in younger cells (Brandes et al., 1972). 
 
 
Figure 8. Morphological changes observed in WI-38 fibroblast. 
Observations at (a) population doubling 20 and (b) population doubling 40 (Shay 
and Wright, 2000). 
 
Other morphological changes include a displacement of the endoplasmic 
reticulum (ER) as well as changes in the cytosol such as an accumulation of 
cytoplasmic microfilaments (Lipetz and Cristofalo, 1972). Finally, cells reaching 
senescence display a decreased density at harvest which is accompanied by a 
rarefaction of cell to cell contact (Cristofalo et al., 1998). 
 
1.2.2.3 Beta-galactosidase  
Beta-galactosidase (SA-β-Gal) is the most commonly used marker to 
quantify senescence at the cellular level. The SA-β-Gal assay was first described 
in 1995 by Dimri et al. in which they observed that at pH 6.0, senescent cells 
expressed the β-galactosidase enzyme in the cytosol when compared with 
fibroblasts from young donors (Dimri et al., 1995). In this assay, the cleavage of 
5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) is performed by β-
galactosidase (Figure 9). 
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Figure 9. The β-Galactosidase reaction with chromogenic substrate. 
X-Gal is cleaved by the enzyme β-galactosidase which leads to the formation of 
galactose and 5-bromo-4-chloro-3-hydroxyindole. This later product then 
undergoes spontaneous dimerization and oxidation from which the insoluble blue 
dye 5,5’-dibromo-4,4’-dichloro-indigo is produced. Senescent cells express β-
galactosidase and are easily quantified by counting cells which produce the blue 
dye. Modified from Berg et al., 2002. 
 
The end result of this reaction is the formation of a characteristic dark blue 
colour which is easily detectable on senescent cells (Figure 10). 
 
              Non-senescent cells         Replicative senescent cells 
Figure 10. Senescence detected by beta-galactosidase activity staining in 
replicative senescent and non-senescent WI-38 human foetal lung fibroblasts. 
Source: Debacq-Chainiaux et al., 2009. 
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1.2.2.4 Lipofuscin  
The pigment lipofuscin (LF) was first discovered in 1842 by Hannover 
(O’Donovan and Tully, 1996). Since over a century, LF pigments deposits is 
considered to be a characteristic of ageing (Jung et al., 2009) as its accumulation 
seems to follow a linear trend when plotted against age of the donor. LF is a 
complex mixture of fluorophores of excitation and emission wavelength ranges 
340 – 390 nm and 430 – 490 nm, respectively - some formed oxidatively, others 
non-oxidatively and also endogenous fluorophoric metabolites (Li et al., 2006; Na 
et al., 2000; Sohal, 1981; Xue et al., 2008a). 
 
1.2.2.5 Activation of tumor suppressor networks 
p53 and p16INK4A–RB signal transduction cascades commonly mediate 
the activation of the senescence program (Lowe et al., 2004) and therefore 
components of these pathways have been proposed as biomarkers of cell 
senescence. In human fibroblasts undergoing RS, an active, hypophosphorylated 
form of RB accumulates (Stein et al., 1990). Moreover, p53 shows increased 
activity and/or levels in human fibroblasts undergoing RS (Atadja et al., 1995). 
An activator of RB, p16INK4A, is induced in senescent cells in vitro. Moreover, 
other proteins such as p21CIP1 and p15INK4B accumulate in cells undergoing 
senescence. These proteins are part of the p16INK4A–RB and p53 pathways 
(Kuilman et al., 2010). The wingless-type mouse mammary tumor virus (MMTV) 
integration site family member 16B (WNT16B) has been found to be a specific 
marker of senescence (Binet et al., 2009). WNT16B is one of two ligand isoforms 
of the WNT family of seven transmembrane receptors and is implicated in 
tumorigenesis and development (Nusse, 2005). The WNT family has been shown 
to be involved in senescence (Maiese et al., 2008) and although WNT16B 
structure and mechanism pathway is yet to be fully understood, it has been found 
to be specifically overexpressed in RS of skin fibroblasts (Binet et al., 2009).  
Immortalisation of HDFs has also been achieved by inactivation of p53 
and pRb (de Magalhaes, 2004). p53 and pRb are both tumour suppressor proteins 
which are involved in the prevention of cancer by suppression of apoptosis (Ben-
Porath and Weinberg, 2005; Matlashewski et al., 1984). The p53/p21 and Rb/p16 
pathways are thought to be the central pathways for senescence activation (Ben-
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Porath and Weinberg, 2005). p53 is encoded by the TP53 gene and is often 
referred to as the ‘guardian of the genome’ (Matlashewski et al., 1984). Indeed, 
the main purpose of p53 is to conserve genome stability (Strachan and Read, 
1999). The structural organisation of p53 (Figure 11) is defined by four small 
nodes and four large nodes, the latest forming the four cores of the structure, and 
an N- and C-terminal (Aramayo et al., 2011). 
 
        
Figure 11. The structural organisation of the tumour suppressor protein p53. 
Four cores are part of the eight nodes that constitute the general structure of p53 
as well as an N- and C-terminus. Source: Aramayo et al., 2011. 
 
The retinoblastoma protein Rb is encoded by the RB1 gene and is 
considered a tumour suppressive factor due to its ability to inhibit cell cycle 
progression (Xiao et al., 2003). pRb has an 18 helixes structure contained in two 
domains: Rb-A and Rb-B (Lee et al., 1998). These two domains form a pocket 
(Figure 12) to which the transcription factor E2F binds, allowing for effective 
transcription of genes involved in DNA replication and cell cycle progression 
(Xiao et al., 2003) 
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Figure 12. The structural organisation of the tumour suppressor protein 
pRb. 
Eighteen helixes constitute the two domains of pRb which form a groove 
allowing the transcription factor E2F to bind for effective transcription of 
genes involved in cell cycle progression and DNA replication. Source: Xiao 
et al., 2003. 
 
Activation of tumour suppressor protein P19ARF, coupled to the Mdm2 
protein, leads to the degradation of p53. This, in turn, leads to direct onset of 
senescence (Lowe et al., 2004) or activation of the cyclin-dependent kinase 
inhibitor 1 (p21) , leading to inactivation of the cyclinE/cyclin dependent kinase 2 
(cdk2) complex (Chuaire-Noack et al., 2010). This later results in the inactivation 
of Rb and subsequently triggers senescence as well as inactivation of E2F 
(Gewirtz et al., 2008). Moreover, senescence activating factors can also turn on 
the p16lnk4a cyclin dependent kinase inhibitor which leads to inhibition of the 
cyclinD/cdk4,6 complex (Roninson, 2003). This later event results in indirect cell 
growth arrest through inhibition of the Rb/E2F complex and leads to senescence 
(Chuaire-Noack et al., 2010). 
 
1.2.3 Replicative senescence in vivo 
Application of biomarkers of senescence to pre-clinical in vivo and 
clinical studies have suggested RS occurs in vivo. An increase in SA-β-Gal 
activity was detected in the skin of elderly people (Dimri et al., 1995) and a 
decrease in telomere length was found in some cell types in aged tissue 
(Cristofalo et al., 2004). Later studies have shown increased DNA damage at 
telomeres and heterochromatinization markers (53BP1, g-H2AX, phospho-Ser 
1981-ATM, HP-1b, and HIRA) were increased in dermal fibroblasts from aging 
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baboons (Herbig et al., 2006). Moreover, cellular senescence is detected in mitotic 
tissues of aging primates (Jeyapalan et al., 2007) and senescent cells have also 
been detected in intestine, kidney, and spleen of mice (Cosme-Blanco et al., 
2007). There is also evidence of increased cell senescence in disease. For 
example, in atherosclerosis there is induction of SA-β-Gal activity (Minamino et 
al., 2002) and telomere shortening (Foreman and Tang, 2003). Senescent cells 
have also been observed in osteoarthritis (Price et al., 2002). These observations 
are in accordance with the proposal that RS contributes to age-related disease 
(Campisis, 2005).  Finally, there has also been findings supporting the suggestion 
by Hayflick that replicative senescence limits tumorigenesis (Hayflick, 1965; 
Kuilman et al., 2010). 
 
1.2.4 Mechanism of cell senescence 
One of the most important triggers for the onset of RS is the shortening of 
telomeres. Telomeres are found in eukaryotes and are nucleo-protein structures 
capping the end of chromosomes in order to conserve normal chromosomal 
function (Foyer et al., 2009). These TTAGGG repeats (Figure 13) are associated 
with an assortment of proteins involved in replication, chromosome maintenance 
and nuclear attachment (Kanoh and Ishikawa, 2003). 
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Figure 13. The telomere shortening process.  
Telomere shortening occurs as a result of normal cell replication, oxidative DNA 
damage and replication errors. In this process, when elongation with telomerase is 
no longer possible, telomeres shortening occurs as cells go through the ageing 
process. ATM: ataxia telangiectasia mutated kinase, ATR: Rad3-related protein. 
Source: Jiang et al., 2007. 
 
Activation of RS in response to telomere DNA damage provides a 
mechanism of cell autonomous RS. Since the observation in the early 1990s that 
telomeres shorten as RS progresses (Harley et al., 1990), the involvement of the 
enzyme telomerase for the control of telomere lengthening as well as the 
expression of the catalytic subunit of human telomerase (hTERT) has been 
suggested (Bodnar et al., 1998). Indeed, some studies even suggest that induction 
of hTERT in ageing human diploid fibroblasts (HDFs) could overcome 
progression of RS (Funk et al., 2000). Rarefaction of the enzyme telomerase, 
responsible for maintaining telomere length, has been observed at the onset and 
throughout the process of senescence (Ahmed and Tollefsbol, 2001). Moreover, 
these observations have been strengthened by the observation that exogenous 
supplementation of telomerase in cell cultures showed beneficial effects in terms 
of cell longevity and viability (Bodnar et al., 1998). 
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The protective ability of telomeres is disturbed when they reach a 
dangerous minimal length. This critical minimal length then leads to the activation 
of a DNA damage response (DDR) which is characterised by the formation of foci 
(Kuilman et al., 2010). These foci are quantified by positive staining to the 
phosphorylated form of the histone variant H2AX (g-H2AX) and proteins 53BP1, 
NBS1, and MDC1. Moreover, DNA damage kinases ATM and ATR are activated 
in senescent cells (d’Adda di Fagagna et al., 2003). These kinases activate CHK1 
and CHK2 kinases and link with cell cycle proteins such as the CDC25 family of 
phosphatases and p53 (Fujita et al., 2009). Transient proliferation arrest for repair 
of damage is induced but if the DNA damage exceeds a critical threshold 
apoptosis, senescence is activated (d’Adda di Fagagna et al., 2003). This 
triggering of cellular senescence by telomere dysfunction, radiation, oncogenes 
activation and tumour suppressor activation is schematised in Figure 14 below. 
 
            
Figure 14. Activating pathways of senescence. 
The mechanisms underlying senescence are triggered by factors such as 
telomere dysfunction, radiation, oncogenes activation and tumour suppressor 
activation. Source: Chuaire-Noack et al., 2010.  
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1.2.4.1 Senescence-associated secretory phenotype 
There are, however, non-cell-autonomous effects observed in cell 
senescence – such as senescence-associated secretory phenotype (SASP) – which 
are linked to functional changes in pathophysiology and likely contribute to 
declining organ function with aging. Senescence may not be a singular state but 
rather a heterogeneous phenotype driven by diverse stresses and multiple effector 
programs in a functional network. Indeed, late passage human fibroblasts or 
fibroblasts derived from subjects with premature aging syndromes secrete proteins 
such as plasminogen activator inhibitor type-1 (PAI-1), a range of cytokines, 
chemokines and proteases (Campisi, 2005; Kuilman and Peeper, 2009). 
Therefore, as seen in Figure 15, cellular senescence supports a range of functions, 
including autocrine and paracrine signalling, protumorigenic and tumor-
suppressive effects, and pro- and anti-inflammatory signalling (Salama et al., 
2014). Indeed, transcription factors, NF-kB and C/EBPb, act cooperatively to 
regulate inflammatory components of SASP whilst IL6 and IL8 enhance 
senescence.  
 
 
Figure 15. Schematic model of senescence and its biological functions. 
Source: Salama et al., 2014. 
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1.2.4.2 Senescence and changes in cellular metabolism - Protein degradation 
pathways 
Autophagy is a cytoplasmic degradation mechanism for usually large 
proteins and organelles (Badadani, 2012). The basal level of autophagy plays an 
important role for quality control of macromolecules and energy homeostasis but 
it can also be induced in response to cytotoxic stresses. Indeed, a gradual shift in 
protein degradation for polyubiquitination of the proteasome pathway to 
autophagy was found in human skin fibroblasts during RS linked to SASP 
(Gamerdinger et al., 2009). mTOR is a nutrient-sensitive kinase which inhibits the 
initial step of autophagy but is involved in facilitating later stages of the process 
using autolysosomes. Moreover, proteasomal protein degradation also plays 
important roles in senescence. Therefore, highly active SASP may overwhelm the 
cellular capacity for synthesis and the processing of secretory proteins, leading to 
proteotoxic stress. 
 
1.2.4.3 Senescence and changes in cellular metabolism - Mitochondria 
metabolism 
Partial uncoupling of oxidative phosphorylation in mitochondria is found 
in RS of human skin fibroblasts (Hutter et al., 2004). Indeed, glycolysis and 
oxygen consumption were shown to be enhanced in RS and that enhanced energy 
production is critical for progression of RS (Hutter et al., 2004). Finally, most 
studies also claim that up-regulation of reactive oxygen species (ROS) is a critical 
mediator of senescence (Lu and Finkel, 2008). 
 
1.2.5 Theories of ageing as applied to cell senescence – accumulation of 
macromolecular damage 
Ageing is associated with the accumulation of macromolecular damage - 
protein, lipid and DNA damaged by spontaneous modifications. This processes 
linked to the formation of macromolecular damage in the onset and progression of 
senescence are thought to be oxidation, glycation, metabolic stress, lipogenic 
stress and failure of clearance mechanisms for macromolecular damage. 
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1.2.5.1 Oxidative damage 
In 1956, Denham Harman established the theory that ageing is caused by 
an accretion of reactive oxygen species (ROS) in cells (Harman, 1956). The 
oxidation of proteins, lipids, saccharides and nucleotides in physiological systems 
occurs by interaction with oxidizing agents such as hydrogen peroxide H2O2, 
hydroperoxides ROOH, hypochlorite ClO-, peroxynitrite and other oxidizing 
reactive intermediates (hydroxyl radical HO•, carbonate radical anion CO3
•¯, and 
others) (Finkel and Holbrook, 2000). These processes may be catalysed by trace 
redox active metal ions such as iron (III) or ferric ion Fe3+, and Cu (II) or cupric 
Cu2+ ion (Castellani et al., 2004). Hydrogen peroxide in physiological systems 
originates mainly from the dismutation of superoxide O2
•- formed by inefficiency 
of mitochondrial respiration (Chance et al., 1979), superoxide-forming enzymes – 
such as phagocyte and vascular NADPH oxidases (Lassegue and Clempus, 2003), 
uncoupling of enzymatic reactions (for example, nitric oxide synthases) (Du et al., 
1999), and autoxidation of reducing metabolites (Finkel and Holbrook, 2000). 
Hypochlorite is formed by the enzymatic reaction of myeloperoxidase in 
neutrophils (Naskalski et al., 2002). Extracellular proteins are more susceptible to 
oxidation than cellular proteins because the non-enzymatic and enzymatic 
activities of antioxidants have mostly an intracellular location. However, one of 
the sources of highest flux of hydrogen peroxide generation, mitochondria 
(Murphy, 2009), is also intracellular. Although the cytoplasm in physiological 
systems is maintained under reducing conditions by the presence of high 
concentrations of low molecular mass peptide thiols (usually glutathione, GSH), 
there is nevertheless a residual low level of oxidative damage to proteins, lipids, 
saccharides and nucleotides in cellular and extracellular compartments. Oxidative 
damage to proteins forms oxidised amino acid residues (Thornalley and Rabbani, 
2014) and are shown in Figure 16. Oxidative damage to lipids forms lipid 
peroxidation products such as F2-isoprostanes, 4-hydroxynonenal and 
malondialdehyde (Negre-Salvayre et al., 2010) and oxidative damage to 
saccharides may form dicarbonyl glycating agents – see below, and oxidation of 
DNA forms 8-dihydro-8-oxo-2’-deoxyguanosine (8-OxodG) (Cooke et al., 2008). 
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Figure 16. Formation of oxidised amino acid residues from oxidative damage 
to proteins. 
Source: Thornalley and Rabbani, 2014. 
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The notion of oxidative stress emerged from the concept that ROS become 
excessively available in cells, leading to impaired cellular functions and 
senescence (Balaban et al., 2005). Oxidative stress is defined as an imbalance of 
oxidants and antioxidants in favour of the former potentially leading to cell 
damage (Sies, 1993). The production of ROS is triggered by endogenous sources 
(mitochondria, lipoxygenases, peroxisomes, autoxidation of thiol and other 
reducing metabolites) and exogenous sources (UV light, environmental toxins) –
Figure 17. Moreover, oxidative damage is thought to be caused by an imbalance 
of the enzymatic members of the anti-oxidant defence such as catalase (CAT), 
glutathione peroxidase (GPx) and superoxide dismutase (SOD) (Finkel, 1998) and 
non-enzymatic members such as Vitamin A, C and E as well as the tripeptide 
glutathione (GSH) (Finkel and Holbrook, 2000). 
 
 
Figure 17. Mechanisms of oxidative damage involved in the ageing process. 
Source: Xue et al., 2008a. 
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1.2.5.2 Glycation 
Glycation is a process which relies upon the non-enzymatic attachment of 
a reducing sugar or sugar derivative to a protein but this process is not available to 
non-reducing oligosaccharides such as sucrose, in which aldehyde or ketone 
groups of component monosaccharides have been converted to ketal and acetal 
groups (Thornalley and Rabbani, 2014). Recently, the glycation of arginine 
residues by dicarbonyl metabolites has been found to be a major feature of protein 
glycation in physiological systems and evidence is also pointing towards an 
involvement of cysteine residues. Protein glycation is possible through sequential 
and parallel reactions known as the Maillard reaction (Thornalley and Rabbani, 
2014). Amongst the adducts formed through glycation are the early glycation 
adducts and the advanced glycation endproducts (AGEs). Early glycation adducts 
are Schiff’s base and Amadori products or fructosamine residues formed at early 
stages of glycation processes whereas AGEs are formed in both early and 
advanced stages (Rabbani and Thornalley, 2012a). Non-oxidative processes allow 
for the formation of the major glycation adducts Nε-fructosyl-lysine (FL) residues 
and methylglyoxal derived hydroimidazolone N-(5-hydro-5-methyl-4-
imidazolon-2-yl)ornithine (MG-H1) in physiological systems. Finally, the 
glycoxidation products Nε-carboxymethyl-lysine (CML) and pentosidine are 
AGEs formed using oxidative processes (Thornalley and Rabbani, 2014). 
Glycation accounts for 0.1 to 0.2% of cellular arginine and lysine residues 
in the body (Thornalley et al., 2003). This physiological process causes damage to 
proteins and results in the formation of glycated amino-acid residues (Xue et al., 
2008a). These residues are formed by the spontaneous reaction between 
monosaccharide and proteins. Glycating agents are formed from the degradation 
of glycated proteins and lipid peroxidation and include dicarbonyls such as 
methylglyoxal, glyoxal and 3-deoxyglucosone (3-DG) (Thornalley et al., 2003) 
which act as precursors for advanced glycation end products (AGEs) directly 
linked with senescence progression. 
 
Glucose modifies the N-terminal and lysine residue amino groups of 
proteins forming mainly fructosamine derivatives (Bookchin and Gallop, 1968). 
This glycation is repaired enzymatically by fructosamine-3-phosphokinase 
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(F3PK) (Delpierre et al., 2000). Gene deletion of F3PK produces marked 
increased in fructosyl-lysine with little adverse effect (Veiga da-Cunha et al., 
2006), suggesting this type of glycation has little effect on ageing and senescence. 
In quantitative assessments of advanced glycation endproducts (AGEs) in 
physiological systems from 2003, it became clear that glycation of proteins by the 
physiological metabolite methylglyoxal (MG) produces levels of cellular and 
extracellular proteins modification approaching and sometimes exceeding that of 
glucose (Thornalley et al., 2003). In contrast to glycation by glucose, protein 
glycation by MG is directed to arginine residues forming hydroimidazolone Nδ-
(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1) residues. MG glycation 
also forms AGEs in DNA by glycation of deoxyguanosine bases, forming MG-
derived imidazopurinone, 3-(2’-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6/7-
methylimidazo-[2,3-b]purine-9(8)one isomers (MGdG). MGdG is a quantitatively 
major type of DNA damage in vivo, often exceeding that of the oxidative marker 
8-oxo-7,8-dihydro-2’-deoxyguanosine (8-OxodG) (Thornalley et al., 2010). MG 
is mainly metabolised by glyoxalase 1 (Glo1) of the glyoxalase system 
(Thornalley, 1993). Gene deletion of GLO1 is lethal to the embryo and GLO1 
silencing and chemical inhibition increases MG concentration, increases MG-H1 
residues of cellular and extracellular proteins and MGdG adducts of DNA and is 
associated with cell dysfunction, premature ageing and development of vascular 
disease (Giacco et al., 2014; Morcos et al., 2008). Overexpression of Glo1 
decreased MG-H1 residue content of protein and increased longevity - 
exemplified by life extension of Glo1 transgenic Caenorhabditis elegans (Morcos 
et al., 2008). Induction of Glo1 expression decreases cellular and extracellular 
concentration of MG, decreased glycation and prevented MG-induced 
mutagenesis and cell dysfunction (Xue et al., 2012b).  MG glycation is therefore 
particularly insidious. As seen in Figure 18 and 19 below, recent research is 
shedding light on the reasons for which these events happen and point out the 
benefits available if Glo1 inducers can be developed and deployed. 
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Figure 18. Mechanisms of formation of AGEs from glucose, glycolytic 
intermediates and lipid peroxidation. 
Source: Xue et al., 2008. 
 
 
 
 
 
 
 
Figure 19. Molecular structure of the physiologically reactive glycating 
dicarbonyls 3-deoxyglucosone (3-DG), glyoxal and methylglyoxal. 
Source: Xue et al., 2008. 
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The involvement of the reactive glycating species in the ageing process is 
summarised in Figure 20 where their fluctuation is triggered by endogenous 
sources and exogenous sources as well as impairment of the anti-glycation 
defence. The resulting impairment of physiological functions leads to an increase 
in hotspot modification at functional sites which contributes to the ageing process. 
 
 
Figure 20. Reactive glycating species function in the ageing process. 
Source: Xue et al., 2008. 
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Figure 21. Mechanism of formation of major protein glycation adducts.  
a.Nε-fructosyl-lysine. b. hydroimidazolone and c. Nδ-(5-hydro-5-methyl-4-
imidazolon-2-yl)ornithine (MG-H1).  
Source: Rabbani and Thornalley, 2012b. 
 
 
 
 
 
 
 
 
 
 
Figure 22. Protein glycation adduct residues in physiological systems.  
a. Early glycation adducts – FL and Nα-(1-deoxy-D-fructos-1yl)amino acid 
residues. Advanced glycation endproducts: b. Hydroimidazolones, c. Monolysyl 
d. Fluorophorescent AGEs, and e. Non-fluorescent crosslinks. For the 
corresponding free adducts at physiological pH, the N-terminal amino group is 
protonated –NH3+ and the C-terminal carbonyl is a carboxylate –CO2- moiety. 
Source: Rabbani and Thornalley, 2012b. 
 
 
Methylglyoxal glycation of protein is damaging to cells as a positive 
charge is loss during the modification process of MG to MG-H1. Indeed, this 
causes a lost in the electrostatic interactions with surrounding ligands and groups 
 33 
 
linked to arginine residues (Rabbani and Thornalley, 2014) – Figure 21 and 22. 
However, fructosamine residues formed as a result of glucose glycation leads to 
the acquisition of a positive charge on the lysine residue on the amino group. 
Therefore, damage to arginine is one of the main cause by which MG glycation is 
damaging as (i) modification is directed to arginine residues which have the 
highest probability of any amino acid residue for location at functional sites of 
proteins (predicted probability that a functional site amino acid residue is arginine 
= 20%); (ii) functionally important arginine residues are often hotspots for 
dicarbonyl glycation; and (iii) MG-H1 is one of the most quantitatively important, 
spontaneous irreversible modifications of the proteome in health and disease 
(Rabbani and Thornalley, 2014).   
 
   
1.3 The Nrf2 system  
One of the key triggers influential for the development of senescence is 
oxidative stress. In relation to this is the Keap1-Nrf2-antioxidant response 
element (ARE) signalling pathway and its role in senescence.  
Stress responsive signalling coordinated by nuclear factor erythroid 2-
related factor 2 (Nrf2) provides an adaptive response for protection of cells 
against toxic insults, oxidative stress and metabolic dysfunction – Figure 23. Nrf2 
regulates a battery of protective genes by binding to regulatory anti-oxidant 
response elements (AREs). Nrf2 regulates the cellular expression of a battery of 
protective genes countering oxidative stress, environment toxic insults, lipid 
peroxidation, macromolecular damage, metabolic dysfunction and cell senescence 
(Kapeta et al., 2010; Malhotra et al., 2010; Taguchi et al., 2011; Xue et al., 2013). 
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Figure 23. Examples of the battery of protective genes regulated by the Nrf2 
system and their role in the anti-stress gene response. 
Provided by Professor Paul J. Thornalley. 
 
The Nrf2 system senses challenges to homeostasis in the cell cytoplasm 
and activates a protective transcriptional response. Such stress-responsive 
signalling is vital in resisting oxidative damage, cell dysfunction, cytotoxicity and 
mutagenesis, thereby contributing to resistance to drug toxicity, wound healing 
and decreasing risk of diabetes, vascular and neurodegenerative disease and 
ageing-related disease (Collins et al., 2009; Hayashi et al., 2013; Okawa et al., 
2006; Pearson et al., 2008). Improved manipulation of the Nrf2 system would 
likely lead to more effective deployment of micronutrient Nrf2 activators in 
functional foods to support healthy ageing where delay of cell senescence may be 
a contributory factor. 
Human Nrf2 is a protein of 68 kDa which is detected in SDS-PAGE as a 
band at 98 kDa of a dominant phosphorylated form (Lau et al., 2013; Xue et al., 
2008b). According to current understanding, under basal conditions, Nrf2 
transactivational activity is repressed by binding to Kelch-like erythroid cell-
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derived protein with CNC homology-associated protein 1 (Keap1). This acts as an 
inhibitor holding Nrf2 in the cytoplasm and facilitating its degradation. Keap1 is a 
substrate adaptor protein for Cullin-3 (Cul3)-dependent E2 ubiquitin ligase 
complex, directing Nrf2 for degradation by the 26S proteasome (Cullinan et al., 
2004). Keap1 and Nrf2 are held together with the protein threonine phosphatase, 
PGAM5, which tethers Keap1 and Nrf2 to the outer mitochondrial membrane (Lo 
and Hannink, 2008). 
The mechanisms of stress sensing and surveillance by the Nrf2 system are 
uncertain but under conditions of oxidative and electrophilic stress Nrf2 is 
released from Keap1. Nrf2 is phosphorylated by casein kinase-2 (CK2) (Apopa et 
al., 2008), translocates to the nucleus via importins α5 and β1 (Theodore et al., 
2008) and therein activates its target genes by binding to regulatory AREs (Pi et 
al., 2007). Thereafter Nrf2 is phosphorylated by Fyn kinase and expelled from the 
nucleus via the nuclear membrane export channel exportin-1/crm1 and degraded 
(Jain et al., 2005) – Figure 24. Endogenous activators are lipid peroxidation and 
arachidonic acid oxidation products, 4-hydroxynonenal and J3-isoprostanes (Gao 
et al., 2007; Ishii et al., 2004) and exogenous activators are typically bioactive 
compounds from fruits and vegetables such as glucosinolates-derived 
isothiocyanates, disulfides, polyphenols, flavonoids, carotenoids and triterpenoids, 
for example - R-sulforaphane (SFN) found in broccoli, diallyldisulfide found in 
garlic, quercetin found in onions, resveratrol found in red grapes, and oleanolic 
acid found in apple, grape and olive pomace (Thimmulappa et al., 2002; Chen et 
al., 2004; Tanigawa et al., 2007; Rubiolo et al., 2008; Dinkova-Kostova et al., 
2005). As Nrf2 is activated in response to toxicity, careful distinction between 
pharmacological activation of Nrf2 and indirect activation of Nrf2 in response to 
chemical toxicity is required.   
Research on the control of Nrf2 has focussed on binding and chemical 
modification of its inhibitor Keap1 by activators, stabilising Nrf2 to proteolysis 
thus increasing cellular Nrf2 protein content  (Kobayashi et al., 2006). Studies in 
this group, however, showed that activation of cells to produce half-maximal 
ARE-linked transcriptional response elicited no significant change in Nrf2 protein 
concentration – although markedly higher and often toxic concentrations of 
activators did so (Tanigawa et al., 2007; Jeong et al., 2005). Under physiological 
and health beneficial conditions, therefore, Nrf2 activation status may be encoded 
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in the time dependence of subcellular Nrf2 location rather than its resistance to 
proteolysis. We found that Nrf2 undergoes translocational oscillations from the 
cytoplasm to the nucleus in the basal state.  When stimulated at physiological 
levels, the translocational oscillations of Nrf2 increase in frequency, decrease in 
amplitude and activate ARE-regulated genes. We presented a mechanism to 
explain this where Nrf2 functionality is linked to reactivation on return to the 
cytoplasm or “refresh rate” which links protective transactivational response to 
increased frequency of direct surveillance of the cytoplasm (Xue et al., 2012) – 
Figure 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Current understanding of transcriptional control of ARE-linked 
gene expression by the Nrf2/Keap1 system. 
Key: P, phosphorylation (coloured-coded for CK2 or Fyn catalysed modification). 
In quiescence, Nrf2 in the cytoplasm is complexed to Keap1 in association with 
Cul-3-Rbx-1 attracting co-association of E2 ubiquitin ligase, Nrf2 ubiquitination 
and proteolysis. Upon activation (yellow arrows), Nrf2 dissociates from Keap1 
and is phosphorylated by CK2; phosphorylated Nrf2 enters the nucleus and binds 
with accessory Maf protein to AREs. Thereafter, Nrf2 is phosphorylated by Fyn, 
exported from the nucleus and degraded by the proteasomal system. SFN and 
QTN are thought to activate Nrf2 by disrupting the Nrf2-Keap1 complex and 
stabilising Nrf2 from proteolysis (Thimmulappa et al., 2002; Tanigawa et al., 
2007). Diagram provided by Professor Paul J. Thornalley. 
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Figure 25. Cell signalling sustaining Nrf2 translocational oscillations for 
control of ARE-linked gene expression. 
Negative feedback is provided by successive de-phosphorylation and 
phosphorylation steps, which induce ultra-sensitivity in Fyn activation and the 
Fyn phosphorylation of nuclear Nrf2 and which produce a delay between Nrf2 
nuclear entry and the Fyn phosphorylation which drives nuclear export. Figure 
provided by Professor Paul J. Thornalley. 
 
 
1.3.1 Antioxidant response element 
The ARE was first thought to be involved in regulation of the expression 
of genes encoding enzymes that catalyse drug metabolism phase II conjugation 
reactions such as glutathione S-transferases (GSTs) and UDP glucoronyl 
transferase (Rushmore et al., 1991). AREs are conserved cis-acting regulatory 
elements in the promoter region of these and other genes with expression 
regulated by Nrf2. ARE gene transcription results in increased production of 
antioxidant proteins and related enzymes and other protective gene products, and 
suppression of the expression of lipogenic genes. The Nrf2/Keap1/ARE system 
regulates a large number of genes in mammals - basal expression of ca. 640 
genes, inducible expression of 650 genes and basal and inducible expression of 
ca. 240 genes has been discovered (Malhotra et al., 2010). The consensus ARE is 
shown in Figure 23.  
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1.3.2 The Nrf2 system in ageing and senescence 
Lifespan extension has been shown in mice models where increased 
activity of Nrf2-dependent enzymes involved in the antioxidant response has been 
observed (Brown-Borg and Rakoczy, 2005). Moreover, in C. elegans, knockout of 
the Nrf2 gene homologue SKN-1 was proven to shorten life span (Bishop and 
Guarante, 2007). These data demonstrate that increased longevity is maintained 
by the Nrf2 system. Studies on the Drosophila melanogaster in which Nrf2 was 
overexpressed (Orr et al., 2005) or Keap1 allele modified for overexpression of 
glutathione-S-transferase D1 (GSTD1) responsible for the detoxifying response in 
cells (Sykiotis and Bohmann, 2008) both resulted in extended life span. This 
suggests that the Nrf2 system is capable of increasing lifespan but it is no clear if 
delayed cell senescence contributes to these effects. 
Dietary activators such as carotenoids (Ben Dor et al., 2005), omega-3 fatty acids 
(Gao et al., 2007), isoflavones (Mann et al., 2007) and others, have been shown to 
activate Nrf2 but the challenge lays in the discovery of dietary bioactives that 
would be able to promote healthy ageing (Xue et al., 2008). Examples of such 
dietary bioactivators are shown in Table 2.  
 
Table 2. Dietary activators of nrf2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Di tary activato s of nrf2. 
Dietary bioactive Example Dietary sources 
Glucosinolate-derived 
isothiocyanates 
Sulforaphane 
N C S
SCH3
O
 
Brassica vegetables (broccoli, cabbage, cauliflower, 
Brussel sprouts and other), rocket salad. 
Glucosinolate-derived indoles 
Indole-3-carbinol
N
H
OH
 
Brassica vegetables (broccoli, cabbage, cauliflower, 
Brussel sprouts and other), rocket salad. 
Thioethers and disulfides 
Diallyldisulfde
S
S
 
Garlic, onions and others. 
Polyphenols and flavonoids Resveratrol                                   Quercetin 
   
OH
OH
HO O
OH
OH
OH
OOH
HO
 
Grape juice, onions, other fruits and vegetables. 
 
Table 1. Dietary activators of nrf2 (cont’d). 
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Sulforaphane (2 μM) delayed senescence of IMR-90 lung fibroblast 
cells in vitro (Hintze et al., 2008). Trans-Resveratrol (1 and 52 μM) delayed 
senescence of human MRC5 lung fibroblast cells in vitro (Giovanelli et al., 
2011). Resveratrol (5 µM) decreased development of SASP in MRC5 
fibroblasts in vitro, decreasing expression and secretion of pro-inflammatory 
cytokines; 1 µM resveratrol had a similar but weaker effect. Cell spreading and 
plating efficiency were increased with type I collagen expression remaining at 
presenescent levels (Pitozzi et al., 2013). Higher concentrations trans-
resveratrol (≥ 25 μM) increased fibroblast senescence in vitro (Faragher et al., 
2011). In human skin fibroblasts, the triterpenoid and Nrf2 activators 18β-
glycyrrhetinic acid (4 μM) was found to delay RS. This was associated with 
induction of proteasomal activity (Kapeta et al., 2010). 
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2. Project-specific background 
 
2.1The human fibroblast model in cellular senescence research 
 Fibroblasts are crucial in order to maintain the homeostasis of connective 
tissues (Robert et al., 1992) and several humoral and cellular factors may activate 
or inhibit fibroblast activity or, after being released from fibroblasts, they may 
reciprocally act on other mesenchymal (Zalatnai, 2006) and epithelial cells 
(Abraham et al., 1989) contributing to the complex network that modulates 
connective tissue homeostasis in physiological as well as in pathological 
conditions, such as during wound healing, inflammation or cancer (Robert and 
Labat-Robert, 2000). Cultured fibroblasts represent a widespread in vitro model 
for investigating genetic and acquired disorders and for exploring the importance 
of specific molecular pathways leading to differentiation, ageing and death 
(Holbrook and Byers, 1989; Van Ganser and Van Lerberghe, 1987).The use of a 
cell culture model for the study of ageing has many advantages such as the ability 
to provide a controlled environment for the study of diverse cellular phenomenon 
(Barnett and Barnett, 2000). Since the 1960s and the discovery of the Hayflick 
Limit (Hayflick and Moorhead, 1961), diploid fibroblast culture has been at the 
heart of cellular ageing studies. Indeed, cultured fibroblast cells are capable of 
sustained proliferative activity in vitro (Norwood and Pendergrass, 1992) which 
represents one of the main advantages for using this type of cells in the study of 
replicative senescence. Moreover, as described by Cristofalo and colleagues 
(Cristofalo et al., 2003) , fibroblasts in culture express human genetic, metabolic, 
and regulatory behaviour allowing cells to undergo changes in a predictable and 
reproducibly constant environment.  
Although human fibroblasts are commonly used for in vitro studies, their 
phenotype remains poorly defined. Indeed, beside their ability to attach to plastic 
cell culture vessel, elongated spindle-shaped morphology and absence of markers 
for other cell lineages (Chang et al., 2002), human fibroblasts phenotypes differ 
due to their diversity in gene expression profiles. As explained by Chang and 
colleagues (2002), the combination of specific groups of genes, rather than a 
single gene type, differentiates fibroblasts depending on their tissue of origin – 
Figure 26. 
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Figure 26. Topographic differentiation of fibroblasts. 
(A) Global gene expression patterns of 50 fibroblast cultures were sorted based on 
similarity by hierarchical clustering. The site of origin of each fibroblast culture is 
indicated and color-coded. Fibroblasts cultured in minimal-serum medium. B) 
Supervised hierarchical clustering of cultured fibroblasts was performed by using 
approximately 1,600 genes that varied according to fibroblast site of origin. (C) 
Topography transcriptome of fibroblasts. The variation in expression of 
approximately 1,600 genes described in B are shown in matrix format. Source: 
Chang et al., 2002. 
 
2.1.1 Human fetal lung MRC-5 fibroblasts 
In 1966, Jacobs and colleagues developed the MRC-5 strain of fibroblasts 
derived from foetal lung tissue, taken from a 14-week male foetus removed for 
psychiatric reasons from a 27 year old woman with a genetically normal family 
history and no sign of neoplastic disease both at abortion and for at least three 
years afterwards (Jacobs et al., 1970). The MRC-5 fibroblast cell line is a normal 
diploid human cell line with a Chromosome Frequency Distribution (CFD) of 50 
cells:2n=46 and 46,XY karyotype (Holliday and Tarrant, 1972). Moreover, this 
adherent cell line is susceptible to viruses such as herpes simplex, human 
poliovirus 1 and vesicular stomatitis (Indiana strain) and is capable of going 
through 42 to 46 population doublings before the onset of senescence (Lawless et 
al., 2010). The human lung fibroblast cell line MRC-5 constitutively produces a 
megakaryocyte potentiator activity, identified in murine bone marrow liquid 
culture assays for acetylcholinesterase and megakaryocyte colony assays in the 
presence of low concentrations of IL-3 (Yamamoto et al., 1990). Finally, MRC-5 
fibroblasts are widely used for the development of vaccines (Jacobs, 1976; Jacobs 
et al., 1970) as well as senescence and ageing studies (Sitte et al., 2000). 
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2.1.2 Human foreskin BJ fibroblasts 
The BJ fibroblast cell line is established from normal human foreskin and 
has an adherent culture property. These cells have a reported normal diploid 
karyotype at population doubling 61 but an abnormal karyotype at population 
doubling 82. 
Moreover, BJ fibroblasts are telomerase negative and have the capacity to 
proliferate to a maximum of 72 - 90 population doublings before the onset of 
senescence with a telomere-shortening rate of only 15–20 bp/PD (Huot et al., 
2002; Lorenz et al., 2001). Ectopic expression of human telomerase (hTERT) in 
BJ cells extended lifespan (Morales et al., 1999). BJ cells had low levels of ROS 
formation - as assessed by fluorescence development with 
dihydrochlorofluorescin, low levels of protein carbonyl – although the method 
used in their assay lacked robust quantitation, and low steady-state lipofuscin 
content as compared to other primary human fibroblasts. BJ cells immortalized by 
transfection with hTERT had the  same telomere-shortening rate as in parental 
cells is observed over a long time despite strong telomerase activity. Hyperoxia 
induced oxidative stress and accelerated telomere shortening in a variety of 
human fibroblast strains but did not in BJ cells in vitro (Lorenz et al., 2001). 
Extracellular superoxide dismutase was a major antioxidant in BJ fibroblasts and 
slowed telomere shortening (Serra et al., 2003). BJ senescence was associated 
with damage in both telomeric and non-telomeric DNA (Nakamura et al., 2008). 
Genetic manipultion to decrease the removal of 8-hydroxydeoxyguanosine - 
oxidative damage to DNA, increased the rate of development of senescence which 
was suppressed by culture under low 3% oxygen atmosphere (Rai et al., 2009). 
Basal levels of DNA-binding activity of NF-kB and phosphorylated ATF-2 were 
different in BJ and hTERT-BJ1 cells and both cell lines displayed a higher DNA-
binding activity of p53 and HIF-1 72 h after exposure to hydrogen peroxide (de 
Magalhes et al., 2002). Microarray analysis showed strong inflammatory-type 
response in senescent fibroblasts - MCP-1, IL-15 and IL-1b, Toll-4 (TLR-4) 
receptor and intercellular adhesion molecule-1 (ICAM-1), and proteins linked to 
the cell cycle – CDK inhibitor p21, growth-arrest-specific protein 1 (Gas1) and 
growth-arrest and DNA-damage inducible protein 153 (GADD153). Insulin-like 
growth factor binding proteins 2 and 5 (IGF-BP2, IGF-BP5), stanniocalcin, 
cathepsin O, and levels of peptidyl-a amidating monooxygenase (PAM) were all 
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increased in senescence (Shelton et al., 1999). During proliferative senescence 
there was a decline in proteasome activity and oxidized and cross-linked proteins 
(Sitte et al., 2000a; Sitte et al, 2000b) – although assessment of damaged proteins 
lacked robust quantitation (Table 3). 
 
Table 3. Comparison of proliferative senescence and the ageing of non-
dividing BJ fibroblasts. 
Source: Sitte et al., 2000a; Sitte et al, 2000b. 
 
 
2.2 Interventions for healthy ageing 
Changes in diet and lifestyle could potentially increase human lifespan by 
suppressing development of disease that is the major cause of mortality in the 
ageing population. For the human population in the developed world major causes 
of mortality are cardiovascular disease and cancer. Healthspan, the period of life 
during which people are healthy and free from serious disease, may be extended 
by also decreasing the impact of these and diseases which contribute to years of 
morbidity and disability – such as skeletal diseases, osteoarthtris and rheumatoid 
arthritis. Impact of disease on health is compared by calculating disability-
adjusted life years (DALYs) where one DALY is one year of healthy life lost 
through premature death or disability. The total DALYs for a population is the 
burden of disease - the difference between current health status and an ideal health 
situation where the whole population lives to an advanced age, free of disease and 
disability.  In 2010 the 3 most important causes of DALYs were: ischaemic heart 
disease, respiratory tract infections and cerebrovascular disease. The leading risk 
factors for DALYs were: high blood pressure, ca. 7%, smoking ca. 6% and 
ischaemic heart disease ca. 5% (IHME, 2013). In 20 years from 1990 – 2010, the 
contribution of risk factors to disease burden has changed from communicable 
diseases in children towards non-communicable diseases in adults. For ischaemic 
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heart disease, a significant majority of associated DALYs is linked to dietary 
factors: for example, a diet low in nuts and seeds, 40%, a diet low in fruit – 30%, 
and a diet low in vegetables, 12% (Lim et al, 2010). Nuts, seeds, fruits and 
vegetables are dietary sources of antioxidants and so this may support the free-
radical theory of ageing. The antioxidants vitamin C, vitamin E and carotenoids 
have shown to inhibit lipid peroxidation (Niki et al., 1995) but since these 
supplements have been found, in certain cases, to increase mortality (Bjelakovic 
et al., 2007). However, meta-analysis of outcomes of randomized controlled trails 
with antioxidants suggests there is no significant benefit of antioxidant 
supplementation (Ye et al., 2013). The free-radical theory of ageing states that an 
accumulation of oxidative damage through respiration leads to ageing and, as a 
result, decreased lifespan (Beckman and Ames, 1998). The link of dietary factors 
to DALYs appears to be more complex than  a simple supplement of antioxidants. 
 The concept of vitagenes – genes influential in lifespan – based on the idea 
that certain genes encoding for heat-shock proteins thioredoxin and sirtuins are 
responsible for maintaining homeostasis in response to oxidative stress (Calabrese 
et al., 2009) , emerged as a broader concept in the healthy ageing process. Based 
on these observations, antioxidants supplementation were predicted to extend 
human lifespan by either removal of free-radicals or activation of vitagenes.  
One of the recent controversies in the debate surrounds the phytoalexin 
found in grapes, resveratrol (Valenzano et al., 2006). The initial claims that 
resveratrol extends lifespan in experimental models of ageing have not been 
confirmed (Agarwal and Baur, 2011). To date, the only intervention known to 
successfully delay ageing is caloric restriction in animal studies, as mentioned 
previously, but evidence in humans is still unavailable. 
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2.3 Experimental interventions: caloric restriction mimetic for increased 
lifespan and decreased senescence 
2.3.1 Caloric restriction and delay of ageing  
The concept of caloric restriction (CR) for life extension has been part of 
the literature since the 1930s. Extension of lifespan and delay of the onset of age-
associated pathologies was first shown in rodents (McCay et al., 1989) and 
particular focus was put on the definition of CR without malnutrition. This 
“undernutrition without malnutrition” typically implies that 10-30% of total 
calorie intake is reduced whilst the physical environment is controlled (Hursting 
et al., 2003). Although CR literature related to ageing is extensive, the debate still 
remains on whether or not CR slows down the ageing process (Masaro, 2005). 
Indeed, this is dependent on the method by which this process is investigated and 
the most accepted method of determining if CR has an effect on ageing is by 
Gompertz parameters analysis (Simons et al., 2013) which is a mathematical 
model based on a sigmoid function representing slower growth at the beginning 
and end of a defined time frame. Several ageing studies in rats based on Gompertz 
analysis have supported the theory of ageing delay in relation to CR (Holehan and 
Merry, 1986; Lewis et al., 1985; Pletcher et al., 2000; Yu et al., 1982). Moreover, 
Mair and colleagues (2003) have reported that Drosophila flies under CR diet at 
any stage of their normal ageing process exhibit the same delay of ageing as 
Drosophila fed CR diets throughout their whole life (Mair et al., 2003). 
 Many hypotheses on the mechanism of action of CR on delay of ageing 
have been put forward since the 1930s. The Retardation of Growth Hypothesis 
rests on the principle that CR increases longevity by delaying growth, therefore 
assuming that ageing is an impairment of continuous development (McCay et al., 
1989). However, this theory was refuted due to the fact that in mouse and rat 
studies, CR at a later development compared to initiation at birth had the strongest 
beneficial effect in delaying ageing (Weindruch and Walford, 1982; Yu et al., 
1982). Another once popular hypothesis on the mechanism of action of CR on 
delay of ageing is the Reduction of Body Fat Hypothesis. As described by Berg 
and Simms (1960), delay of ageing by CR is due to a decrease in body fat content 
(Berg and Simms, 1960). This hypothesis has been supported by experimental 
evidence obtained in mice and rat studies showing that CR leads to a reduction in 
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body fat content (Bertrand et al., 1980; Garthwaite et al., 1986, Harrison et al., 
1984). Moreover, the Reduction of Body Fat Hypothesis has similarly been 
demonstrated in rhesus and cynomolgus monkeys (Cefalu et al., 1997; Colman et 
al., 1999; Lane et al., 1995). Table 4 summarises the effects of CR on selected 
parameters of morphology, physiology, ageing, and disease in rhesus monkeys. 
 
Table 4. Effects of CR on selected parameters of morphology, physiology, 
ageing, and disease in rhesus monkeys. 
Source: Lane et al., 2007. 
 
 47 
 
Anderson and Weindruch (2007) proposed  metabolic reprogramming may 
be one of the pathways by which CR exerts its delay of ageing effect (Anderson 
and Weindruch, 2007). Indeed, the Reduction in Metabolic Rate Hypothesis is 
based on experimental human and animal data showing that a decrease in food 
intake is directly related to a decrease in metabolic rate per kilogram body mass 
(Garrow, 1974; Pearl, 1928). However, this hypothesis has been disputed. Indeed, 
the “rate of living theory of ageing” is challenged by studies done in primates 
indicating that metabolic rate per gram of lean body mass is decreased following 
initiation of CR but gradually increases to the metabolic rate per gram of lean 
body mass of primates that have not been subjected to CR (Lane et al., 1996; 
Ramsey et al., 1996). Moreover, the method used to normalize for body size in 
CR studies does not take into account metabolic rate measurements for individual 
organs and tissues and has been heavily criticised (Gallagher et al., 2003; 
Speakman et al., 2004). Another theory by which CR is thought to delay ageing is 
through the decrease of accumulation of oxidative damage. This Oxidative 
Damage Attenuation Hypothesis has been shown to be relevant in rodents (Yu, 
1996) as well as primate models (Zainal et al., 2000). Moreover, CR leads to an 
increase in the levels of reduced glutathione (GSH) (Someya et al., 2010) as well 
as increase in oxidative DNA damage repair and decrease in protein damage 
expression (Lambert et al., 2004). However, studies using long-lived Drosophila 
disagree with these findings as they show no increase in antioxidant enzymes (Orr 
et al., 2003). The effect of lifelong CR on plasma concentrations of glucose and 
insulin has been linked with delay of ageing through the Altered Glucose-Insulin 
System Hypothesis. Indeed, CR has been found to increase insulin sensitivity and 
lower blood glucose levels in rhesus monkeys (Kemnitz et al., 1994) and loss-of-
function mutations of the insulin signaling systems have been shown to result in 
life extension of C. elegans (Kenyon et al., 1993), Drosophila Melanogaster 
(Wolkow et al., 2000) and mice (Clancy et al., 2001).  
 
2.3.2 Caloric restriction mimetic compounds 
Caloric restriction mimetic (CRM) was a term first described by Lane and 
colleagues (1998) as a hypothetical class of drugs which imitates the anti-ageing 
effects associated with CR in vivo and which would act upon the same metabolic 
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pathways without the need for a decrease in caloric intake. CRM have been 
proposed to regulate a vast number of pathways associated with energy 
metabolism (Lane et al., 2007). Indeed, inhibitors of glycolysis have been shown 
to mimic metabolic and protective effects of CR (Guo et al., 2001). Also, sirtuin 
regulators have been shown to delay the ageing process and extend lifespan in 
short-lived organisms (Guarente and Picard, 2005). Finally, insulin sensitizers 
have been explored as possible CRM due to the fact that insulin sensitivity has 
been shown to increase in animal CR studies (Kemnitz et al., 1994; Kenyon et al., 
1993; Wolkow et al., 2000; Clancy et al., 2001). However, this theory has been 
disputed for the compound phenformin, a treatment for diabetes, due to the fact 
that in vivo treatment failed to show markers related to CR and lifespan (Lane et 
al., 2007). However, particular attention has been given to the compound trans-
resveratrol (3,4’,5-trihydroxy-trans-stilbene, RES) – Figure 27 – and rapamycin 
over the past 10 years with regards to their caloric restriction mimetics effect. 
Indeed the beneficial properties of RES have been known since the 1940s when 
this polyphenolic compound was first isolated from white hellebore (Baur and 
Sinclair, 2006).  
 
Figure 27. Chemical structure of resveratrol. 
Source: Pirola and Frojdo, 2008. 
 
Moreover, this phytoalexin is commonly found in nuts, berries and in 
grape skin and has been often mediatised as the source of the “French paradox” as 
moderate wine consumption has been shown to inhibit platelet activity (Demrow 
et al., 1995) as well as induce nitric oxide, protein kinase C and adenosine, all of 
which are responsible for cardiac preconditioning (Das and Maulik, 2006). Over 
the past decade, RES mechanism of action has been linked as a CRM for the 
prolongation of longevity. Indeed, RES has been shown to improve insulin 
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sensitivity which in turn leads to a decrease in glucose and insulin in the body 
(Bauer et al., 2006; Bluher et al., 2003; Lagouge et al., 2006). However, the 
mechanism by which RES is thought to act as a CRM involved in the delay of 
ageing is through the activation of the NAD-dependent deacetylase sirtuin-1 
(Sirt1). Indeed, RES was found to be the most potent Sirt1 activator (Howitz et 
al., 2003) in S. Cerevisiae whereas in aging delay studies conducted in metazoans, 
Sir2 seemed to be activated by RES (Wood et al., 2004). However, this delay of 
ageing and CRM with RES through the activation of Sir2 and Sirt1 is still unclear 
and has been refuted on many occasions (Bass et al., 2007; Kaeberlein et al., 
2005). Nonetheless, RES is thought to improve mitochondrial function and 
glucose tolerance in an AMP-activated kinase (AMPK) manner. Indeed, as seen in 
Figure 28, upon caloric restriction and fasting, the levels of glucagon and 
catecholamines increase which then binds to their receptors and increases cAMP 
production. This increase in cAMP production then activates adenylate cyclase. 
Resveratrol acts by increasing cAMP levels by inhibiting cAMP 
phosphodiesterases (PDEs) (Chung et al., 2012). 
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Figure 28. Resveratrol mimics caloric restriction by inhibiting cAMP 
phopshodiesterases (PDEs). 
Source: Chung et al., 2012. 
 
 
Another CRM that has been persistently studied in anti-ageing research is 
rapamycin. This compound (Figure 29) is an immunosuppressant drug used to 
prevent organ rejection after organ transplantation and is a non-competitive and 
specific inhibitor of the nutrient-responsive mammalian target of rapamycin 
(mTOR) kinase (Dazer and Hall, 2011). 
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Figure 29. Molecular structure of rapamycin. 
Source: Argyropoulos et al., 2013. 
 
The role of the target of rapamycin (TOR) in the delay of ageing was first 
demonstrated in Drosophila and C. elegans in which its down-regulation was 
associated with an extension of lifespan (Passtoors et al., 2013). Moreover, this 
effect was also shown to be replicable in mouse models (Selman et al., 2009) and 
with treatment with rapamycin (Harrison et al., 2009). Although there is no 
primate evidence for delay of ageing through the mTOR pathway with rapamycin 
treatment, it was recently shown that mTOR signalling gene downregulation is 
associated with life extension as seen in a Dutch cohort of families with extended 
life-span (Passtoors et al., 2013). The nutrient-responsive mammalian target of 
rapamycin (mTOR) is composed of two distinct complexes: the mTOR complex 1 
(mTORC1) which is rapamycin sensitive and contains Raptor (rapamycin-
sensitive adaptor protein of mTOR) and the mTOR complex 2 (mTORC2) which 
is rapamycin insensitive and which contains Rictor (Testa et al., 2014). Moreover, 
mTORC1 encourages cell proliferation and protein synthesis as well as inhibits 
autophagy (Wullschleger et al., 2006). CR and rapamycin treatment acts by 
downregulation of insulin-like growth factor (IGF-1) which in turn leads to SIT1 
and AMPK activation and consequent inactivation of the TSC1/TSC2 complex. 
Upon inactivation of the TSC1/TSC2 complex, the bonds between Guanosine-5'-
triphosphate (GTP) and Rheb protein cannot be broken which leads to an increase 
in GTP-Rheb complexes therefore activating mTORC1 and increasing cell 
proliferation and protein synthesis as well as inhibition of autophagy (Testa et al., 
2014). Activators of TOR (rapamycin), sirtuins (resveratrol), AMPK (metformin), 
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autophagy inhibitors (spermidine) as well as activators of antioxidative gene 
translation (cucurmin, quercetin and others) have been proposed as CRMs 
(Argyropoulos et al., 2013) – Figure 30. 
 
 
Figure 30. Summary of the main signalling pathways responsible for the 
delay of ageing by diverse dietary activators. 
Source: Argyropoulos et al., 2013. 
 
 
Although RES and rapamicin have been the focus of many anti-ageing 
studies considering their CRM effect, these two compounds are often used at such 
high concentration that their effect cannot be replicated using normal 
physiological conditions and their beneficial outcome is therefore lacking strong 
scientific evidence. Many studies in human subjects with RES are on-going. 
Resveratrol (150 mg/day) given to 11 healthy obese men in a randomized double-
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blind crossover study for 30 days decreased sleeping and resting metabolic rate. In 
muscle it activated AMPK, increased SIRT1 and PGC-1a protein levels, increased 
citrate synthase activity without change in mitochondrial content, and improved 
muscle mitochondrial respiration on a fatty acid-derived substrate. It also elevated 
intramyocellular lipid levels and decreased intrahepatic lipid content, circulating 
glucose, triglycerides, alanine-aminotransferase, and inflammation markers. 
Systolic blood pressure decreased and HOMA index improved after resveratrol. In 
the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol 
decreased  (Timmers et al., 2011). Many of these effects were small however and 
RES has shown beneficial effects on glucose and lipid metabolism in some, but 
not all studies. Currently, despite the strong preclinical evidence of potential 
beneficial effects for cardiovascular health, RES benefit in human subjects 
remains uncertain (Pollack et al., 2013). 
 
2.3.3 Nrf2 activation by dietary activators 
The main hypothesis of this project proposes that genes regulated by 
transcription factor Nrf2 have a key role in cell senescence and Nrf2 activators 
may thereby delay senescence. If correct and translated clinically, functional 
foods may be formulated to support healthy ageing. The main focus of this study 
is to assess if an established Nrf2 activator, dietary isothiocyanate sulforaphane 
(SFN), may delay cell senescence and, if so, identify the mechanism of action.  
Other compounds have been found to delay senescence – Table 5. 
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Table 5. Examples of divergent effects of dietary bioactive and other compounds on human cellular senescence in vitro. 
Modified from: Malavolta et al., 2014. 
 
Compound Molecular structure Effect 
Model & 
type of senescence 
Concentration 
(timing) 
Reference 
Resveratrol 
 D MSC (RS) 0.1 µM (30d) Peltz et al., 2012 
D Tenocytes (SIPS) 30 µM (72 hr in SIPS) Carroll et al., 2011 
I MSC >10 µM (4d) Peltz et al., 2012 
I EC 10 µM (chronic) Schilder et al., 2009 
Tocotrienol 
 
D/R Fibroblasts (RS) 
Gold Tri E 50,  
0.5 mg/ml 
Makpol et al., 2011 
Berberine  
 
D hF (RS) 60 µM (24h) Halicka et al., 2012 
Curcumin 
 
D Fibroblasts (SIPS) 
20 µM  
(pre-treatment 48 h) 
Li et al., 2013 
Quercetin 
 
D/R 
Fibroblasts 
(RS/SIPS) 
6-7 µM (chronic) Chondrogianni  et al., 2010 
Vitamin C 
 
D (RS) EmC, fibroblasts 0.2 mM (chronic) Kashino et al., 2003 
D (RS) EC 0.13 mM (chronic) Furumoto et al., 1998 
Ginsenoside 
Rg1 
 
D(SIPS) Fibroblasts 
5-20 µM  
(chronic pretreatment 
from 24-30 PD) 
Chen  et al., 2008 
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L-Carnosine 
 
D/R Fibroblasts (RS) 20-50 mM (chronic) 
McFarland and Holliday, 
1999 
*Model: MSC = mesenchymal stem cells; EC = endothelial cells; EmC = embryonic cells. **Type of senescence: SIPS = stress induced premature senescence; 
RS = replicative senescence. ***Effect: I = inducer of a senescent-like phenotype; R = rejuvenator of the senescent state; D = delayer of senescence markers 
onset. 
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The Nrf2 system has been implicated in longevity studies using C. elegans 
through the activation of the transcription factor Skn-1 which is responsible for 
mesodermal development and also is an orthologue of Nrf2 in mammalian cells 
(An et al. 2005; Tullet et al. 2008). Moreover, Skn-1 activation is crucial in the 
delay of ageing caused by CR in C. elegans (Bishop and Guarente 2007) and 
long-lived C. elegans models show upregulated expression of Skn-1-dependent 
enzymes (Jasper, 2008). The link between Nrf2 activation and lifespan extension 
has been seen in the Drosophila melanogaster in which the deletion of Keap1 
allele has led to the increase in the expression of glutathione transferase D1 (GST 
D1) (Sykiotis and Bohmann, 2008). Finally, studies in the nematode and fruit flies 
have shown that the overexpression of the downstream components of the Nrf2 
signalling pathway extend their lifespan, and decrease of lifespan is observed 
when homologues of Nrf2 are knocked out in both species (Orr et al. 2005; 
Bishop and Guarente, 2007). Therefore, by taking into consideration the in vivo 
studies linking Nrf2 activation, CR and extension of lifespan, the Nrf2-ARE ought 
to be considered as a major target for CRM. 
 Several dietary bioactives that delay cellular senescence are Nrf2 
activators. Fruit and vegetable-derived bioactive compounds often exert their 
antioxidant activity indirectly through Nrf2 signalling (Jung and Kwak, 2010). 
Surh et al. (2008) have shown that isothiocyanates, dithiolethiones, RES, 
curcumin, caffeic acid phenethyl ester (CAPE; from honey), epigallicatechin 
gallate (from green tea), allyl sulfides (from garlic), xanthohumols (from hops), 
and cinnamaldehyde are activators of Nrf2. Many studies with putative Nrf2 
activators have, however, used high concentrations which are not translatable 
clinically and/or activate Nrf2 within the toxic concentration range. In the latter 
case toxicity prevents use of such compounds and activation of Nrf2 is likely as 
part of the response to toxicity rather than a direct agonism of the Nrf2 system. 
For some Nrf2 activators the optimum dietary dose range (Figure 31) may be 
narrow and very low concentrations or very high concentrations of compound 
administration can lead to an exponential increase in the risk of developing 
chronic diseases (Argyropoulou et al., 2013). 
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Figure 31. Dose-response of natural compounds against risk of chronic 
disease. 
Source: Argyropoulou et al., 2013. 
 
 
Moreover, the current in vitro and in vivo models of Nrf2 activation have so far 
not been able to explain the exact mechanism by which Nrf2 is activated – see 
Chapter 1.3. 
2.4 Dietary bioactive compounds: Sulforaphane (SFN) and Hesperetin 
(HESP) 
2.4.1 Sulforaphane (SFN) 
SFN is an alkyl isothiocyanate formed by hydrolysis of its glucoside 
derivative, glucoraphanin, by the enzyme myrosinase.  Glucoraphanin is a 
glucosinolate enriched in the plant family of Brassicaceae and present in high 
concentration in broccoli. SFN inhibits phase 1 cytochrome P450 enzymes, 
induces phase 2 metabolic enzymes, and acts as an antioxidant by increasing 
reduced glutathione levels as well as inducing cell cycle arrest and apoptosis (Herr 
and Buchler, 2010). It exhibits anti-inflammatory properties and inhibits 
angiogenesis (Herr and Buchler, 2010). SFN has also been shown to sensitize 
pancreatic CSCs by downregulation of NF-κB along with inhibition of CSC 
properties (Kallifatidis et al., 2009). 
The cruciferae plant family is characterized by a unique phytochemistry: 
their high content (often several percent by weight) of glucosinolates, which are 
β-thioglucoside N-hydroxysulfates with more than 120 unique amino acid side 
chains (Fahey et al., 2001). Sulforaphane and other isothiocyanates are 
synthesized and stored in plants in the form of the inactive glucosinolate 
precursors (Figure 32).  
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Figure 32. Glucosinolates and myrosinase are stored in separate cell 
compartments. 
Break down of the cell, e.g. by chewing, cutting or boiling, leads to the release of 
glucosinolates and myrosinase. Myrosinase causes hydrolytic cleavage of 
glucosinolate. Thereby, preventive or therapeutically active degradation products 
arise, such the isothiocyanate sulforaphane present in high concentration in 
broccoli. Source: Herr and Buchler, 2010. 
 
Myrosinase is physically segregated from glucosinolates in plant cells but 
is released when the cells are damaged, e.g. by microbial attack, insect predation, 
mechanical food processing, such as by chewing or food preparation (Herr and 
Buchler, 2010). This hydrolysis can be also mediated by the microflora of the 
mammalian gastrointestinal tract (Shapiro et al., 1998). Glucoraphanin is the 
major glucosinolate contained in broccoli (Fahey et al., 1997). Because of the 
widely varying content of glucoraphanin in mature broccoli, 3-day-old sprouts are 
commonly used for human delivery of standardized amounts of glucoraphanin and 
sulforaphane (Herr and Buchler, 2010). Moreover, amongst all the 
isothiocyanates, L-sulforaphane, which is found in broccoli and broccoli sprouts 
at particular high levels, has been the most extensively studied (Lampe, 2009). 
The mechanism of anti-carcinogenic action of SFN probably involves the 
detoxication of carcinogens and procarcinogens and prevention of procarcinogen 
activation (Herr and Buchler, 2010). This is mediated by induction of expression 
of enzymes catalyzing phase II biotransformation enzymes (GSTs, UDP 
glucuronosyltransferases, etc.) (Clarke et al., 2008) and inhibition of cytochrome 
P450 system (Shishu et al., 2003), respectively. SFN is readily available in the 
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healthy diet through the consumption of cruciferous vegetables such as broccoli. 
SFN reacts with specific thiol groups on Keap1, promoting Nrf2 dissociation from 
Keap1. Keum and colleagues (2006) found SFN increased expression of heme 
oxygenase-1 (HO-1) in HepG2 cells in vitro.   Nrf2-independent effects of SFN 
have also been found – such as effects on MAP kinases in expression of keratin in 
skin epithelial cells (Kerns et al., 2010). 
 
2.4.2 Hesperetin (HESP) 
Hesperetin is a flavonoid found in citrus fruits (Erlund et al., 2001; Erlund 
et al., 2004). Several epidemiological studies have suggested a protective effect of 
these compounds on cardiovascular diseases (Knekt et al., 1996). The flavanones, 
also called citrus flavonoids, have been studied extensively in the past 20 years as 
their intake from the diet can be quite high and they exhibit promising biological 
activities (Erlund et al., 2001). Hesperetin chemical structure is represented in 
Figure 33.  
 
 
Figure 33. Chemical structure of the bioflavanoid Hesperetin (Mw = 302 
g/mol). 
Source: Erlund, 2004. 
 
Epidemiological studies indicate a protective relationship between the 
consumption of citrus fruits or juices and the risk of ischemic stroke (Joshipura et 
al., 1999) and lung cancer (Le Marchand et al., 2000). In the United States, the 
mean daily individual consumption of citrus fruits and juices has been estimated 
as 68 g, of which 59 g was consumed as juices (Erlund et al., 2001). The most 
commonly used citrus juices (i.e., orange and grapefruit juices) contain high 
amounts of the flavanone hesperetin (Kawaii et al., 1999). Mean dietary intakes of 
hesperetin were ca. 7 mg/day, undetectable in a diet low in fruit and vegetables 
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and 132 mg in a diet rich in fruit and vegetables (Erlund et al, 2002). Hesperetin is 
a phytoestrogen, which could affect sex hormone mediated biological responses 
by several different mechanisms, including binding to oestrogen receptors 
(Dechaud et al., 1999). The compound also possesses anticarcinogenic (So et al., 
1996), antioxidant (van Acker et al., 2000) and blood lipid–lowering  (Shin et al., 
1999) activities. 
Other possible effects of hesperetin and naringenin are on lipid metabolism. 
They have been reported to regulate apolipoprotein B secretion by HepG2 cells, 
possibly through inhibition of cholesterol ester synthesis (Borradaile et al., 1999), 
and to inhibit 3-hydroxy-3 methylglutaryl-coenzyme A reductase and acyl 
coenzyme A:cholesterol O acyltransferase in rats (Lee et al., 1999). Furthermore, 
a decrease in plasma low-density lipoprotein levels and hepatic cholesterol levels 
in rabbits fed a high-cholesterol diet has been observed (Kurowska et al., 2000). 
An increase of high-density lipoprotein levels in hypercholesterolemic human 
subjects after consumption of orange juice was also reported (Kurowska et al., 
2000). Finally, hesperetin urinary recovery is thought to be 3% in subjects 
ingesting 500 mg of naringin and 500 mg of hesperidin once and 24% in 5 
subjects ingesting 1250 mL of grapefruit juice and 1250 mL of orange juice daily 
for 4 weeks (Ameer et al., 1996). 
 
2.5 Nutrient sensing via the ChREBP/MondoA–Mlx complex 
Multicellular animals sense and control their glucose homeostasis at several 
levels. Systemic regulation by insulin and glucagon maintains levels of circulating 
glucose constant during fluctuating nutritional conditions. Upon feeding, elevated 
circulating glucose is taken up by muscle, liver and adipose tissue through the 
actions of insulin signaling, while starvation elevates glucagon levels to promote 
glycogenolysis and gluconeogenesis (Havua and Hietakangas 2012). The 
intracellular glucose is rapidly converted into glucose-6-phosphate. Through a 
yet-unknown mechanism, glucose-6-phosphate activates two paralogous basic 
helix-loop-helix-leucine zipper (bHLHZ) transcription factors (TFs) ChREBP and 
MondoA, which heterodimerize with their common binding partner Mlx. This 
bHLHZ complex resembles the evolutionarily related Myc–Max complex. As 
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shown by Havua and Hietakangas (2012) ChREBP/Mondo–Mlx is known to 
mediate a majority of the glucose-induced transcriptional response by binding to 
target gene promoters containing so-called carbohydrate response elements 
(ChoREs). 
As demonstrated by Billin and colleagues (2000), regulation of 
ChREBP/MondoA–Mlx complexes involves shuttling between cytoplasm and 
nucleus (Figure 34). 
 
Figure 34. Regulation of ChREBP/MondoA–Mlx activity. 
Source: Havua and Hietakangas, 2012. 
 
MondoA–Mlx localizes to the outer mitochondrial membrane (OMM) in its 
inactive state (Sans et al., 2006). While mitochondrial localization has not been 
demonstrated for ChREBP, it displays punctuated cytoplasmic localization upon 
low glucose in hepatocytes (Kawaguchi et al., 2001). In response to elevated 
glucose, MondoA and ChREBP concentrate strongly into the nucleus (Stoltzman 
et al., 2008). Heterodimerization of ChREBP/MondoA with Mlx is required for 
their nuclear entry in response to glucose  and is a prerequisite for their binding to 
ChoREs (Ma et al., 2007). ChREBP and MondoA activity is, however, regulated 
at several levels, since forced nuclear accumulation of ChREBP or MondoA is 
insufficient in target gene transactivation (Peterson et al., 2010). Several lines of 
evidence imply that ChREBP/MondoA–Mlx activation is induced by intracellular 
glucose-6-phosphate (G6P), the immediate metabolite of glucose (Figure 34) 
(Stoltzman et al., 2008). The formation of G6P is catalyzed by hexokinases or 
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glucokinase, which also localize to the OMM (Gerbitz et al., 1996). The 
responsiveness of MondoA–Mlx to G6P was shown elegantly by the use of a 
glucose analog 2-deoxyglucose (2-DG). 2-DG is phosphorylated into 2-
deoxyglucose-6-phosphate (2-DG6P), but it cannot be processed further, leading 
to 2-DG6P accumulation (Stoltzman et al., 2008). In response to 2-DG treatment, 
MondoA–Mlx translocates into the nucleus and strongly transactivates target 
genes (Havua and Hietakangas, 2012) and furthermore, ChREBP was shown to be 
activated by fructose 2,6 bisphosphate in hepatocytes.  
ChREBP and MondoA are multidomain proteins with highly homologous 
N- and C terminal regions. They contain a bHLHZ region and a C-terminal 
dimerization domain mediating DNA binding and heterodimerization with Mlx 
(Figure 35) (Eilers et al., 2002).  
 
 
Figure 35. Domain structure of ChREBP/MondoA and Mlx. 
The C-termini of ChREBP/MondoA and Mlx are similar and contain a 
dimerization and cytoplasmic localization domain (DCD) and a basic helix-loop-
helix leucine zipper region (bHLHZ). Source: Havua and Hietakangas, 2012. 
 
Both ChREBP and MondoA contain transcriptional activation domains, 
while Mlx is much shorter and lacks intrinsic transactivation capacity (Billin et 
al., 2000). The loop region of Mlx bHLHZ domain mediates the interaction 
between two ChREBP/ MondoA–Mlx heterodimers, stabilizing their binding to 
the tandem E-boxes in ChoRE (Ma et al., 2007). In terms of glucose sensing the 
most important region is the highly conserved N-terminal part of MondoA and 
ChREBP, called Mondo conserved region (MCR) (Billin et al., 2000) or glucose-
sensing module (GSM) (Li et al., 2006). Li and colleagues (2006) have shown that 
the GSM can be functionally divided into low-glucose inhibitory domain (LID) 
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and glucose-response activation conserved element (GRACE) (Figure 35). LID 
inhibits the transactivation capacity of GRACE under low glucose conditions and 
this inhibition can be relieved by high glucose. LID and GRACE are functionally 
distinct modules as the glucose responsiveness is retained even when the domains 
are physically separated by intervening GFP. The N terminus is functionally 
conserved: the MCR/GSM region of ChREBP can be replaced by the 
corresponding region of MondoA while retaining the glucose responsiveness (Li 
et al., 2006). Finally, consistent with its role as a regulator of glycolytic genes, 
MondoA activity corresponds to the rate of glycolysis (Sans et al., 2006). 
 
2.6 Aim and objectives 
2.6.1 Aim 
The aim of this investigation is to study the prevention of human fibroblasts 
senescence in vitro by chronic treatment with dietary bioactive compounds and to 
determine the mechanism by which these compounds delay senescence. 
 
2.6.2 Objectives 
2.6.2.1 Objective 1: To study the effects of SFN and HESP on MRC-5 and BJ 
senescence in vitro  
Transcription factor Nrf2 regulates the expression of a battery of genes via 
interaction with one or more AREs that provide protection against proteome, 
lipidome and genome damage by glycation, oxidation and nitration. In this 
project, the delay of MRC-5 and BJ senescence by the nrf2-activating dietary 
bioactive compounds SFN and HESP will be studied. Initially, growth patterns of 
MRC-5 and BJ fibroblasts will be studied by constructing a growth curve for 
these two cell types. Moreover, the median growth inhibitory concentration of 
SFN and HESP will be analysed on MRC-5 and BJ fibroblasts by constructing 
dose-response curves for these two compounds. The Population Doubling Limit 
(PDL) as well as cumulative PDL (cPDL) will also be analyzed in order to 
represent MRC-5 and BJ fibroblast growth as progression of senescence occurred. 
Moreover, the percentage of cells expressing β-galactosidase and protein 
 64 
 
expression of the human β-galactosidase-1 in MRC-5 fibroblasts at early and late 
passage will be determined in order to evaluate the senescent state of these cells 
with or without SFN treatment.   
 
2.6.2.2 Objective 2: To characterize gene expression and cell metabolism in cells 
escaping senescence by treatment with SFN and HESP  
Custom real time RT-PCR and antibody arrays will be used to assess 
expression of ARE-linked genes. Moreover, expression of genes involved in 
protection against oxidative damage, protection against proteasomal proteolysis, 
autophagy and glycation, protection against metabolic stress and senescence-
linked genes will be determined in young and senescent MRC-5 fibroblasts 
treated with SFN or HESP using NanoString technology. Proteome, lipidome and 
genome damage will be assessed by quantitative screening of protein oxidation, 
nitration and glycation adducts, isoprostanes and deoxyguanosine glycation and 
oxidation adducts by stable isotopic dilution analysis tandem mass spectrometry. 
This will allow for the identification of gene expression patterns linked to healthy 
ageing and dietary bioactives supplementation to be characterized. 
 
2.6.2.3 Objective 3: To characterize the mechanism of decrease glucose 
metabolism by SFN and HESP action linked to delay of fibroblast senescence 
The effect of SFN and HESP treatment on D-glucose consumption in 
young and senescent MRC-5 fibroblasts will be determined in order to evaluate 
the caloric restriction mimetic of SFN and HESP linked to delay of fibroblast 
senescence. This will be further confirmed by analysis of L-lactate production in 
the cells - leaking into the culture medium of MRC-5 and BJ fibroblasts treated 
with SFN and HESP. The formation of D-lactate - terminal product of the 
metabolism of the senescence inducing glycating agent, MG, will also be studied 
(Sejersen and Rattan, 2009). Moreover, glycolytic intermediates expression in 
MRC-5 fibroblasts treated with SFN at early and late passage will be analysed by 
stable isotopic dilution analysis tandem mass spectrometry in order to characterize 
the mechanism of caloric restriction mimetic further in response to SFN-linked 
delay of MRC-5 senescence. Finally, glucose sensing by ChREBP/MondoA-Mlx 
transcription factors in response to SFN treatment in MRC-5 fibroblasts will be 
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studied by nuclear translocation observations of MondoA using immunostaining 
analysis. 
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3. Materials and Methods 
 
3.1 Materials 
3.1.1 Human fibroblasts 
Human foetal lung MRC-5 fibroblasts, human foreskin BJ fibroblasts and 
human leukemia HL60 leukemia cells were purchased from the European 
Collection of Animal Cell Cultures (ECACC, Porton Down, U.K), London, 
United Kingdom (U.K.). 
MRC-5 and BJ cells were grown in Eagle’s Minimum Essential Medium 
(MEM) purchased from Invitrogen (Paisley, Scotland). MEM culture media 
contained non-essential amino acids (NEAA) and was supplemented with 10% 
foetal bovine serum (FBS) (Biosera; UK agent - Labtech International Ltd, 
Uckfield, UK), 1% penicillin-streptomycin (Sigma-Aldrich, Poole, Dorset, UK), 2 
mM L-glutamine and 100 mM sodium pyruvate (Invitrogen). The solution of 
tryspin-ethylenediaminetetra-acetic acid trypsin-EDTA (trypsin, 0.25%, EDTA, 
0.02% (w/v)) was purchased from Sigma-Aldrich (Poole, Dorset, U.K.). 
Phosphate-buffered-saline (PBS) was prepared in-house by the technical staff and 
had composition: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM 
KH2PO4. MRC-5 and BJ fibroblasts were passaged every 7 days: seeding density 
10,000- 40,000 cells/cm2 for MRC-5 fibroblasts and 10,000 - 30,000 cells/cm2 for 
BJ fibroblasts. MRC-5 and BJ fibroblasts were harvested with trypsin-EDTA. 
Cells were all passaged using the following method. Conditioned medium was 
removed from above the cells adhered to the bottom of the culture flask, the cells 
were gently rinsed with PBS at 37°C. Approximately 1 ml/25 cm2 of trypsin-
EDTA solution (0.25% trypsin, 0.02% EDTA) was then added to each flask and 
cells returned to the 37°C incubator for 3 - 5 min until cells acquired a rounded 
appearance when viewed under an inverted microscope. Trypsin was then 
neutralised with 4 ml/25 cm2 of fresh cell culture medium. Cells were sedimented 
by centrifugation (125g, 10 min, 25°C) and the supernatant removed. Cells were 
then re-suspended in culture media and assessed for cell viability for seeding. 
Unless mentioned otherwise, all cell types were passaged in the above conditions. 
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3.1.2 Human leukaemia 60 cells 
Human leukaemia 60 (HL60) cells were used to prepare 13C-labelled 
glycolytic intermediates. They were grown in Roswell Park Memorial Institute 
(RPMI) 1640 medium purchased from Invitrogen (UK) supplemented with 10% 
FBS (complete medium). RPMI 1640 medium without glucose was purchased 
from Invitrogen (UK) and used to make HL60 for cell growth with serum-free 
medium (defined medium). This defined medium was supplemented with 10.0 
mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonice acid HEPES (Fisher 
Scientific, Loughborough, UK) and 1 mM sodium pyruvate, 25 mM D-Glucose, 5 
µg/ml human insulin and 5 µg/ml human transferrin - all purchased from Sigma-
Aldrich (Poole, Dorset, UK). 
   
3.1.3 Cell viability 
Cell viability was assessed by the Trypan blue dye exclusion technique 
(Kenyon et al., 1993).  Cell suspension (20 µl) containing 1 - 10 x 104 cells was 
mixed with 20 µl 0.4% solution of Trypan blue in buffered isotonic salt solution 
(PBS), pH 7.2 to 7.3. Viability was then determined using a Neubauer 
haemocytometer ensuring a total count of 100 – 200 cells. The number of cells 
excluding Trypan blue gives the viable cell count N and the number of cells 
stained with Trypan blue gives the non-viable cell count NV. Percentage cell 
viability is given by V/(V+NV) x 100. All experiments were performed with cell 
viability of 98% or more. 
 
3.1.4 Enzymes, substrates, co-factors, antibodies, primers, other biochemical 
and miscellaneous reagents  
3.1.4.1 Enzymes, co-factors and substrates 
D-Lactic dehydrogenase enzyme (from Staphylococcus epidermidis, ≥80 
units/mg activity, lyophilized powder) and L-lactic dehydrogenase (from rabbit 
muscle),  pepsin (from porcine stomach mucosa, specific activity 3460 units/mg 
protein), pronase E (from bacterial Streptomyces griseus, specific activity 4.4 
units/mg protein), leucine aminopeptidase type VI (from porcine kidney 
microsomes, specific activity 22 units/mg protein) and prolidase (from porcine 
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kidney, specific activity 145 units/mg protein), nicotinamide adenine 
dinucleotide-oxidised form (NAD+), sodium L-lactate and L-lactic acid sodium D-
lactate (≥99.0%) was purchased from Sigma-Aldrich. 
 
3.1.4.2 Antibodies and primers for RT-PCR 
Rabbit polyclonal anti-β-galactosidase (BGAL) antibody (supplied as 1 
mg IgG in 100µl of 1% BSA, 0.15 M sodium chloride, 20 mM potassium 
phosphate buffer, pH 7.2), rabbit polyclonal anti-MLX-interacting protein 
(MondoA) antibody and rabbit polyclonal anti-β-actin antibody were purchased 
from Abcam (Cambridge, UK). Alexa fluor 488 goat anti-rabbit IgG conjugate 
was purchased from Molecular Probes (Paisley, Scotland). 
RT-PCR primers for β-actin (ACTB), NAD(P)H:quinone oxidoreductase-
1 (NQO1), nuclear factor (erythroid-derived 2)-like 2 (NFE2L2), transketolase 
(TKT), glyoxalase 1 (GLO1), aldoketo-reductase B1 (AKRB1), Kelch-like ECH-
associated protein 1 (KEAP1), γ-glutamylcysteine ligase – catalytic subunit  
(GCLC), γ-glutamylcysteine ligase – modulatory subunit (GCLM), carbonyl 
reductase-1 (CBR1), transaldolase-1 (TALDO1), glutathione reductase (GSR), 
haem oxygenase-1 (HMOX1), aldoketo-reductase B2 (AKRB2) and thioredoxin 
(TXN) were all purchased from Sigma-Aldrich. BioScriptTM (Moloney murine 
leukaemia virus reverse transcriptase), Oligo(dT)18, Rnase inhibitor, buffer RT 
and master mixture/50 SYBR Green were all purchased from BioLine (London, 
U.K).  
 
3.1.4.3 Reagents for Agilent one-colour microarray-based gene expression 
analysis 
The following reagents were purchased from Agilent Technologies UK 
Ltd. (Wokingham, Berkshire) and provided by Unilever Laboratories (Colworth, 
UK): One-colour Spike-Mix stock, Dilution Buffer, T7 Promoter primer, 5X first 
strand buffer, DTT, dNTP mix, MMLV-RT, RNase out, 50% PEG, 4X 
transcription buffer, NTP mix, inorganic pyrophosphatase, T7 RNA Polymerase, 
Cyanine 3-CTP, Cyanine 3 dye absorbance, 10X Blocking Agent from Agilent 
Gene Expression Hybridization Kit, 25X Fragmentation Buffer, 2X GEx 
Hybridization Buffer HI-RPM, GE wash buffer 1, GE wash buffer 2, acetonitrile , 
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Stabilization and Drying solution. Qiagen RNeasy mini spin columns was 
purchased from Qiagen (West Sussex, U.K). 
 
3.1.4.4 Other biochemical and miscellaneous reagents 
The senescence cells staining kit (cat. no. CS0030) and glucose assay kit 
for the hexokinase method (cat. no. GAHK20) was obtained from Sigma Aldrich.  
The RNeasy Mini Kit was purchased from Qiagen (West Sussex, U.K). Bovine 
Serum Albumin (BSA) was purchased from Sigma-Aldrich (Poole, Dorset, U.K). 
R-Sulforaphane (SFN, ≥95%) was purchased from Sigma-Aldrich and hesperetin 
((2S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-
benzopyran-4-one, ≥95%)  from LKT Laboratories – UK distributors: Cambridge 
Bioscience Ltd (Cambridge, UK). Sodium glycinate, perchloric acid, sodium 
chloride, potassium bicarbonate, glycine and HPLC methanol and acetonitrile 
were all purchased from Fisher Scientific (Loughborough, UK). All other 
reagents, acids, salts, buffers and based were analytical grade reagents and 
purchased from Fisher Scientific (Loughborough, U.K) and Sigma-Aldrich.  
 
3.1.5 Immunocytochemistry, electrophoresis and Western blotting reagents 
Glass bottom dishes (35 mm, round, cat. no. P35GC-1.5-14-C) were from 
MatTek Corporation (Ashland, Massachusetts, U.S.A) and glass coverslips (13 
mm, round, cat. no. 631-0149) from VWR International (Lutterworth, 
Leicestershire, UK).  Mounting medium containing 4’,6-diamidino-2-
phenylindole (DAPI) was purchased from Vector Laboratories (Peterborough, 
UK).  
For electrophoresis, acrylamide:N,N’-methylenebisacrylamide solution 
(30% w/v, 37.5: 1, Ultrapure grade), 4 X Protogel resolving buffer (0.375 M Tris-
HCl and 0.1% SDS, pH 8.8), protogel stacking buffer (0.125 M Tris-HCl and 
0.1% SDS, pH 6.8), and 10 X Tris/glycine electroblotting buffer containing 0.25 
M Tris base and 1.92 M glycine (Ultrapure, electrophoresis grade) were all 
purchased from National Diagnostics (Hessle, UK). Tween-20, N,N,N’,N’-
tetramethylethylene-1,2-diamine (TEMED, ≥ 99% electrophoresis grade), β-
mercaptoethanol, 3', 3'', 5', 5''-tetrabromophenolsulfonphthalein sodium salt 
(bromophenol blue, electrophoresis grade) and protease inhibitor cocktail 
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containing 104 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF), 80 μM aprotinin, 4 mM bestatin, 1.4 mM E-64, 2 mM leupeptin and 1.5 
mM pepstatin A  were all purchased from Sigma-Aldrich. Coomassie Brilliant 
Blue G-250 (analytical grade) was purchased from Fluka (Poole, UK). Polyvinyl 
difluoride (PVDF) membrane and photographic film were purchased from GE 
Healthcare (Little Chalfont, UK). SpectroTM multicolor broad range protein ladder 
(10-260 kDa, for 4 – 20% Tris-glycine SDS-PAGE) used for western-blotting was 
purchased from Fisher Scientific. 
 
3.1.6 Analytical standards for stable isotopic analysis of metabolites 
3.1.6.1 GSH and GSSG  
GSH, GSSG and [glycine-13C2,
15N1]Glutathione (99%; [
13C2,
15N1]GSH) 
were purchased from Sigma Aldrich.  [13C4
15N2]GSSG was synthesised from 
[glycine-13C2, 
15N1]GSH – Figure 36. Briefly, [13C215N1]GSH was oxidised using 
diamide  to form [13C4
15N2]GSSG for use in the LC-MS/MS method to quantify 
cellular GSSG. An aliquot of [13C2
15N1]GSH solution (3.2 mM, 100 µl) and 10 
mM diamide in methanol (30 µl) was added to 100 µl of 10 mM sodium 
phosphate buffer, pH 7.4 and incubated at 37°C for 30 min.  The product mixture 
was purified by elution onto a strong anion-exchange solid-phase extraction (SAX 
SPE) cartridge, 500 mg, formate form.  [13C4
15N2]GSSG was retained on the 
SAX-SPE cartridge whereas diamide and reduced diamide were not.  The SAX-
SPE cartridge was washed with 10 mL water to remove the diamide and residual 
GSH.  [13C4
15N2]GSSG was collected by elution from the SAX-SPE cartridge 
with 5 ml 100 mM formic acid.  The solution was lyophilised to dryness, 
reconstituted in water (1 ml) and filtered through a 0.2 µm nylon filter.  The 
concentration of [13C4
15N2]GSSG was deduced by isotopic dilution analysis with 
known amounts of GSSG.  The yield was 28%.  
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Figure 36. Oxidation of glutathione by diamide. 
 
3.1.6.2 Glyoxal, methylglyoxal and 3-deoxyglucosone 
Normal and isotopic standards for assay of dicarbonyl metabolites, 
glyoxal, MG and 3-DG, were available in house. Glyoxal (8.8 M aqueous 
solution) was purchased from Sigma and [13C2]glyoxal was prepared from 
[13C2]ethylene glycol by alcohol oxidase in the presence of catalase (Isobe and 
Nishise, 1994). High purity methylglyoxal and [13C3]methylglyoxal were 
available in house, prepared and purified as described (McLellan and Thornalley, 
1992). [13C3]MG was prepared from [
13C3]acetone by oxidation with selenium 
dioxide and purified by distillation (Clelland and Thornalley, 1990). 3-DG and 
[13C6]3-DG were synthesised from glucose and [
13C6]glucose as described 
(Madson and Feather, 1981). [13C2]Ethylene glycol and [
13C3]acetone  were 
purchased form Sigma and [13C6]Glucose Cambridge Isotope Laboratories 
(Andover, MA, USA). 
 
3.1.6.3 Amino acids and glycated, oxidized and nitrated derivatives  
L-Amino acids were purchased from Sigma, stable isotope-substituted 
amino acids were purchased from Cambridge Isotope Laboratories (Andover, 
MA, USA) and 2,5,5[2H3]DL-α-aminoadipic acid (d3-AAA) was purchased from 
CDN Isotopes (Quebec, Canada). Glycated, oxidized and nitrated amino acid 
derivatives and stable isotope-substituted isotopomers were available in house, 
prepared and purified as described (Kenyon et al., 1993)(Kenyon et al., 1993). ε-
(γ-L-glutamyl)–L-lysine was purchased from Bachem AG (Bubendorf, 
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Switzerland) and [13C5]ε-(γ-L-glutamyl)–L-lysine was available in house, 
prepared and purified as described .  
 
3.1.6.4 13C-Labelled glycolytic intermediate isotopomers  
HL60 cells (1 x 106) were seeded in T-175 flasks in 30 ml of complete 
media – see section 3.1.2. Cells cultured in these conditions were passaged for 
four or more passages when exponential growth of cultures free of cell debris was 
attained. HL60 cells (1 x 106) were then seeded in T-175 flasks in 30 ml defined 
media for 5 days until cells reached 80-90% confluence according to the method 
described by Breitman et al. (1980). The resulting culture was used to seed 6 
further cultures of 1 x 106 cells in 30 ml of RPMI 1640 medium without glucose 
supplemented with 10.0 mM HEPES, 1 mM sodium pyruvate, 25 mM 
[13C6]glucose, 5 µg/ml insulin and 5 µg/ml transferrin. After 5 days in culture, the 
cells were collected by centrifugation (200g, 10 min), washed twice with ice-cold 
PBS and cell pellets (3 x 106 cells) were collected and stored at -80°C as stock 
13C6-labelled glycolytic intermediates.  
 
3.1.7 Equipment, instrumentation and software 
The Neubauer Haemacytometer used for cell counting was from 
Marienfield (Germany). Water used for all experiments was filtered through a 
Milli-Q Advantage A-10 System from Millipore (Watford, UK).  The inverted 
microscope Nikon Eclipse TE2000-S (U.S.A) was used for picture recording. The 
FLUOstar OPTIMA microplate reader (BMG Labtech, U.K) was used for the 
enzymatic assays. LC- MS/MS was performed with a AcquityTM ultra high 
performance liquid chromatography (UPLC) system with a Quattro Premier XE 
Tandem mass spectrometer or an AcquityTM UPLC system with a Xevo-TQS 
Quattro tandem mass spectrometer (Waters, Elstree, U.K.). Enzymatic hydrolysis 
was performed using a CTC-PAL Automation System (CTC-Analytics, Zwingen, 
Switzerland). The 7500 Fast Real - Time PCR system (Applied Biosystem by Life 
Technologies, U.K) was used for gene expression analysis and the Nanodrop 
Spectrophotometer ND- 1000 (Labtech International, U.K) was used to determine 
protein concentration in media. Confocal microscopy was performed using an 
 73 
 
AxioVert 200M laser scanning confocal microscope from Carl Zeiss Microscopy 
(Thornwood, NY, USA).   
Protein expression level was analysed with ImageQuant densitometry 
software from Amersham Biosciences (Little Chalfont, UK). Related data outputs 
were processed with software Masslynx version 4.1. Confocal microscopy images 
were viewed using LSM Image Browser (Carl Zeiss Microscopy, Thornwood, 
NY, USA). RNA primers were designed using the Oligo perfect design tool 
(Invitrogen Life Technologies, Paisley, UK) with mRNA and genomic sequences 
obtained using the University of California, Santa Cruz genome browser tool 
(Genome Bioinformatics Group, University of California, Santa Cruz). Agilent 
SureHyb, SureHyb gasket slide, Agilent scanner and Agilent Feature Extraction 
Software were all purchased from Agilent Technologies UK Ltd. (Wokingham, 
Berkshire) and provided by Unilever Laboratories (Colworth, UK).  
 
 
3.2 Cell culture 
3.2.1 Effect of sulforaphane treatment on growth of MRC-5 cells in vitro. 
Human MRC-5 fibroblasts were seeded in 6-well cell culture plates 
(30,000 cells/well) in 3 ml Eagle’s MEM per well with and without 0.5 – 10.0 µM 
SFN. Stock SFN solution (50 mM) was prepared in DMSO and sterilized in 
microspin filters (0.2 μm, nylon filters). Immediately before use, an aliquot of the 
stock solution was diluted 1000-fold and then diluted further to the required 
concentration. The maximum concentration of vehicle, dimethyl sulfoxide 
(DMSO), was therefore 0.002% (v/v) and control incubations therefore contained 
0.002% DMSO.  The cells were cultured for 24 h and 48 h and the viable cell 
number recorded. Viable cell number - SFN concentration response curves were 
constructed with data fitted to the logistic equation V = Vmax x GC50
n/(GC50
n + 
[SFN]n) where V is the viable cell number, Vmax the viable cell number of control 
cultures incubated without SFN, GC50 is the median growth inhibitory 
concentration value, [SFN] the concentration of SFN (0.5 – 10 µM) and n the 
logistic regression coefficient. Data were fitted by non-linear regression using the 
ENZFITTER programme (Biosoft, Cambridge, U.K.) solving for GC50 and n. 
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3.2.2 Effect of hesperetin on growth of MRC-5 cells in vitro. 
Human MRC-5 fibroblasts were seeded in 6-well cell culture plates 
(30,000 cells/well) in 3 ml Eagle’s MEM per well with and without 0.5 – 40.0 µM 
hesperetin. Stock hesperetin solution (100 mM) was prepared in DMSO and 
sterilized in microspin filters (0.2 μm, nylon filters). Immediately before use, an 
aliquot of the stock solution was diluted 1000-fold and then diluted further to the 
required concentration. The maximum concentration of vehicle, DMSO, was 
therefore 0.005% (v/v) and control incubations therefore contained 0.005% 
DMSO.  The cells were cultured for 24 h and 48 h and the viable cell number 
recorded. Viable cell number - hesperetin concentration response curves were 
constructed with data fitted to the logistic equation V = Vmax x GC50
n/(GC50
n + 
[Hesperetin]n) solving for GC50 and n. 
 
3.2.3 Effect of chronic treatment with sulforaphane on the development of 
MRC-5 cell senescence in vitro 
MRC-5 cells were seeded in T-75 cell culture flasks (300,000 cells/flask) 
in 5 ml Eagle’s MEM per well supplemented with either 1 µM SFN or with 
vehicle (0.002% DMSO). Cells cultured in these two conditions were cultured for 
7 days and then cell number and viability recorded and passaged. Viable cell 
counts determined at every passage were used to deduce population doubling 
level (PDL) and cumulative PDL with passage. PDL = ln(NH/NS)/ln2, where NH 
and NS are the cell population numbers at harvest and seeding, respectively at 
each passage. Cell viability was assessed by Trypan blue exclusion. 
 
3.2.4 Effect of chronic treatment with hesperetin on the development of 
MRC-5 cell senescence in vitro. 
MRC-5 cells were seeded in T-75 cell culture flasks (300,000 cells/flask) 
in 5 ml Eagle’s MEM per well supplemented with either 5 µM HESP in DMSO or 
with vehicle (0.005% DMSO). Cells cultured in these two conditions were 
passaged and counted every 7 days. Viable cell counts determined at every 
passage were plotted against number of days in culture to deduce PDL and 
cumulative PDL. Cell viability was assessed by Trypan blue exclusion. 
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3.3 Analytical methods 
3.3.1 Senescence-associated beta-galactosidase staining 
MRC-5 fibroblasts were seeded at a density of 30,000 cells per well in a 
12-well plate with 3 ml Eagle’s MEM media with 1 µM SFN or 0.002% DMSO 
vehicle control. After 24 h, the growth medium was aspirated from the cells. The 
cells were then washed twice with 1 ml of PBS per well. Residual wash solution 
was carefully removed by aspiration. The senescence cells staining kit from 
Sigma-Aldrich was used for the following steps. An aliquot of fixation buffer (0.4 
ml, containing 20% formaldehyde, 2% glutaraldehyde, 70.4 mM Na2HPO4, 14.7 
mM KH2PO4, 1.37 M NaCl and 26.8 mM KCl) was added per well and the plates 
were incubated for 6 to 7 min at room temperature. During the fixation process, 7 
ml of the staining mixture was prepared as follows: 700 µl Staining Solution (10-
fold concentrated) was added to 87.5 µl of 400 mM potassium ferricyanide, 87.5 
µl of 400 mM potassium ferrocyanide, 175 µl of 40 mg/ml 5-bromo-4-chloro-3-
indolyl β-D-galactopyranoside (X-gal) solution and 5.95 ml of water. The staining 
mixtures was then filtered using a 0.2 µm filter and then an aliquot (0.35 ml) was 
added to each per well and incubated at 37°C overnight. The senescent cells were 
stained blue. For long-term storage of the stained plate, and later senescence 
quantification, the staining mixture was aspirated, and cells were overlayed with 
0.4 ml of a 70% glycerol in PBS, and stored at 4°C. 
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3.3.2 Bradford Assay 
Protein concentration in cell lysates was determined by the Bradford 
method (Bradford, 1976) using bovine serum albumin (BSA) as calibration 
standard.  Stock solutions of BSA were calibrated by spectrophotometry; ε279 
(1%) = 6.59 cm-1 (Peters Jr., 1995).  
 
3.3.3 Real-time polymerase chain reaction analysis of mRNA 
Human MRC-5 fibroblasts at the end of each passage, processed as 
described in Section 3.2.3, were collected in 1.5 ml microcentrifuge tubes and 
washed 3 times with 1 ml ice-cold PBS. After final centrifugation and removal of 
supernatant PBS, the cell pellets were stored at -80°C for later analysis. 
 
3.3.3.1 Primer design and testing 
Primers were designed using the Invitrogen OligoperfectTM designer tool 
using mRNA and genomic DNA sequences obtained from the University of 
California, Santa Cruz genome browser.  Multiple primer pairs were selected for 
each gene. Amplicon length (optimal 100-150 base pairs) was considered and 
primers spanning exon-exon junctions were chosen when possible; this acted as 
an additional quality control since any contaminant genomic DNA would not act 
as a template for amplification.  Dissociation plots were performed for all primers 
to test performance.  An example of dissociation plot is shown in Figure 37.  
Dissociation plots were routinely performed for each assay plate; this ensured that 
the primers performed consistently. 
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Figure 37. Representative dissociation plot for primers.   
Y-axis represents the change in fluorescence with temperature (dRFU/dT) and X-
axis represents increases in temperature in °C. 
 
3.3.3.2 RNA extraction 
Sedimented cells were re-suspended and homogenized in 350 µl RLT 
buffer (RNeasy Mini Kit) and Ethanol (350 µl) was then added and samples 
mixed well. Samples were then transferred to an RNeasy column in 2 ml tube and 
centrifuged (15s, 8000g, room temperature). The eluate was discarded and 700 µl 
RW1 buffer (RNeasy Mini Kit) was added to the RNeasy column. The column 
was centrifuged (8000g, 15s, room temperature) and the eluate was discarded. 
Buffer RPE (500 µl, RNeasy Mini Kit) was added to the RNeasy column and 
centrifugation and flow-through discarding was repeated. This later step was 
performed a second time. The RNeasy column was then placed in a new 2 ml tube 
and centrifuged (10,000g , 1 min, room temperature). Finally, the column was 
placed in a clean 1.5 ml tube and 40 µl RNase-free water added to the microspin 
column before centrifugation (8000xg, 1 min, room temperature).The eluate was 
retained as mRNA extract.  
 
3.3.3.3 RNA quality control 
RNA content and purity of samples was determined by nanodrop 
spectrophotometry. The quality and concentration of RNA was determined 
spectrophotometrically using the NanoDrop 1000 spectrophotometer. An aliquot 
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of RNA solution (2 µl) was used to determine the RNA concentration; the 
absorbance at 260 nm was measured and RNA concentration deduced – ε260 (1 
mg/ml) = 23 cm-1. The quality of RNA was determined using the A260/A280 ratio 
where a ratio of 1.9 - 2.1 is indicative of high purity (Glasel, 1995).  
 
3.3.3.4 Reverse transcription 
Synthesis of cDNA was performed using the BIOLINE cDNA synthesis 
kit. From the protein concentrations obtained, 0.1 µg mRNA was mixed with 1.0 
µl Oligo(dT)18 and RNase-free water was added to a total volume of 12 µl. 
Samples were then heated at 700C for 5 min and put on ice immediately 
thereafter. The following mixture was then added to each sample: 1.0 µl RNase 
inhibitor (10 units/µl), 1.0 µl dNTPs (10 mM each), 4.0 µl  5x Buffer RT, 1.0 µl 
BioScriptTM and 1.0 µl RNase-free water. Samples were then heated at 400C for 
60 min. Finally, 2.0 µl of sample was loaded in a clear 96-well plate for RT-PCR 
analysis along with the following mixture: 10 µl of Master Mixture/50 SYBR 
Green, 0.5 µl primer solution of interest and 7.5 µl nuclease-free water. RNA was 
quantified as a ratio to β-actin RNA in the sample. Gene expression was recorded 
using the 7500 Fast Real-Time PCR system described in Materials. 
 
3.3.3.5 Preparation of standards 
Samples with the highest mRNA concentration were used to construct the 
standard curve. A standard curve of serially diluted pooled cDNA over the range 
0.1 pg – 1,000 ng was run alongside assay samples and used for quantification 
using β-actin as a reference gene.   A typical standard curve is shown in Figure 38. 
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Figure 38. Typical calibration curve for RT-PCR. 
Linear regression equation: Threshold cycle = (-3.73 ± 0.03) x log input of mRNA 
(pg); R2=0.999; n = 21.  
 
The following primers were used for analysis: β-actin (ACTB), NAD(P)H: 
quinone oxidoreductase-1 (NQO1), nuclear factor (erythroid-derived 2)-like 2 
(NFE2L2), transketolase (TKT), glyoxalase 1 (GLO1), aldoketo-reductase 
B1(AKRB1), kelch-like ECH-associated protein 1 (KEAP1), glutamate-cysteine 
ligase-C (GCLC), glutamate-cysteine ligase-M (GCLM), carbonyl reductase 1 
(CBR1), transaldolase 1 (TALDO1), glutathione reductase (GSR), haem 
oxygenase (decycling) 1 (HMOX1), aldoketo-reductase B2 (AKRB2), thioredoxin 
(TXN). 
 
 
3.3.4 Custom mRNA array analysis by the Nanostring method 
3.3.4.1 Sample preparation: Time course with SFN treatment on young MRC-5 
fibroblasts 
MRC-5 fibroblasts after passage 4 were seeded in 6-well plates at a 
density of 200,000 cells per well. After 24 h, cells were treated with either 1 µM 
SFN or vehicle control (0.002% DMSO). The media contained in each well was 
removed, cells were washed twice with ice cold PBS and the plate was stored at - 
80⁰C after rigorous sealing at time points 0, 4, 8, 12, 24, 36, 48 and 72 hours. 
MRC-5 and BJ fibroblasts treated with 1 µM SFN or vehicle (0.002% DMSO) at 
early and late passages were also analysed.  
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3.3.4.2 Sample preparation: Effect of SFN and HESP treatment on young and 
senescent MRC-5 fibroblasts 
MRC-5 cells were seeded in T-175 cell culture flasks (1 million 
cells/flask) in 30 ml Eagle’s MEM per well supplemented with either 1 µM SFN 
or with vehicle (0.002% DMSO). MRC-5 cells were also seeded in T-175 cell 
culture flasks (1 million cells/flask) in 30 ml Eagle’s MEM per well supplemented 
with either 5 µM HESP or with vehicle (0.005% DMSO). Cells cultured in these 
two conditions were cultured for 7 days and then cell number and viability 
recorded and passaged. MRC-5 fibroblasts treated with SFN after passage 3 and 
11 were used and MRC-5 fibroblasts treated with HESP after passage 3 and 9 
were used for Nanostring analysis. The media contained in each flask was 
removed, trypsinised and collected cells were washed twice with ice cold PBS and 
stored at - 80⁰C until further analysis.  
 
3.3.4.3 Processing of samples 
Total RNA was extracted as described in Method 3.3.3. 2. Total RNA (600 
– 800 ng) was analyzed for mRNA copy number of target genes by the 
NanoString nCounter Gene Expression method (Geiss et al., 2008) - outsourced to 
Nanostring, Seattle, USA. Two sequence-specific probes were constructed for 
each gene of interest (Table 6 and 7). The probes were complementary to a 100-
base region of the target mRNA. One probe was covalently linked to an 
oligonucleotide containing biotin (the capture probe), and the other was linked to 
a color-coded molecular tag that provided the signal (the reporter probe; see 
Figure 39). In this study, a custom codeset of 47 genes linked to Nrf2 system 
(anti-glycation related genes, antioxidant related genes, phase II conjugation 
genes, pentophosphate pathway genes, lipogenesis related genes, proteasome 
subunit genes and Nrf2 regulation related genes), inflammatory and immune 
response genes, extracellular matrix regulating genes, lysosomal and plasminogen 
activator inhibitor genes, senescence-associated genes and three reference genes 
(β-actin, clathrin heavy chain and β-glucuronidase) was designed. Triplicate 
samples were used for each treatment and time point. NanoString processing was 
performed by NanoString TechnologyTM (Seattle, Washington). The response 
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gives an estimate of relative mRNA copy number. Correction with the reference 
genes is made by normalizing to the geometric mean of reference genes at 
baseline – thereby controlling for technical variability in the mRNA copy number 
response. Data were analyzed using the nCounter™ digital analyser software.  
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Figure 39. Overview of NanoString nCounter gene expression system. 
(a) A schematic  representation of the hybridized complex (not to scale). The 
capture probe and reporter probe hybridize to a complementary target mRNA in 
solution via the gene-specific sequences.  After hybridization, the tripartite 
molecule is affinity-purified first by the 3’- repeat sequence and then by the 5’-
repeat sequence to remove excess reporter and capture probes, respectively. (b) 
Schematic representation of binding, electrophoresis, and immobilization. (i) The 
purified complexes are attached to a streptavidin-coated slide via biotinylated 
capture probes. (ii) Voltage is applied to elongate and align the molecules. 
Biotinylated anti-5’ oligonucleotides that hybridize to the 5’-repeat sequence are 
added. (iii) The stretched reporters are immobilized by the binding of the anti-5’ 
oligonucleotides to the slide surface via the biotin. Voltage is turned off and the 
immobilized reporters are prepared for imaging and counting. (c) False-color 
image of immobilized reporter probes. Source: Geiss et al., 2008. 
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Table 6. Genes of interest for Nanostring analysis in MRC-5 fibroblasts 
treated with or without SFN at passage 4. 
Gene list for time course of expression analysis in response to sulforaphane  
Codeset design included in Appendix A. 
  Name Symbol 
Anti-glycation related genes 
Aldoketo reductase 1C1 AKR1C1 
Glyoxalase 1 GLO1 
 Anti-oxidant related genes 
  
  
  
  
  
  
  
  
  
  
  
Catalase CAT 
γ-Glu-cys ligase-catalytic subunit GCLC 
γ-Glu-cys ligase-modulatory subunit GCLM 
Quinone reductase NQO1 
Thioredoxin reductase-1 TXNRD1 
Thioredoxin TXN 
Glutathione reductase GSR 
Heme oxygenase HMOX1 
Superoxide dismutase-1 SOD1 
Peroxiredoxin-1 PRDX1 
Glutathione peroxidase-1 GPX1 
Ferritin FTH1 
 Phase II conjugation genes Glutathione transferase P1 GSTP1 
Multidrug resistance-associated protein 
2 Mrp2 
Pentose phosphate pathway and 
glycolysis regulation 
Transaldolase TALDO1 
Transketolase TKT 
Glucose-6-phosphate dehydrogenase G6PD 
6-Phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-4 PFKFB4 
 Lipogenesis related genes Sterol response element binding 
protein-1 SREBF1 
Fatty acid synthase FASN 
Nrf2 regulation related genes Nrf2 NFE2L2 
Keap1 (inrf2) KEAP1 
Maf protein-G MAFG 
Fyn kinase FYN 
Proteasome and autophagy genes 
 
Proteasome subunit A1 PSMA1 
Proteasome subunit B5 PSMB5 
Sequestosome 1 SQSTM1 
Inflammatory and immune 
response genes 
  
  
  
  
  
  
  
Monocyte chemotactic protein-
1/Chemokine (C-C motif) ligand 2 CCL2 
GRO-alpha oncogene/Chemokine (C-
X-C motif) ligand 1 CXCL1 
Interleukin-15 IL15 
Interleukin 1-beta IL1B 
Toll-like receptor 4 TLR4 
Transcription factor p65 NFKB3 
Nuclear factor NF-kappa-B p105 
subunit/p50 NFKB1 
Intracellular adhesion molecule-1 ICAM1 
Matrix regulating genes Stromelysin-1/matrix 
metalloproteinase-3 MMP3 
Collagenase-3/matrix MMP13 
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metalloproteinase-13  
Mitochondrial superoxide dismutase  SOD2 
Elastin ELN 
Lysosome regulating gene  Cathepsin O CTSO 
Plasminogen activator inhibitor 
genes 
  
Plasminogen activator inhibitor-1 SERPINE1 
Plasminogen activator inhibitor-2 SERPINB2 
Senescence-associated genes 
  
  
Senescence-associated beta-
galactosidase GLB1 
Cyclin-dependent kinase inhibitor 
2A/P16INK4a CDKN2A 
Cyclin-dependent kinase inhibitor 1/p21 CDKN1A 
Reference genes 
  
  
Beta Actin ACTB 
Clathrin, heavy chain CLTC 
Beta-glucuronidase GUSB 
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Table 7. Genes of interest for Nanostring analysis analysis in MRC-5 
fibroblasts treated with or without SFN or HESP at passage 3 and 11. 
Gene list for early and late passage expression analysis in response to 
sulforaphane and hesperetin. Codeset design included in Appendix B. 
 
 
Name Symbol 
Anti-glycation related genes   
  Aldoketo reductase 1C1 AKR1C1 
  Glyoxalase 1 GLO1 
Anti-oxidant related genes   
  Catalase CAT 
  Gamma-glu-cys ligase-catalytic subunit GCLC 
  Gamma-glu-cys ligase-modulatory subunit GCLM 
  Quinone reductase NQO1 
  Thioredoxin reductase-1 TXNRD1 
  Thioredoxin TXN 
  Glutathione reductase GSR 
  Heme oxygenase HMOX1 
  Superoxide dismutase-1 SOD1 
  Peroxiredoxin-1 PRDX1 
  Glutathione peroxidase-1 GPX1 
  Ferritin FTH1 
Phase II conjugation genes   
  Glutathione transferase P1 GSTP1 
  
Glutathione conjugate transporter (ABCC2) 
UDP glucuronosyltransferase 1 
Mrp2/UGT1
A1 
Pentophosphate pathway genes   
  Transaldolase TALDO1 
  Transketolase TKT 
  Glucose-6-phosphate dehydrogenase G6PD 
 
Lipogenesis related genes   
  Sterol response element binding protein-1 SREBF1 
  Fatty acid synthase FASN 
Nutrient sensing     
  
6-Phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-2 PFKFB2 
  
Thioredoxin interacting protein (Thioredoxin-
Binding Protein 2) TXNIP 
  MondoA (MLX interacting protein) MLXIP 
  Max-Like BHLHZip Protein2 MLX 
  HIF1-α HIF1A 
  Hexokinase-1 HK1 
Nrf2 regulation related genes   
  Nrf2 NFE2L2 
  Keap1 (inrf2) KEAP1 
  Maf protein-G MAFG 
Proteasome subunits genes (protein turnover)   
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  Proteasome subunit A1 PSMA1 
  Proteasome subunit B5 PSMB5 
  Sequestosome 1 SQSTM1 
Inflammatory and immune response genes 
 
  
Monocyte chemotactic protein-1/Chemokine 
(C-C motif) ligand 2 CCL2 
  Toll-like receptor 4 TLR4 
  Transcription factor p65 NFKB3 
  Nuclear factor NF-kappa-B p105 subunit/p50 NFKB1 
  Intracellular adhesion molecule-1 ICAM1 
Extracellular matrix 
   Collagen 1-alpha COL1A1 
Matrix regulating genes   
  
Fibroblast collagenase/matrix 
metolloproteinase-1 MMP1 
  Stromelysin-1/matrix metalloproteinase-3 MMP3 
  Collagenase-3/matrix metalloproteinase-13  MMP13 
  Mitochondrial superoxide dismutase  SOD2 
  Elastin ELN 
Plasminogen activator inhibitor genes   
  Plasminogen activator inhibitor-2 SERPINB2 
Senescence-associated genes   
  Senescence-associated beta-galactosidase GLB1 
  Cyclin-dependent kinase inhibitor 1/p21 CDKN1A 
Reference genes     
  Beta Actin ACTB 
  Clathrin, heavy chain CLTC 
  Beta-glucuronidase GUSB 
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3.3.5 Glycation, oxidation and nitration of cellular protein  
Protein damage by glycation, oxidation and nitration in MRC-5 cells in 
vitro cultures was assessed by measuring the glycation, oxidation and nitration 
adduct residues of cell protein and also glycation, oxidation and nitration free 
adducts (glycated, oxidised and nitrated amino acids) released into the culture 
medium. The latter also contain contributions from glycation, oxidation and 
nitration of amino acids in the culture medium. Protein glycation, oxidation and 
nitration adducts were assayed by stable isotopic dilution analysis liquid 
chromatography with tandem mass spectrometric detection (LC-MS/MS) . 
Analytes determined were: the major early glycation adduct Nε fructosyllysine 
(FL); advanced glycation endproducts (AGEs) - the major quantitative advanced 
glycation endproduct (AGE) methylglyoxal-derived hydroimidazolone (MG-H1) 
and others; the oxidation marker methionine sulfoxide (MetSO), protein carbonyls 
- α-aminoadipic semialdehyde (AASA) and glutamic semialdehyde (GSA), and 
others; and the protein nitration marker nitrotyrosine (NT) - Figure 40. 
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Figure 40. Protein glycation, oxidation and nitration adduct residues in physiological systems. 
a. Early glycation adducts – FL and Nα-(1-deoxy-D-fructos-1yl)amino acid residues. Advanced glycation endproducts: b. 
Hydroimidazolones, c. Monolysyl d. Fluorophores, AGEs, e. Non-fluorescent crosslinks, f. Oxidation adducts, and g. Nitration 
adduct. Protein glycation, oxidation and nitration adduct residues are shown. For the corresponding free adducts at physiological pH, 
the N-terminal amino group is protonated –NH3+ and the C-terminal carbonyl is a carboxylate –CO2- moiety. Source: Rabbani et al., 
2014. 
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In addition, increased expression of transglutaminase is also implicated 
in fibroblast senescence (Kim et al., 2001; Dellorco et al., 1985) with expected 
increased formation of increased Nε(γ-glutamyl)lysine (GEEK) – Figure 41, 
although protein content of GEEK has not been reported. 
CO
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CO
HC
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Figure 41. Formation of Nε(γ-glutamyl)lysine (GEEK). 
 
3.3.5.1 Sample preparation: MRC-5 cell protein for adduct residues  
MRC-5 Cells (ca. 1 x 106) were washed thrice with ice-cold PBS, re-
suspended in 10 mM sodium phosphate buffer, pH 7.4 (100 µl), sonicated (100 
W, 30 s) and then centrifuged (20,000g, 30 min, 4 oC). The supernatant containing 
cytosolic protein was washed over 10 kDa cut-off membrane filters, using ice-cold 
argon purged water by 4 cycles of dilution to 500 μl and concentration to 50 μl by 
microspin ultrafiltration (10,000g, 1 h, 4 oC). The protein content was assayed by the 
Bradford method and 100 µg used for exhaustive enzymatic hydrolysis. 
Cytosolic protein (100 µg diluted to 25 µl with water) were washed in a 
glass vial (2 ml vial with 200 µl glass insert). Samples and enzyme reagents were 
flushed with argon by 3 cycles of applying vacuum (32 mmHg, 1 min, 18 oC) and 
re-gassing with argon in a centrifugal evaporator. Argon-gassed samples were 
placed in a robotic processor (PAL HTS9, CTC Analytics, Switzerland) for 
automated enzymatic hydrolysis. The processor is programmed to perform series 
of additions as follows: 
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a. Additions 1: 100 mM HCl (10 µl), pepsin solution (2 mg/ml in 20 mM 
HCl; 5 µl) and thymol solution (2 mg/ml in 20 mM HCl; 5 µl). The 
samples were then incubated at 37oC for 24 h. 
b. Additions 2 (order critical): 100 mM KH2PO4/K2HPO4 buffer, pH 7.4 
(12.5 µl); 260 mM KOH (5 µl). Pronase E solution (2 mg/ml in 10 mM 
KH2PO4/K2HPO4 buffer, pH 7.4; 5 µl) and penicillin-streptomycin 
solution (1000 U/ml and 1 mg/ml, respectively; 5 µl). The samples were 
then incubated at 37oC for 24 h. 
c. Additions 3: aminopeptidase solution (2 mg/ml in 10 mM 
KH2PO4/K2HPO4 buffer, pH 7.4; 5 µl) and prolidase solution (2 mg/ml in 
10 mM KH2PO4/K2HPO4 buffer, pH 7.4; 5 µl). Samples were then 
incubated at 37oC for 48 h. The final enzymatic hydrolysate (77.5 µl) is 
ready for LC-MS/MS analysis. 
 
3.3.5.2 Sample preparation: culture medium for free adducts  
An aliquot of culture medium (100 μl), baseline medium and end of 
passage conditioned medium, was used to prepare ultrafiltrate with a 3 kDa cut-
off microspin ultrafilter. An aliquot of the resulting ultrafiltrate (25 μl) was mixed 
with 25μl of stable isotopic internal standard mixture. An aliquot (50-100 l) is 
filtered by microspin ultrafiltration (10 kDa cut-off, 4 oC). Ultrafiltrate was 
retained for free adduct analysis. Plasma protein was diluted 5-fold with water and 
washed by 4 cycles of concentration to 50 μl and dilution to 500 μl with ice cold 
argon purged water over a microspin ultrafilter (10 kDa cut-off) at 4 oC. 
 
3.3.5.3 LC-MS/MS analysis  
Detection of analytes was performed by LC-MS/MS in electrospray-positive 
ionization multiple reaction monitoring (MRM) mode. Quantification was 
performed using stable isotopic dilution analysis. LC-MS/MS was performed 
using a Waters AcquityTM ultra high performance liquid chromatography (UPLC) 
system with a Quattro Premier XE tandem mass spectrometer. Chromatography 
was performed with two Hypercarb columns in series: column 1, 2.1 x 50 mm, 5 
μm particle size; and column 2, 2.1 x 250 mm 5 μm particle size. The mobile 
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phase was made of two solvents: Solvent A (0.1% TFA in water) and Solvent B 
(0.1% TFA in 50% acetonitrile (MeCN)). Solvent A (0.1% TFA in water) and 
solvent B (0.1% TFA in 50% tetrahydrofuran (THF)) were used for postrun 
washing. Both solvents were used for 37.5 min and their gradient is shown in 
Table 8 as well as the column switching programme in Table 9. 
 
 
Table 8. Gradient table for protein damage analytes detection on LC-
MS/MS. 
Time 
(min) 
Flow rate 
(ml/min) 
Solvent 
A 1 
(%) 
Solvent 
B1 (%) 
Solvent 
B2 
Comment 
0 0.2 100 0 0 
Multi-step linear gradient with 
column switching. Data collection 
period: 4 – 35 min. 
5 0.2 100 0 0 
8 0.2 97 3 0 
12 0.2 97 3 0 
24 0.2 40 60 0 
24 0.2 97 3 0 
26 0.2 3 0 0 
27 0.2 50 50 0 
35 0.2 50 50 0 
35 0.4 0 0 100 
Column washing 
45 0.4 0 0 100 
45 0.2 100 0 0 
Column re-equilibration 
57.5 0.2 100 0 0 
57.5 0.4 100 0 0 
72.5 0.4 100 0 0 
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Table 9. Column switching programme for protein damage analytes 
detection on LC-MS/MS. 
Time (min) Columns in-line Comment 
0 1+ 2 Elution of analytes retained only 
by column 1 and 2 in series 10 1+ 2 
10 1 Elution of analytes retained strongly 
by only column 1 26 1 
26 1 + 2 Elution of analytes trapped on 
column 2 during prior column 
switching 
35 1 + 2 
35 1 
Washing of column 1 
45 1 
45 1 + 2 Washing of action column 2 and re-
equilibration 72.5 1 + 2 
 
 
Flow from the Column was directed to the MS/MS detector at 4 to 35 min. 
The ionisation source temperature and desolvation temperatures were set at 120°C 
and 350°C respectively. The cone gas and desolvation gas flow was set as 99 L/h 
and 901 L/h. Table 10 shows the optimised molecular ion and fragment ion 
masses and collision energies for MRM. Typical calibration curves for AGEs is 
shown in Figure 42.
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Table 10. Mass spectrometric multiple reaction monitoring detection of protein oxidation and glycation adducts. 
Analyte group Analyte Rt (min) Parent 
ion 
(Da) 
Fragment 
 ion (Da) 
CE 
(eV) 
Neutral fragment loss(es) Isotopic standard 
Amino acids        
 Arg 29.2 175.2 70.3 15 H2CO2, NH2C(=NH)NH2 [
15N2]arg 
Lys 5.5 147.1 84.3 15 H2CO2, NH3 [
13C6]lys 
Met 29.5 150.0 104.2 11 H2CO2 [
2H3]met 
Tyr 18.3 182.1 136.2 13 H2CO2 [
2H4]tyr 
Trp 23.5 205.0 159.1 15 H2CO2 [
15N2]trp 
 Val 8.6 117.8 72.0 19 H2CO2 [
2H8]val 
Early-stage 
glycation adduct 
       
Fructosamines FL 28.5 291.0 84.3 31 H2CO2, fructosylamine [
2H4]FL 
AGEs        
Hydroimidazolones† G-H1        12.4 215.0 100.2 14 NH2CH(CO2H)CH2CH=CH2 [15N2]G-H1 
MG-H1 11.6 & 12.5 229.2 114.3 14 NH2CH(CO2H)CH2CH=CH2 [
15N2]MG-H1 
3DG-H 11.2, 12.6 & 13.5  319.1 114.8 20 NH2CH(CO2H)CH2CH=CH2 [
15N2]3DG-H 
Monolysyl AGEs CEL 28.8 219.2 130.1 13 NH2CH(CH3)CO2H [
13C6]CEL 
CML 28.5 204.9 130.1 12 NH2CH2CO2H [
13C6]CML 
Pyrraline 17.9 255.2 84.3 23 2-CHO-5-HOCH2-pyrrole, H2CO2 [
13C6, 
2N2]Pyrraline 
Fluorescent AGEs Argpyrimidine 17.7 255.3 140.3 17 NH2CH(CO2H)CH2CH=CH2 [
15N2]argpyrimidine 
 Pentosidine‡ 21.1 379.3 250.4 22 NH2CH(CO2H)CH2CH2CH=CH2 [13C6]pentosidine 
Non-fluorescent 
crosslinks 
MOLD 14.0 341.2 212.3 21 NH2CH(CO2H)CH2CH2CH=CH2 [
2H8]MOLD 
Glucosepane 16.5 429.2 382.1 38 C2H5O [
13C6] Glucosepane 
Other CMA 12.1 233.0 70.1 27 H2CO2, NH2C(=NH)NHCH2CO2H [
13C2]CMA 
 Orn 5.2 133.1 70.1 9 H2CO2, NH3 [
2H6]orn 
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Table 10. (cont.) 
Analyte group Analyte Rt (min) Parent 
ion (Da) 
Fragment 
 ion (Da) 
CE 
(eV) 
Neutral fragment loss(es) Isotopic standard 
Oxidative damage         
Met oxidation MetSO 8.7 166.1 102.2 14 CH3-SOH [
2H3]MetSO 
Tyr oxidation Dityrosine 19.9 361.2 315.3 15 H2CO2 [
2H6]DT 
Tyr oxidation NFK 21.5 235.8 191.2 18 H2CO2 [
15N2]NFK 
Lys oxidation AASA 10.7 128.0 82.0 15 H2CO2 AAA (Rt = 29.4) 
Arg & Pro oxidation GSA 32.2 114.0 68.0 15 H2CO2 AAA 
Nitration damage        
Tyrosine nitration 3-NT 23.2 227.1 181.2 13 H2CO2 [
2H3]3-NT 
†For hydroimidazolones, Rt values for the 2 epimers if MG-H1 are given and of the 3 structural isomers of 3DG-H, 3DG-H1, 3DG-
H2 and 3DG-H3 are all detected.. ‡ Pentosidine is detected to higher sensitivity by in-line fluorimetry, excitation wavelength 320 nm, 
emission wavelength 365 nm.  From: Thornalley, P. J. et al. Quantitative screening of advanced glycation endproducts in cellular and 
extracellular proteins by tandem mass spectrometry. Source: Rabbani et al., 2014.
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(a)  
(b)  
(c)  
Figure 42. Typical calibration curves for glycation adducts – AGEs. 
(a) Calibration curve for FL. Linear regression equation: FL/[2H4]FL peak area 
ratio = (0.104 ± 0.002) x FL (pmol); R2 = 0.999 (n = 7). (b) Calibration curve for 
CML. Linear regression equation: CML/[13C6]CML peak area ratio = (0.185 ± 
0.004) x CML (pmol); R2 = 0.998 (n = 7). (c) Calibration curve for MG-H1. 
Linear regression equation: MG-H1/[15N2]MG-H1 peak area ratio = (0.0594 ± 
0.0009) x MG-H1 (pmol); R2 = 0.999 (n = 7). 
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(d)  
(e)  
Figure 42. Typical calibration curves for glycation adducts – AGEs (cont’). 
(d) Calibration curve for CEL. Linear regression equation: CEL/[13C6]CEL peak 
area ratio = (0.320 ± 0.010) x CEL (pmol); R2 = 0.996 (n = 7). (e) Calibration 
curve for CMA. Linear regression equation: CMA/[13C2]CMA peak area ratio = 
(0.171 ± 0.003) x CMA (pmol); R2 = 0.998 (n = 7).    
   
  
3.3.5.4 Measurements of protein glycation, oxidation and nitration adduct 
residues - correction for autohydrolysis in exhaustive enzymatic hydrolysis 
In the analysis of protein glycation, oxidation and nitration adduct residues 
of cell protein, a robust basis for correction of the contribution to protein 
glycation, oxidation and nitration adducts by autohydrolysis of proteases is 
required. Hydrolysis in protein free blanks overestimates this contribution since 
autohydrolysis of proteases is faster when no protein substrate is present. An 
initial strategy employed was correction from digestion of a polypeptide that 
could not contain protein glycation, oxidation and nitration adduct residues – such 
as polythreonine. This only presents the proteases with one type of peptide bond, 
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however – different from all other samples. The current method uses triplicate 
digests of zero protein blanks and a known amount of human serum albumin 
(HSA) and quantitation of an amino acid that is not modified – valine. In the HSA 
digests the amount of valine detected is that from HSA + autohydrolysis of 
proteases (VHSA + VProteases (Protein)).In the zero protein blanks the valine detected is 
only from autohydrolysis (VProteases (Blank)). The valine liberated from proteases in 
the presence of HSA is decreased by the suppression of autohydrolysis by 
presence of HSA. The factor VProteases (Protein)/ VProteases (Blank), typically ca. 0.7, is 
applied to the amount of protein glycation, oxidation and nitration adduct 
quantified in the blank to produce corrections applied to digests of sample protein. 
That is, the presence of protein substrate slows autohydrolysis of proteases by ca. 
30%. This correction factor is determined for each samples batch for enzymatic 
hydrolysis samples.   
 
3.3.6 Analysis of Nɛ-(γ-L-glutamyl)-L-lysine (GEEK) 
 Analysis of GEEK samples was done by LC-MS/MS using an AcquityTM 
UPLC system with a Xevo-TQS Quattro tandem mass spectrometer. Samples 
were prepared as described in section 3.3.5.1 and 3.3.5.2. Standards were prepared 
as shown in Table 11. – Figure 43 shows a typical calibration curve. 
 
Table 11. Calibration standard-cocktail of stock solution for GEEK analysis. 
Calibration no GEEK [13C5] GEEK 
 Amount (pmol) 
0 0 10 
1 20 10 
2 40 10 
3 80 10 
4 120 10 
5 160 10 
6 200 10 
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Figure 43. A typical calibration curve for glutamyl lysine. 
Linear regression equation: GEEK/[13C5] GEEK peak area ratio = (0.446 ± 0.002) 
x GEEK (pmol); R2 = 0.999 (n = 7). 
 
 A 3µm particle size Hypercarb columns were used 150 x 2.1 mm. The 
mobile phase solvent A: 0.1% TFA and 3.75% acetonitrile (CAN) in water and 
solvent B: 0.1% TFA in 50% THF in water. The gradient is shown in 12. 
Electrospray positive ionisation mass spectrometric multiple reaction monitoring 
(MRM) was used to detect all protein damage analytes. The ionisation source 
temperature and desolvation temperature were 120⁰C and 350⁰C, respectively. 
The cone gas and desolvation gas flow were 96 L/h and 900 L/h, respectively. 
Optimised molecular ion and fragment ion masses and collision energies for 
MRM detection are given in Table 13. Masslynx was used to integrate the peaks 
and GEEK was normalised to lysine. 
 
Table 12. Gradient table for Nɛ-(γ-L-glutamyl)-L-lysine detection on LC-
MS/MS. 
Time Flow Rate Solvent A Solvent B 
Gradient 
(min) (ml/min) (%) (%) 
0 0.2 100 0  
5 0.2 100 0 Isocratic 
15 0.2 100 0 Isocratic 
35 0.2 0 100 Isocratic 
40 0.2 100 0 Isocratic 
55 0.4 100 0 Isocratic 
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Table 13. Mass-spectrometric multiple reaction monitoring detection of Nɛ-
(γ-L-glutamyl)-L-lysine. 
Analyte 
Rt Precursor Fragment CV CE 
(min) (Da) (Da) (V) (eV) 
GEEK 9.9 276.1 147.1 32 12 
[13C5] GEEK 9.9 281.1 147.1 32 12 
Lys 5.6 147.1 84.1 20 18 
[13C6] Lys 5.6 153.1 89.1 20 18 
 
 
3.3.7 Nucleotide oxidation and glycation 
Markers of glycation of DNA by glyoxal and methylglyoxal - 3-(2’-
deoxyribosyl)-6,7-dihydro-6,7-dihydroxyimidazo-[2,3-b]purine-9(8)one (GdG) 
and 3-(2’-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6/7-methylimidazo-[2,3-
b]purine-9(8)one (MGdG) respectively, and DNA oxidation – 7,8-dihydro-8-oxo-
2’-deoxyguanosine (Figure 44) – were measured by quantifying the increased 
concentration of glycated and oxidised nucleosides in the cell culture medium 
during a passage. Ultrafiltrates of baseline and end of passage conditioned culture 
medium were prepared by microspin ultrafiltration of medium (3 kDa cut-off, 100 
μl), collecting ca. 50 μl ultrafiltrate. For LC-MS/MS, ultrafiltrates (40 μl) were 
spiked with 10 μl isotopic standard mixture containing: 0.1 nmol [13C10,15N5]dG, 
1 pmol [13C10,
15N5]8-OxodG, 0.73 pmol [13C10,
15N5]MGdG, 0.09 pmol 
[13C10,
15N5]CEdG and 1.4 pmol [13C10,
15N5]GdG. LC-MS/MS was performed 
using an AcquityTM UPLC-Quattro Premier tandem mass spectrometer with a 
BEH C18 1.7 µm particle size, 2.1 x 100 mm column. The mobile phase was 
0.1% formic acid with a linear gradient of 0 – 10% acetonitrile from 2 – 10 min 
and isocratic 10% acetonitrile from 10 -15 min; the flow rate was 0.25 ml/min. 
After analysis, the column was washed with 50% acetonitrile containing 0.1% 
formic acid for 10 min and thereafter re-equilibrated with initial mobile phase for 
10 min. The column temperature was 10 oC. For GdG, MGdG and 8-OxodG, 
limits of detection were 0.8, 2.5 and 0.7 fmol; analytical recoveries were 104, 97 
and 99%, respectively, and coefficients of variation 2 – 7%. Detection of 
imidazopurinones and related deoxyguanosine-derived adducts by liquid 
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chromatography-tandem mass spectrometry multiple reaction monitoring is 
shown in Table 14. 
 
Figure 44. The conversion of GdG into dG and MGdG. 
Source: (Lampe, 2009)(Lampe, 2009)(Herr and Buchler, 2010). 
 
 
Table 14. Detection of imidazopurinones and related deoxyguanosine-derived 
adducts by liquid chromatography-tandem mass spectrometry multiple 
reaction monitoring. 
 
The neutral fragment loss was 2-dehydro-2-deoxyribose. † Multiple retention 
times are shown for adduct structural and stereoisomers isomers. 
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3.3.8 Dicarbonyls analysis 
Dicarbonyl metabolites glyoxal, methylglyoxal and 3-deoxyglucosone 
(3-DG) were assayed by derivatisation with 1,2-diaminobenzene and 
quantitation of the resulting quinoxaline adducts by stable isotopic dilution 
analysis LC-MS/MS (Kurz et al., 2010). Media from MRC-5 cell cultures 
treated with either 1 µM SFN or vehicle (0.002% DMSO) was collected as 
mentioned in 3.3.5.1 and, after storage at -80°C, used for analysis. 
The media was de-proteinised by addition of 10 μl of 20% ice-cold 
trichloroacetic acid (TCA). Stable isotopic standards were then added (2 pmol 
of each of [13C2]glyoxal, [
13C3]methylglyoxal and [
13C6]3-DG), the samples 
mixed and then centrifuged at 10,000xg for 10 min at 4°C. An aliquot of 
supernatant (35 μl) was removed and after addition of 5 μl 3% sodium azide, 10 
μl 0.5 mM 1,2-diaminobenzene solution containing 0.5 mM diethylenetriamine 
penta-acetic acid (DETAPAC) and 0.2 M HCl were added. The samples were 
then incubated for 4 h in the dark. The assay was calibrated by concurrent 
derivatisation of analyte standard: 0 to 10 pmol of glyoxal, MG and 3-DG. The 
samples were assayed by LC-MS/MS. The column was 100 x 2.1mm, 1.7 μm 
particle size BEH C18. The mobile phase contained 0.1% of trifloroacetic acid 
(TFA) in water with a linear gradient of 0 to 50% of acetonitrile (MeCN) for 10 
min with a 0.2 min/ml flow rate and gradient shown in Table 15. 
 
 
Table 15. Gradients for the dicarbonyl assay using LC-MS/MS. 
Time  
(min) 
Flow rate 
(ml/min) 
Solvent A 
(%) 
Solvent B 
(%) 
Curve 
0 0.2 100.0 0.0 0 
10.0 0.2 100.0 0.0 6 
15.0 0.2 100.0 3.0 1 
30.0 0.2 100.0 3.0 1  
 
The capillary voltage used for mass spectrometric detection was of 0.6 kV 
and the ionisation as well as desolvation temperatures used were 120°C and 
350°C respectively. The flow for the cone gas was 149 L/h and 901 L/h for 
desolvation gas flow. The optimised molecular ion and fragment ion masses and 
collision energies for MRM detection are shown in Table 16. 
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Table 16. Mass-spectrometric multiple reaction for detection of dicarbonyls. 
Analyte 
Parent ion 
(Da) 
Fragment ion 
(Da) 
Cone voltage 
(V) 
Collision energy 
(eV) 
MG 145.1 77.1 24 24 
3-DG 235.5 199.0 21 15 
Glyoxal 131.1 77.1 24 23 
 
 
3.3.9 Assay of D-glucose 
The concentration of glucose in cell culture medium at baseline and end of 
passage in control and SFN treatment groups was made by end-point enzymatic 
assay with hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PDH). 
The procedure is shown in Figure 45. and based on the following coupled 
enzymatic reaction. 
 
 
 
Figure 45. Coupled enzymatic assay for glucose – hexokinase method. 
 
 
The concentration of glucose is coupled to equimolar formation of 
NADH. The resulting concentration of NADH is determined 
spectrophotometrically at 340 nm. Media samples were diluted 3-fold for 
both treatment groups (SFN and DMSO) and 5-fold for baseline media added 
at the beginning of each passage.  Aliquots of standard and diluted sample (25 
µl) were added to wells of a clear 96-well microplate and 225 µl of the assay 
reagent was added. The HK-based glucose assay reagent was prepared by 
addition of 20 ml of water to reagent solid mix such that final concentrations 
of assay components were: 1.5 mM NAD, 1.0 mM ATP, 1.0 U/ml of HK and 
1.0 U/ml of G6PDH. The microplate was then incubated at room temperature 
(18-25ºC) for 15 min and absorbance measured using a FLUOstar OPTIMA 
microplate reader. The concentration of glucose in each sample was deduced 
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from the standard curve and the glucose standards prepared in the range of 0 
to 1.4 mM in water (Figure 46).  
 
 
Figure 46. Typical calibration curve for D-glucose. 
Linear regression equation: A340 = (0.529 ± 0.008) x D-glucose (mM); R
2 = 0.995 
(n = 21). 
 
The absorbance is corrected for absorbance of reagent (reagent blank, y-
axis intercept on the calibration curve) and medium (sample blank). The 
concentration of D-glucose was deduced from the standard curve and is given in 
mM. The consumption of D-glucose by MRC-5 cells during passage was 
calculated by subtracting the amount of D-glucose in media at the end of the 
passage from the amount at baseline and given as nmol/day/106 cells.  
 
3.3.10 D-Lactate assay 
The concentration of D-lactate in culture medium was determined using an 
end-point enzymatic assay with the enzyme D-Lactic dehydrogenase and 
microplate fluorimetric detection of NADH formed in the forward reaction. 
Wavelengths used for the detection of NADH were: excitation, 340 nm, and 
emission, 460 nm (McLellan et al., 1992). Hydrazine is added to remove pyruvate 
from the assay reaction equilibrium by formation of pyruvate hydrazone and take 
the forward assay reaction to completion.  The formation of pyruvate by 
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enzymatic reaction of D-lactate with D-lactic dehydrogenase and reaction with 
pyruvate is shown in Figure 47.   
 
 
Figure 47. The formation of pyruvate from D-lactate via the enzymatic 
reaction with D-lactic dehydrogenase. 
 
 
An aliquot of media (500 μl) was deproteinised by addition of 1.0 ml 0.6M 
perchloric acid (PCA), mixed well and left on ice for 10 min incubation for 
protein to precipitate. The precipitate was then sedimented by centrifugation (5 
min, 7000g, 4 oC). An aliquot of supernatant (700 μl) was removed and 
neutralised to pH 7 by addition of 230 µl 2 M potassium bicarbonate and 
centrifuged again (10 min,7000g, 4 ºC) to sediment the resulting potassium 
perchlorate precipitate. An aliquot of the neutralised PCA extract (100 μl) was 
assayed for D-lactate by incubation for 4 h with 100 μl glycine hydrazine buffer 
(1.2 M glycine, 0.5 M hydrazine dihydrochloride, 2.5 mM DETAPAC, pH 9.2), 
25 μl 4 mM NAD+ and 25 μl 500 U/ml of D-lactic dehydrogenase. Control 
samples were run in parallel without the enzyme. The calibration curve for D-
lactate was constructed in the range 0 - 6 nmol D-lactate (Figure 48). 
 
 
Figure 48. Typical calibration curve for D-lactate. 
Linear regression equation: Fluorescence = (83468 ± 1779) x D-lactate (nmol); 
R2= 0.9919 (n = 21). 
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3.3.11 L-Lactate assay 
L-Lactate was assayed as described for D-lactate but instead using L-lactic 
dehydrogenase.  The sample content of L-lactate is 50-100 folds higher than D-
lactate and so media samples were diluted with water prior to assay.  L-Lactate 
calibration standards were prepared over the range 1 - 10 nmol (Figure 49).  
 
 
Figure 49. Typical calibration curve for L-lactate. 
Linear regression equation: Fluorescence = (1997 ± 18) x L-lactate (nmol); 
R2=0.9983 (n=21). 
 
Samples were prepared and assayed according to the protocol for D-lactate 
(section 3.3.10).  
 
3.3.12 Assay of cellular reduced and oxidised glutathione and glyoxalase 
pathway intermediate S-D-lactoylglutathione   
MRC-5 cells (1 X 106 cells) were washed 3 times in PBS. The cell pellet 
was treated with 40 µl 10% TCA containing 0.15% NaCl and 0.25% sodium azide 
in water.  This solution precipitates proteins and inhibits acid stable, TCA soluble 
peroxidase activity.  Samples were centrifuged (20,000g, 30 min, 4 °C) and 
aliquots of supernatant (10 µl) transferred to vials for LC-MS/MS analysis with 
the addition of 10 µl isotopic standard cocktail containing 100 pmol 
[13C2
15N1]GSH and 20 pmol [
13C4
15N2]GSSG. Two graphite Hypercarb HPLC 
columns were used in series (50 x 2.1 mm and 250 x 2.1 mm, particle size 5 µm) 
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with column temperature of 30 °C.  Solvents used were 0.1% TFA in water 
(Solvent A) and 0.1% TFA in 50:50 MeCN: water (Solvent B1) and 0.1% TFA in 
50:50 Tetrahydrafuran (THF): water (Solvent B2).  The gradients used during the 
analytical run and post run are displayed in Table 17. 
 
Table 17. UPLC Elution profile for glutathione analysis. 
Injection Run 
Time (min) 
Flow rate 
(ml/min) 
Solvent A1 
(%) 
Solvent B1 
(%) 
Solvent B2 
(%) 
Gradient 
Initial 0.2 100 0 -  
1 0.2 100 0 - Isocratic 
15 0.2 40 60 - Linear 
16 0.2 40 60 - Isocratic 
Postrun      
0 0.4 0 - 100 Column 
washing 10 0.4 0 - 100 
10 0.4 100 - 0 Re-
equilibration 25 0.4 100 - 0 
 
The eluate from the column was eluted into the electrospray source of the 
MS/MS detector for 4 - 16 min for data collection.  Mass spectrometric analysis 
was performed using electrospray positive ionisation mode.  For mass 
spectrometric detection, the capillary voltage was 3.4 kV, the ion source 
temperature 120 °C, the desolvation gas temperature 350 °C and cone and 
desolvation gas flows 146 and 550 L/h respectively.  Table 18 shows the 
optimised MRM conditions used for detection, along with their retention times, 
cone voltage and collision energy.  Fragmentation analysis of the MRM 
transitions is detailed in Figure 50. 
 
Table 18. Optimised MRMs for glutathione analysis. 
Analyte 
Parent 
ion (Da) 
Fragment 
ion (Da) 
Retention 
time 
(min) 
Cone 
voltage 
(V) 
Collision 
energy 
(eV) 
GSH 308.2 179.1 11.7 30 13 
[13C2
15N1]GSH 311.2 182.1 11.7 30 13 
GSSG 613.2 483.7 14.4 52 18 
[13C4
15N2]GSSG 619.2 489.7 14.4 52 18 
S-D-
lactoylglutathione 
380.2 76.2 13.1 32 35 
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Figure 50. Fragmentation of glutathione in multiple reaction monitoring 
mass transitions. 
A. GSH, B. GSSG and C. S-D-lactoylglutathione.  
 
Data analysis was performed using MassLynx software.  Calibration 
curves were constructed plotting peak area ratio of analyte/isotopic standard 
against analyte concentration.  The amount of glutathione in assayed aliquots was 
deduced using the peak area ratio and the appropriate calibration curve and the 
amount in the original sample calculated taking account of any dilution factors.   
 
3.3.13 Immunocytochemistry 
MRC-5 fibroblasts were cultured in 4 cm glass bottomed dish (30,000 
cells per dish) and incubated for 24 h under normal growth conditions. A total of 8 
groups (n = 3 per group) was seeded using the conditions described in Table 19. 
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Table 19. Immunocytochemistry conditions. 
Condition After 24 h seeding Treatment next morning 
1 Low glucose media High glucose for 6 hours 
2 Low glucose media High glucose and 1 µM SFN for 6 hours 
3 Low glucose media High glucose and 2 µM SFN for 6 hours 
4 Normal glucose media N/A 
5 Normal glucose media High glucose for 6 hours 
6 Normal glucose media High glucose and 1 µM SFN for 6 hours 
7 High glucose media N/A 
8 High glucose media and 1 µM SFN N/A 
 
The low glucose media was made with MEM containing: 0.2 mM glucose, 
non-essential amino acids and supplemented with 2% FBS, 1% penicillin-
streptomycin, 2 mM L-glutamine, 100 mM sodium pyruvate. The normal glucose 
media was made with MEM containing non-essential amino acids and 
supplemented with 10% FBS, 1% penicillin-streptomycin, 2 mM L-glutamine, 
100 mM sodium pyruvate. The high glucose media was made with MEM 
containing: 20 mM D-glucose, non-essential amino acids and supplemented with 
10% FBS, 1% penicillin-streptomycin, 2mM L-glutamine, 100 mM sodium 
pyruvate. The cells were incubated at 37°C in 5% CO2 atmosphere. After 6 hours 
treatment and removal of media, MRC-5 fibroblasts were washed 3 times with 
PBS. After final aspiration, cells were covered with 250 µl of a 1:1 
acetone/methanol solution for 20 minutes at -20ºC. Following aspiration of this 
fixative, cells were rinsed 3 times in TBST for 5 minutes each. Specimens were 
then blocked for 60 minutes in a solution of 1% BSA in TBST. Following this 
procedure, cells were incubated with primary antibody (Mondo A) overnight at 
4 °C. Cells were then washed with PBS (2 x 5 min) and incubated with the Alexa 
labelled secondary antibodies for 1 h at room temperature.  Secondary antibody 
was goat anti-rabbit IgG-Alexa488 conjugate diluted to 5 µg/mL.  Samples were 
then mounted using mounting medium containing 4’,6-diamidino-2-phenylindole 
(DAPI).  Images were acquired under a 63x NA oil immersion objective using a 
laser scanning Zeiss confocal microscope at 20x zoom.   
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3.3.14 Western Blotting 
MRC-5 fibroblasts samples treated with 1 µM SFN or 0.002 % DMSO 
were collected after passage 5 (young) and passage 9 (senescence). Cell pellets 
were washed 3 times with cold PBS and re-suspended in re-suspension buffer (50 
mM Tris-HCl, 3 mM MgCl2, 2% SDS pH 7.4 at room temperature) with addition 
of the protease inhibitor cocktail from Sigma (1% in resuspension buffer). Protein 
extracts were assayed for protein concentration by the Bradford Assay and stored 
at -80 ºC until use.       
Total β-galactosidase (BGAL) was measured by Western blotting using anti-
BGAL and anti-β-actin antibodies. Protein samples (25 µg) were separated by 
SDS-PAGE gel electrophoresis using 12% polyacrylamide gels (Table 20.). 
Separated proteins were transferred from the gel to PVDF membrane with the 
semi-dry transfer cell as described in Figure 51. The sandwich containing filter 
paper, gel and PVDF was immersed with transfer buffer (100 ml 10 X 
Tris/glycine buffer, 100 ml methanol, top up to 1 L with water) and transferred 
under 240 mA for 2.5 h. 
 
Table 20. Composition of 10% SDS-PAGE gel for western blotting. 
Name of solutions 12% resolving gel 
(Total volume of 60.66 
ml for 2 gels) 
5% stacking gel 
(Total volume of 26.53 
ml for 2 gels) 
4X Protogel resolving buffer 15 ml ---- 
Protogel stacking buffer ---- 6.4 ml 
30% Acrylamide 15 ml 3 ml 
10% APS 600 µl 300 µl 
Water 30 ml 16.8 ml 
TEMED 60 µl 30 µl 
 
 
Figure 51. Layout of semi-dry transfer for Western blotting. 
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The membrane was blocked with 5% BSA in Tris-Buffered Saline with 
Tween-20 (TBS-T, 30 ml of 5 M NaCl, 10 ml of 1 M Tris-HCl pH 7.6, 0.5 ml 
Tween- 20, top up to 1 L with water) at room temperature on a shaking platform 
for 1hr, followed by blotting with anti-BGAL antibody in 1% milk (in TBS-T) at 
4ºC overnight. The membrane was then washed every 10 min for 3 times and 
blotted with secondary antibody in 1% milk for 1 h at room temperature. The 
membrane was washed again for 3 times at 10 min intervals and added with ECL 
reagent. Photographic films were developed after exposed with the membrane for 
detection of protein bands. The exposure time was 1 min for BGAL and 10 
seconds for β-actin. Protein bands was analysed by densitometry and BGAL (101 
kDa) levels were normalised against β-actin (42 kDa) levels. 
 
3.3.15 Assay of glycolytic intermediates in MRC-5 fibroblasts treated with 
SFN and/or high glucose 
 
3.3.15.1 Cell incubations 
MRC-5 cells were seeded in T-175 cell culture flasks (106 cells per flask) in 30 ml 
Eagle’s MEM.  After 24 h the cultures were supplemented with either 25 mM 
glucose or 25 mM glucose with 1 µM SFN and incubated for 6 h. The cells were 
then trypsinized, collected by centrifugation and washed 3 times in PBS. MRC-5 
fibroblasts from previous experiments treated with and without 1 µM SFN from 
cPDL ca. 33.58  and collected at passage 5 and 9 (see Section 4, Figure 56) were 
also analysed. Approximately 0.3 – 1.0 x 106 cells was collected and cell pellets 
stored at - 80⁰C until sample processing. 
 
3.3.15.2 Sample processing 
MRC-5 pellets and HL-60 [13C]glucose labelled cell pellets (Internal Standard - 
collected in Method 3.1.6.4) were re-suspended in an aliquot  of 0.1% TFA (200 
µl). Samples were sonicated for 30 s on ice and cell membranes sedimented by 
centrifugation (20,000g, 30 min, 4 ⁰C). The supernatant was then transferred in 3 
kDa microspin filters and centrifuged (14,000g, 1 h, 4 ⁰C) and ultrafiltrate 
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retained. Sample and HL60 cell-derived internal standard ultrafiltrates were stored 
at -20⁰C until further analysis. 
 
3.3.15.3 Stable isotopic dilution analysis of glycolytic intermediates 
Key intermediates of early-stage glycolysis, glucose-6-phosphate (G6P), 
fructose-6-phosphate (F6P) and 6-phosphogluconate (PGA) were analysed in cell 
extracts by modification of the method of Bucholtz et al. (2001). Metabollites 
were detected by fragmentation to phosphate anions and specificity of G6P and 
F6P detection was further enhanced by concurrent loss of water in the multiple 
reaction monitoring (MRM) transitions . A aliquot of sample (30 µl) was mixed 
with internal standard extract (20 µl) and analysed by LC-MS/MS; injection 
volume 50 µl. Chromatography was performed with two graphite Hypercarb 
HPLC columns in series (150 x 2.1 mm and 250 mm x 2.1 mm, 5 µm particle 
size) with column temperature 30 °C.  Solvents used were: 0.1% TFA in water 
(Solvent A1), 0.1% TFA in 50:50 MeCN:water (Solvent B1), and 0.1% TFA in 
50:50 tetrhydrofuran:water (Solvent B2).  The elution gradient programme used 
during the analytical run and post run are displayed in Table 21. 
 
Table 21. UPLC Elution profile for glycolytic intermediates analysis. 
Analytical run elution gradient programme: 
Time (min) 
Flow rate 
(ml/min) 
Solvent A1 
(%) 
Solvent B1 
(%) 
Solvent B2 
(%) 
Curve 
Initial 0.2 100 0 0 Initial 
16 0.2 100 0 0 Linear 
40 0.2 40 60 0 Linear 
 
 
Post-run elution gradient programme: 
 
Time 
(min) 
Flow rate 
(ml/min) 
Solvent 
A1 (%) 
Solvent 
B1 (%) 
Solvent 
B2 (%) 
Column 
in-line 
Curve 
0 0.4 0 0 100 1 Initial 
10 0.4 0 0 100 1 Isocratic 
20 0.2 0 0 100 1 + 2 Immediate change 
25 0.2 100 0 0 1 + 2 Immediate change 
40 0.4 100 0 0 1 + 2 Immediate change 
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The eluate from the column was eluted into the electrospray source of the 
MS/MS detector for 4 - 40 min for data collection in the analytical run.  Mass 
spectrometric analysis was performed using electrospray negative ionisation 
mode.  For mass spectrometric detection, the capillary voltage was 0.60 kV, the 
ion source temperature 150 °C, the desolvation gas temperature 500 °C and cone 
and desolvation gas flows 992 and 1000 L/h respectively. Table 22 shows the 
optimised MRM conditions used for detection, along with their retention times, 
cone voltage and collision energy.   
 
 
Table 22. Optimised MRMs for glycolytic intermediates analysis. 
 
Analyte 
Parent 
ion (Da) 
Fragment 
ion (Da) 
Fragment  Fragment loss Retention 
time (min) 
Cone 
voltage (V) 
Collision 
energy (eV) 
F6P 259.0 78.9 H2PO4
-
 Fructose, H2O 12.9 8 14 
[13C6]F6P 265.0 78.9 H2PO4
-
 [
13C6]Fructose, H2O 12.9 8 14 
G6P 259.0 78.9 H2PO4
-
 Glucose, H2O 14.0 8 32 
[13C6]G6P 265.0 78.9 H2PO4
-
 [
13C6]Glucose, H2O 14.0 8 32 
PGA 275.0 96.9 H2PO4
-
 Gluconic acid 22.2 38 16 
[13C6]PGA 281.0 96.9 H2PO4
-
  [
13C6]Gluconic acid 22.2 38 16 
Limits of detection were: F6P, 0.09 pmol, G6P, 0.7 pmol and 3.0 pmol. 
 
3.3.16 Microarray analysis 
3.3.16.1 Sample collection 
MRC-5 cells were seeded in T-175 cell culture flasks (1 million 
cells/flask) in 30 ml Eagle’s MEM per well supplemented with either 1 µM SFN 
or with vehicle (0.002% DMSO). Cells cultured in these two conditions were 
cultured for 7 days and then cell number and viability recorded and passaged. 
MRC-5 fibroblasts after passage 3 and 11 were used for microarray analysis. The 
media contained flask was removed, cells were trypsinised and washed twice with 
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ice cold PBS. Cells were stored at - 80⁰C after until further analysis. Total RNA 
was then extracted as described in Method 3.3.3.2.  
 
3.3.16.2 Sample preparation 
Total RNA (600 ng) was used for microarray analysis. For this purpose, 
One-colour Spike-Mix stock was diluted 50 times with dilution buffer and mixed 
thoroughly. Volume corresponding to 600ng total RNA was added to 3 µl of 1:50 
diluted One-colour Spike-Mix and 1.2 µl T7 Promoter primer. Nuclease-free 
water was added so that total reaction volume was 11.5 µl. The primer and 
template were then denatured in a Thermocycler at 65°C for 10 min. Samples 
were then incubated on ice for 5 minutes. In the meantime, the 5X first strand 
buffer was pre-warmed at 80 °C for 4 min to resuspend. The 5X first strand buffer 
was then briefly vortexed and span down. This solution was kept at room 
temperature until needed. cDNA mastermix was then made using the following 
components for each sample: 4 µl 5X first strand buffer, 2 µl 0.1M DTT, 1 µl 
10mM dNTP mix, 1 µl MMLV-RT, 0.5 µl RNase out. A volume of 8.5 µl cDNA 
master mix was then added to each samples and mixed by pipetting. Samples were 
then incubated for 2 hrs at 40 °C. Following this 2hrs incubation, samples were 
incubated at 65 °C for 15 min and incubated at 4 °C for 5 min. In the meantime, 
50% PEG was pre-warmed at 40 °C for 1 min. 50% PEG was then briefly 
vortexed and span down and kept at room temperature until needed. The 
Transcription Master Mix was then made using the following components for 
each sample – Table 23. 
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Table 23. Transcription Master Mix components. 
Volumes are expressed per sample. 
Component Per Reaction 
Nuclease-free water 15.3 µl 
4X Transcription Buffer 20 µl 
0.1M DTT 6 µl 
NTP mix 8 µl 
50% PEG 6.4 µl 
RNase OUT 0.5 µl 
Inorganic pyrophosphatase 0.6 µl 
T7 RNA Polymerase 0.8 µl 
Cyanine 3-CTP 2.4 µl 
Total Volume 60 µl 
 
A volume of 60 µl of Transcription Master Mix was added to each samples and 
mixed by pipetting. Samples were incubated for 2 hrs at 40 °C.  
 
3.3.16.3 Sample cRNA purification using Quiagen RNeasy mini spin columns 
A volume of 20 µl nuclease-free water and 350 µl was added to each 
sample and mixed by pipetting. After quick centrifugation, 250 µl 70% ethanol 
was added and mixed by pipetting. The resulting 700 µl samples were then 
transferred to RNeasy mini columns in collection tubes. Columns were then span 
for 30 sec at 13,000 rpm. Flow-through was discarded and collection tube 
replaced. A volume of 500 µl of buffer RPE was added and the column was span 
down for 30 sec at 13,000 rpm. Flow-through was discarded and another 500 µl 
buffer RPE was added to the column. The column was then span down at 13,000 
rpm for 1 min to dry the column. After discarding of the collection tube, the 
column was transferred to a clean 1.5 ml collection tube and 40 µl of RNase-free 
water was added directly to the column membrane to elute cRNA. After 1 min 
incubation at room temperature, the column was span for 30 sec at 13,000 rpm to 
elute. The eluate was then transferred to a 0.5 ml ependorf and kept in the dark. 
cRNA was then quantified using a UV-VIS Spectrophotometer. The following 
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values were recorded: RNA absorbance (OD260 nm) and Cyanine 3 dye 
absorbance (OD550 nm). From these absorbances, the cRNA concentration 
(ng/µl) and the cyanine 3 dye concentration (pmol/µl) was calculated. Finally, the 
yield and specific activity for each sample reaction was calculated as follows:  
Yield (µg cRNA) = (ng/µl cRNA) * 30 µl elution volume / 1000 
Specific activity (pmol Cyr3 per µg cRNA) = (pmol/µl Cyr3) / (ng/µl cRNA) * 
1000 
 
3.3.16.4 Hybridization – 8X60K 
A volume of 500 µl nuclease-free water was added to lyophilized 10X 
Blocking Agent from Agilent Gene Expression Hybridization Kit, and gently 
vortexed. After equilibration of water bath to 60 °C, 600 ng cyanine 3-labelled 
cRNA was made to a volume of 19 µl using nuclease-free water. To this cyanine 
3-labelled cRNA, 5 µl of 10X Blocking Agent as well as 1 µl of 25X 
Fragmentation Buffer was added and gently mixed. After 30 min incubation at 60 
°C to fragment RNA, the samples were immediately cooled on ice for 1 min. The 
fragmentation reaction was stopped by addition of 25 µl 2X GEx Hybridization 
Buffer HI-RPM. After mixing by pipetting, samples were span 1 min at 13,000 
rpm at room temperature and collected.  
 
3.3.16.5 Sample processing 
A volume of 40 µl of hybridization sample was loaded on each Agilent 
SureHyb chamber and SureHyb gasket slide was used to seal. Each sealed slide 
was placed in a hybridization oven at 65 °C for 17 hrs at 10 rpm. After 
disassembly of the hybridization chamber, slides were washed 1 min in GE wash 
buffer 1 at room temperature followed by 1 min wash at 37 °C in GE wash buffer 
2, 10 sec wash with acetonitrile at room temperature and finally 20 sec wash with 
Stabilization and Drying solution at room temperature. Slides were immediately 
scanned using an Agilent scanner to minimize the impact of environmental 
oxidants on signal intensities and data was extracted using the Agilent Feature 
Extraction Software. 
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3.3.17 Statistical analysis 
Experiments were performed using biological replicates in triplicates or 
greater. Data are presented as mean ± standard deviation when normally 
distributed and median (lower – upper quartile) when of nonparametric 
distribution. Significance testing was performed using Student’s t-test (parametric 
data) and Mann Whitney-U test (non-parametric data). For testing of repeated 
observations, repeated measures analysis was used. For correlation analysis 
Pearson correlation was used for parametric data and Spearman correlation for 
non-parametric data. Statistical significance was performed using the Statistical 
Package for the Social Sciences (SPSS) Version 17.0 (SPSS Inc). Significance 
was defined as p<0.05. 
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4. Results 
 
4.1 Effects of sulforaphane and hesperetin on MRC-5 fibroblast senescence in 
vitro 
4.1.1 Growth curve of MRC-5 fibroblasts in vitro 
MRC-5 fibroblasts were grown in Eagle’s MEM medium in vitro. The 
growth curve was done over 5 days and viable cell number was recorder at time 0, 
1, 2, 3, 4 and 5. The fibroblast viable cell number increased from 20,000 cells per 
well at time 0 to 412,000 cells per well after 5 days – Figure 52. 
 
  
 
Figure 52. Growth curve for MRC-5 fibroblasts in vitro. 
a. Growth curve. b. Growth curve with log transformation of viable cell number. 
Data are mean ± SD, n = 3. 
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MRC-5 cells showed an exponential growth curve in the initial 3 days of culture 
which thereafter slowed to quiescence as the cells reached confluence. Cell 
viability remained at >98% (Trypan blue exclusion) throughout the culture period. 
 
 
4.1.2 Dose-response of MRC-5 fibroblasts treated with sulforaphane 
MRC-5 cells were incubated with sulforaphane (SFN), 0-8 µM for 48 h. 
The dose-response curve is shown in Figure 53. 
 
 
Figure 53. Dose-response curve for the effect of sulforaphane on growth of 
MRC-5 fibroblasts in vitro. 
Data were fitted to a logistic regression equation. The median growth inhibitory 
concentration GC50 of SFN was 2.60 ± 0.03µM and the logistic regression 
coefficient n = 2.02 ± 0.03 (N = 21). Control cell growth was 23.6 ± 3.1 x 105 
cells (n = 3). Legend: □, viable cell count after 48 h incubation for each cultured 
well. 
From this dose-response curve, the median growth inhibitory concentration GC50 
value of SFN was 2.60 ± 0.03 µM and the logistic regression coefficient n was 
2.02 ± 0.03. There was no significant inhibition of MRC-5 cell growth at SFN 
concentrations up to 1.5 µM SFN. For all concentrations used, there was 
negligible toxicity (< 5%). At ≥ 2 µM SFN there was growth arrest.  
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4.1.3 Dose-response of MRC-5 fibroblasts treated with hesperetin 
MRC-5 cells were incubated with hesperetin (HESP), 0 - 40 µM, for 48 h. 
The dose-response curve is shown in Figure 54. 
 
 
 
 
 
Figure 54. Dose-response curve for the effect of hesperetin on growth of 
MRC-5 fibroblasts in vitro. 
Data were fitted to a logistic regression equation. The median growth inhibitory 
concentration GC50 of HESP was 4.83 ± 0.45 µM and the logistic regression 
coefficient n was 1.38 ± 0.16 (N = 21). Control cell growth was 21.5 ± 1.1 x 105 
cells (n = 3). Legend: □, viable cell count after 48 h incubation for each cultured 
well. 
From this dose-response curve, the median growth inhibitory concentration GC50 
value of HESP was 4.83±0.45 µM and n was 1.38±0.16. There was no significant 
inhibition of MRC-5 cell growth at 1.0 µM HESP. For all concentrations used, 
there was negligible toxicity (< 5%). At higher concentrations, however, HESP 
decreased MRC-5 cell growth.  
 
4.1.4 Effect of sulforaphane treatment on MRC-5 fibroblasts growth 
MRC-5 fibroblasts were grown in Eagle’s MEM media supplemented each 
week with either 0.002% DMSO (control) or 1 µM SFN (treatment). The 
population doubling limit (PDL) as well as cumulative PDL (cPDL) were 
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analyzed in order to represent MRC-5 fibroblast growth as progression of 
senescence occurred. Cumulative PDL was calculated from addition of PDL from 
one passage to another. Three flasks of MRC-5 cells were cultured from cPDL 
33.5 for 2 passages, and then each divided into  two flasks and one thereafter 
cultured with 1 µM SFN added after 24 h  and once only during the passage. The 
cell seeding varied slightly in the early passages and then decreased markedly as 
cell numbers declined. All changes in seeding density were, however, identical for 
SFN treated incubations and controls – Table 24 to 27. Data of PDL and cPDL 
recorded are given in Figure 55 and 56. 
  
Table 24. Seeding density of MRC-5 cells in passages for the sulforaphane 
treatment study. 
Passage no 
Cell seeding density 
 (cells/cm2) 
Treatment 
1 62400 None 
2 26742 “ 
3 30674 ± 1 µM SFN 
4 40000 “ 
5 40000 “ 
6 11429 “ 
7 11429 “ 
8 11429 “ 
9 11429 “ 
10 5714 “ 
11 1714 “ 
12 1743 “ 
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Figure 55. MRC-5 fibroblasts PDL as a function of passage number – Study 
1. 
Key: □▬□, 0.002% DMSO (control), ▬, + 1 µM SFN. Data are mean ± SD, 
n = 3. The arrow indicates where SFN treatment was initiated. ‖ indicates cells 
had stopped growing and were decreasing number (PDL < 0; P<0.05) 
Significance: ** and ***, P<0.01 and P<0.001, respectively (t-test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56. MRC-5 fibroblasts cPDL as a function of passage number – Study 
1. 
Key: □▬□, 0.002% DMSO (control), ▬, + 1 µM SFN. Data are mean ± SD, 
n = 3. The arrow indicates where SFN treatment was initiated. ‖ indicates cells 
stopped growing and were decreasing in number (cPDL decreasing; P<0.05) 
Significance: ** and ***, P<0.01 and P<0.001, respectively (t-test).  
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In control cultures, the PDL was initially ca. 0.72 and declined to 0.16 at 
passage 5. When the seeding density was decreased to 11,429 cells/cm2 from 
passages 6 – 9, the initial PDL increased to 1.31 and then decreased to -0.03 by 
passage 9. At later passages the PDL was negative, indicating that the cells were 
no longer growing and viable cell number was progressively decreasing. The 
maximum cPDL of 38.7 ± 0.1 was reached at passage 8. With SFN treatment, the 
combined increase in PDL over passages 3 – 5 was increased (repeated measures 
analysis, P<0.001). PDL was also increased in SFN treated cells from passages 6 
– 12 – with significance achieved at all passages except 8 and 9 and overall in a 
combined repeated measures analysis (P<0.001). From regression analysis of PDL 
on passage number, the rate of decline in PDL per passage with and without SFN 
was similar (-0.40 ± 0.06 versus -0.40 ± 0.03) whereas the intercept (when PDL = 
0) was higher with SFN (4.06 ± 0.29 versus 3.59 ± 0.24, P<0.001). This suggests 
the rate of decline in MRC-5 cell growth on approach to senescence with and 
without SFN is similar; treatment with SFN, however, delayed the onset of 
approach to senescence. The maximum cPDL with SFN treatment was reached at 
passage 11 and was higher than in control (40.9 ± 0.2 versus 38.7 ± 0.1, P<0.001). 
 Repeat analysis of delay of MRC-5 cell senescence with a similar 
experimental protocol gave similar results although in one of the three studies the 
delay of senescence developed late as cPDL progressed. In the four replicate 
studies, the increase in cPDL achieved with SFN treatment was 2.29, 2.06, 1.56 
and 1.99; mean ± SD, 1.98 ± 0.31 – Figures 57, 58 and 59a. SFN therefore 
induced a 2 unit increase in cPDL or two additional population doublings. This 
was achieved by initiation of SFN treatment in the cPDL range 32 – 37. The effect 
was also investigated of late initiation of SFN treatment at cPDL = 41. 
Remarkably, this also achieved an increase in cPDL of 1.49 ± 0.13 above control 
after only treatment of 4 passages – Figure 59b. 
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Figure 57. MRC-5 fibroblasts cPDL as a function of passage number. 
Replicate study 2. 
Key: □▬□, 0.002% DMSO (control), ▬, + 1 µM SFN. Data are mean ± SD, 
n = 3. The arrow indicates where SFN treatment was initiated. ‖ indicates cells 
stopped growing and were decreasing in number (cPDL decreasing; P<0.05) 
Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001, respectively (t-test). 
 
 
 
Table 25. Seeding density of MRC-5 cells in passages for the sulforaphane 
treatment study. Replicate study 2. 
Passage no 
Cell seeding density 
 (cells/cm2) 
Treatment 
1 16068 None 
2 29088 “ 
3 46628 ± 1 µM SFN 
4 3428 “ 
5 22857 “ 
6 22857 “ 
7 22857 “ 
8 11428 “ 
9 11428 “ 
10 11428 “ 
11 5714 “ 
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Figure 58. MRC-5 fibroblasts cPDL as a function of passage number. 
Replicate study 3. 
Key: □▬□, 0.002% DMSO (control), ▬, + 1 µM SFN. Data are mean ± SD, 
n = 3. The arrow indicates where SFN treatment was initiated. ‖ indicates cells 
stopped growing and were decreasing in number (cPDL decreasing; P<0.05) 
Significance: * and **, P<0.05 and P<0.01, respectively (t-test).  
 
 
 
Table 26. Seeding density of MRC-5 cells in passages for the sulforaphane 
treatment study. Replicate study 3. 
Passage no 
Cell seeding density 
 (cells/cm2) 
Treatment 
1 12267 None 
2 15289 “ 
3 4000 ± 1 µM SFN 
4 4000 “ 
5 4000 “ 
6 4000 “ 
7 4000 “ 
8 4000 “ 
9 4000 “ 
10 4000 “ 
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Figure 59. MRC-5 fibroblasts cPDL as a function of passage number. 
Replicate study 4 – effect of early and late treatment. 
a. Early SFN treatment. b. Late SFN treatment. Key: □▬□, 0.002% DMSO 
(control), ▬, + 1 µM SFN from cPDL 31.6. ▲▬▲, + 1 µM SFN from cPDL 
41.0. Data are mean ± SD, n = 3. The arrow indicates where SFN treatment was 
initiated. ‖ indicates cells stopped growing and were decreasing in number 
thereafter. Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001, respectively 
(t-test).  
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Table 27. Seeding density of MRC-5 cells in passages for the sulforaphane 
treatment study. Replicate study 4. 
Passage no 
Cell seeding density 
 (cells/cm2) 
Treatment-1 Treatment-2 
1                16800 None None 
2 36960 “ “ 
3 34416 ± 1 µM SFN “ 
4 24679 “ “ 
5 11000 “ “ 
6 11428 “ “ 
7 11428 “ “ 
8 5714 “ “ 
9 11428 “ ± 1 µM SFN 
10 11428 “ “ 
11 5714 “ “ 
12 4000 “ “ 
 
 
 
4.1.5 Effect of hesperetin treatment on MRC-5 fibroblasts growth 
MRC-5 fibroblasts were grown in Eagle’s MEM media supplemented each 
week with either 0.005% DMSO (control) or 5 µM HESP (treatment). The 
population doubling limit (PDL) as well as cumulative PDL (cPDL) were 
analyzed in order to represent MRC-5 fibroblast growth as progression of 
senescence occurred. Cumulative PDL was calculated from addition of PDL from 
one passage to another. Three flasks of MRC-5 cells were cultured from cPDL 
33.5 for 2 passages, and then each divided into  two flasks and one thereafter 
cultured with 5 µM HESP added after 24 h  and once only during the passage. 
The cell seeding varied slightly and in the early passages and then decreased 
steadily as cell numbers declined. All changes in seeding density were, however, 
identical for HESP treated incubations and controls – Table 28. Data of PDL and 
cPDL recorded are given in Figures 60 and 61. 
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Table 28. Seeding density of MRC-5 cells in passages for the hesperetin 
treatment study. 
Passage no 
Cell seeding density 
 (cells/cm2) 
Treatment 
1                17466 None 
2 42971 “ 
3 4000 ± 5 µM HESP 
4 4000 “ 
5 3428 “ 
6 2857 “ 
7 5714 “ 
8 2057 “ 
9 2533 “ 
   
 
 
 
 
 
Figure 60. MRC-5 fibroblasts PDL as a function of passage number - HESP 
study. 
Key: □▬□, 0.005% DMSO (control), ▬, + 5 µM HESP. Data are mean ± SD, 
n = 3. The arrow indicates where HESP treatment was initiated. ‖ indicates cells 
had stopped growing and were decreasing number (PDL < 0; P<0.05) 
Significance: * and **, P<0.05 and P<0.01, respectively (t-test).  
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Figure 61. MRC-5 fibroblasts cPDL as a function of passage number - HESP 
study. 
Key: □▬□, 0.005% DMSO (control), ▬, + 5 µM HESP. Data are mean ± SD, 
n = 3. The arrow indicates where HESP treatment was initiated. ‖ indicates cells 
stopped growing and were decreasing in number (cPDL decreasing; P<0.05) 
Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001, respectively (t-test).  
 
In control cultures, the PDL was initially ca. 0.98 and increased to 3.10 at passage 
4. When the seeding density was decreased to 2,857-3,428 cells/cm2 for passages 
5 and 6, the initial PDL decreased 1.5-1.9 then increased to 2.1 at passage 7 in 
accordance with higher seeding density of 5,714 cells/cm2. Control PDL then 
decreased to -0.4 by passage 9. At later passages the PDL was negative, indicating 
that the cells were no longer growing and viable cell number was progressively 
decreasing. The maximum cPDL of 44.6 ± 0.3 was reached at passage 8. With 
HESP treatment, the combined increase in PDL over passages 3 – 6 was increased 
(repeated measures analysis, P<0.001). PDL was also increased in HESP treated 
cells at passage 3 and from passages 5 – 9 – with significance achieved at 
passages 6 and 9 and overall in a combined repeated measures analysis (P<0.001). 
From regression analysis of PDL on passage number, the rate of decline in PDL 
per passage with and without HESP was similar (-0.13 ± 0.15 versus -0.17 ± 0.16) 
whereas the intercept (when PDL = 0) was higher with HESP (2.45 ± 0.05 versus 
2.27 ± 0.06, P<0.001). This suggests the rate of decline in MRC-5 cell growth on 
approach to senescence with and without HESP is similar; treatment with HESP, 
however, delayed the onset of approach to senescence. The maximum cPDL with 
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HESP treatment was reached at passage 9 and was higher than in control (45.7 ± 
0.2 versus 44.2 ± 0.1, P<0.001). 
 
 
 
4.1.6 Senescence-associated beta-galactosidase staining of MRC-5 fibroblasts 
treated with SFN 
Onset of cell senescence in MRC-5 cells was assessed by staining for the 
senescence marker, beta-galactosidase. A total of 300 MRC-5 cells were analysed 
per well, analysing 3 wells per treatment, and the percentage of cells expressing β-
galactosidase (blue stain) determined for passages 4 to 9. Micrographs of 
characteristic blue staining is shown in Figure 62 and related cell counting 
quantitation are shown in Figure 63.  
 
 
 
 
Figure 62. Characteristic blue staining indicating β-galactosidase expression 
in senescent MRC-5 fibroblasts. 
Key: left-hand panel young, non-senescent cells; right-hand panel – old, senescent 
cells. Inverted microscopy, x20 magnification. 
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Figure 63. Percentage of senescent MRC-5 fibroblasts as a function of 
passage. 
Key: ▬, 0.002% DMSO (control), □▬□, + 1 µM SFN. Data are mean ± SD, 
n = 3. Significance: *, P<0.05 (t-test) 
Control MRC-5 fibroblasts had a higher percentage of senescent cells in culture 
than SFN-treated MRC-5 cells at passages 6 and 9 (P<0.05) indicating that 
treatment delayed senescence marked by decreased β-galactosidase expression 
compared to control in these two passages. 
 
 
4.1.7 Cell senescence marker beta-galactosidase – assessment of beta-
galactosidase protein 
Human β-galactosidase-1 expression in MRC-5 fibroblasts was assessed at 
the protein level by Western blotting of cell extracts at passage 5 (young) and 
passage 9 (senescence) treated with either 1 µM SFN or 0.002% DMSO – Figure 
64 and 65. 
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Figure 64. Western blotting of young and senescent MRC-5 fibroblasts for 
beta-galactosidase. 
Key: BGAL, beta-galactosidase protein; and ACTB - β-actin housekeeping 
protein. SFN-P5 and CTRL-P5, cell extracts from passage 5 treated with and 
without 1 μM SFN; and SFN-P9 and CTRL-P9, cell extracts from passage 9 
treated with and without 1 μM SFN. 
 
 
 
Figure 65. Quantitation of Western blotting of young and senescent MRC-5 
fibroblasts for beta-galactosidase. 
Key:          , control; and           + 1 μM SFN. Data are mean ± SD ( n = 3). 
Significance: *, P<0.05, SFN treated cells with respect to control; o and oo, 
P<0.05 and P<0.01, passage 9 with respect passage 5. 
Control MRC-5 fibroblasts had a higher expression of β-galactosidase protein 
compared to the SFN-treated group at passage 9. Unexpectedly β-galactosidase 
protein, normalized to β-actin, was higher in extracts of cells at passage 5 than at 
passage 9. 
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4.1.8 Changes in gene expression induced by sulforaphane in early passage, 
non-senescent MRC-5 cells in vitro. 
 The time course of changes in gene expression induced by 1 μM SFN in 
early passage, non-senescent MRC-5 cells in vitro was investigated by 
quantifying mRNA of genes of selected metabolic pathways with Nrf2 regulated, 
ARE-linked genes by the Nanostring method – quantifying relative mRNA copy 
number. The outputs are given in Figures 66-77. Reference genes were β-actin, β-
glucosidase and clathrin, heavy chain with responses normalized to the geometric 
mean of these genes. 
 SFN induced a 2-fold increase in the Nrf2, ARE-linked transcriptional 
response marker gene quinone reductase NQO1. For other antioxidant linked 
genes, there were ca. 2-fold increases in mRNA of γ-glutamylcysteine ligase-
modulatory subunit (GCLM), glutathione reductase (GSR), thioredoxin reductase 
(TXNRD1) and haem oxygenase (HMOX1), and smaller increases in mRNA of 
ferritin and thioredoxin by SFN. Expression of γ-glutamylcysteine ligase-catalytic 
subunit, glutathione peroxidase-1, peroxiredoxon-1, superoxide dismutases SOD1 
and SOD2 and catalase were little changed. Increased NQO1 mRNA stimulated 
by SFN maximized after ca. 24 h and remained increased up to 72 h post-
stimulation. In contrast, increased GCLM and GSR mRNA maximized after 12 h 
and retuned to baseline levels after 36 – 48 h. The increase in HMOX1 mRNA 
was even more short-lived, maximizing at 4 h and returning to levels in 
unstimulated cells by 24 h. SFN also increased mRNA of aldoketo reductase 1C1 
but not of glyoxalase 1. It also had little effect on phase II conjugating genes, 
glutathione transferase P1 and MRP2. Pentosephosphate pathway genes were 
more responsive, with mRNA of glucose-6-phosphate dehydrogenase (G6PDH), 
transketolase (TKT) and transaldolase (TALDO) all increasing in SFN stimulated 
cells. For lipogenic genes, sterol response element binding protein-1 (SREBF1) 
was decreased in SFN stimulated cells but expression of fatty acid synthase 
(FASN) was unchanged. The expression of Fructose-2,6-bisphate kinase-4 
(PFKBP4) was also unchanged by SFN. For the Nrf2 system itself, SFN did not 
increase expression of Nrf2, Keap1 nor Fyn kinase but did increase small maf 
protein-G (MAFG) in the 24 h immediately post-stimulation. Inflammatory gene 
responses were examined. Monocyte chemotactic protein-1 (CCL2), chemokine 
(C-X-C motif) ligand 1 (CXCL1), interleukin-15 (IL15), interleukin 1β1 (IL1), 
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toll-like receptor 4 (TLR4), transcription factor p65 (NFKB3), nuclear factor NF-
kappa-B p105 subunit/p50 (NFKB1) and intracellular adhesion molecule-1 
(ICAM1) were all unresponsive. Genes associated with extracellular matrix 
proteolysis, matrix metalloproteinase-3 (MMP3) and matrix metalloproteinase-13 
(MMP13), were unchanged whereas the expression of elastin was decreased. The 
expression of serpins and senescence associated genes, β-galactosidase (GLB1), 
cyclin-dependent kinase inhibitor 1/p21 (CDKN1A) and cyclin-dependent kinase 
inhibitor 2A/P16INK4a (CDKN2A), were all unchanged. 
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Figure 66. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Antioxidant genes. 
a. Quinone reductase NQO1, b. γ-Glutamylcysteine ligase – catalytic subunit 
GCLC, c. γ-Glutamylcysteine ligase – modulatory subunit GCLM, d. Glutathione 
reductase GSR, e. Glutathione peroxidase-1 GPX1, and f. Peroxiredoxin-1 
PRDX1. Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
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Figure 66. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Antioxidant genes (cont’d) .  
g. thioredoxin TXN, h. thioredoxin reductase TXNRD1, i. haem oxygenase 
HMOX1, j. ferridoxin FTH1, k. Superoxide dismutase-1 SOD1, and l. Superoxide 
dismutase-2 SOD2. Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n 
= 3. 
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Figure 66. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Antioxidant genes (cont’d).  
m. Catalase CAT. Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 
3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Antiglycation genes.  
a. Aldoketo reductase 1C1 (AKR1C1). b. Glyoxalase 1 (GLO1). Key: ○‒○, 
control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Phase II conjugation genes. 
a. Glutathione transferase P1 (GSTP1). b. Glutathione conjugate transporter 
(ABCC2) MRP2. Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 
3.  
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Figure 69. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Pentophosphate pathway genes. 
a. Glucose-6-phosphate dehydrogenase G6PDH. b. Transketolase TKT. c. 
Transaldolase TALDO. Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± 
SD, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Lipogenic and glycolytic regulation genes. 
a. Sterol response element binding factor-1 (SREBF1). b. Fatty acid synthase 
(FASN). Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
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Figure 70. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Lipogenic and glycolytic regulation genes (cont’d).  
c. Fructose-2,6-bisphoahate kinase-4 (PFKBP4). Key: ○‒○, control; ●‒●, + 1 μM 
SFN. Data are mean ± SD, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 71. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Nrf2 regulation genes. 
a. Nrf2. b.Keap1. c. Small maf protein-G MAFG. d. Fyn kinase FYN. Key: ○‒○, 
control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
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Figure 72. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Proteolysis related genes. 
a. Proteasomal subunit A1 (PSMA1). b. Proteasomal subunit B5 (PSMB5). c. 
Sequestosome-1/p62 (SQSTM1). d. Cathepsin O (CTSO). Key: ○‒○, control; ●‒
●, + 1 μM SFN. Data are mean ± SD, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 73. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Inflammatory/immune response genes. 
a. Monocyte chemotactic protein-1 (CCL2). b. Chemokine (C-X-C motif) ligand 1 
(CXCL1). Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
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Figure 73. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Inflammatory/immune response genes (cont’d).  
c. Interleukin-15 (IL15). d. Interleukin 1β1 (IL1). e. Toll-like receptor 4 (TLR4), 
f. Transcription factor p65 (NFKB3), g. Nuclear factor NF-kappa-B p105 
subunit/p50 (NFKB1), h. Intracellular adhesion molecule-1 (ICAM1). Key: ○‒○, 
control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
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Figure 74. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Extracellular matrix regulating genes. 
a. Matrix metalloproteinase-3 (MMP3). b. Matrix metalloproteinase-13 (MMP13). 
c. Elastin (ELN). Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 
3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 75. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study. Serpines. 
a. Plasminogen activator inhibitor-1 (SERPINE1). b. Plasminogen activator 
inhibitor-2 (SERPINE2). Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± 
SD, n = 3. 
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Figure 76. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study Senescence-associated genes. 
a. β-Galactosidase (GLB1). b. Cyclin-dependent kinase inhibitor 1/p21 
(CDKN1A). c. Cyclin-dependent kinase inhibitor 2A/P16INK4a (CDKN2A). 
Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 77. Gene expression of MRC-5 fibroblasts induced by sulforaphane. 
Nanostring study Reference genes. 
a. β-Actin (ACTB). b Clathrin, heavy chain (CLTC). c. β-glucuronidase (GUSB). 
Key: ○‒○, control; ●‒●, + 1 μM SFN. Data are mean ± SD, n = 3. 
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4.2 Characterization of gene expression and cell metabolism in cells escaping 
senescence by treatment with sulforaphane and hesperetin.  
 
 The changes in gene expression induced by 1 μM SFN and 5 μM HESP in 
young and senescent MRC-5 cells in vitro was investigated by quantifying mRNA 
of genes of selected metabolic pathways with Nrf2 regulated, ARE-linked genes 
by the Nanostring method – quantifying relative mRNA copy number. The 
outputs are given in Table 29 and 30 and most significant changes genes of 
interest are shown in Figures 78 and 79. The reference gene was clathrin (heavy 
chain) only as β-actin and β-glucosidase has been shown to change with 
senescence. Moreover, following analysis of data using a 2-tailed T-test, a 
Bonferroni correction of 49 was applied in order to account for multiple 
comparison errors. The Bonferroni correction was set to 49 as the number of 
genes used for comparison was 49 and did not include the reference gene clathrin 
in the analysis. 
 At late passage, when a Bonferroni correction factor of 49 was applied 
(P<0.001), there was a significant increase in mRNA of the anti-oxidant related 
gene GCLM in the SFN treatment compared to control. Moreover, using the same 
inclusion criteria for significance, mRNA of the pentose-phosphate pathway gene 
glucose-6-phosphate dehydrogenase was significantly (P<0.001) increased in the 
treatment group compared to the control. The same effect was seen in the 
expression of the nutrient sensing thioredoxin interacting protein (TXNIP) which 
was increased by more than 2-fold. Moreover, expression of the extracellular 
matrix regulator collagen 1-alpha (COL1A1) was significantly increased 
(Bonferroni correction 49, P<0.001) in the SFN treated group compared to control 
by 0.5 fold.  
Finally the following observations can be made regarding gene expression of both 
treatment and control in senescence when compared to control at passage 3 with a 
Bonferroni correction factor of 49 and significance of P<0.001: expression of 
beta-glucoronidase (GUSB) was significantly halved at passage 11 for both 
groups compared to control at passage 3. Moreover, expression of the anti-
glycation related gene aldoketoreductase 1C1 was reduced by two thirds in both 
groups at late passage compared to control at passage 3. Expression of the anti-
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oxidant related gene GCLM was increased by 3 folds in late passage for the SFN 
treated group compared to control at early passage. Expression of the anti-oxidant 
related gene ferritin (FTH1) of both control and treatment group at late passage 
was halved compared control at passage 3. Moreover, mRNA of the lipogenesis 
related gene sterol response element binding protein (SREBF1) was decreased by 
two-thirds in both groups at late passage compared to control at passage 3. 
Expression of the proteasome subunit gene sequestosome 1 was significantly 
(Bonferroni correction 49, P<0.001) decreased at late passage by 3 folds in both 
groups compared to control at early passage.  
When Bonferroni correction of 49 (P<0.001) was applied, expression of the 
antiglycation-related gene glyoxalase 1 (GLO1) did not change with treatment or 
approach of senescence. This was also the case for the antioxidant-related gene 
gamma-glutamyl-cys ligase-catalytic subunit (GCLC), the anti-oxidant related 
gene superoxide dismutase-1 (SOD1), the phase II conjugation gene glutathione 
conjugate transporter (ABCC2) UDP glucoronosyltransferase (Mrp2/UGT1A1), 
the inflammatory and immune response genes toll-like receptor 4 (TLR4) and 
transcription factor p65 (NFKB3) as well as the matrix regulating gene 
collagenase-3/matrix metalloproteinase-13 (MMP13). 
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Table 29. Relative mRNA copy number in young (Passage 3) and senescent (Passage 11) MRC-5 fibroblasts with or without 
treatment with 1µM SFN. 
Data are presented as mean ± SD. (n=3) 
  Passage 3 Passage 11 
Gene 0.002% DMSO 1µM SFN 0.002% DMSO 1µM SFN 
ACTB 129212 ± 8628 126896 ± 10147 89335 ± 1834  97683 ± 2191  
GUSB 502 ± 10 444 ± 29  230 ± 14  ‡ 219 ± 14  ‡ 
Anti-glycation related genes 
AKR1C1 3751 ± 88 5816 ± 128  1049 ± 44 
‡
 1525 ± 30 
‡, ◊
 
GLO1 1690 ± 22 1725 ± 53 1659 ± 11 1707 ± 6  
Anti-oxidant related genes 
CAT 1199 ± 50 1188 ± 62 1420 ± 29  1725 ± 64 
GCLC 884 ± 68 857 ± 2 818 ± 57 973 ± 65  
GCLM 1579 ± 108 2033 ± 67 2610 ± 7  3490 ± 41  †, ‡, ◊ 
NQO1 4887 ± 200 6947 ± 244  3572 ± 45  5432 ± 135  
TXNRD1 14250 ± 490 17271 ± 881  12429 ± 148 15237 ± 279  
TXN 14505 ± 332 18269 ± 807  11887 ± 151 14742 ± 298  
GSR 1736 ± 46 2033 ± 20  1258 ± 47  1532 ± 14
 ◊
 
HMOX1 2104 ± 118 2435 ± 35  789 ± 44  1033 ± 24 ◊ 
SOD1 421 ± 40 457 ± 11 331 ± 13 361 ± 8  
PRDX1 24708 ± 460 27887 ± 790  26675 ± 224  29312 ± 395  
GPX1 2477 ± 165 2377 ± 136 1707 ± 65  1982 ± 30  
FTH1 288261 ± 8554 349031 ± 14995  143852 ± 1002
 ‡
 159043 ± 1797 
‡
 
 146 
 
 
Phase II conjugation genes 
GSTP1 10935 ± 635 10783 ± 938 6166 ± 150  8053 ± 132  
Mrp2/UGT1A1 83 ± 24 68 ± 11 35 ± 3 40 ± 8  
Pentosephosphate pathway genes 
TALDO1 6283 ± 129 7292 ± 309  5589 ± 94  6666 ± 28  
TKT 6369 ± 430 6384 ± 234 2288 ± 68  2836 ± 47  
G6PD 6458 ± 285 7895 ± 278 3036 ± 28  3768 ± 42 
†
 
Lipogenesis related genes 
SREBF1 1492 ± 58 1329 ± 194 390 ± 18 
‡
 335 ± 17 
‡
 
FASN 2267 ± 71 2220 ± 84 591 ± 22 
‡
 628 ± 8  
Nutrient sensing 
PFKFB2 58 ± 10 79 ± 16 25 ± 1  26 ± 3  
TXNIP 345 ± 9 356 ± 43 2864 ± 130 
‡
 7076 ± 96 
†, ◊
 
MLXIP 904 ± 114 961 ± 39 518 ± 32  534 ± 4  
MLX 1222 ± 11 1264 ± 37 1128 ± 52  1125 ± 20  
HIF1A 6084 ± 405 5702 ± 200 5913 ± 124 7236 ± 125  
HK1 2078 ± 86 2229 ± 92 1500 ± 42  1529 ± 30  
Nrf2 regulation related genes 
NFE2L2 2468 ± 85 2452 ± 81 2808 ± 5  3439 ± 76  
KEAP1 289 ± 39 297 ± 23 169 ± 21  169 ± 13  
MAFG 691 ± 97 747 ± 53 406 ± 36 386 ± 17  
 
 147 
 
 
Proteasome subunits genes (protein turnover) 
PSMA1 7060 ± 132 7055 ± 480 5783 ± 68  5622 ± 65  
PSMB5 3833 ± 83 4034 ± 59  5291 ± 11  5533 ± 69 
‡, ◊
 
SQSTM1 13389 ± 545 14990 ± 764  3881 ± 85
 ‡
 3331 ± 57 
 ‡, ◊
 
Inflammatory and immune response genes 
CCL2 904 ± 73 904 ± 92 2150 ± 32 
‡
 1710 ± 52  
TLR4 100 ± 38 81 ± 17 33 ± 3  52 ± 7  
NFKB1 241 ± 20 235 ± 27 157 ± 13  181 ± 14  
NFKB3 368 ± 23 370 ± 25 405 ± 18 402 ± 38 
ICAM1 3014 ± 260 2695 ± 53 1604 ± 9  1132 ± 43 
 ◊
 
Extracellular matrix 
COL1A1 13812 ± 1079 11901 ± 222  9964 ± 54  12635 ± 75
 †
 
Matrix regulating genes 
MMP1 1096 ± 146 1061 ± 102 986 ± 39 3806 ± 117
 †, ‡, ◊
 
MMP13 31 ± 14 27 ± 7 25 ± 2 24 ± 3 
MMP3 86 ± 18 81 ± 13 268 ± 14  339 ± 17  
SOD2 14696 ± 134 14842 ± 266 9212 ± 86 ‡ 9362 ± 148 ‡, ◊ 
ELN 57 ± 11 21 ± 8  16 ± 3  25 ± 4  
Plasminogen activator inhibitor genes 
SERPINB2 2467 ± 339 2828 ± 97 603 ± 24  769 ± 35  ◊ 
 
 
 
 148 
 
Senescence-associated genes 
CDKN1A 20515 ± 207 22929 ± 968  18695 ± 566  18543 ± 184  
GLB1 1835 ± 215 1644 ± 51 1314 ± 43  1292 ± 29  
† Significance with respect to treatment control, p<0.001, Bonferroni Correction of 49    
‡ Significance with respect to P3 control, p<0.001, Bonferroni Correction of 49       
◊ Significance with respect to P3 treated, p<0.001, Bonferroni Correction of 49 
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a.  
b.  
c.  
Figure 78. Relative mRNA copy number in young (Passage 3) and senescent 
(Passage 11) MRC-5 fibroblasts with or without treatment with 1µM SFN 
after Bonferroni correction of 49. 
Data are presented as mean ± SD. (n=3). a. aldoketoreductase 1C1. b. collagen 1-
alpha. c. glucose-6-phosphate dehydrogenase. Significance: †, significance with 
respect to treatment control, P<0.001, Bonferroni Correction of 49; ‡, significance 
with respect to passage 3 control, P<0.001, Bonferroni Correction of 49; and ◊, 
significance with respect to passage 3 treated, P<0.001, Bonferroni Correction of 
49. 
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d.  
e.  
Figure 78. Relative mRNA copy number in young (Passage 3) and senescent 
(Passage 11) MRC-5 fibroblasts with or without treatment with 1µM SFN 
after Bonferroni correction of 49 (cont’).  
Data are presented as mean ± SD. (n=3).d. gamma-glutamyl-cys-ligase 
modulatory subunit. e. fibroblast collagenase/matrix metalloproteinase-1. 
Significance: †, significance with respect to treatment control, P<0.001, 
Bonferroni Correction of 49; ‡, significance with respect to passage 3 control, 
P<0.001, Bonferroni Correction of 49; and ◊, significance with respect to passage 
3 treated, P<0.001, Bonferroni Correction of 49. 
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f.  
g.  
h.  
 
Figure 78. Relative mRNA copy number in young (Passage 3) and senescent 
(Passage 11) MRC-5 fibroblasts with or without treatment with 1µM SFN 
after Bonferroni correction of 49 (cont’).  
Data are presented as mean ± SD. (n=3).f. mitochondrial superoxide dismutase. g. 
sequestome 1. h. thioredoxin interacting protein. Significance: †, significance with 
respect to treatment control, P<0.001, Bonferroni Correction of 49; ‡, significance 
with respect to passage 3 control, P<0.001, Bonferroni Correction of 49; and ◊, 
significance with respect to passage 3 treated, P<0.001, Bonferroni Correction of 
49. 
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At late passage, when a Bonferroni correction factor of 49 was applied 
(P<0.001), there was no significant change in mRNA in the HESP treatment 
compared to control at passage 9. The following observations can be made 
regarding gene expression of both treatment and control in senescence when 
compared to control at passage 3 with a Bonferroni correction factor of 49 and 
significance of P<0.001: expression of the anti-oxidant related gene quinone 
reductase (NQO1) was decreased by two-fold at passage 11 for both groups 
compared to control at passage 3. Moreover, expression of the anti-oxidant related 
gene heme oxygenase (HMOX) was decreased by two-fold in the control group at 
passage 9 compared to control at passage 3. Expression of the anti-oxidant related 
gene ferritin (FTH1) was also decreased two-fold in late passage for the SFN 
treated group compared to control at early passage. Expression of the 
pentosephosphate pathway gene glucose-6-phosphate dehydrogenase (G6PD) of 
both control and treatment group at late passage was halved compared control at 
passage 3.  
When Bonferroni correction of 49 (P<0.001) was applied, expression of the anti-
oxidant-related gene gamma-glutamyl-cys ligase-catalytic subunit (GCLC) did 
not change with treatment or approach of senescence. Similar observations were 
made for the phase II conjugation gene Mrp2/UGT1A1, the nutrient sensing gene 
Max-Like BHLHZip Protein 2 (MLX), the inflammatory and immune response 
gene toll-like receptor 4 (TLR4) and transcription factor p65 (NFKB3), the matrix 
regulating genes collagenase-3/matrix metalloproteinase-13 (MMP13) and elastin 
(ELN). 
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Table 30. Relative mRNA copy number in young (Passage 3) and senescent (Passage 9) MRC-5 fibroblasts with or without 
treatment with 5µM HESP. 
Data are presented as mean ± SD. (n=3) 
 
  Passage 3 Passage 9 
Gene 0.005% DMSO 5µM HESP 0.005% DMSO 5µM HESP 
ACTB 73589 ± 8634 74576 ± 4894 89839 ± 7803 99619 ± 2711  
GUSB 359 ± 37 320 ± 32 185 ± 13  175 ± 5  
Anti-glycation related genes 
AKR1C1 3924 ± 71 3979 ± 64 2231 ± 280  1395 ± 180 ◊ 
GLO1 2016 ± 131 2319 ± 83  1952 ± 147 1961 ± 69 
Anti-oxidant related genes 
CAT 1283 ± 30 1236 ± 40 1904 ± 187  2047 ± 182  
GCLC 849 ± 74 767 ± 17 867 ± 53 784 ± 48 
GCLM 1747 ± 22 1616 ± 59  3721 ± 177  3094 ± 244  
NQO1 6629 ± 211 6612 ± 249 3401 ± 109 
 ‡ 2378 ± 161 
◊
 
TXNRD1 19382 ± 140 20450 ± 823 16797 ± 1005  14174 ± 220 
‡
 
TXN 22420 ± 715 21366 ± 905 17633 ± 116  16311 ± 306  
GSR 2141 ± 29 2309 ± 82  1494 ± 52  1388 ± 83  
HMOX1 3830 ± 73 3884 ± 41 1975 ± 93 ‡ 1879 ± 240  
SOD1 319 ± 11 363 ± 9  356 ± 36 354 ± 5  
PRDX1 23285 ± 348 22749 ± 444 30248 ± 1430  28249 ± 970 
GPX1 1541 ± 52 1589 ± 65 2936 ± 606 3025 ± 517  
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FTH1 426109 ± 4407 463248 ± 11526  285456 ± 10673  249220 ± 5761 
 ‡, ◊ 
Phase II conjugation genes 
GSTP1 7884 ± 160 8646 ± 355  9154 ± 1101 8518 ± 422 
Mrp2/UGT1A1 52 ± 16 56 ± 6 49 ± 8 51 ± 1 
Pentosephosphate pathway genes 
TALDO1 6560 ± 150 6916 ± 183 5878 ± 162 4824 ± 242  
TKT 6889 ± 273 7833 ± 730 2784 ± 262  2604 ± 118 
‡
 
G6PD 6382 ± 62 6197 ± 271 3387 ± 178 
‡
 2793 ± 178  
‡
 
Lipogenesis related genes 
SREBF1 1119 ± 28 1171 ± 51 388 ± 62 354 ± 29 
‡, ◊
 
FASN 1668 ± 120 1990 ± 110  698 ± 22  623 ± 71  
Nutrient sensing 
PFKFB2 76 ± 3 81 ± 11 27 ± 7  33 ± 2  
TXNIP 90 ± 8 67 ± 10  2849 ± 1769 3619 ± 1636  
MLXIP 821 ± 59 802 ± 59 684 ± 37  654 ± 51  
MLX 1136 ± 20 1131 ± 36 1157 ± 77 1191 ± 30 
HIF1A 7963 ± 415 7590 ± 376 8168 ± 334 9289 ± 439  
HK1 1918 ± 143 1887 ± 124 1501 ± 92  1461 ± 32  
Nrf2 regulation related genes 
NFE2L2 4026 ± 167 3368 ± 60 4137 ± 306 3133 ± 203  
KEAP1 220 ± 21 223 ± 35 164 ± 22  160 ± 20 
MAFG 743 ± 57 718 ± 75 354 ± 27 353 ± 30  
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Proteasome subunits genes (protein turnover) 
PSMA1 6969 ± 99 7161 ± 97 5460 ± 198  5421 ± 137  
PSMB5 5465 ± 102 5513 ± 132 6669 ± 401 6786 ± 510  
SQSTM1 17334 ± 585 19138 ± 636  5968 ± 383 
‡
 5232 ± 431 
‡, ◊
 
Inflammatory and immune response genes 
CCL2 416 ± 77 377 ± 27 2068 ± 395  1404 ± 165  
TLR4 55 ± 7 52 ± 14 56 ± 5 48 ± 9 
NFKB1 263 ± 16 292 ± 49 209 ± 8  196 ± 13  
NFKB3 415 ± 6 428 ± 26 410 ± 12 443 ± 31 
ICAM1 2505 ± 137 2854 ± 272 988 ± 59  727 ± 47 
Extracellular matrix 
COL1A1 4844 ± 764 3420 ± 463 16782 ± 652  19684 ± 3027  
Matrix regulating genes 
MMP1 489 ± 12 474 ± 10 358 ± 77  321 ± 92  
MMP13 19 ± 5 19 ± 3 25 ± 4 24 ± 8 
MMP3 19 ± 3 22 ± 1 252 ± 38 177 ± 29  
SOD2 19182 ± 458 24861 ± 642 11510 ± 327 ‡ 10368 ± 725 ◊ 
ELN 18 ± 6 15 ± 4 15 ± 3 16 ± 6 
Plasminogen activator inhibitor genes 
SERPINB2 1112 ± 105 785 ± 13  748 ± 185  327 ± 70  
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Senescence-associated genes 
CDKN1A 21791 ± 366 21157 ± 864 22774 ± 1545 22812 ± 454  
GLB1 1256 ± 51 1178 ± 14 1433 ± 52  1332 ± 28 
† Significance with respect to treatment control, p<0.001, Bonferroni Correction of 49    
‡ Significance with respect to P3 control, p<0.001, Bonferroni Correction of 49       
◊ Significance with respect to P3 treated, p<0.001, Bonferroni Correction of 49 
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a.  
 
b.  
Figure 79. Relative mRNA copy number in young (Passage 3) and senescent 
(Passage 9) MRC-5 fibroblasts with or without treatment with 5µM HESP 
after Bonferroni correction of 49. 
Data are presented as mean ± SD. (n=3).a. ferritin. b. glucose-6-phosphate 
dehydrogenase. Significance: ‡, significance with respect to passage 3 control, 
P<0.001, Bonferroni Correction of 49; and ◊, significance with respect to passage 
3 treated, P<0.001, Bonferroni Correction of 49. 
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c.  
 
d.  
Figure 79. Relative mRNA copy number in young (Passage 3) and senescent 
(Passage 9) MRC-5 fibroblasts with or without treatment with 5µM HESP 
after Bonferroni correction of 49 (cont’).  
Data are presented as mean ± SD. (n=3).c. quinone reductase. d. sequestosome 1. 
Significance: ‡, significance with respect to passage 3 control, P<0.001, 
Bonferroni Correction of 49; and ◊, significance with respect to passage 3 treated, 
P<0.001, Bonferroni Correction of 49. 
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e.  
f.  
g.  
Figure 79. Relative mRNA copy number in young (Passage 3) and senescent 
(Passage 9) MRC-5 fibroblasts with or without treatment with 5µM HESP 
after Bonferroni correction of 49 (cont’).  
Data are presented as mean ± SD. (n=3).e. sterol response element binding 
protein-1. f. transketolase. g. thioredoxin reductase-1. Significance: ‡, significance 
with respect to passage 3 control, P<0.001, Bonferroni Correction of 49; and ◊, 
significance with respect to passage 3 treated, P<0.001, Bonferroni Correction of 
49. 
 
0
200
400
600
800
1000
1200
1400
P3_CONH P3_HESP P9_CONH P9_HESP
S
R
E
B
F
1
(r
e
la
ti
v
e
 m
R
N
A
 c
o
p
y
 n
u
m
b
e
r)
‡, ◊
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
P3_CONH P3_HESP P9_CONH P9_HESP
T
K
T
(r
e
la
ti
v
e
 m
R
N
A
 c
o
p
y
 n
u
m
b
e
r)
‡
0
5000
10000
15000
20000
25000
P3_CONH P3_HESP P9_CONH P9_HESP
T
X
N
R
D
1
(r
e
la
ti
v
e
 m
R
N
A
 c
o
p
y
 n
u
m
b
e
r)
‡
 160 
 
4.3 Characterisation of gene expression in MRC-5 fibroblasts escaping 
senescence by treatment with sulforaphane using genome-wide microarray 
analysis 
 The changes in gene expression induced by 1 μM SFN treatment in young 
(passage 3) and senescent (passage 11) MRC-5 cells in vitro was investigated by 
quantifying mRNA of 20773 genes throughout the whole human genome by the 
Microarray Agilent method – quantifying total RNA copy number. The outputs 
are given in Table 31, 32 and 33  in which the most significant changes in gene 
expression are shown. Moreover, following analysis of data using a 2-tailed T-
test, a Bonferroni correction of 20773 was applied in order to account for multiple 
comparison errors and gene expression was assessed for regulation and 
downregulation using log2 differential analysis. The Bonferroni correction was set 
to 20733 as this represents the number of genes used for comparison. 
 After Bonferroni factor of 20773 was applied (P<0.05), there was no 
significant changes in gene expression between the treatment and control group at 
passage 3. Moreover, the colon-cancer secreted protein 1 (KIAA1199) was the 
only gene for which expression was significantly different in the treatment and 
control group at passage 11. Indeed, KIAA1199 was downregulated by 0.6 folds 
with SFN treatment compared to control in senescence. 
 Expression of 131 genes (Appendix E.) was significantly changed between 
controls at passage 3 and passage 11. Table  31 shows gene expression changes of 
the most significant genes. Indeed, expression of the DnaJ (Hsp40) homolog, 
subfamily C, member 6 (DNAJC6) was increased 6-fold with senescence in the 
control group compared to young fibroblasts. Moreover, expression of the C-C 
chemokine receptor type 11 (CCRL1) was increased 5-folds in the control at 
passage 11 compared to early passage control. Finally, expression of chemokine 
(C-X-C motif) ligand (CXCL2) was decreased by 3-folds and expression of 
Coiled-coil domain containing 144A (CCDC144A) was decreased by 4-fold in 
senescent controls compared to young controls. 
 Expression of 18 genes was significantly changed between SFN treated 
groups at passage 3 and passage 11. As seen in Table 32, all genes were 
significantly upregulated at passage 11 compared to passage 3 in SFN treated 
groups apart from Sad1 and UNC84 domain containing 1 (SUN1) which was 
downregulated by 0.7 folds with senescence. Expression of the C-C chemokine 
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receptor type 11 (CCRL1) and thioredoxin interacting protein (TXNIP) were 
amongst the highest upregulated genes in SFN treated senescent cells, increasing 
5 and 7 folds respectively. 
 Expression of 274 genes (Appendix F.) was significantly changed between 
SFN treated groups at passage 11 and control at passage 3. Table 33 shows gene 
expression changes of the most significant genes. Indeed, SFN treatment in 
senescence showed a 5 and 7 fold increase in expression of  the major 
histocompatibility complex, class II, DM beta (HLA-DMB) and nuclear receptor 
subfamily 5, group A, member 2 (NR5A2) respectively compared to control at 
passage 3. Moreover, there was a 5-fold decreased in the expression of the small 
nucleolar RNA, C/D box 99 (SNORD) in the late passage SFN treated group 
compared to early control. 
 
Unfortunately, when comparing the expression analysis of the 49 genes of interest 
used in the Nanostring method and the transcriptomic method, it was noticeable 
that there was considerably less significant changes in gene expression in the SFN 
treated and control groups at passage 3 and 11 – Table 34.  
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Table 31. Comparison of significant changes in gene expression in MRC-5 fibroblasts controls at passage 3 and passage 11 
using a Bonferroni correction factor of 20773. 
Gene ID Gene Name 
Significance with BF 
correction of 20773 
Expression 
C11orf70 Chromosome 11 open reading frame 70  1.326E-08 3.873 
CXCL2 Chemokine (C-X-C motif) ligand 2 1.945E-08 -3.042 
MOB4 MOB family member 4, phocein  2.398E-08 1.810 
COL4A3BP Collagen, type IV, alpha 3 (Goodpasture antigen) binding protein 2.690E-08 0.808 
ZMAT2 Zinc finger, matrin-type 2 3.835E-08 1.089 
PDE4DIP Phosphodiesterase 4D interacting protein  6.129E-08 -1.856 
SCARNA13 Small Cajal body-specific RNA 13  9.806E-08 -2.984 
HLA-E Major histocompatibility complex, class I, E 1.014E-07 1.248 
DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 1.063E-07 6.408 
ABTB2 Ankyrin repeat and BTB (POZ) domain containing 2  1.160E-07 0.989 
BANK1 B-cell scaffold protein with ankyrin repeats 1 1.211E-07 3.530 
CPPED1 Calcineurin-like phosphoesterase domain containing 1  1.405E-07 3.103 
CCDC144A Coiled-coil domain containing 144A  1.457E-07 -3.928 
COLEC11 Collectin sub-family member 11  1.556E-07 -1.782 
CCRL1 C-C chemokine receptor type 11  1.667E-07 5.636 
CCDC144A Coiled-coil domain containing 144A  1.678E-07 -4.259 
HSD11B1L Hydroxysteroid (11-beta) dehydrogenase 1-like  1.738E-07 0.754 
 
Correlation is significant at the 0.05 level (2-tailed) with Bonferroni correction factor 20773. 
Grey areas highlight gene downregulation. 
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Table 32. Comparison of significant changes in gene expression in MRC-5 fibroblasts SFN treatments at passage 3 and 
passage 11 using a Bonferroni correction factor of 20773. 
Gene ID Gene Name 
Significance with BF 
correction of 20773 
Expression 
ARSJ Arylsulfatase family, member J 1.967E-07 0.897 
FZD4 Frizzled family receptor 4 2.280E-07 2.468 
MOB4 MOB family member 4, phocein  3.559E-07 1.784 
ACTR2 ARP2 actin-related protein 2 homolog  6.857E-07 1.149 
MAEA Macrophage erythroblast attacher  7.728E-07 1.137 
VAT1 Vesicle amine transport 1 9.179E-07 1.080 
CSNK1G1 Casein kinase 1, gamma 1  1.119E-06 1.499 
ACAA2 Acetyl-CoA acyltransferase 2 1.137E-06 2.461 
GALC Galactosylceramidase 1.142E-06 1.103 
CCRL1 C-C chemokine receptor type 11  1.170E-06 5.628 
SLC46A1 Solute carrier family 46 (folate transporter), member 1  1.665E-06 1.682 
C11orf87 Chromosome 11 open reading frame 87  1.878E-06 3.764 
TXNIP Thioredoxin interacting protein  1.898E-06 6.776 
SUN1 Sad1 and UNC84 domain containing 1 2.187E-06 -0.713 
PRRX2 Paired related homeobox 2 2.234E-06 3.310 
 
Correlation is significant at the 0.05 level (2-tailed) with Bonferroni correction factor 20773. 
Grey areas highlight gene downregulation. 
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Table 33. Comparison of significant changes in gene expression in MRC-5 fibroblasts control at passage 3 and treatment at 
passage 11 using a Bonferroni correction factor of 20773. 
Gene ID Gene Name 
Significance with BF 
correction of 20773 
Expression 
FAM46C Family with sequence similarity 46, member C 4.842E-11 1.645 
FAM63A Family with sequence similarity 63, member A  3.662E-10 1.669 
DIXDC1 DIX domain containing 1 9.153E-10 2.502 
FAM134A Family with sequence similarity 134, member A  1.159E-09 1.434 
FOSB FBJ murine osteosarcoma viral oncogene homolog B  4.031E-09 -3.437 
KIAA1826 Myb/SANT-like DNA-binding domain containing 4 with coiled-coils  1.935E-08 1.233 
NR5A2 Nuclear receptor subfamily 5, group A, member 2  2.379E-08 6.621 
DUSP11 Dual specificity phosphatase 11 (RNA/RNP complex 1-interacting)  2.664E-08 2.858 
SNORD99 Small nucleolar RNA, C/D box 99  2.724E-08 -4.627 
MYO15B Myosin XVB pseudogene  2.949E-08 -1.737 
HLA-DMB Major histocompatibility complex, class II, DM beta  3.606E-08 5.228 
SNORD113-3 Small nucleolar RNA, C/D box 113-3  3.925E-08 -2.784 
MOB4 MOB family member 4, phocein  3.939E-08 1.922 
FNBP4 Formin binding protein 4  4.649E-08 -1.462 
USP39 Ubiquitin specific peptidase 39  6.608E-08 0.898 
TPD52L2 Tumor protein D52-like 2 6.789E-08 1.538 
INPP5F Inositol polyphosphate-5-phosphatase F  6.914E-08 1.869 
D4S234E D4S234E p53-responsive gene 7.372E-08 2.701 
 
Correlation is significant at the 0.05 level (2-tailed) with Bonferroni correction factor 20773. 
Grey areas highlight gene downregulation. 
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Table 34. Comparison of significance in gene expression using Microarray and Nanostring methods in MRC-5 fibroblasts 
treated with SFN at passage 3 and 11. 
 
SFN_P3 vs CONP3 SFN_P11 vs CON_P11 CONP_11 vs CON_P3 SFN_P11 vs SFN_P3 SFN_P11 vs CON_P3 
Gene 
Microarray 
Nanostri
ng 
Microarray Nanostring Microarray Nanostring 
Microarra
y 
Nanostring Microarray Nanostring 
ACTB 0.5078395 0.778258 0.953887 0.007177 0.111226 0.001436 0.562944 0.008196 0.207102 0.003579 
AKR1C1 
0.6255313 
0.000021 
†† 
0.668126 0.000103 †† 0.057895 
1.157045E-06 
††† 
0.231992 
5.914137E-07 
††† 
0.023261 
1.984714E-06 
††† 
CAT 0.5300721 0.817453 0.089673 0.001693 0.600443 0.002736 0.093422 0.000477 † 0.008105 0.000364 † 
CCL2 0.9089091 0.996076 0.240249 0.000232 † 0.000006 0.000010 ††† 0.000144 0.000185 †† 0.000090 0.000096 †† 
CDKN1A 0.2325053 0.013422 0.005559 0.680075 0.024883 0.006403 0.255465 0.013423 0.003122 0.000247 † 
COL1A1 
0.1104167 0.039808 0.361072 
9.389386E-07 
††† 
0.050912 0.003511 0.008947 0.005634 0.002654 0.132615 
FASN 
0.6129978 0.498363 0.740251 0.050875 0.464149 
2.576196E-06 
††† 
0.746034 0.000847 † 0.904901 0.000542 † 
FTH1 
0.2159656 0.003660 0.031383 0.000215 † 0.062286 
8.369158E-06 
††† 
0.417169 0.000026 †† 0.010605 0.000013 ††† 
G6PD 0.3077296 0.003352 0.021608 0.000014 ††† 0.955278 0.002125 0.507139 0.001225 0.038012 0.003171 
GCLC 
0.1193425 0.554664 0.042408 0.036472 0.000201 0.265009 0.000022 0.090946 
9.788935E-
06 * 
0.177840 
GCLM 
0.5148279 0.003468 0.922263 
3.205701E-06 
††† 
0.000360 0.000079 †† 0.000336 
5.500113E-06 
††† 
0.000589 0.000008 ††† 
GLB1 0.7161448 0.260062 0.838345 0.520151 0.000134 0.047182 0.000057 0.000478 † 0.000054 0.046080 
GLO1 0.5113778 0.346354 0.785427 0.002392 0.003302 0.095323 0.002336 0.584274 0.001712 0.261231 
GPX1 0.7613199 0.461273 0.058076 0.002631 0.001774 0.001658 0.003407 0.007914 0.002705 0.006877 
GSR 
0.0958830 
0.000517 
† 
0.107405 0.000636 †† 0.570153 0.000232 † 0.862327 
3.821775E-06 
††† 
0.031966 0.001869 
GSTP1 0.8123289 0.827294 0.047692 0.000081 †† 0.025978 0.000224 † 0.015146 0.007525 0.008579 0.001536 
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GUSB 
0.2238274 0.032612 0.919002 0.365177 0.345490 0.000010 ††† 0.780614 0.000273 † 0.174576 
8.645483E-06 
††† 
HIF1A 0.9571877 0.217084 0.074851 0.000199 †† 0.000409 0.523463 0.000047 0.000352 † 0.000000 0.009265 
HK1 0.8667444 0.105063 0.178091 0.388649 0.000748 0.000466 † 0.026090 0.000228 † 0.000458 0.000465 † 
HMOX1 
0.3112500 0.009592 0.065540 0.001097 0.271926 0.000055 †† 0.621719 
5.659236E-07 
††† 
0.122502 0.002985 
ICAM1 
0.7271304 0.105776 0.018691 0.000048 †† 0.633366 0.011062 0.162345 
2.424939E-06 
††† 
0.022605 0.005293 
KEAP1 0.5011426 0.780362 0.217247 0.997422 0.028091 0.009352 0.024264 0.001123 0.000218 0.007372 
MAFG 0.4240826 0.437122 0.724163 0.439050 0.019652 0.008836 0.031218 0.000366 † 0.000239 0.005895 
MLX 0.5626195 0.134079 0.451840 0.929443 0.001029 0.036205 0.004760 0.004680 0.003644 0.001819 
MLXIP 0.8961230 0.458417 0.055415 0.451655 0.003576 0.004809 0.589627 0.002635 0.033436 0.029867 
MMP1 
0.8135520 0.745987 0.000066 
2.465839E-06 
††† 
0.000876 0.274834 0.000042 
6.850904E-06 
††† 
0.000037 0.000015 ††† 
MMP13 0.7943929 0.703127 0.577719 0.574042 0.001158 0.516765 0.007542 0.454166 0.000778 0.447737 
MMP3 
0.5202946 0.715062 0.000986 0.005131 
4.622103E-
07 * 
0.000174 †† 0.000143 0.000029 †† 
3.782573E-
07 * 
0.000063 †† 
MRP2/UG 0.6157666 0.375265 0.094351 0.281087 0.342144 0.070467 0.329361 0.026078 0.033357 0.042658 
NFE2L2 0.8338989 0.820796 0.731077 0.000137 †† 0.001251 0.019874 0.002102 0.000103 0.000978 0.000122 †† 
NFKB1 0.8880151 0.771298 0.053116 0.088329 0.017648 0.003498 0.679392 0.036254 0.733255 0.013064 
NFKB3 0.7006818 0.930094 0.370583 0.901248 0.149410 0.093041 0.175023 0.295010 0.021861 0.261105 
NQO1 
0.0155181 
0.000348 
† 
0.000751 0.000022 †† 0.000479 0.000372 † 0.003905 0.000711 † 
8.185903E-
06 * 
0.017338 
PFKFB2 0.8571489 0.115368 0.087489 0.492137 0.190958 0.025668 0.882081 0.004713 0.894420 0.005316 
PRDX1 0.4349963 0.003832 0.127454 0.000546 † 0.000382 0.002641 0.000595 0.049059 0.000475 0.000192 †† 
PSMA1 0.4542982 0.986704 0.081367 0.041389 0.000039 0.000119 †† 0.000262 0.033438 0.000118 0.000071 †† 
PSMB5 
0.4442480 0.027065 0.099738 0.023982 0.000562 0.000916 † 0.003041 
8.999051E-06 
††† 
0.000070 0.000010 ††† 
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SERPINB2 
0.6386232 0.150557 0.141027 0.002470 0.000338 0.000682 0.057659 
4.142766E-06 
††† 
0.002315 0.000988 † 
SOD1 0.4955507 0.198408 0.158794 0.025677 0.913658 0.020292 0.193479 0.000272† 0.037302 0.063683 
SOD2 
0.4807792 0.442777 0.277868 0.204452 0.298633 
4.725874E-07 
††† 
0.693610 
6.275164E-06 
††† 
0.960254 
1.304272E-06 
††† 
SQSTM1 
0.5147259 0.041815 0.749566 0.000739 † 0.027662 
7.497274E-06 
††† 
0.168243 0.000012 ††† 0.042220 
5.840064E-06 
††† 
SREBF1 
0.4279976 0.233453 0.350304 0.018941 0.028862 
6.127240E-06 
††† 
0.008250 0.000898 † 0.008739 
4.916657E-06 
††† 
TALDO1 0.1087712 0.006461 0.032028 0.000044 †† 0.000059 0.001638 0.001412 0.071569 0.000051 0.007301 
TKT 0.4788010 0.959092 0.071636 0.000329 † 0.035752 0.000084 †† 0.570977 0.000993 † 0.195466 0.000145 †† 
TLR4 0.3957951 0.478228 0.002563 0.010787 0.000013 0.037159 0.000063 0.051904 0.000003 0.098409 
TXN 0.3600658 0.001715 0.013078 0.000121 †† 0.857321 0.000239 † 0.050023 0.002079 0.012978 0.409588 
TXNIP 
0.2788078 0.683395 0.003598 
1.441395E-06 
††† 
0.000011 
4.745044E-06 
††† 
1.898324
E-06 * 
4.038172E-08 
††† 
6.785231E-
07 * 
0.000059 †† 
TXNRD1 0.1411390 0.006573 0.137183 0.000104 †† 0.028510 0.003527 0.066967 0.018957 0.000115 0.038777 
* P<0.05 for transcriptomic analysis with Bonferroni correction factor of 20773 
† P<0.05 for nanostring analysis with Bonferroni correction factor of 49 
†† P<0.01 for nanostring analysis with Bonferroni correction factor of 49 
††† P<0.001 for nanostring analysis with Bonferroni correction factor of 49 
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4.4 Expression of fructose-2,6-bisphosphate 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 2 protein PFKFB2 
Human fructose-2,6-bisphosphate 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2 expression in MRC-5 fibroblasts was assessed at the protein level 
by Western blotting of cell extracts at passage 5 (young) and passage 9 
(senescence) treated with either 1 µM SFN or 0.002% DMSO - Figure 80 and 81.  
 
 
Figure 80. Western blotting of young and senescent MRC-5 fibroblasts for 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2. 
Key: PFKFB2, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2 protein; 
and ACTB - β-actin housekeeping protein. SFN-P5 and CTRL-P5, cell extracts 
from passage 5 treated with and without 1 μM SFN; and SFN-P9 and CTRL-P9, 
cell extracts from passage 9 treated with and without 1 μM SFN. 
 
 
Figure 81. Quantitation of Western blotting of young and senescent MRC-5 
fibroblasts for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2. 
Key:          , control; and          + 1 μM SFN. Data are mean ± SD ( n = 3). 
Significance: *, P<0.05, SFN treated cells with respect to control; o, P<0.05, 
passage 9 SFN with respect passage 5 SFN. 
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Expression of PFKFB2 protein by western blotting analysis shows that control 
MRC-5 fibroblasts have a significantly higher expression of PFKFB2 protein 
compared to the SFN-treated group at later passage (passage 9).  
 
4.5 Change in gene expression of MRC-5 fibroblasts in vitro during the 
approach to senescence 
The time course of changes in gene expression of MRC-5 fibroblasts in vitro was 
investigated by quantifying mRNA of genes of selected metabolic pathways with 
Nrf2 regulated, ARE-linked genes by the RT-PCR method – quantifying relative 
mRNA expression. The outputs are given in Figures 82-86. The reference gene 
was β-actin with responses normalized to the relative expression of this gene. 
 Expression of the anti glycation related gene aldoketo reductase 1B1 
(AKR1B1) was significantly decreased (P<0.001) by a third of its value in 
senescence (passage 11) compared to young fibroblasts (passage 3). Expression of 
AKR1B1 was stable from passage 3 but decreased dramatically after passage 5. 
Moreover, the expression of the anti-glycation related gene glyoxalase 1 (GLO1) 
was also decreased significantly (P<0.01) with approach to senescence. 
Expression of GLO1 was stable at passage 3, 5 and 6 but declined rapidly 
thereafter. At the approach of senescence, the expression of the anti-oxidant 
related genes thioredoxin (TXN) as well as quinone reductase (NQO1) and heme 
oxygenase (HMOX1) was significantly decreased (P<0.001 and P<0.05, 
respectively) when compared to passage 3. Decline in expression of TXN was 
steady from passage 3 to 9 but increased slightly at the approach to senescence. 
Moreover, NQO1 and HMOX1 gene expression decline with approach to 
senescence was relatively consistent at each passage. Expression of the anti-
oxidant related gene gamma-glutamyl-cys ligase-catalytic subunit (GCLC), 
gamma-glutamyl-cys ligase-modulatory subunit (GCLM) and glutathione 
reductase (GSR) however did not significantly decline with approach to 
senescence. Expression of both pentosephosphate pathway genes transaldolase 
(TALDO1) and transketolase (TKT) was significantly (P<0.05) decreased from 
passage 3 to passage 11, showing almost linear decline with passage. Moreover, 
expression of the NADPH-dependent oxidoreductase carbonyl reductase 1 
(CBR1) was also significantly decreased (P<0.05) with approach to senescence. 
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This decline was drastic from passage 3 to 9 but was steady thereafter until 
senescence at passage 11. Finally the expression of the Nrf2 regulation related 
genes Nrf2 was not significantly decreased at passage 11, although 30% decrease 
in Keap 1 expression at the approach to senescence was very significant 
(P<0.001). 
 
 
 
a.   b.  
Figure 82. Gene expression of MRC-5 fibroblasts at the approach to 
senescence. RT-PCR study. Anti-glycation related genes. 
a. aldoketo reductase 1B1 (AKR1B1). b. glyoxalase 1 (GLO1). Data are mean ± 
SD, n = 3. 
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a.   b.  
c.  d.
e.  f.  
 
Figure 83. Gene expression of MRC-5 fibroblasts at the approach to 
senescence. RT-PCR study. Anti-oxidant related genes. 
a. gamma-glutamyl-cys ligase-catalytic subunit (GCLC). b. gamma-glutamyl-cys 
ligase-modulatory subunit (GCLM). c. quinone reductase (NQO1). d. thioredoxin 
(TXN). e. glutathione reductase (GSR). f. heme oxygenase (HMOX1). Data are 
mean ± SD, n = 3. 
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a.  b.  
 
Figure 84. Gene expression of MRC-5 fibroblasts at the approach to 
senescence. RT-PCR study. Pentosephosphate pathway genes. 
a. transaldolase (TALDO1). b. transketolase (TKT). Data are mean ± SD, n = 3. 
 
 
 
a.  b.  
Figure 85. Gene expression of MRC-5 fibroblasts at the approach to 
senescence. RT-PCR study. Nrf2 regulation related genes. 
a. Nrf2. b. Keap1. Data are mean ± SD, n = 3. 
 
 
 
Figure 86. Gene expression of MRC-5 fibroblasts at the approach to 
senescence. RT-PCR study. NADPH-dependent oxidoreductase genes 
carbonyl reductase 1 (CBR1). 
Data are mean ± SD, n = 3. 
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Analysis of gene expression in MRC-5 cells from passage 3 to 11 showed that, for genes NQO1, NRF2,  TKT, GLO1, AKR1B1, 
KEAP1, CBR-1, TALDO, GSR, HMOX1 and TXN, expression was maintained until passages 5 – 6 and then decline to lower levels 
at passages 10 – 11. Genes GCLC and GCLM did not change significantly with increased passage. Correlation analysis of gene 
expression was also performed – Table 35. Changes in expression of many ARE-linked genes, including Nrf2 and Keap1, were 
highly correlated. 
 
Table 35 Correlation analysis of gene expression in ageing MRC-5 fibroblasts. 
NQO1 0.622
**            
TKT 0.476
* 0.893**           
GLO1 0.595
** 0.785** 0.884**          
AKR1B1 0.548
* 0.884** 0.847** 0.779**         
KEAP1 0.721
** 0.843** 0.769** 0.756** 0.856**        
GCLC 0.544
* 0.810** 0.808** 0.715** 0.692** 0.626**       
CBR1 0.723
** 0.882** 0.851** 0.785** 0.851** 0.839** 0.806**      
TALDO1 0.602
** 0.928** 0.889** 0.767** 0.895** 0.886** 0.773** 0.856**     
GSR  0.802
** 0.868** 0.649** 0.763** 0.620** 0.643** 0.707** 0.794**    
HMOX1 0.691
** 0.794** 0.745** 0.716** 0.716** 0.777** 0.647** 0.797** 0.748** 0.559*   
AKR1B2 0.626
** 0.845** 0.767** 0.775** 0.897** 0.800** 0.773** 0.792** 0.796** 0.612** 0.809**  
TXN 0.662
** 0.787** 0.765** 0.728** 0.781** 0.711** 0.765** 0.818** 0.773** 0.525* 0.804** 0.858** 
 NFE2L2 NQO1 TKT GLO1 AKR1B1 KEAP1 GCLC CBR1 TALDO1 GSR HMOX1 AKR1B2 
*Spearman correlation is significant at the 0.05 level (2-tailed).   
** Spearman correlation is significant at the 0.01 level (2-tailed).  
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4.6 Effect of progression towards senescence and sulforaphane on protein 
glycation, oxidation and nitration markers in MRC-5 fibroblasts in vitro. 
Increased damage to the proteome by glycation, oxidation and nitration 
has been implicated in fibroblast senescence. In this study a comprehensive range 
of protein damage markers were quantified. Protein damage adduct residues of 
cell cytosolic protein and flux of free adducts in culture medium were quantified 
in MRC-5 fibroblasts at passage 4 and 8 after incubation from passage 3 with and 
without 1 µM SFN – Table 36 and 37. 
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Table 36. Protein damage adduct residues of cell cytosolic protein in MRC-5 fibroblasts treated with or without 1µM SFN at 
passage 4 and 8. 
   Passage 4 Passage 8 
Damage marker type Analyte Control + SFN Control + SFN 
Early glycation FL  (mmol/mol lys) 5.29 ± 1.61 4.10 ± 0.49 5.56 ± 0.89 2.83 ± 0.44 *** 
AGE CML  (mmol/mol lys) 0.264 ± 0.085 0.160 ± 0.020 0.243 ± 0.028 0.221 ± 0.051 
 CML/FL ratio 0.054 ± 0.029 0.039 ± 0.005 0.044 ± 0.002 0.079 ± 0.021 * 
 3DG-H (mmol/mol arg) 0.249 ± 0.028 0.313 ± 0.003** 0.329 ± 0.043 0.377 ± 0.051 
 MG-H1  (mmol/mol arg) 0.43 ± 0.10 0.25 ± 0.01 * 0.35 ± 0.02 0.35 ± 0.05 
 CMA (mmol/mol arg) 0.093 ± 0.018 0.054 ± 0.012 * 0.088 ± 0.013 0.074 ± 0.003 
 Glucosepane (mmol/mol lys) 0.122 ± 0.037 0.055 ± 0.004 * 0.079 ± 0.016 0.071 ± 0.025 
Oxidation DT  (mmol/mol tyr) 1.23 ± 0.26 1.71 ± 0.70 0.89 ± 0.26 0.77 ± 0.12 ○ 
 GSA (mmol/mol arg) 0.219 ± 0.050 0.112 ± 0.010 * 0.226 ± 0.092 0.214 ± 0.021 ○○ 
Nitration 3-NT  (mmol/mol tyr) 0.023 ± 0.005 0.017 ± 0.001 0.014 ± 0.001 0.019 ± 0.002 * 
Significance: *, P<0.05, **, P<0.01 and ***, P<0.001 with respect to DMSO control; o, P<0.05 and  ○○, P<0.01 with respect to treatment control 
at passage 4. 
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Table 37. Protein damage adduct residues and flux of free adducts in culture medium in MRC-5 fibroblasts treated with or 
without 1µM SFN at passage 4 and 8. 
 
 
 
                            Passage 4                            Passage 8 
Damage  
marker type 
Analyte flux 
  
  Control             + SFN          Control          + SFN 
Early glycation FL (nmol/day/106 cells) 
      
2.32 ± 0.89 1.16 ± 0.27 
AGE MG-H1 (nmol/day/106 cells) 0.0278 ± 0.0044 0.0194 ± 0.0058 0.0838 ± 0.0086 °°° 0.0833 ± 0.0061 °°° 
 CML (nmol/day/106 cells) 
      
0.0745 ± 0.0268 0.0311 ± 0.0076 
 3DG-H (nmol/day/106 cells) 0.0155 ± 0.0039 0.00518 ± 0.00300 * 0.119 ± 0.023 °°° 0.0763 ± 0.0085 *, °°° 
 CMA (nmol/day/106 cells)  0.0189 ± 0.0012 0.0112 ± 0.0024 *** 0.0611 ± 0.0060 °°° 0.0492 ± 0.0035 **, °°° 
 Glucosepane (pmol/day/106 cells) 1.42 ± 1.33 0.516 ± 0.056       
Oxidation DT (nmol/day/106 cells) 0.081 ± 0.115 0.208 ± 0.059 1.631 ± 0.866 ° 1.179 ± 0.293 °° 
 GSA (nmol/day/106 cells) 0.014 ± 0.015 0.009 ± 0.013 0.259 ± 0.076 ⁰⁰ 0.041 ± 0.017 ** 
Nitration 3-NT (pmol/day/106 cells) 0.341 ± 0.037 0.362 ± 0.085        
 
*P<0.05, **P<0.01 and ***P<0.001 with respect to treatment control. ⁰P<0.05, ⁰⁰P<0.01, ⁰⁰⁰P<0.001 with respect to baseline. 
(2-tailed t-test) 
 
Areas marked in grey indicate that flux was below limit of detection for this passage.
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4.6.1 Protein glycation 
Protein glycation adducts studied were the early glycation adduct FL 
and advanced glycation adducts (AGEs) – hydroimidazolones MG-H1 and 
3DG-H, mono-lysine and arginine adducts CML and CMA, and 
glucosepane. They were determined in cell protein and baseline and end of 
passage culture medium of MRC-5 cell cultures at passage 4 and passage 8 
that had been incubated with and without 1 µM SFN since passage 3 (when 
cPDL was 35.8) – Figure 87 to 92. There was no significant change of any 
protein damage marker at passage 8 compared to passage 4 in control 
cultures. For protein carbonyls, GSA was detected but AASA was below the 
limit of detection – indicating that GSA is the major protein carbonyl in 
MRC-5 cell protein. At passage 4, treatment with SFN decreased residue 
contents of MG-H1, CMA, glucosepane and GSA but increased residue 
content of 3DG-H. At passage 8, treatment with SFN decreased residue 
contents of FL but increased residue content of 3-NT and CML/FL residue 
content ratio. Treatment with SFN also decreased DT residue content but 
increased GSA residue content in passage 8 compared to passage 4. 
Flux of the following analytes was not calculated as they were below 
the limit of detection for the given passages: FL (passage 4), CML (passage 
4), glucosepane (passage 8) and 3-NT (passage 8). There was a significant 
(P<0.001) increase in the flux of the AGEs MG-H1, 3DG-H and at passage 
8 compared to passage 4 in control cultures. This was also true for the flux 
of the oxidative damage markers DT and GSA (P<0.05 and P<0.01 
respectively). At passage 4, treatment with SFN significantly decreased the 
flux of 3DG-H and CMA (P<0.05 and P<0.01 respectively). At passage 8, 
treatment with SFN decreased the flux of AGEs 3DG-H and CMA (P<0.05 
and P<0.01 respectively) as well as the flux of the oxidative damage marker 
GSA (P<0.01). 
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Figure 87. FL residue content of MRC-5 cell protein and flux of formation of 
FL free adducts. 
a. FL residue content of cell protein at passage termination. b. Flux of formation 
of FL free adduct at passage 8.  Key:             ,– control cultures;            , cultures 
with 1 μM SFN. Data are mean ± SD (n = 3). Significance: **, P<0.01 with 
respect to DMSO control at respective passages (2-tailed t-test). 
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Figure 88. MG-H1 residue content of MRC-5 cell protein and flux of 
formation of MG-H1 free adducts. 
a. MG-H1 residue content of cell protein at passage termination. b. Flux of 
formation of MG-H1 free adduct.  Key:             ,– control cultures;            , 
cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: *, P<0.05 
with respect to DMSO control at respective passages; ooo,  P<0.001 with respect 
to control cultures within same passage (2-tailed t-test). 
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Figure 89. 3DG-H1 residue content of MRC-5 cell protein and flux of 
formation of 3-DG-H free adducts. 
a. 3DG-H1 residue content of cell protein at passage termination. b. Flux of 
formation of 3DG-H1 free adduct. Key:             ,– control cultures;            , 
cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: * and **, 
P<0.05 and P<0.01 with respect to DMSO control at respective passages; ooo, 
P<0.001 with respect to control cultures within same passage (2-tailed t-test). 
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Figure 90. CMA residue content of MRC-5 cell protein and flux of formation 
of CMA free adducts. 
a. CMA residue content of cell protein at passage termination. b. Flux of 
formation of CMA free adduct. Key:             ,– control cultures;            , cultures 
with 1 μM SFN. Data are mean ± SD (n = 3). Significance: *, **, ***, P<0.05, 
P<0.01 and P<0.001 with respect to DMSO control at respective passages; ooo, 
P<0.001 with respect to control cultures within same passage (2-tailed t-test). 
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Figure 91. GSA residue content of MRC-5 cell protein and flux of formation 
of GSA free adducts. 
a. GSA residue content of cell protein at passage termination. b. Flux of formation 
of GSA free adduct. Key:             ,– control cultures;            , cultures with 1 μM 
SFN. Data are mean ± SD (n = 3). Significance: * and **, P<0.05 and P<0.01 
with respect to DMSO control at respective passages; oo, P<0.01 with respect to 
control cultures within same passage (2-tailed t-test). 
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Figure 92. 3-NT residue content of MRC-5 cell protein and flux of formation 
of 3-NT free adducts. 
a. 3-NT residue content of cell protein at passage termination. b. Flux of 
formation of 3-NT free adduct. Key:             ,– control cultures;            , cultures 
with 1 μM SFN. Data are mean ± SD (n = 3). Significance: *, P<0.05 with respect 
to DMSO control at respective passages (2-tailed t-test). 
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4.7 Effect of progression towards senescence and sulforaphane on nucleotide 
glycation and oxidation in MRC-5 fibroblast cultures. 
The concentration of the nucleotide damage markers MGdG, GdG 
and 8-OxodG in baseline and end of passage conditioned medium at 
passages 5 and 8 were determined in cultures of MRC-5 cells that had been 
incubated with and without 1 µM SFN since passage 3 (when cPDL was 
35.8). 
 For 8-oxodG, typical analytical chromatograms for determination of 
8-OxodG in 20 μl culture medium are given in Figure 93 a. and b. The 
concentration of 8-oxodG in baseline medium at passage 5 was 8.93 ± 0.63 
nM and was not changed significantly at the end of the passage in MRC-5 
cells incubated with or without 1 μM SFN (9.13 ± 1.71 nM and 8.22 ± 1.62 
nM respectively; P>0.05).  From the data dispersion in estimates of 8-
OxodG concentration, the minimum detectable flux of formation of 8-
OxodG was 2.3 pmol/million cells/day and hence the actual flux of 
formation of 8-OxodG is less than this. 
 
At passage 8, however, the concentration of 8-oxodG in baseline 
medium was 6.16 ± 0.43 nM and was increased at the end of the passage in 
MRC-5 cells incubated with and without 1 μM SFN (7.91 ± 0.52 nM and 
10.06 ± 1.43 nM, respectively, P<0.05) – Figure 94. The increase in 8-
oxodG during the passage was normalized to cell number the mean rates of 
8-oxodG formation computed.  Incubation with SFN decreased the flux of 
formation of 8-OxodG: control 3.56 ± 0.44 versus + SFN 2.42 ± 0.30 
pmol/day/million cells, P<0.05.  
For nucleotide AGEs, GdG, MGdG and CEdG, these analytes were 
not detectable in fresh or end of passage conditioned medium. The 
concentrations of these analytes were <0.04 nM, < 0.13 nM  and <0.11 nM 
respectively. 
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Figure 93. Detection and quantitation of 8-oxodG in culture medium of 
MRC-5 cell in culture. 
a. Detection of 8-OxodG in culture medium. Sample: end of passage 8 with 
addition of 1 μM SFN. Injection volume: 20 μl. b. Internal standard (8.24 
pmol) [13C10,
15N5]8-OxodG. c. Calibration curve. Regression equation: Peak 
area ratio = (0.121 ±0.003) 8-OxodG (pmol) + (0.0024 ± 0.017); R = 0.998 
(n = 7). 
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Figure 94. Concentration of 8-oxodG in medium of cultures of MRC-5 cells 
and 8-oxodG efflux from cells. 
a. Concentration of 8-oxoG in culture medium. b. 8-oxodG efflux into the 
medium from cells at passage termination.  Key:             , medium at baseline;            
, medium at passage termination – control cultures;            , medium at passage 
termination – cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: 
*,  P<0.05 with respect to baseline at respective passages; oo and ooo, P<0.01 and 
P<0.001 with respect to control cultures (2-tailed t-test).  
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4.8 Effect of progression towards senescence and sulforaphane on formation 
of Nε(γ-glutamyl)lysine (GEEK) in MRC-5 fibroblast cultures. 
Increased expression of transglutaminase is implicated in fibroblast 
senescence (Kim et al., 2001; Dellorco et al., 1985) with expected increased 
formation of increased Nε(γ-glutamyl)lysine (GEEK). The cell protein content of 
GEEK residues and the flux of formation of GEEK released into the culture media 
in MRC-5 cell cultures at passages 4 and 8 were determined. 
 Typical analytical chromatograms for determination of GEEK in 20 μl 
cellular protein are given in Figure 95 (a. and b).  The GEEK residue content of 
cell protein at passage 4 in the control culture and culture treated with 1 µM SFN 
was 1.11 ± 0.61 mmol/mol lys and 0.91 ± 0.48 mmol/mol lys, respectively, which 
were not significantly different. At passage 8, however, the GEEK residue content 
of cell protein in the control cultures was increased by 3-fold compared to passage 
4. The GEEK residue content of cell protein of the SFN treatment group was also 
increased with respect to passage 4 but was decreased ca. 45% with respect to 
control – Figure 97. GEEK free adduct release into culture medium was ca. 0.2 
nmol/day/106 cells in control and SFN treated cultures at passage 4. By passage 8 
this had increased to ca. 0.8 nmol/day/106 cells in control and SFN treated 
cultures with no significant effect on SFN treated cultures – Figure 96. 
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a.
b.  
Figure 95. Detection and quantitation of Nε(γ-glutamyl)lysine (GEEK) in 
cellular protein of MRC-5 cell in culture. 
a. Detection of GEEK in cellular protein. Sample: passage 8 with addition 
of 1 μM SFN. Injection volume: 20 μl. b. Internal standard (32.8 pmol) 
[13C5]GEEK. 
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b.  
Figure 96. Concentration of Nε(γ-glutamyl)lysine (GEEK) in medium of 
cultures of MRC-5 cells and GEEK efflux from cells. 
a. Concentration of GEEK in culture medium. b. GEEK efflux into the medium 
from cells at passage termination. Key:             , medium at baseline;            , 
medium at passage termination – control cultures;            , medium at passage 
termination – cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: 
** and ***, P<0.01 and P<0.001 with respect to baseline at respective passages; 
ooo, P<0.001 with respect to control cultures (2-tailed t-test).  
 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
4 8
G
EE
K
 e
ff
lu
x 
(n
m
o
l/
d
ay
/1
0
6
ce
lls
)
Passage no
°°°
°°°
 190 
 
 
Figure 97. Cellular protein concentration of Nε(γ-glutamyl)lysine (GEEK) in 
MRC-5 cells at passage 4 and 8 with and without 1µM SFN. 
Key:             , 0.002% DMSO;            , 1 μM SFN. Data are mean ± SD (n = 3). 
Significance: *, P<0.05 to control cultures; o, P<0.05 with respect to related 
control culture at passage 4 (2-tailed t-test).  
 
 
 
4.9 Effect of sulforaphane on dicarbonyl precursors of protein and nucleotide 
glycation in cultures of MRC-5 fibroblasts in vitro 
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(P<0.05). The concentration of glyoxal in medium of MRC-5 cells in control 
cultures was decreased at passage 8 with respect to passage 5; 71 ± 20 nM versus 
150  ± 47 nM, P<0.05 – Figure 98,  a. Glyoxal partitions across the cell plasma 
membrane where amount of glyoxal in the medium will relate to cell number. 
Therefore, the efflux of glyoxal from cells at passage termination (pmol per 106 
cells) was deduced. The efflux of glyoxal was increased in control cultures at 
passage 11 with respect to passage 5 but not in similar cultures treated with SFN. 
Combining measurement for passages 8 and 11 as “late passages”, the efflux of 
glyoxal was increased in control cultures in late passages with respect to passage 
5 (4919 ± 1697 versus 1041 ± 413 pmol/106 cells, P<0.01) but not in similar 
cultures treated with SFN – Figure 98,  b. 
For MG, the concentration of MG was decreased at the end of passage 
with respect to baseline level at passage 5 (-32%, P<0.05) and increased at the end 
of passage 11 with respect to baseline (+52%, P<0.05) for MRC-5 cells incubated 
with SFN but was unchanged in MRC-5 cells in control cultures.  The 
concentration of MG in medium of MRC-5 cells in cultures with SFN was 
increased at passage 8 with respect to passage 5, P<0.05, but was unchanged in 
control cultures – Figure 99,  a. MG partitions across the cell plasma membrane 
where amount of glyoxal in the medium will relate to cell number. Therefore, the 
efflux of MG from cells at passage termination (pmol per 106 cells) was deduced. 
The efflux of MG was increased in control cultures at passage 11 with respect to 
passage 5 and increased at passage 8 with respect to passage 5 in cultures with 
SFN. Combining measurement for passages 8 and 11 as “late passages”, the efflux 
of MG was increased in control cultures in late passages with respect to passage 5 
(10297 ± 3614 versus 640 ± 230 pmol/106 cells, P<0.01) and also in cultures 
treated with SFN (8163 ± 4964 versus 566 ± 79 pmol/106 cells, P<0.01) – Figure 
99,  b. 
For 3-DG, the concentration of 3-DG was increased at the end of passage 
with respect to baseline level at passage 5 (+48%, P<0.01), at passage 8 (+215%, 
P<0.001) and at passage 11 (+36%, P<0.05) for control cultures of MRC-5 cells 
and increased at passage 8 (+198%, P<0.001) for MRC-5 cells incubated with 
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SFN. The concentration of 3-DG in cultures at the end of the passage was not 
changed significantly by addiction of SFN for passages 5, 8 and 11. The 
concentration of 3DG in baseline medium at passage 5 was higher than at passage 
8 (268 ± 33 nM versus 163 ± 37 nM, P<0.05) and lower than at passage 11 (268 ± 
33 nM versus 383 ± 20 nM, P<0.01) – Figure 100,  a. 3-DG partitions across the 
cell plasma membrane where amount of glyoxal in the medium will relate to cell 
number. Therefore, the efflux of 3-DG from cells at passage termination (pmol 
per 106 cells) was deduced. The efflux of 3-DG was increased in control cultures 
at passages 8 and 11 with respect to passage 5 and also increased at passage 1l 
with respect to passage 8. The efflux of 3-DG was increased at passages 8 with 
respect to passage 5 in cultures with SFN. Combining measurement for passages 8 
and 11 as “late passages”, the efflux of 3-DG was increased in control cultures in 
late passages with respect to passage 5 (22481 ± 10871 versus 2752 ± 907 
pmol/106 cells, P<0.01) but not in cultures treated with SFN  – Figure 100,  b. 
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Figure 98. Concentration of glyoxal in medium of cultures of MRC-5 cells 
and glyoxal efflux from cells. 
a. Concentration of glyoxal in culture medium. b. Glyoxal efflux into the medium 
from cells at passage termination. Key:             , medium at baseline;            , 
medium at passage termination – control cultures;            , medium at passage 
termination – cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: 
* and **, P<0.05 and P<0.01 with respect to baseline control cultures; o and oo, 
P<0.05 and P<0.01 with respect to related control culture at passage 5 (t-test and 
paired t-test, as appropriate).  
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Figure 99. Concentration of methylglyoxal in medium of cultures of MRC-5 
cells and methylglyoxal efflux from cells.  
a. Concentration of MG in culture medium. b. MG efflux into the medium from 
cells at passage termination. Key:             , medium at baseline;            , medium at 
passage termination – control cultures;            , medium at passage termination – 
cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: *, P<0.05 
with respect to baseline control cultures; o P<0.05 with respect to related control 
culture at passage 5 (t-test and paired t-test, as appropriate).  
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Figure 100. Concentration of 3-deoxyglucosone in medium of cultures of 
MRC-5 cells and 3-deoxyglucosone efflux from cells. 
a. Concentration of 3-DG in culture medium. b. 3-DG efflux into the medium 
from cells at passage termination. Key:             , medium at baseline;            , 
medium at passage termination – control cultures;           ,  medium at passage 
termination – cultures with 1 μM SFN. Data are mean ± SD (n = 3). Significance: 
*, ** and ***, P<0.05, P<0.01 and P<0.001 with respect to baseline control 
cultures; o, oo and ooo, P<0.05, P<0.01 and P<0.001 with respect to related 
control culture at passage 5; and +, P<0.05 with respect to related control culture 
at passage 8 (t-test and paired t-test, as appropriate).  
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4.10 Effect of treatments at the approach to senescence on the consumption 
of glucose by MRC-5 and BJ fibroblasts in vitro 
4.10.1 Effect of the approach to senescence and treatment with sulforaphane 
on the consumption of glucose by MRC-5 fibroblasts in vitro 
The concentration of glucose in in cultures of MRC-5 fibroblasts at the 
beginning and end of passages 4, 8 and 12 was determined and the flux of glucose 
metabolized deduced.  
The consumption of glucose increased progressively from 2.59 ± 0.40 μmol per 
day per 106 cells at passage 4 to a maximum of 30.74 ± 2.20 μmol per day per 106 
cells at passage 12. Incubation with 1 μM SFN from passage 3 decreased glucose 
consumption which was statistically significant at passages 10, 11 and 12 with 
glucose consumption decreased by 34%, 60% and 53% respectively (P<0.01) – 
Figure 101. 
 
 
 
 
 
 
 
 
Figure 101. Effect of approach to senescence and sulforaphane on the 
consumption of D-glucose by MRC-5 fibroblasts in vitro. 
Data are mean ± SD (n = 3). Key:           , control;           , + 1 μM SFN. 
Significance: **, P<0.01 with respect to control cultures; o, oo and ooo, P<0.05, 
P<0.01 and P<0.001 with respect to related culture at passage 4 (t-test and paired 
t-test, as appropriate).  
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4.10.2 Effect of the approach to senescence and treatment with sulforaphane 
on the consumption of glucose by BJ fibroblasts in vitro 
Culture media samples were available from a similar study of the approach 
of human BJ fibroblasts to senescence and delay by treatment with 1 μM SFN. 
The consumption of glucose increased progressively from 3.48 ± 0.09 μmol per 
day per 106 cells at passage 6 to a maximum of 14.80 ± 1.50 μmol per day per 106 
cells at passage 19. Incubation with 1 μM SFN from passage 3 decreased glucose 
consumption by 30% at passage 19 (P<0.001), although at earlier passage 
treatment with SFN had increased consumption of glucose – Figure 102. 
 
 
Figure 102. Effect of approach to senescence and sulforaphane on the 
consumption of D-glucose by BJ fibroblasts in vitro. 
Data are mean ± SD (n = 3). Key:           , control;           , + 1 μM SFN. 
Significance: ** and ***, P<0.01 and P<0.001 with respect to control cultures; o 
and oo, P<0.05 and P<0.01 with respect to related culture at passage 6 (t-test and 
paired t-test, as appropriate).  
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4.10.3 Effect of the approach to senescence and treatment with hesperetin on 
the consumption of glucose by MRC-5 fibroblasts in vitro 
The consumption of glucose increased progressively from 4.11 ± 0.24 
μmol per day per 106 cells at passage 7 to a maximum of 38.41 ± 4.72 μmol per 
day per 106 cells at passage 9. Incubation with 5 μM hesperetin from passage 3 
decreased glucose consumption which was statistically significant at passages 7 
and 12 with glucose consumption decreased by 29% and 33% respectively 
(P<0.05) – Figure 103. 
 
 
Figure 103. Effect of approach to senescence and hesperetin on the 
consumption of D-glucose by MRC-5 fibroblasts in vitro. 
Data are mean ± SD (n = 3). Key:           , control;           , + 5 μM Hesperetin. 
Significance: *, P<0.05 with respect to control cultures; o and oo, P<0.05 and 
P<0.01 with respect to related culture at passage 7 (t-test and paired t-test, as 
appropriate).  
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4.11 Effect of approach to senescence and sulforaphane on reduced 
glutathione concentration in MRC-5 fibroblasts cell pellets 
MRC-5 fibroblasts were cultured in media supplemented with and 
without 1 µM SFN from passage 3. Cell pellets were collected at the end of 
passages 4 and 10 and the cell content of GSH was determined by stable isotopic 
dilution analysis LC-MS/MS. The cellular content of GSH increased ca. 3-fold in 
control cultures in passage 10 with respect to passage 4. Treatment with SFN did 
not change the cellular content of GSH at passage 4 but increased cellular content 
of GSH by 34% at passage 10 – Figure 104.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 104. Effect of approach to senescence and sulforaphane on the 
reduced glutathione content of MRC-5 fibroblasts in vitro. 
Data are mean ± SD (n = 3). Key:           , control;           , + 1 μM SFN. 
Significance: ** and ***, P<0.01 and P<0.001 with respect to control cultures; o 
and oo, P<0.05 and P<0.01 with respect to related culture at passage 4 (t-test and 
paired t-test, as appropriate).  
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4.12 Characterization of the mechanism of decrease glucose metabolism by 
SFN and HESP action linked to delay of fibroblast senescence 
 
4.12.1 Effect of approach to senescence and sulforaphane on the 
concentration of L-lactate in cultures of MRC-5 fibroblasts in vitro. 
 L-Lactate is a major metabolite of glucose metabolism and although it is 
formed and metabolized by MRC-5 cells in vitro there was a marked export from 
cells into the culture medium. In fresh culture medium used for passages 4, 8 and 
12, the concentration of L-lactate was 0.31 – 0.93 mM. At the end of the passages 
this has increased 3 – 4 fold. The flux of L-lactate export into the medium relates 
to cell number therefore the net increase of L-lactate in cell cultures during the 
passage was computed from the difference in baseline and end of passage L-
lactate concentrations and reported as nmol per day per 106 cells. In control 
cultures the apparent flux of L-lactate was not increased significantly at passage 8 
with respect to passage 4. However, at passage 12 the apparent flux of L-lactate 
was increased ca. 11 fold with respect to passage 4. In cells treated with SFN the 
apparent flux of L-lactate was increased similarly excepting a 23% decrease in 
apparent flux of L-lactate at passage 12 compared to control cultures –Figure 105. 
 
Figure 105. Effect of approach to senescence and sulforaphane on the 
apparent flux of L-lactate production by MRC-5 cells in vitro. 
Data are mean ± SD (n = 3). Key:           , control;           , + 1 μM SFN. 
Significance: *, P<0.05 with respect to control culture; o and oo, P<0.05 and 
P<0.01 with respect to related culture at passage 4 (t-test and paired t-test, as 
appropriate).  
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4.12.2 Effect of the approach to senescence, sulforaphane and hesperetin on 
D-lactate production in MRC-5 fibroblasts in vitro. 
D-Lactate is the terminal product of MG metabolism by the glyoxalase 
system. It is weakly metabolized in human cells and is a measure of flux of MG 
formation. The concentration of D-lactate in the medium of cultures at baseline 
and end of passage were determined and the mean flux of formation of D-lactate 
deduced. The flux of D-lactate by MRC-5 fibroblasts was 0.31 ± 0.04 nmol per 
day per 106 cells at passage 4 of control cultures. This did not increase 
significantly at passage 8 but increased 11-fold at passage 12.  At passage 12 SFN 
decreased the flux of formation of D-lactate by 28% - Figure 106. 
 
 
Figure 106. Effect of approach to senescence and sulforaphane on the flux of 
formation of D-lactate by MRC-5 cells in vitro. 
Data are mean ± SD (n = 3). Key:          control;        , + 1 μM SFN. Significance: 
**, P<0.01 with respect to control culture; oo and ooo, P<0.01 and P<0.001 with 
respect to related culture at passage 4 (t-test and paired t-test, as appropriate).  
 
In a similar experiment with and without hesperetin the flux of formation 
of D-lactate was quantified in MRC-5 cell cultures at passages 7, 8 and 9. The 
flux of formation of D-lactate increased in control cultures at passage 9 with 
respect to the flux of formation of D-lactate at passage 7 and in HESP treated 
cultures at passages 8 and 9 with respect to the flux of formation of D-lactate at 
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passage 7. However, HESP did not decrease the flux of formation of D-lactate 
significantly -  Figure 107. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 107. Effect of approach to senescence and hesperetin on the flux of 
formation of D-lactate by MRC-5 cells in vitro.  
Data are mean ± SD (n = 3). Key:          control;        , + 5 μM HESP. 
Significance: o and oo, P<0.05 and P<0.01 with respect to related culture at 
passage 4 (paired t-test).  
 
4.13 Effect of sulforaphane on the cellular content of glycolytic intermediates 
 To investigate the effect of SFN on early-stage glycolysis in MRC-5 cells, 
the changes in the cellular concentrations of glycolytic intermediates were 
quantified. Key initial intermediates potentially regulated by SFN are G6P, F6P 
and PGA –  Figure 108.  
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Figure 108. Glycolytic intermediates for entry of glucose into glycolysis and 
the pentose phosphate pathway. 
  
G6P and F6P are isobaric and hence must be resolved chromatographically before 
mass spectrometric analysis. This is achieved by retention on Hypercarb graphitic 
columns – although a substantial column volume is required to achieve this 
(effectively 400 mm x 2.1 mm column) – Figure 109, a. and c. Stable isotopic 
standards from prepared [13C]labelled cell extracts provide for robust internal 
standardisation – Figure 109, b. and d.  The calibration curves were linear over a 
wide dynamic range and the limits of detection appropriate for quantitation in the 
cell samples – Figure 109, e. and f.  G6P, F6P and PGA were quantified in MRC-
5 cells with and without SFN treatment – Table 38. 
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Figure 109. Detection of glucose-6-phosphate and fructose 6-phosphate by 
liquid chromatography-tandem mass spectrometry. MRM chromatograms. 
a. and b. G6P (10 pmol), b. F6P (10 pmol). Calibration standard containing 6 
pmol G6P, 6 pmol F6P, 14.7 pmol [13C6]G6P and 19.8 pmol [
13C6]F6P. c. 
Detection of G6P and F6P, MRM transition 259.0 > 78.9 Da. d. Detection of 
[13C6]G6P and [
13C6]F6P, MRM transition 265.0 > 78.9 Da. c. and d. quantitation 
of G6P and F6P in a test samples (MRC-5 cells incubated with SFN). e. G6P and 
F6P, , MRM transition 259.0 > 78.9 Da. f. Stable isotopic standards, [13C6]G6P 
and [13C6]F6P, MRM transition 265.0 > 78.9 Da. g. and h. Calibration curves for 
the quantitation of G6P and F6P, respectively. g. G6P. Regression equation: 
G6P/[13C6]G6P peak are ratio  = (0.0680 ± 0.0006)G6P (pmol). h. Regression 
equation: F6P/[13C6]F6P peak are ratio  = (0.147 ± 0.001)F6P (pmol). 
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Table 38. Effect of sulforaphane on early-stage glycolytic intermediates in 
MRC-5 cells in vitro. 
Treatment 
G6P 
(pmol/106 cells) 
F6P 
(pmol/106 cells) 
PGA 
(pmol/106 cells) 
Passage 4, 6 h with 25 mM 
glucose 
205  ± 20 877  ± 247 95  ± 13 
Passage 4, 6 h with 25 mM 
glucose + 1 µM SFN 
115  ± 40 
(P<0.05) 
747  ± 61 
120  ± 7 
(P<0.05) 
Passage 5 (Control) 79  ± 1 212  ± 18 89 ± 18 
Passage 5, + 1 µM SFN 87  ± 19 
160 ± 25 
(P<0.05) 
70 ± 32 
Passage 9 (Control) 293  ± 6 327  ± 29 1104 ± 197 
Passage 9, + 1 µM SFN 326  ± 58 329  ± 45 983 ± 185 
 
Short term incubation with SFN in high glucose concentration medium decreased 
the cellular content of G6P and concurrently increased the cellular content of PGA 
without change in the cellular content of F6P. The cellular contents of G6P, PGA 
and F6P were higher in control cells at passage 9 than at passage 5. Addition of 
SFN decreased F6P in passage 5 but was without effect on other glycolytic 
intermediate in passage 5 and passage 9. However, it must be noted that the lower 
concentration of G6P relative to F6P could be due to changes during cell 
harvesting with trypsin. 
 
4.14 Immunostaining for Mondo A in MRC-5 fibroblasts in vitro 
 A transcription factor sensitive to the cellular content of G6P is 
carbohydrate response element binding protein or Mondo A in fibroblasts. When 
Mondo A is activated it binds G6P and translocates to the cell nucleus. To study 
the effect of SFN on cellular activation of Mondo A, MRC-5 cells were incubated 
with and without SFN with low and high glucose concentrations. MRC-5 cells 
were then fixed and immunocytofluorescence microscopy performed to study the 
subcellular location of Mondo A. 
 When MRC-5 cells were incubated overnight in low glucose concentration 
(0.2 mM) followed by 6 h with high glucose concentration (25 mM), 
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immunostaining for Mondo A showed high intensity staining in the cell nucleus in 
control cultures which was suppressed by incubation with 1 µM SFN – Figure 
110.  Following incubation in normal glucose concentration (5.5 mM) of MRC-5 
cells, immunostaining for Mondo A showed no staining in the cell nucleus. 
However, high intensity staining was seen in the cell nucleus of cultures receiving 
subsequent treatment with high glucose concentration (25 mM) for 6h. which was 
then suppressed by incubation with 1 µM SFN – Figure 111. When MRC-5 cells 
were incubated overnight in high glucose concentration (25 mM), immunostaining 
for Mondo A showed no staining in the cell nucleus in control cultures. 
Surprisingly, in the same cultures, when MRC-5 cells were incubated overnight in 
high glucose concentration (25 mM) with addition of 1 µM SFN, immunostaining 
for Mondo A showed slightly higher intensity staining in the cell nucleus – Figure 
112. 
 
Figure 110. Immunostaining for localization of Mondo A in MRC-5 cells in 
vitro. 
Cells were incubated overnight in medium containing 0.2 mM glucose and then 
incubated with 25 mM glucose for 6 h. Key: a. – c. Control, a. DAPI nuclear 
stain, b. immunostaining with anti-Mondo A IgG, and c. Overlay of a. and b.; d. – 
f., + 1 µM SFN, d. DAPI nuclear stain, e. immunostaining with anti-Mondo A 
IgG, and f. Overlay of d. and e. 
 
 
 207 
 
 
Figure 111. Immunostaining for localization of Mondo A in MRC-5 cells in 
vitro. 
Cells were incubated overnight in medium containing 5.5 mM glucose. Key: a. – 
c. Control, a. DAPI nuclear stain, b. immunostaining with anti-Mondo A IgG, and 
c. Overlay of a. and b.; d. – f., + 25 mM glucose for 6 h., d. DAPI nuclear stain, 
e. immunostaining with anti-Mondo A IgG, and f. Overlay of d. and e.; g. – i. + 
25 mM glucose and 1 µM SFN for 6 h. g. DAPI nuclear stain, h. immunostaining 
with anti-Mondo A IgG, and i. Overlay of g. and h. 
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Figure 112. Immunostaining for localization of Mondo A in MRC-5 cells in 
vitro. 
Cells were incubated overnight in medium containing 25 mM glucose. Key: a. – 
c. Control, a. DAPI nuclear stain, b. immunostaining with anti-Mondo A IgG, and 
c. Overlay of a. and b.; d. – f., + 1 µM SFN, d. DAPI nuclear stain, e. 
immunostaining with anti-Mondo A IgG, and f. Overlay of d. and e. 
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5. Discussion 
 
The concept of cellular senescence is based on the notion that proliferation 
of normal diploid cells can only occur for a limited period of time after which 
cells slowly cease to divide and die (Cristofalo and Pignolo, 1993). This limitation 
of lifespan for in vitro cell cultures was first described by Leonard Hayflick in 
1961, going against the theory formulated by Alexis Carrel claiming that cells 
kept in culture have an unlimited potential for division (Carrel and Ebeling, 1921). 
Evidence from cell senescence studies have been used to explain the basis of 
healthy ageing as well as develop food supplements promoting the delay of 
ageing. Main mechanisms thought to contribute to cellular senescence are thought 
to include shortening of telomeres, autophagy, as well as mitochondria 
metabolism. Moreover, theories of ageing as applied to cell senescence are 
thought to be the result of accumulation of macromolecular damage such as 
oxidative damage and glycation. Stress responsive signalling coordinated by 
nuclear factor erythroid 2-related factor 2 (Nrf2) provides an adaptive response 
for protection of cells against toxic insults, oxidative stress and metabolic 
dysfunction. Nrf2 regulates a battery of protective genes by binding to regulatory 
anti-oxidant response elements (AREs). Nrf2 regulates the cellular expression of a 
battery of protective genes countering oxidative stress, environment toxic insults, 
lipid peroxidation, macromolecular damage, metabolic dysfunction and cell 
senescence (Kapeta et al., 2010; Malhotra et al., 2010; Taguchi et al., 2011; Xue 
et al., 2013). 
 Since these discoveries, there has been marked expansion of anti-stress 
gene response research with relation to the role of the transcription factor NF-E2-
related factor-2 as well as healthy ageing with regards to dietary activators intake. 
Dietary activators such as carotenoids (Bishop and Guarente, 2007), omega-3 
fatty acids (Orr et al., 2005), isoflavones (Sykiotis and Bohmann, 2008) and 
others, have been shown to activate Nrf2 but the challenge lays in the discovery 
of dietary bioactives that would be able to promote healthy ageing (Ben-Dor et 
al., 2005). Finally, the current Nrf2 system model does not explain how Nrf2 is 
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activated without change in Nrf2 protein content, how Nrf2 oscillation in and out 
of the nucleus does not require activation and how Nrf2 is inactivated when 
trapped in the cell nucleus. This is the rationale of this project for the production 
of healthy ageing though a better understanding of the activation of the Nrf2 
system with dietary bioactive compounds. 
 
 
5.1 Effects of SFN and HESP on MRC-5 and BJ senescence in vitro  
5.1.1 Effect of sulforaphane treatment on MRC-5 fibroblasts growth  
Transcription factor Nrf2 regulates the expression of a battery of genes via 
interaction with one or more AREs that provide protection against proteome, 
lipidome and genome damage by glycation, oxidation and nitration (Kapeta et al., 
2010; Malhotra et al., 2010; Tagichi et al., 2011; Xue et al., 2013). The delay of 
MRC-5 senescence by the Nrf2-activating dietary bioactive compound SFN was 
studied. Initially, growth patterns of MRC-5 fibroblasts was studied by 
construction of a growth curve and showed an exponential growth curve in the 
initial 3 days of culture which thereafter slowed to quiescence as the cells reached 
confluence. Cell viability remained at >98% (Trypan blue exclusion) throughout 
the culture period. Moreover, MRC-5 cells were incubated with SFN, 0-8 µM for 
48 h and the dose-response curve showed that the median growth inhibitory 
concentration GC50 value of SFN was 2.60 ± 0.03 µM and the logistic regression 
coefficient n was 2.02 ± 0.03. Also, there was no significant inhibition of MRC-5 
cell growth at SFN concentrations up to 1.5 µM SFN and negligible toxicity (< 
5%) although at ≥ 2 µM SFN there was growth arrest. Surh et al. (2008) have 
shown that isothiocyanates are activators of Nrf2. Many studies with putative 
Nrf2 activators have, however, used high concentrations which are not 
translatable clinically and/or activate Nrf2 within the toxic concentration range. In 
the latter case toxicity prevents use of such compounds and activation of Nrf2 is 
likely as part of the response to toxicity rather than a direct agonism of the Nrf2 
system. Therefore, it was crucial to determine toxicity of SFN in MRC-5 
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fibroblasts prior to use in senescence delay study to avoid toxic effects of the 
bioactive compounds investigated.  
To study the effect of SFN treatment on MRC-5 fibroblasts growth, cells 
were grown in Eagle’s MEM media supplemented each week with or without 1 
µM SFN. The population doubling limit (PDL) as well as cumulative PDL 
(cPDL) were analyzed in order to represent MRC-5 fibroblast growth as 
progression of senescence occurred and cumulative PDL was calculated from 
addition of PDL from one passage to another. This work shows that, in four 
similar experiments, weekly treatment with 1 µM SFN in young MRC-5 
fibroblasts in culture treated until the onset of senescence delayed cellular ageing 
in these cells. Indeed, in control cultures, PDL increased at early passages but 
decreased progressively by reaching the onset of senescence. At later passages the 
PDL was negative, indicating that the cells were no longer growing and viable cell 
number was progressively decreasing. With SFN treatment, the combined 
increase in PDL over early passage (3 to 5) was significantly increased compared 
to control cPDL. Indeed, with 1 µM SFN treatment, not only did the maximum 
cPDL was higher than in control cultures, but also, maximum cPDL was reached 
at later passage compared to control. From regression analysis of PDL on passage 
number, the rate of decline in PDL per passage with and without SFN was similar 
whereas the intercept was higher with SFN in all repeated cultures. This suggests 
the rate of decline in MRC-5 cell growth on approach to senescence with and 
without SFN is similar; treatment with SFN, however, delayed the onset of 
approach to senescence. In the three replicate studies, the increase in cPDL 
achieved with SFN treatment was a 2 unit increase in cPDL or two additional 
population doublings. When this effect was also investigated regarding late 
initiation of SFN treatment at cPDL = 41, this also achieved a significant increase 
in cPDL compared to control after only treatment of 4 passages. These findings 
are similar to findings by Hintze and Nabor (2008) who discovered that 2 μM 
SFN delayed senescence of IMR-90 lung fibroblast cells in vitro. The findings 
herein were demonstrably reproducible using a concentration of SFN that may be 
readily achieved in plasma by consumption of broccoli. The SFN concentration 
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was 50% lower than that used by Hintze and Nabor (2008). Herein there was 
significant decrease of cell growth with 2 µM SFN. Hintze and Nabor (2008) did 
not report the effect of 2 µM SFN on cell growth in their investigation. Use of low 
concentrations of SFN is important for clinical translation as SFN has a relatively 
narrow therapeutic concentration range – typically activating Nrf2 and related 
ARE-linked gene expression at 1 – 2 µM but decreasing cell growth and viability 
at concentrations greater than this (Xue et al., 2012). This study is the first to 
show that SFN delays cell senescence of MRC-5 cells in vitro. More 
extraordinarily, SFN treatment initiated only 2 passages before onset of 
senescence also delayed senescence. This is innovative and suggests last stage 
interventions of in senescence-related phenomena may still be effective. This 
finding holds great hope in ageing research as it would imply that the 
accumulation of cellular damage as seen in ageing is a reversible process which 
can be delayed even at later stages in life. Similar work in the host team found the 
same response in BJ fibroblast in  vitro  (Xue, M and Thornalley, PJ, 2014, 
unpublished observation).   
 
5.1.2 Effect of hesperetin treatment on MRC-5 fibroblasts growth  
The median growth inhibitory concentration GC50 value of HESP with 
MRC-5 cells was 4.83±0.45 µM. There was no significant inhibition of MRC-5 
cell growth at 1.0 µM HESP and for all concentrations used, there was no toxicity. 
Low toxicity at higher dose of HESP was expected as intake of flavonoids such as 
hesperetin from the diet can be quite high but without toxic consequences in vivo 
(Erlund et al., 2001). At higher concentrations, however, our study has shown that 
HESP decreased MRC-5 cell growth, therefore affecting cellular development and 
questioning the validity of in vivo and in vitro studies found in the literature using 
this compound which do not show dose-response analysis.  
To study the effect of HESP treatment on MRC-5 fibroblast growth, cells 
were grown in Eagle’s MEM media supplemented each week with or without 5 
µM HESP. Similarly to our study of SFN, treatment with HESP delayed cell 
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senescence. The maximum cPDL with HESP treatment increased cPDL by 1.5. 
The peak plasma concentration of HESP after consumption of orange juice (8 
ml/kg) in human subjects was 0.5 – 5 μM (Erlund et al., 2001), hence hesperetin 
concentrations from dietary intake of HESP and glycosides may be 
pharmacologically competent to delay cells senescence. 
Although several epidemiological studies have suggested a protective 
effect of HESP on cardiovascular diseases (Knekt et al., 1996), decrease of risk of 
ischemic stroke (Joshipura et al., 1999) and lung cancer (Le Marchand et al., 
2000) as well as anticarcinogenic (So et al., 1996), antioxidant (van Acker et al., 
2000) and blood lipid–lowering (Shin et al., 1999) properties, this compound has 
never been studied individually as part of a senescence-delay study. Indeed, 
pummelo juice which contains hesperetin amongst other flavonoids, has been 
shown to delay senescence in the cardiac cell line H9c2 derived from embryonic 
rat heart (Chularojmontri et al., 2013).  However, our findings have not only 
established that 5 µM of HESP is suitable for study of senescence in MRC-5 
fibroblasts without triggering cell toxicity or growth delay, but also that HESP 
only successfully delays senescence in these fibroblasts.  
 
5.1.3 Effect of sulforaphane on staining and expression of senescence-
associated beta-galactosidase in MRC-5 fibroblasts  
Onset of cell senescence in MRC-5 cells was assessed by staining for the 
senescence marker, beta-galactosidase. For this purpose, the percentage of cells 
expressing β-galactosidase was determined for passages 4 to 9. Control MRC-5 
fibroblasts had a higher percentage of senescent cells in culture than SFN-treated 
MRC-5 cells at passages 6 and 9 (P<0.05) indicating that treatment delayed 
senescence marked by decreased β-galactosidase expression compared to control 
in these two passages. This is an important finding as it supports the findings 
arising from the performed SFN senescence delay study based on PDL and 
cPDL. Indeed, beta-galactosidase (SA-β-Gal) is the most commonly used 
marker to quantify senescence at the cellular level. The SA-β-Gal assay is a 
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reliable and well established method as it was first described in 1995 by Dimri et 
al. in which they observed that at pH 6.0, senescent cells expressed the β-
galactosidase enzyme in the cytosol when compared with fibroblasts from young 
donors (Dimri et al., 1995). Therefore, this means that not only MRC-5 
fibroblasts growth arrest was delayed by SFN treatment but also decreased the 
expression of beta-galactosidase.  
In order to confirm our findings on delay of senescence by SFN treatment 
on MRC-5 fibroblasts with beta-galactosidase staining experiments, human β-
galactosidase-1 expression in MRC-5 fibroblasts was assessed at the protein level 
by Western blotting of cell extracts at passage 5 (young) and passage 9 
(senescence) treated with either 1 µM SFN or 0.002% DMSO. Control MRC-5 
fibroblasts had a higher expression of β-galactosidase protein compared to the 
SFN-treated group at passage 9. Our findings further supports the argument that 
SFN acts on RS by delaying the onset of senescence not only targeting the MRC-5 
fibroblasts replication ability but also affecting cellular protein levels of human β-
galactosidase-1 in senescence. Indeed, as demonstrated by Kurz et al. (2000), β-
galactosidase protein content increases with replicative age. However, levels of 
cellular human β-galactosidase-1 protein were higher in cell at early passages than 
in cells of later passage approaching senescence. Beta-Galactosidase is considered 
to reflect lysosomal mass in cells (Kurz et al., 2000). Beta-Galactosidase 
expression is a marker of senescence but not essential for senescence to occur 
(Lee et al., 2006). Previous quantitative assessement of beta-galactosidase in  
MRC-5 cells has shown moderate levels at passage 25 with a ca. 40% decline to 
passage 41 and then a ca. 10-fold increase in advanced senescence at passage 45 
(Lawless et al., 2010). The apparent dichotomy of the well-accepted increase in 
beta-galactosidase expression in cells senescence with the decrease in beta-
galactosidase at passage 9 herein is probably due to cells at passage 9 approaching 
senescence but not in fully developed senescence when beta-galactosidase 
increased 10-fold and more than counters the moderate decrease on approach to 
senescence. 
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5.2 Characterization of gene expression and cell metabolism in cells escaping 
senescence by treatment with SFN and HESP in vitro 
 
5.2.1 Changes in gene expression induced by sulforaphane in early passage, 
non-senescent MRC-5 cells in vitro. 
The time course of changes in gene expression induced by 1 μM SFN in early 
passage, non-senescent MRC-5 cells in vitro was investigated by quantifying 
mRNA of genes of selected metabolic pathways with Nrf2 regulated, ARE-linked 
genes by the Nanostring method – quantifying relative mRNA copy number. One 
of the key triggers influential for the development of senescence is oxidative 
stress. In relation to this, the Keap1-Nrf2-antioxidant response element (ARE) 
signalling pathway has a key role in the delay of senescence. Stress responsive 
signalling coordinated by nuclear factor erythroid 2-related factor 2 (Nrf2) 
provides an adaptive response for protection of cells against toxic insults, 
oxidative stress and metabolic dysfunction. Nrf2 regulates a multitude of 
protective genes by binding to regulatory anti-oxidant response elements (AREs) 
(Kapeta et al., 2010; Malhotra et al., 2010; Tagichi et al., 2011; Xue et al., 2013). 
Our findings showed that SFN induced a 2-fold increase in the Nrf2, ARE-linked 
transcriptional response marker gene quinone reductase NQO1. For other 
antioxidant linked genes, there were ca. 2-fold increases in mRNA of γ-
glutamylcysteine ligase-modulatory subunit (GCLM), glutathione reductase 
(GSR), thioredoxin reductase (TXNRD1) and haem oxygenase (HMOX1), and 
smaller increases in mRNA of ferritin and thioredoxin by SFN. As demonstrated 
by this mRNA expression study, even in non-senescent young fibroblasts, SFN 
treatment had the ability to confer protection against oxidative damage by 
activating their transcription. Moreover, increased expression in NQO1 by SFN 
acts as a positive control for activation through the Nrf2 system (Jain and Jaiswal, 
2007) and confirms its regulation of the ARE. Indeed, expression of anti-oxidant 
genes (NQO1, GCLM, GSR, TXNRD1 and HMOX1 as well as FTH1 and TXN) 
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were increased at early passage 4 even though these cells had only been receiving 
SFN treatment since passage 3. Expression of γ-glutamylcysteine ligase-catalytic 
subunit, glutathione peroxidase-1, peroxiredoxon-1, superoxide dismutases SOD1 
and SOD2 and catalase were little changed. Increased NQO1 mRNA stimulated 
by SFN maximized after ca. 24 h and remained increased up to 72 h post-
stimulation. In contrast, increased GCLM and GSR mRNA maximized after 12 h 
and retuned to baseline levels after 36 – 48 h. The increase in HMOX1 mRNA 
was even more short-lived, maximizing at 4 h and returning to levels in 
unstimulated cells by 24 h. SFN also increased mRNA of aldoketo reductase 1C1 
but not of glyoxalase 1. It also had little effect on phase II conjugating genes, 
glutathione transferase P1 and MRP2. Our study showed that pentosephosphate 
pathway genes were more responsive, with mRNA of glucose-6-phospahte 
dehydrogenase (G6PDH), transketolase (TKT) and transaldolase (TALDO) all 
increasing in SFN stimulated cells. This finding has very important implications 
as although CR studies have consistently shown a beneficial effect towards 
extended life span in animals (Murphy and Partridge, 2008; Weindruch et al., 
1986), the mechanism by which fluctuations of glucose metabolism acts on the 
Nrf2 system and senescence is still under scrutiny.  Indeed, gene array studies 
reveal that activated Nrf2 regulates clusters of genes involved in lipid and glucose 
metabolism such as insulin-associated signalling genes and glucose homeostasis 
regulators (Yates et al., 2009). Moreover, certain cancer cells exploit constructive 
activation of Nrf2 to reprogram their metabolism for securing optimal supply with 
biosynthetic building blocks (Mitsuishi et al., 2012). Indeed, proliferating cells 
take up abundant nutrients, including glucose and glutamine, and shunt their 
metabolites into anabolic pathways (Mitsuishi et al., 2012). Although the PPP is a 
well-established metabolic pathway, a direct regulator that activates the PPP 
during metabolic reprogramming has yet to be identified (Mitsuishi et al., 2012). 
However, our study indicates that SFN can activate the PPP at very early stages of 
treatment and increase the transcription of G6PDH, TKT and TALDO, which are 
therefore contributing to possible delay of senescence and healthy ageing cell 
programming.  For lipogenic genes, sterol response element binding protein-1 
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(SREBF1) was decreased in SFN stimulated cells but expression of fatty acid 
synthase (FASN) was unchanged. The expression of Fructose-2,6-bisphate kinase-
4 (PFKBP4) was also unchanged by SFN. For the Nrf2 system itself, SFN did not 
increase expression of Nrf2, Keap1 nor Fyn kinase but did increase small maf 
protein-G (MAFG) in the 24 h immediately post-stimulation. This increase in 
MAFG expression is a very important finding in itself as upon activation, Nrf2 
dissociates from Keap1, is phosphorylated by CK2 and enters the nucleus and 
binds with accessory Maf protein to AREs (Jeong et al., 2005; Tanigawa et al., 
2007). Therefore our finding indicates that, although Nrf2 and Keap1 mRNA 
expression are unchanged with SFN-treatment compared to control, MAFG 
increase in expression is a strong indicator of the activation of the Nrf2 system 
with SFN-treatment after early stage treatment. When inflammatory gene 
responses were examined, monocyte chemotactic protein-1 (CCL2), chemokine 
(C-X-C motif) ligand 1 (CXCL1), interleukin-15 (IL15), interleukin 1β1 (IL1), 
toll-like receptor 4 (TLR4), transcription factor p65 (NFKB3), nuclear factor NF-
kappa-B p105 subunit/p50 (NFKB1) and intracellular adhesion molecule-1 
(ICAM1) were all unresponsive. This may indicate that expression of these genes 
can only be affected by cumulative treatment with SFN rather than acute 
treatment. Genes associated with extracellular matrix proteolysis, matrix 
metalloproteinase-3 (MMP3) and matrix metalloproteinase-13 (MMP13), were 
unchanged whereas the expression of elastin was decreased. This is probably due 
to the fact that these MRC-5 fibroblasts are young and therefore the extracellular 
matrix is not yet damaged by ageing, which means that these fibroblasts do not 
need to activate extracellular matrix repair. The expression of serpins and 
senescence associated genes, β-galactosidase (GLB1), cyclin-dependent kinase 
inhibitor 1/p21 (CDKN1A) and cyclin-dependent kinase inhibitor 2A/P16INK4a 
(CDKN2A), were all unchanged.  
From these mRNA expression results, it can be seen that the Nrf2 system 
senses challenge to homeostasis in the cell cytoplasm and this could therefore 
mean that a protective transcriptional response is activated at early passages 
mainly from the transcription of anti-oxidant genes. Such stress-responsive 
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signalling is vital in resisting oxidative damage, cell dysfunction, cytotoxicity and 
mutagenesis, and similar studies have found that decline of these processes 
contribute to resistance to drug toxicity, wound healing and decreasing risk of 
diabetes, vascular and neurodegenerative disease and ageing-related disease 
(Collins et al., 2009; Hayashi et al., 2013; Okawa et al., 2006; Pearson et al., 
2008). 
 
5.2.2 Characterization of gene expression and cell metabolism in cells 
escaping senescence by treatment with sulforaphane and hesperetin. 
In order to characterize the expression of genes and cell metabolism in 
cells escaping senescence by treatment with sulforaphane and hesperetin, the 
changes in gene expression induced by 1 μM SFN and 5 μM HESP in young and 
senescent MRC-5 cells in vitro was investigated by quantifying mRNA of genes 
of selected metabolic pathways with Nrf2 regulated, ARE-linked genes by the 
Nanostring method – quantifying relative mRNA copy number.  
At late passage, there was a significant increase in mRNA of the anti-
oxidant related gene GCLM in the SFN treatment compared to control. GCLM 
expression has been linked with extension of life span. Indeed, overexpression of 
GCLM in fruit flies has been shown to extend mean and maximum life span by up 
to 50% (Orr et al., 2005). The notion of oxidative stress emerged from the concept 
that ROS become excessively available in cells, leading to impaired cellular 
functions and senescence (Balaban et al., 2005). Oxidative stress is defined as an 
imbalance of oxidants and antioxidants in favour of the former potentially leading 
to cell damage (Sies, 1993).  This increase of the anti-oxidant related gene GCLM 
with 1 µM SFN treatment therefore counterbalances the normal decrease of anti-
oxidant genes with senescence, which ultimately leads to a decrease in oxidative 
stress and senescence.  
Moreover, mRNA of the pentose-phosphate pathway gene glucose-6-
phosphate dehydrogenase was significantly (P<0.001) increased in the treatment 
group compared to the control. As described by Singh et al. (2013), Nrf2 
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coordinates the regulation of key genes involved in various pathways of glucose 
metabolism, including the pentose phosphate pathway (PPP), therefore, G6PDH 
mRNA expression increase with treatment confirms Nrf2 activation with SFN 
which may affect glucose metabolism in MRC-5 fibroblasts. The same effect was 
seen in the expression of the nutrient sensing thioredoxin interacting protein 
(TXNIP) which was increased by more than 2-fold. This finding has been 
demonstrated to link SFN supplementation to CR mimetics as TXNIP expression 
increases (Swindell, 2009).  Moreover, expression of the extracellular matrix 
regulator collagen 1-alpha (COL1A1) was significantly increased in the SFN 
treated group compared to control by 0.5 fold, therefore indicating that SFN 
treatment at late passage conserves the function of the extracellular matrix hence 
contributing to delay of RS in these cells.  
Oxidative damage is thought to be caused by an imbalance of the 
enzymatic members of the anti-oxidant defence such as catalase (CAT), 
glutathione peroxidase (GPx) and superoxide dismutase (SOD) (Finkel, 1998) and 
non-enzymatic members such as Vitamin A, C and E as well as the tripeptide 
glutathione (GSH) (Finkel and Holbrook, 2000). At early passage, HESP induced 
a significant increase (P<0.001) in the expression of the matrix regulating gene 
mitochondrial superoxide dismutase (SOD2). This means that HESP acts on 
restoring the balance between oxidative stress and anti-oxidants from the very 
first attribution of treatment. This increase in gene expression of SOD2 at early 
passage with HESP treatment has very important implications on HESP effects in 
delay of ageing. Indeed, SOD2 is an antioxidant, the mitochondrial form of SOD 
and an important defence against oxidative damage. Evidence from invertebrates 
suggests it may play a role in ageing as overexpression of SOD2 in flies 
significantly extends lifespan  (Sun et al., 2002) and mice without SOD2 are not 
viable (Li et al., 1995). Although  reducing the activity of SOD2 in mice increases 
the levels of oxidative damage to DNA but does not affect lifespan (Van Remmen 
et al., 2003), SOD2 overexpression in mice slightly increases lifespan, while gene 
deletion in connective tissue only resulted in mutant mice with a reduced lifespan 
and premature onset of aging-related phenotypes such as weight loss, skin 
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atrophy, kyphosis, osteoporosis and muscle degeneration  (Trieber et al., 2011). 
At late passage, there was no significant change in mRNA in the HESP treatment 
compared to control at passage 9. Finally our study showed that gene expression 
of the anti-oxidant related gene quinone reductase (NQO1) was decreased by two-
fold at passage 11 for both treatment and control groups compared to control at 
passage 3. Moreover, expression of the anti-oxidant related gene heme oxygenase 
(HMOX) decreased by two-fold the control group at passage 9 compared to 
control at passage 3. Expression of the anti-oxidant related gene ferritin (FTH1) 
was also decreased two-fold in late passage for the SFN treated group compared 
to control at early passage. Expression of the pentosephosphate pathway gene 
glucose-6-phosphate dehydrogenase (G6PD) of both control and treatment group 
at late passage was halved compared control at passage 3. Although this gene 
expression pattern decrease with approach to senescence is expected , Weidruch 
and colleagues (2001) have shown that they can be counteracted in mice models 
using CR.  
 
5.2.3 Characterisation of gene expression in MRC-5 fibroblasts escaping 
senescence by treatment with sulforaphane using genome-wide microarray 
analysis. 
 The changes in gene expression induced by 1 μM SFN treatment in young 
(passage 3) and senescent (passage 11) MRC-5 cells in vitro was investigated by 
quantifying mRNA of 20773 genes throughout the whole human genome by the 
Microarray Agilent method – quantifying total RNA copy number.  
 The results herein showed that there was no significant changes in gene 
expression between the SFN treatment and control group at passage 3 detectable 
by conventional transcriptomic array analysis. Moreover, the colon-cancer 
secreted protein 1 (KIAA1199) was the only gene for which expression was 
significantly different in the treatment and control group at passage 11. Indeed, 
KIAA1199 was downregulated by SFN treatment compared to control in 
senescence. This result is in accordance with the findings by Michishita et al. 
(2006) who showed that upregulation of the KIAA1199 gene is associated with 
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cellular mortality. This, therefore means that treatment of MRC-5 fibroblasts with 
1 µM SFN upon reaching senescence delays cellular mortality in these cells and is 
strenghtened by cPDL decline results obtained on the control group at passage 11. 
Expression of 131 genes (Appendix E.) was significantly changed between 
controls at passage 3 and passage 11.  Indeed, expression of the DnaJ (Hsp40) 
homolog, subfamily C, member 6 (DNAJC6) was increased 6-fold with 
senescence in the control group compared to young fibroblasts. Moreover, 
expression of the C-C chemokine receptor type 11 (CCRL1) was increased 5-
folds in the control at passage 11 compared to early passage control. Finally, 
expression of chemokine (C-X-C motif) ligand (CXCL2) was decreased by 3-
folds and expression of Coiled-coil domain containing 144A (CCDC144A) was 
decreased by 4-fold in senescent controls compared to young controls. 
 Expression of 18 genes was significantly changed between SFN treated 
groups at passage 3 and passage 11. All genes were significantly upregulated at 
passage 11 compared to passage 3 in SFN treated groups apart from Sad1 and 
UNC84 domain containing 1 (SUN1) which was downregulated by 0.7 folds with 
senescence. Expression of the C-C chemokine receptor type 11 (CCRL1) and 
thioredoxin interacting protein (TXNIP) were amongst the highest upregulated 
genes in SFN treated senescent cells, increasing 5 and 7 fold respectively. 
 Expression of 274 genes (Appendix F.) was significantly changed between 
SFN treated groups at passage 11 and control at passage 3. Indeed, SFN treatment 
in senescence showed a 5 and 7 fold increase in expression of  the major 
histocompatibility complex, class II, DM beta (HLA-DMB) and nuclear receptor 
subfamily 5, group A, member 2 (NR5A2) respectively compared to control at 
passage 3. Moreover, there was a 5-fold decreased in the expression of  the small 
nucleolar RNA, C/D box 99 (SNORD) in the late passage SFN treated group 
compared to early control. 
When comparing the expression analysis of the 49 genes of interest used 
in the Nanostring method and the transcriptomic method, it was noticeable that 
there was considerably less significant changes in gene expression in the SFN 
treated and control groups at passage 3 and 11using the transcriptomic method. 
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Measurement of the level of each transcript, by using microarray-based 
approaches can lead to identification of many pharmacological or toxicological 
agents which alter gene expression (Kopec et al. 2012; Yao et al. 2012), and 
mRNA abundance profiles can be used to create biomarkers of exposure to 
foreign chemicals as well as to facilitate understanding of mechanisms of basic 
physiological responses (Van Hummelen and Sasaki 2010; Uehara et al. 2011). 
However, signal noise, and data-analysis limitations have limited the adoption of 
transcriptome-wide profiling methods and the limited length of microarray probes 
(25–100 bp) can result in nonspecific binding of transcripts (Zhang et al. 2002), 
particularly in disease states. The length of the probes used for NanoString 
analysis is similar to that used for microarray hybridization; however, the dual-
probe system results in more accurate signal capture as ensured by three factors: 
first, both probes are present in solution, allowing for more direct interaction with 
targets; second, the reaction is carried through to completion to ensure all targets 
are counted; and finally, the digital readout provides less noisy results than analog 
systems (Geiss et al. 2008). Therefore, we recommend the use of NanoString 
methods rather than Microarray for the successful analysis of biomarkers in 
response to compounds which are shown to delay senescence in vitro. 
 
5.2.4 Characterisation of gene expression in MRC-5 fibroblasts in vitro 
during the approach to senescence. 
The time course of changes in gene expression of MRC-5 fibroblasts in vitro was 
investigated by quantifying mRNA of genes of selected metabolic pathways with 
Nrf2 regulated, ARE-linked genes by the RT-PCR method – quantifying relative 
mRNA expression. Expression of the anti glycation related gene aldoketo 
reductase 1B1 (AKR1B1) was significantly decreased (P<0.001) by a third of its 
value in senescence (passage 11) compared to young fibroblasts (passage 3). 
Expression of AKR1B1 was stable from passage 3 but decreased dramatically 
after passage 5. Moreover, the expression of the anti-glycation related gene 
glyoxalase 1 (GLO1) was also decreased significantly (P<0.01) with approach to 
senescence. Expression of GLO1 was stable at passage 3, 5 and 6 but declined 
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rapidly thereafter. At the approach of senescence, the expression of the anti-
oxidant related genes thioredoxin (TXN) as well as quinone reductase (NQO1) 
and heme oxygenase (HMOX1) was significantly decreased (P<0.001 and 
P<0.05, respectively) when compared to passage 3. Decline in expression of TXN 
was steady from passage 3 to 9 but increased slightly at the approach to 
senescence. Moreover, NQO1 and HMOX1 gene expression decline with 
approach to senescence was relatively consistent at each passage. Expression of 
the anti-oxidant related gene gamma-glutamyl-cys ligase-catalytic subunit 
(GCLC), gamma-glutamyl-cys ligase-modulatory subunit (GCLM) and 
glutathione reductase (GSR) however did not significantly decline with approach 
to senescence. Expression of both pentosephosphate pathway genes transaldolase 
(TALDO1) and transketolase (TKT) was significantly (P<0.05) decreased from 
passage 3 to passage 11, showing almost linear decline with passage. Moreover, 
expression of the NADPH-dependent oxidoreductase carbonyl reductase 1 
(CBR1) was also significantly decreased (P<0.05) with approach to senescence. 
This decline was drastic from passage 3 to 9 but was steady thereafter until 
senescence at passage 11. Finally the expression of the Nrf2 regulation related 
genes Nrf2 was not significantly decreased at passage 11, although 30% decrease 
in Keap 1 expression at the approach to senescence was very significant 
(P<0.001). Analysis of gene expression in MRC-5 cells from passage 3 to 11 
showed that, for genes NQO1, NRF2,  TKT, GLO1, AKR1B1, KEAP1, CBR-1, 
TALDO, GSR, HMOX1 and TXN, expression was maintained until passages 5 – 
6 and then decline to lower levels at passages 10 – 11. These findings confirm 
similar findings of gene expression decline related to approach to senescence, and 
also confirms the involvement of ARE in preserving normal cell functions. 
 
5.2.5 Effect of progression towards senescence and sulforaphane on protein 
glycation, oxidation and nitration markers in MRC-5 fibroblasts in vitro. 
Proteome and genome damage was assessed by quantitative screening of 
protein oxidation, nitration and glycation adducts, and deoxyguanosine glycation 
and oxidation adducts by stable isotopic dilution analysis LC-MS/MS. There were 
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no changes in cell protein content of glycation, oxidation and nitration adducts 
from passage 4 to passage 8. There were, however, increases in protein glycation, 
oxidation and nitration free adduct flux at passage 8 – decrease in flux of early 
glycation adduct FL, increases in flux of formation of AGEs (MG-H1, CML, 
3DG-H and CMA) and oxidation adducts DT and GSA. This indicates that the in 
situ rates of protein glycation and oxidation in cells are increased in the later 
passage but this is within the capacity of the cell to remove these damaged 
proteins. This may nevertheless stress cell metabolism by decreasing the level of 
unmodified protein if there is not compensatory increase in expression to replace 
the proteolysed damage protein and strain cell metabolism for increased protein 
synthesis if the damaged protein is replaced. Previous studies with MRC-5 cells 
and BJ fibroblasts have found increased protein carbonyls by qualitative 
chromophoric derivatisation (Sitte et al., 1998; Sitte et al., 2000a; Sitte et al., 
2000b.). Such methods are not robustly quantitative and often give higher 
response in assay blanks than test samples – reviewed in Thornalley and Rabbani 
(2014). Herein protein carbonyls were assayed directly and quantitatively as 
AASA and GSA. GSA was found to be the major protein carbonyl. The flux of 
GSA increased markedly in the later passage MRC-5 cells examined – consistent 
with previous findings of increased protein carbonyls being due to increased 
formation of GSA. Unlike previous findings, however, it is identified that the 
change in protein carbonyls in cell senescence is increased flux of formation 
rather than increased steady-state carbonyl residues in cell protein. This may 
change, however, in more advanced stages for senescence when cell proteolysis 
decline. 
 
 SFN changed the steady-state levels of damage to cell protein. It decreased 
dicarbonyl metabolite-derived AGEs, MG-H1, 3DG-H, CMA and glucosepane 
residues, and GSA residues in cell protein at passage 3. This may be due to 
increased expression of aldoketo reductases and antioxidant enzymes that 
metabolise dicarbonyls and oxidising metabolites. SFN decreased FL residue 
content of cell protein at passage 8 which may be due to the decreased glucose 
 225 
 
uptake and metabolism found in SFN-treated cells. It also increased 3-NT residue 
content which may relate to increased NO availability through increased 
antioxidant activity and prevention of NO synthase inactivation.  Importantly, 
SFN treatment also decreased flux of formation of FL, AGEs and oxidative 
damage adducts DT and GSA. This is probably related to enhanced protection 
against protein damage by increasing the metabolism of glycating and oxidizing 
agents. Flux of 3-NT was increased in late passage cells – again, as for the 3-NT 
residue increase with SFN, this likely reflects increased availability of NO with 
SFN treatment. 
These findings indicate that SFN allows for counteracting the effects of 
senescence on damage caused by glycation of proteins. Indeed, SFN is thought to 
act through CR mimetics and decrease in caloric intake is a proven intervention 
that increases lifespan in rodents and nematodes (Pletcher et al., 2005; Walker et 
al, 2005; Wang et al., 2004 and Walford, 1982).  The decrease in intracellular 
levels of protein glycation markers with SFN treatment in our study demonstrated 
this compound’s ability to counteract glycating damage that would normally occur 
during the normal ageing process. Indeed, there have been few studies of 
quantitative changes in protein glycation in cell senescence but studies with anti-
AGE antibodies suggested that protein AGE residue content increased during 
replicative senescence of WI-38 human embryonic fibroblasts (Ahmed et al., 
2007). Moreover, in the BJ fibroblast model of proliferative and non-dividing cell 
senescence, protein carbonyls and lipofuscin fluorescence increased as cells 
entered senescence (Sitte et al., 2000). A similar effect was found in MRC-5 
fibroblasts during proliferative senescence (Sitte et al., 1998). Therefore, by 
counteracting the effects seen in normal senescence (Sitte et al., 1998; Sitte et al., 
2000; Ahmed et al., 2007), SFN successfully counteracts glycolytic damage to 
cell proteins. 
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5.2.6 Effect of progression towards senescence and sulforaphane on 
nucleotide glycation and oxidation in MRC-5 fibroblasts in vitro. 
The concentration of the nucleotide damage markers MGdG, GdG and 8-
OxodG in baseline and end of passage conditioned medium at passages 5 and 8 
were determined in cultures of MRC-5 cells that had been incubated with and 
without 1 µM SFN since passage 3 (when cPDL was 35.8).  Incubation with SFN 
decreased the flux of formation of 8-OxodG but for nucleotide AGEs, GdG, 
MGdG and CEdG, these analytes were not detectable in fresh or end of passage 
conditioned medium. As demonstrated by Thornalley et al. (2010), increased 8-
OxodG cellular content is correlated with increase DNA damage in tumour cell 
lines (Thornalley et al., 2010). Therefore, our results show that this decrease in 8-
oxodG with SFN treatment indicate that this isothiocyanate counteracts nucleotide 
oxidation caused by cellular senescence in MRC-5 fibroblasts.  
 
5.2.7 Effect of sulforaphane on dicarbonyl precursors of protein and 
nucleotide glycation in cultures of MRC-5 fibroblasts in vitro. 
Dicarbonyl precursors of glycation, methylglyoxal (MG), 3-
deoxyglucosone (3-DG) and glyoxal, were assessed by stable isotopic dilution 
analysis LC-MS/MS in cell culture media at baseline and at the end of the passage 
of MRC-5 cell cultures for passages 5, 8 and 11. 
For glyoxal, the concentration of glyoxal was decreased at the end of 
passage with respect to baseline level at passages 8 (-37%, P<0.05) and 11 (-52%, 
P<0.01) for MRC-5 cells in control cultures but not for MRC-5 cells incubated 
with SFN.  The concentration of glyoxal was decreased at the end of the passage 
with respect to baseline level in control cultures for all 3 passages combined: 171 
± 53 nM versus 105 ± 45 nM, P<0.05 (n = 9). Combining measurement for 
passages 8 and 11 as “late passages”, the efflux of glyoxal was increased in 
control cultures in late passages with respect to passage 5 (4919 ± 1697 versus 
1041 ± 413 pmol/106 cells, P<0.01) but not in similar cultures treated with SFN. 
Glycation accounts for 0.1 to 0.2% of cellular arginine and lysine residues in the 
body (Thornalley et al., 2003). This physiological process causes damage to 
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proteins and results in the formation of glycated amino-acid residues (Xue et al., 
2008a).  These residues are formed by the spontaneous reaction between 
monosaccharide and proteins. Glycating agents are formed from the degradation 
of glycated proteins and lipid peroxidation and include dicarbonyls such as 
methylglyoxal, glyoxal and 3-deoxyglucosone (3-DG) (Thornalley et al., 2003) 
which act as precursors for advanced glycation end products (AGEs) directly 
linked with senescence progression. Therefore, our findings demonstrate that 
treatment with SFN in MRC-5 fibroblasts not only delays senescence but also 
confers protection against glycating damage through the decrease in glyoxal flux 
at the approach to senescence. 
For MG, the concentration of MG was decreased at the end of passage 
with respect to baseline level at passage 5 (-32%, P<0.05) and increased at the end 
of passage 11 with respect to baseline (+52%, P<0.05) for MRC-5 cells incubated 
with SFN but was unchanged in MRC-5 cells in control cultures.  The 
concentration of MG in medium of MRC-5 cells in cultures with SFN was 
increased at passage 8 with respect to passage 5, P<0.05, but was unchanged in 
control cultures. Therefore, the efflux of MG from cells at passage termination 
(pmol per 106 cells) was deduced. The efflux of MG was increased in control 
cultures at passage 11 with respect to passage 5 and increased at passage 8 with 
respect to passage 5 in cultures with SFN. Combining measurement for passages 8 
and 11 as “late passages”, the efflux of MG was increased in control cultures in 
late passages with respect to passage 5 (10297 ± 3614 versus 640 ± 230 pmol/106 
cells, P<0.01) and also in cultures treated with SFN (8163 ± 4964 versus 566 ± 79 
pmol/106 cells, P<0.01). In quantitative assessments of advanced glycation 
endproducts (AGEs) in physiological systems, glycation of proteins by the 
physiological metabolite MG produced levels of cellular and extracellular proteins 
modification approaching and sometimes exceeding that of glucose (Thornalley et 
al., 2003). Our findings, alongside results obtained by Thornalley et al. (2003) 
strengthen the argument that SFN successfully delays the increase damage of the 
dicarbonyl MG inside the cell proteins as seen by the approach of senescence. 
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For 3-DG, the concentration of 3-DG was increased at the end of passage 
with respect to baseline level at passage 5 (+48%, P<0.01), at passage 8 (+215%, 
P<0.001) and at passage 11 (+36%, P<0.05) for control cultures of MRC-5 cells 
and increased at passage 8 (+198%, P<0.001) for MRC-5 cells incubated with 
SFN. The concentration of 3-DG in cultures at the end of the passage was not 
changed significantly by addition of SFN for passages 5, 8 and 11. The 
concentration of 3DG in baseline medium at passage 5 was higher than at passage 
8 (268 ± 33 nM versus 163 ± 37 nM, P<0.05) and lower than at passage 11 (268 ± 
33 nM versus 383 ± 20 nM, P<0.01). Therefore, the efflux of 3-DG from cells at 
passage termination (pmol per 106 cells) was deduced. The efflux of 3-DG was 
increased in control cultures at passages 8 and 11 with respect to passage 5 and 
also increased at passage 1l with respect to passage 8. The efflux of 3-DG was 
increased at passages 8 with respect to passage 5 in cultures with SFN. Combining 
measurement for passages 8 and 11 as “late passages”, the efflux of 3-DG was 
increased in control cultures in late passages with respect to passage 5 (22481 ± 
10871 versus 2752 ± 907 pmol/106 cells, P<0.01) but not in cultures treated with 
SFN. This is due to the fact that the decrease in 3-DG flux is countered by 
decreased metabolism by aldoreducatse (3-DG reductase activity) to 3-
deoxyfructose and by aldehyde dehydrogenase to 2-keto-3-deoxyglucoronic acid 
(Baba et al., 2009; Collard et al., 2007).  
 
5.2.8 Effect of progression towards senescence and sulforaphane on 
formation of Nε(γ-glutamyl)lysine (GEEK) in MRC-5 fibroblast cultures. 
Increased expression of transglutaminase is implicated in fibroblast 
senescence (Kim et al., 2001; Dellorco et al., 1985) with expected increased 
formation of Nε(γ-glutamyl)lysine (GEEK). The culture media and intracellular 
protein concentration of GEEK in MRC-5 fibroblasts at passages 4 and 8 were 
determined in cultures of MRC-5 cells that had been incubated with and without 1 
µM SFN since passage 3 (when cPDL was 35.8).  The concentration of GEEK 
in baseline medium at passage 4 and 8 was increased significantly at the end of 
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the passage in MRC-5 cells incubated with and without 1 µM SFN (P<0.01 and 
P<0.001, respectively). Moreover, the flux of GEEK outside the cells was 
increased by 4 fold at passage 8 in both groups compared to passage 4, although 
there was no significant difference in efflux between treatment and control within 
the same passage. The concentration of GEEK at early passage 4 in the control 
culture and culture treated with 1µM SFN was 1.11 ± 0.61 mmol/mol(lys) and 
0.91 ± 0.48 mmol/mol(lys) respectively. At passage 8, however, cellular protein 
concentration of GEEK in the control culture was significantly (P<0.05) increased 
by 3-folds compared to control at passage 4. The concentration of GEEK in 
control at passage 8 was therefore 3.15 ± 0.71 mmol/mol(lys). Moreover, cellular 
protein concentration of GEEK in the 1µM SFN treatment group did not 
significantly fluctuate compared to control GEEK concentration at passage 4, but 
was 2-fold higher (P<0.05) than GEEK concentration in the SFN-treated group at 
passage 4. However, there was a significant (P<0.05) 1.5-fold decrease in cellular 
protein GEEK concentration at passage 8 in the 1µM SFN treated group when 
compared to the control. Indeed, at passage 8, cellular protein GEEK 
concentration was 1.74 ± 0.29 mmol/mol(lys) in the 1µM SFN treated group. 
These data indicate the following: 
1. Transglutaminase-mediated crosslinking impose a significant increased 
covalent crosslinking on cell protein on the approach to senescence. This 
reflects a mean crosslink of ca. 2-6 % of proteins from passage 4 to 8 
respectively. 
2. The effect of SFN in decreasing GEEK residue content of cell protein 
rather than flux of formation of GEEK reflects SFN-induced increased 
clearance of crosslinked proteins which is likely protective for function. 
GEEK residues and free adducts have not been hitherto robustly quantified. The 
method used herein is an adaptation of the published LC-MS/MS method (Schafer 
et al., 2005) which was improved in the host team by synthesis and use of stable 
isotopic GEEK for robust internal standardisation and by combining this with 
enzymatic hydrolysis and ultrafiltration methods to quantify GEEK residues and 
free adducts flux. 
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5.3 Characterization of the mechanism of decrease glucose metabolism by 
SFN and HESP action linked to delay of fibroblast senescence 
 
5.3.1 Effect of the approach to senescence and treatment with sulforaphane 
and hesperetin on the consumption of glucose by MRC-5 and BJ fibroblasts 
in vitro 
The concentration of glucose in cultures of MRC-5 fibroblasts at the 
beginning and end of passages 4, 8 and 12 was determined and the flux of glucose 
metabolized deduced. The consumption of glucose increased progressively from 
2.59 ± 0.40 μmol per day per 106 cells at passage 4 to a maximum of 30.74 ± 2.20 
μmol per day per 106 cells at passage 12. Incubation with 1 μM SFN from passage 
3 decreased glucose consumption which was statistically significant at passages 
10, 11 and 12 with glucose consumption decreased by 34%, 60% and 53% 
respectively (P<0.01). Following observation of these results, treatment with 1 
µM SFN of MRC-5 fibroblasts is thought to delay senescence through a caloric 
restriction mimetic effect. Caloric restriction mimetic (CRM) was a term first 
described by Lane and colleagues (1998) as a hypothetical class of drugs which 
imitates the anti-ageing effects associated with CR in vivo and which would act 
upon the same metabolic pathways without the need for a decrease in caloric 
intake. CRM have been proposed to regulate a vast number of pathways 
associated with energy metabolism (Lane et al., 2007). Indeed, inhibitors of 
glycolysis have been shown to mimic metabolic and protective effects of CR (Guo 
et al., 2001). Also, sirtuin regulators have been shown to delay the ageing process 
and extend lifespan in short-lived organisms (Guarente and Picard, 2005). Finally, 
insulin sensitisers have been explored as possible CRM due to the fact that insulin 
sensitivity has been shown to increase in animal CR studies (Kemnitz et al., 1994; 
Kenyon et al., 1993; Wolkow et al., 2000; Clancy et al., 2001). However, this 
theory has been disputed for the compound phenformin, a treatment for diabetes, 
due to the fact that in vivo treatment failed to show markers related to CR and 
lifespan (Lane et al., 2007).  
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Culture media samples were available from a similar study of the approach 
of human BJ fibroblasts to senescence and delay by treatment with 1 μM SFN. 
The consumption of glucose increased progressively from 3.48 ± 0.09 μmol per 
day per 106 cells at passage 6 to a maximum of 14.80 ± 1.50 μmol per day per 106 
cells at passage 19. Incubation with 1 μM SFN from passage 3 decreased glucose 
consumption by 30% at passage 19 (P<0.001), although at earlier passage 
treatment with SFN had increased consumption of glucose. In the HESP study, the 
consumption of glucose increased progressively from 4.11 ± 0.24 μmol per day 
per 106 cells at passage 7 to a maximum of 38.41 ± 4.72 μmol per day per 106 
cells at passage 9. Incubation with 5 μM hesperetin from passage 3 decreased 
glucose consumption which was statistically significant at passages 7 and 12 with 
glucose consumption decreased by 29% and 33% respectively (P<0.05). These 
results therefore show that, like SFN, treatment with 5 µM HESP acts as a CRM 
activator by decreasing metabolism and glucose intake by MRC-5 fibroblast. 
Finally, MRC-5 cell pellets (passage 4 and 10) content of GSH was 
determined by stable isotopic dilution analysis LC-MS/MS for SFN and control 
group and the cellular content of GSH increased ca. 3-fold in control cultures in 
passage 10 with respect to passage 4. Treatment with SFN did not change the 
cellular content of GSH at passage 4 but increased cellular content of GSH by 
34% compared to control at passage 10. This higher cellular content of GSH in 
the SFN-treated group compared to control is in accordance with findings by 
Chen (2009) that increases in intracellular GSH prevents premature senescence 
and is supported by the findings that induction of WI38 cell senescence is initiated 
by a transient depletion of intracellular GSH and followed by a continuous 
increase in ROS formation. Along with our findings on decrease in L-lactate 
formation at the onset of senescence compared to control, this GSH increase has 
been linked similarly with decrease in the flux of formation of L-lactate in CR of 
ageing in mice models (Hargopan, Ramsey and Weindruch, 2003).  
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5.3.2 Characterization of the mechanism of decreased glucose metabolism by 
SFN and HESP action linked to delay of fibroblast senescence. 
 
D-Lactate is the terminal product of MG metabolism by the glyoxalase 
system. It is weakly metabolized in human cells and is a measure of flux of MG 
formation. Increases in D-lactate levels have been associated with hyperglycaemia 
(Shinohara et al., 1998; Talasniemi et al., 2008, Thornalley et al., 2001).  The 
concentration of D-lactate in the medium of cultures at baseline and end of 
passage were determined and the mean flux of formation of D-lactate deduced. 
The flux of D-lactate by MRC-5 fibroblasts was 0.31 ± 0.04 nmol per day per 106 
cells at passage 4 of control cultures. This did not increase significantly at passage 
8 but increased 11-fold at passage 12.  At passage 11, SFN decreased the flux of 
formation of D-lactate by 28%.  This CR restriction mimetic effect and decrease 
in the flux of formation of D-lactate is consistent with decreased formation of 
methylglyoxal as a consequence of decreased glycolysis. In a similar experiment 
with and without hesperetin the flux of formation of D-lactate was quantified in 
MRC-5 cell cultures at passages 7, 8 and 9. The flux of formation of D-lactate 
increased in control cultures at passage 9 with respect to the flux of formation of 
D-lactate at passage 7 and in HESP treated cultures at passages 8 and 9 with 
respect to the flux of formation of D-lactate at passage 7. However, HESP did not 
decrease the flux of formation of D-lactate significantly. This is in accordance 
with the fact that HESP has less ability to delay senescence by CR mimetics as 
shown in the glucose consumption results and senescence delay results in this 
study. 
L-Lactate is a major metabolite of glucose metabolism and although it is 
formed and metabolized by MRC-5 cells in vitro there was a marked export from 
cells into the culture medium. In fresh culture medium used for passages 4, 8 and 
12, the concentration of L-lactate was 0.31 – 0.93 mM which may be interpreted 
as background interference. At the end of the passages this has increased 3 – 4 
fold. The flux of L-lactate export into the medium relates to cell number therefore 
the net increase of L-lactate in cell cultures during the passage was computed 
 233 
 
from the difference in baseline and end of passage L-lactate concentrations and 
reported as nmol per day per 106 cells. In control cultures the apparent flux of L-
lactate was not increased significantly at passage 8 with respect to passage 5. 
However, at passage 12 the apparent flux of L-lactate was increased ca. 11 fold 
with respect to passage 5. In cells treated with SFN the apparent flux of L-lactate 
was increased similarly excepting a 23% decrease in apparent flux of L-lactate at 
passage 12 compared to control cultures. This was reflected by a decrease in 
glycolytic activity as well as the flux of formation of D-lactate (% glucotriose) 
increase (**p<0.02) in senescent MRC-5 fibroblasts treated with 1 µM SFN 
compared to control. 
 
5.3.3 Effect of sulforaphane on the cellular content of glycolytic intermediates 
 To investigate the effect of SFN on early-stage glycolysis in MRC-5 cells, 
the changes in the cellular concentrations of glycolytic intermediates were 
quantified. Key initial intermediates potentially regulated by SFN are G6P, F6P 
and PGA were quantified in MRC-5 cells with and without SFN. Short term 
incubation with SFN in high glucose concentration medium decreased the 
cellular content of G6P and concurrently increased the cellular content of PGA 
without change in the cellular content of F6P. The cellular contents of G6P, PGA 
and F6P were higher in control cells at passage 9 than at passage 5. Addition of 
SFN decreased F6P in passage 5 but was without effect on other glycolytic 
intermediates in passage 5 and passage 9. Although CR studies have consistently 
shown a beneficial effect towards extended life span in animals (Murphy and 
Partridge, 2008; Weindruch  et al., 1986), the mechanism by which fluctuations 
of glucose metabolism acts on the Nrf2 system and senescence is still under 
scrutiny. Although the PPP is a well-established metabolic pathway, a direct 
regulator that activates the PPP during metabolic reprogramming has yet to be 
identified (Mitsuishi et al., 2012). As shown by Bensaad et al. (2006), SFN has 
been shown to act as a CRM dietary bioactive through cellular contents of 
glycolytic intermediates with SFN-treatment. However, because glycolysis is 
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often facilitated in proliferating cells, alternative mechanisms that actively 
promote the PPP are expected to be involved. Also, as described by Singh et al. 
(2013), Nrf2 coordinates the regulation of key genes involved in various 
pathways of glucose metabolism, including the pentose phosphate pathway 
(PPP). Our study demonstrates the effects of SFN in delaying senescence by CR 
mimetics through the PPP by decreasing the cellular content of G6P and 
concurrently increasing the cellular content of PGA. 
 
5.3.4. Characterization of glucose sensing by ChREBP/MondoA-Mlx 
transcription factors in response to SFN treatment in MRC-5 fibroblasts. 
 A transcription factor sensitive to the cellular content of G6P is 
carbohydrate response element binding protein or Mondo A in fibroblasts. When 
Mondo A is activated it binds G6P and translocates to the cell nucleus. To study 
the effect of SFN on cellular activation of Mondo A, MRC-5 cells were incubated 
with and without SFN with low and high glucose concentrations. MRC-5 cells 
were then fixed and immunocytofluorescence microscopy performed to study the 
subcellular location of Mondo A. 
 When MRC-5 cells were incubated overnight in low glucose concentration 
(0.2 mM) followed by 6 h with high glucose concentration (25 mM), 
immunostaining for Mondo A showed high intensity staining in the cell nucleus in 
control cultures which was suppressed by incubation with 1 µM SFN. Following 
incubation in normal glucose concentration (5.5 mM) of MRC-5 cells, 
immunostaining for Mondo A showed no staining in the cell nucleus. However, 
high intensity staining was seen in the cell nucleus of cultures receiving 
subsequent treatment with high glucose concentration (25 mM) for 6h. which was 
then suppressed by incubation with 1 µM SFN. When MRC-5 cells were 
incubated overnight in high glucose concentration (25 mM), immunostaining for 
Mondo A showed no staining in the cell nucleus in control cultures. Surprisingly, 
in the same cultures, when MRC-5 cells were incubated overnight in high glucose 
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concentration (25 mM) with addition of 1 µM SFN, immunostaining for Mondo A 
showed slightly higher intensity staining in the cell nucleus.  
Multicellular animals sense and control their glucose homeostasis at several 
levels. Systemic regulation by insulin and glucagon maintains levels of circulating 
glucose constant during fluctuating nutritional conditions. Upon feeding, elevated 
circulating glucose is taken up by muscle, liver and adipose tissue through the 
actions of insulin signaling, while starvation elevates glucagon levels to promote 
glycogenolysis and gluconeogenesis (Havua and Hietakangas 2012). The 
intracellular glucose is rapidly converted into glucose-6-phosphate and glucose-6-
phosphate activates two paralogous basic helix-loop-helix-leucine zipper 
(bHLHZ) transcription factors (TFs) ChREBP and MondoA, which 
heterodimerize with their common binding partner Mlx. This bHLHZ complex 
resembles the evolutionarily related Myc–Max complex. As reviewed by Havua 
and Hietakangas (2012) ChREBP/Mondo–Mlx is known to mediate a majority of 
the glucose-induced transcriptional response by binding to target gene promoters 
containing so-called carbohydrate response elements (ChoREs). 
The findings of this immunofluorescence study confirm findings by Billin and 
colleagues (2000), that regulation of ChREBP/MondoA–Mlx complexes involves 
shuttling between cytoplasm and nucleus. Moreover, treatment with SFN 
counteracted this translocation to the nucleus which is thought to be though CR 
mimetics activity of this bioactive compound. Moreover, translocation of Mondo 
A inside the nucleus as shown by immunostaining was more pronounced as a 
result of incubation with high glucose (25 mM) incubation which was also shown 
in the literature by the use of a glucose analog 2-deoxyglucose (2-DG) which was 
phosphorylated into 2-deoxyglucose-6-phosphate (2-DG6P), but which cannot be 
processed further, leading to 2-DG6P accumulation. In response to 2-DG 
treatment, MondoA–Mlx translocated into the nucleus and strongly transactivated 
target genes (Havua and Hietakangas, 2012) and furthermore, ChREBP was 
shown to be activated by fructose 2,6 bisphosphate in hepatocytes. Summary of 
the mechanism of activation of the Nrf2 system and delay of senescence by SFN 
in MRC-5 fibroblasts is shown in Figure 113. 
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Figure 113. Summary of mechanism of activation of Nrf2 system and delay of senescence by 
SFN in MRC-5 fibroblasts. 
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6. Conclusion and Further work 
 
6.1 Conclusion 
 
This PhD project was comprised of three parts: 
 
i. To study the effects of SFN and HESP on MRC-5 cell senescence in vitro 
ii. To characterize gene expression and cell metabolism in cells escaping 
senescence by treatment with SFN and HESP 
iii. To characterize the mechanism of decrease glucose metabolism by SFN 
and HESP action linked to delay of fibroblast senescence 
The effects of treatment of MRC-5 with the dietary bioactivators SFN and HESP 
was studied and shown to delay cellular senescence in these cells in vitro. Similar 
findings for SFN treatment of BJ cells were found previously by studies of the 
host team. SFN and HESP are compounds available in a diet rich in vegetables 
and fruit. The cell senescence model may translate to some aspects of human 
ageing – for example, immunosenescence and ageing of pre and post-mitotic 
cells. Therefore, this work may indicates routes to functional foods to support 
healthy ageing and reveal cell responses which may underlie the epidemiological 
evidence linking healthy ageing to a diet rich in fruits and vegetables.   
SFN and HESP are thought to mediate health benefits by activation of 
transcription factor Nrf2 system which  regulates the cellular expression of a 
battery of protective genes countering oxidative stress, environment toxic insults, 
lipid peroxidation, macromolecular damage, metabolic dysfunction and cell 
senescence (Rabbani and Thornalley, 2012b; Rabbani and Thornalley, 2014; 
Kapeta et al., 2010).  Moreover, even in non-senescent young fibroblasts, SFN 
treatment had the ability to confer protection against oxidative damage by 
activating their transcription. Moreover, increased expression in NQO1 by SFN 
acts as a positive control for activation through the Nrf2 system (Jain and Jaiswal, 
2007) and confirms its regulation of the ARE. Indeed, expression of anti-oxidant 
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genes were increased at early passage. These effects were replicated in young and 
senescent MRC-5 fibroblasts treated with and without 1µM SFN or 5µM HESP. 
Comparison of Nanostring and transcriptomic methods showed that Nanostring 
method has a better power of identification of changes in mRNA expression. ARE 
linked gene expression analysis from early to senescent MRC-5 findings 
confirmed gene expression decline related to approach to senescence, and also 
confirmed the involvement of ARE in preserving normal cell functions. 
One aspect of Nrf2-regulated, ARE-linked gene expression is involvement in 
pathways of glucose metabolism, including the pentose phosphate pathway (PPP), 
therefore, G6PDH mRNA expression increase with treatment confirmed Nrf2 
activation with SFN which may affect glucose metabolism in MRC-5 fibroblasts. 
The same effect was seen in the expression of the nutrient sensing thioredoxin 
interacting protein (TXNIP) which was increased by more than 2-fold. This 
finding has been demonstrated to link SFN supplementation to CR mimetics as 
TXNIP expression increases (Swindell, 2009). Importantly, Nrf2 activators 
through increasing expression of G6PDH may decreased G6P and thereby 
decrease activation of Mondo A and down-regulate expression of glycolytic and 
lipogenic genes, 
Protection of the cellular proteome and genome was shown to be conferred by 1 
µM SFN treatment of MRC-5 cells. Decreased protein glycation and oxidation is 
part of the beneficial effects found in delay of cells senescence by SFN. A new 
finding was the effect of major quantitative covalent crosslink of cell protein by 
transglutaminases forming GEEK residues at up to 0.8% total lysine residues in 
cells approaching senescence. Suppression of the functional effects of this by 
enhancing clearance of crosslinked protein by SFN is likely a further contributory 
factor in the delay of cell senescence.  
 Caloric restriction mimetic mechanisms by treatment with 1 µM SFN and 
5 µM HESP was shown due to the decrease in culture glucose consumption 
increase with senescence in these treatment groups and this CR restriction 
mimetic effect and decrease in the flux of formation of D- and L-lactate in the 
SFN-treated group was consistent with previous studies done in CR and ageing in 
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mice models (Hargopan, Ramsey and Weindruch, 2003). However, HESP did not 
decrease the flux of formation of D-lactate significantly. Moreover, in this study, 
SFN has been shown to act as a CRM dietary bioactive through cellular contents 
of glycolytic intermediates with SFN-treatment (Bensaad et al., 2006).  
 Finally, the mechanism by which SFN induces delay of senescence 
through CR has been shown to be due to the extraction of Mondo A from the cell 
nucleus to the cytoplasm.  
 
6.2 Further Work 
 
In this study, the delay of senescence of MRC-5 cells by SFN in vitro was 
discovered and the mechanism of action was investigated – discovered a major 
caloric restriction mimetic activity likely mediated through suppression of 
activation of MondoA, enhanced protection against protein and nucleotide 
damage and increased clearance of major crosslinked proteins. Further studies are 
required to build on this and secure the major aspects of this mechanism. 
Quantification of MondoA protein inside and outside the cell by Western Blotting 
was not performed and would provide essential corroborate evidence to confirm 
the MondoA down regulation hypothesis. Finally, in order to be of significance in 
the field of physiological ageing delay, experimental methods should be repeated 
in vivo in mouse models. 
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Appendix A. Isoforms Codeset design of genes of interest for Nanostring analysis: 
sulforaphane treatment in young MRC-5 fibroblasts in vitro 
Gene Probe NSID Tot Isoforms Isoforms Hit by Probe # Hit 
ACTB NM_001101.2:1010 1 NM_001101 1 
AKR1C1 NM_001353.5:1210 1 NM_001353 1 
CAT NM_001752.2:1130 1 NM_001752 1 
CCL2 NM_002982.3:0 1 NM_002982 1 
CDKN1A NM_000389.2:1975 4 
NM_000389;NM_078467;NM_001220778;N
M_001220777 4 
CDKN2A NM_000077.3:975 4 
NM_000077;NM_058197;NM_058195;NM_
001195132 4 
CLTC NM_004859.2:290 1 NM_004859 1 
CTSO NM_001334.2:725 1 NM_001334 1 
CXCL1 NM_001511.1:742 1 NM_001511 1 
ELN NM_000501.1:765 5 
NM_000501;NM_001081755;NM_0010817
54;NM_001081753;NM_001081752 5 
FASN NM_004104.4:5387 1 NM_004104 1 
FTH1 NM_002032.2:941 1 NM_002032 1 
FYN NM_002037.3:765 3 NM_002037;NM_153047;NM_153048 3 
G6PD NM_000402.2:1155 2 NM_000402;NM_001042351 2 
GCLC NM_001498.2:520 2 NM_001498;NM_001197115 2 
GCLM NM_002061.2:599 1 NM_002061 1 
GLB1 NM_000404.2:955 3 
NM_000404;NM_001079811;NM_0011356
02 3 
GLO1 NM_006708.1:1240 1 NM_006708 1 
GPX1 NM_000581.2:745 2 NM_000581;NM_201397 2 
GSR NM_000637.2:1525 4 
NM_000637;NM_001195104;NM_0011951
03;NM_001195102 4 
GSTP1 NM_000852.2:415 1 NM_000852 1 
GUSB NM_000181.1:1350 1 NM_000181 1 
HMOX1 NM_002133.1:1430 1 NM_002133 1 
ICAM1 NM_000201.1:1990 1 NM_000201 1 
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IL15 NM_172174.1:1685 3 
NM_172174;NR_037840;NM_172175;NM_
000585 4 
IL1B NM_000576.2:840 1 NM_000576 1 
KEAP1 NM_012289.3:561 2 NM_012289;NM_203500 2 
MAFG NM_002359.2:3529 2 NM_002359;NM_032711 2 
MMP13 NM_002427.2:951 1 NM_002427 1 
MMP3 NM_002422.3:25 1 NM_002422 1 
ABCC2 NM_000392.3:3150 1 NM_000392 1 
NFE2L2 NM_006164.3:995 3 
NM_006164;NM_001145413;NM_0011454
12 3 
NFKB1 NM_003998.2:1675 2 NM_003998;NM_001165412 2 
RELA NM_021975.2:360 2 NM_021975;NM_001145138 2 
NQO1 NM_000903.2:790 3 
NM_000903;NM_001025434;NM_0010254
33 3 
PFKFB4 NM_004567.2:400 1 NM_004567 1 
PRDX1 NM_002574.2:632 4 
NM_002574;NM_001202431;NM_181696;N
M_181697 4 
PSMA1 NM_148976.2:500 3 NM_148976;NM_001143937;NM_002786 3 
PSMB5 NM_001130725.1:716 3 
NM_001130725;NM_001144932;NM_0027
97 3 
SERPINB2 NM_002575.1:305 2 NM_002575;NM_001143818 2 
SERPINE1 NM_000602.2:2470 2 NM_000602;NM_001165413 2 
SOD1 NM_000454.4:35 1 NM_000454 1 
SOD2 NM_000636.2:640 3 
NM_000636;NM_001024466;NM_0010244
65 3 
SQSTM1 NM_001142298.1:1470 3 
NM_001142298;NM_001142299;NM_0039
00 3 
SREBF1 NM_001005291.1:1392 2 NM_001005291;NM_004176 2 
TALDO1 NM_006755.1:262 1 NM_006755 1 
TKT NM_001064.2:1235 2 NM_001064;NM_001135055 2 
TLR4 NM_138554.2:2570 3 NM_138554;NR_024169;NR_024168 3 
TXN NM_003329.2:55 1 NM_003329 1 
TXNRD1 NM_001093771.1:1009 5 
NM_001093771;NM_182729;NM_003330;N
M_182743;NM_182742 5 
 
 242 
 
 
 
Appendix B. Targets Codeset design of genes of interest for Nanostring analysis: sulforaphane 
treatment in young MRC-5 fibroblasts in vitro 
 
Gene 
Targ 
Regi
on  Target Sequence 
AKR1C1 
1210
-
1310 
AGAGGATGGCTCTATGCTGGTGACTGGACACATCGCCTCTGGTTAAATCTCTCCTGCTTGGTGATTTCAGCAAGCTAC
AGCAAAGCCCATTGGCCAGAAA 
GLO1 
1240
-
1340 
GGAAATGATATGGTACCCAGACACTGGGCTAGGCTGCAACTTTATCTCATTTAATACTCCCAGCTGTCATGTGAGAAA
GAAAGCAGGCTAGGCATGTGAA 
CAT 
1130
-
1230 
ATGCTTCAGGGCCGCCTTTTTGCCTATCCTGACACTCACCGCCATCGCCTGGGACCCAATTATCTTCATATACCTGTG
AACTGTCCCTACCGTGCTCGAG 
GCLC 
520-
620 
CTCAAGTGGGGCGATGAGGTGGAATACATGTTGGTATCTTTTGATCATGAAAATAAAAAAGTCCGGTTGGTCCTGTCT
GGGGAGAAAGTTCTTGAAACTC 
GCLM 
599-
699 
TCATCATCAACTAGAAGTGCAGTTGACATGGCCTGTTCAGTCCTTGGAGTTGCACAGCTGGATTCTGTGATCATTGCTT
CACCTCCTATTGAAGATGGAG 
NQO1 
790-
890 
CCGAATTCAAATCCTGGAAGGATGGAAGAAACGCCTGGAGAATATTTGGGATGAGACACCACTGTATTTTGCTCCAAG
CAGCCTCTTTGACCTAAACTTC 
TXNRD1 
1009
-
1109 
AGTGATGATCTTTTCTCCTTGCCTTACTGCCCGGGTAAGACCCTGGTTGTTGGAGCATCCTATGTCGCTTTGGAGTGC
GCTGGATTTCTTGCTGGTATTG 
TXN 
55-
155 
CAGCCAAGATGGTGAAGCAGATCGAGAGCAAGACTGCTTTTCAGGAAGCCTTGGACGCTGCAGGTGATAAACTTGTA
GTAGTTGACTTCTCAGCCACGTG 
GSR 
1525
-
1625 
ATGCAGGGACTTGGGTGTGATGAAATGCTGCAGGGTTTTGCTGTTGCAGTGAAGATGGGAGCAACGAAGGCAGACTT
TGACAACACAGTCGCCATTCACC 
HMOX1 
1430
-
1530 
TGTTGTTTTTATAGCAGGGTTGGGGTGGTTTTTGAGCCATGCGTGGGTGGGGAGGGAGGTGTTTAACGGCACTGTGG
CCTTGGTCTAACTTTTGTGTGAA 
SOD1 
35-
135 
GCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGCAGCGTCTGGGGTTTCCGTTGCAGT
CCTCGGAACCAGGACCTCGGCGT 
 243 
 
PRDX1 
632-
732 
GACCCATGAACATTCCTTTGGTATCAGACCCGAAGCGCACCATTGCTCAGGATTATGGGGTCTTAAAGGCTGATGAAG
GCATCTCGTTCAGGGGCCTTTT 
GPX1 
745-
845 
GGTTTTCATCTATGAGGGTGTTTCCTCTAAACCTACGAGGGAGGAACACCTGATCTTACAGAAAATACCACCTCGAGA
TGGGTGCTGGTCCTGTTGATCC 
FTH1 
941-
1041 
GGTACCCAGGTGTTGTCTTTGAGGTCTTGGGATGAATCAGAAATCTATCCAGGCTATCTTCCAGATTCCTTAAGTGCC
GTTGTTCAGTTCTAATCACACT 
GSTP1 
415-
515 
TTTTGAGACCCTGCTGTCCCAGAACCAGGGAGGCAAGACCTTCATTGTGGGAGACCAGATCTCCTTCGCTGACTACAA
CCTGCTGGACTTGCTGCTGATC 
Mrp2/UGT
1A1 
3150
-
3250 
CAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGGGACATGAGAGTTGGAGTCTACGGAGCTCT
GGGATTAGCCCAAGGTATATTT 
TALDO1 
262-
362 
GCTGGGCGGGTCACAAGAGGACCAGATTAAAAATGCTATTGATAAACTTTTTGTGTTGTTTGGAGCAGAAATACTAAAG
AAGATTCCGGGCCGAGTATCC 
TKT 
1235
-
1335 
TGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTCG
CATGGCCGCCATCTCCGAGAGCA 
G6PD 
1155
-
1255 
ACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCCTTTGGCACTGAGGGTCGCGGGGGCTATTTCGATGAATTTG
GGATCATCCGGGACGTGATGCA 
SREBF1 
1392
-
1492 
TTCGCTTTCTGCAACACAGCAACCAGAAACTCAAGCAGGAGAACCTAAGTCTGCGCACTGCTGTCCACAAAAGCAAAT
CTCTGAAGGATCTGGTGTCGGC 
FASN 
5387
-
5487 
GAGGTGCTTGGCTACGCACGGTCGCTTCCTGGAAATTGGCAAATTCGACCTTTCTCAGAACCACCCGCTCGGCATGG
CTATCTTCCTGAAGAACGTGACA 
PFKFB4 
400-
500 
TGATGCCACAAACACCACCCGAGAACGGAGAGCGACCATCTTTAATTTTGGAGAACAGAATGGCTACAAGACCTTTTT
TGTCGAGTCCATCTGTGTGGAT 
NFE2L2 
995-
1095 
TCCCGGTCACATCGAGAGCCCAGTCTTCATTGCTACTAATCAGGCTCAGTCACCTGAAACTTCTGTTGCTCAGGTAGC
CCCTGTTGATTTAGACGGTATG 
KEAP1 
561-
661 
CTCATTGAATTCGCCTACACGGCCTCCATCTCCATGGGCGAGAAGTGTGTCCTCCACGTCATGAACGGTGCTGTCATG
TACCAGATCGACAGCGTTGTCC 
MAFG 
3529
-
3629 
CTTCCCCTGGATTTCCTGACATAGATGGTGTGTTCATGTGCAGGTGTGAGTGTGCTGTCCTTCTGATCTCTGTTGATCC
CGCTTTCCTACTGAGAGGGTG 
FYN 
765-
865 
GTCTTTGGAGGTGTGAACTCTTCGTCTCATACGGGGACCTTGCGTACGAGAGGAGGAACAGGAGTGACACTCTTTGT
GGCCCTTTATGACTATGAAGCAC 
PSMA1 
500-
600 
GGTTGCATTGAAAAGGGCGCAATCAGAGCTTGCAGCTCATCAGAAAAAAATTCTCCATGTTGACAACCATATTGGTATC
TCAATTGCGGGGCTTACTGCT 
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PSMB5 
716-
816 
CAGCTGCTTGTGTTTCTTGGGGTGACTGTCATTGGTAATACGGACACAGTGACCCATCCTCCATCCTATTTATAGTGGA
AGGGCCTTCAATTGTATCAGT 
SQSTM1 
1470
-
1570 
TCATAGTTGTGTTAAGCTTGCGTAGAATTGCAGGTCTCTGTACGGGCCAGTTTCTCTGCCTTCTTCCAGGATCAGGGG
TTAGGGTGCAAGAAGCCATTTA 
CCL2 
0-
100 
GAGGAACCGAGAGGCTGAGACTAACCCAGAAACATCCAATTCTCAAACTGAAGCTCGCACTCTCGCCTCCAGCATGA
AAGTCTCTGCCGCCCTTCTGTGC 
CXCL1 
742-
842 
TATGTTAATATTTCTGAGGAGCCTGCAACATGCCAGCCACTGTGATAGAGGCTGGCGGATCCAAGCAAATGGCCAATG
AGATCATTGTGAAGGCAGGGGA 
IL15 
1685
-
1785 
AGGGTGATAGTCAAATTATGTATTGGTGGGGCTGGGTACCAATGCTGCAGGTCAACAGCTATGCTGGTAGGCTCCTG
CCAGTGTGGAACCACTGACTACT 
IL1B 
840-
940 
GGGACCAAAGGCGGCCAGGATATAACTGACTTCACCATGCAATTTGTGTCTTCCTAAAGAGAGCTGTACCCAGAGAGT
CCTGTGCTGAATGTGGACTCAA 
TLR4 
2570
-
2670 
ACTCAGAAAAGCCCTGCTGGATGGTAAATCATGGAATCCAGAAGGAACAGTGGGTACAGGATGCAATTGGCAGGAAG
CAACATCTATCTGAAGAGGAAAA 
NFKB3 
360-
460 
GATGGCTTCTATGAGGCTGAGCTCTGCCCGGACCGCTGCATCCACAGTTTCCAGAACCTGGGAATCCAGTGTGTGAA
GAAGCGGGACCTGGAGCAGGCTA 
NFKB1 
1675
-
1775 
AGGGTATAGCTTCCCACACTATGGATTTCCTACTTATGGTGGGATTACTTTCCATCCTGGAACTACTAAATCTAATGCT
GGGATGAAGCATGGAACCATG 
ICAM1 
1990
-
2090 
GAAATACTGAAACTTGCTGCCTATTGGGTATGCTGAGGCCCACAGACTTACAGAAGAAGTGGCCCTCCATAGACATGT
GTAGCATCAAAACACAAAGGCC 
MMP3 
25-
125 
AGGCATAGAGACAACATAGAGCTAAGTAAAGCCAGTGGAAATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGC
AGTTTGCTCAGCCTATCCATTG 
MMP13 
951-
1051 
CTGGCGCCTGCATCCTCAGCAGGTTGATGCGGAGCTGTTTTTAACGAAATCATTTTGGCCAGAACTTCCCAACCGTAT
TGATGCTGCATATGAGCACCCT 
SOD2 
640-
740 
GCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGC
TTACTACCTTCAGTATAAAAATG 
ELN 
765-
865 
GCAGCAGCGGCAGCTAAAGCAGCAGCAAAGTTCGGTGCTGGAGCAGCCGGAGTCCTCCCTGGTGTTGGAGGGGCT
GGTGTTCCTGGCGTGCCTGGGGCAA 
CTSO 
725-
825 
ACCAAGAAGATGAAATGGCAAAAGCACTTCTTACCTTTGGCCCTTTGGTAGTCATAGTAGATGCAGTGAGCTGGCAAG
ATTATCTGGGAGGCATTATACA 
SERPINE
1 
2470
-
2570 
TGTGTTCAATAGATTTAGGAGCAGAAATGCAAGGGGCTGCATGACCTACCAGGACAGAACTTTCCCCAATTACAGGGT
GACTCACAGCCGCATTGGTGAC 
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SERPINB
2 
305-
405 
CTGTGGGTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCAGATAAAATCCA
TTCATCCTTCCGCTCTCTCAGC 
GLB1 
955-
1055 
CTCACTCCACAATCAAGACCGAAGCAGTGGCTTCCTCCCTCTATGATATACTTGCCCGTGGGGCGAGTGTGAACTTGT
ACATGTTTATAGGTGGGACCAA 
CDKN2A 
975-
1075 
AAGCGCACATTCATGTGGGCATTTCTTGCGAGCCTCGCAGCCTCCGGAAGCTGTCGACTTCATGACAAGCATTTTGTG
AACTAGGGAAGCTCAGGGGGGT 
CDKN1A 
1975
-
2075 
CATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAGGGACCACACCCTGTACTGTTCTGTG
TCTTTCACAGCTCCTCCCACAA 
ACTB 
1010
-
1110 
TGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGATCAAGATCATTGCTCCTCCTGAGCGCAAGTACTCC
GTGTGGATCGGCGGCTCCATCCT 
CLTC 
290-
390 
GGGTATCAACCCAGCAAACATTGGCTTCAGTACCCTGACTATGGAGTCTGACAAATTCATCTGCATTAGAGAAAAAGTA
GGAGAGCAGGCCCAGGTGGTA 
GUSB 
1350
-
1450 
CGGTCGTGATGTGGTCTGTGGCCAACGAGCCTGCGTCCCACCTAGAATCTGCTGGCTACTACTTGAAGATGGTGATC
GCTCACACCAAATCCTTGGACCC 
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Appendix C. Isoforms Codeset design of genes of interest for Nanostring analysis: early and 
late passage expression analysis in response to sulforaphane and hesperetin 
 
Gene Probe NSID Tot Isoforms Isoforms Hit by Probe 
# 
Hit 
ABCC2 NM_000392.3:3150 1 NM_000392 1 
ACTB NM_001101.2:1010 1 NM_001101 1 
AKR1C1 NM_001353.5:1210 1 NM_001353 1 
CAT NM_001752.2:1130 1 NM_001752 1 
CCL2 NM_002982.3:0 1 NM_002982 1 
CDKN1A NM_000389.2:1975 4 
NM_000389;NM_078467;NM_001220778;NM_0
01220777 4 
CLTC NM_004859.2:290 1 NM_004859 1 
COL1A1 NM_000088.3:5210 1 NM_000088 1 
ELN NM_001081754.1:2666 13 
NM_001081754;NM_000501;NM_001278918;N
M_001278917;NM_001278916;NM_001278915;
NM_001278914;NM_001278913;NM_00127891
2;NM_001081755;NM_001081753;NM_001081
752;NM_001278939 13 
FASN NM_004104.4:5387 1 NM_004104 1 
FTH1 NM_002032.2:392 1 NM_002032 1 
G6PD NM_000402.2:1155 2 NM_000402;NM_001042351 2 
GCLC NM_001498.2:520 2 NM_001498;NM_001197115 2 
GCLM NM_002061.2:599 1 NM_002061 1 
GLB1 NM_000404.2:955 3 NM_000404;NM_001079811;NM_001135602 3 
GLO1 NM_006708.1:1240 1 NM_006708 1 
GPX1 NM_000581.2:745 2 NM_000581;NM_201397 2 
GSR NM_000637.2:1525 4 
NM_000637;NM_001195104;NM_001195103;N
M_001195102 4 
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GSTP1 NM_000852.2:415 1 NM_000852 1 
GUSB NM_000181.1:1350 1 NM_000181 1 
HIF1A NM_001530.2:1985 3 NM_001530;NM_001243084;NM_181054 3 
HK1 NM_000188.2:3355 5 
NM_000188;NM_033497;NM_033498;NM_0335
00;NM_033496 5 
HMOX1 NM_002133.1:1430 1 NM_002133 1 
ICAM1 NM_000201.2:2253 1 NM_000201 1 
KEAP1 NM_012289.3:561 2 NM_012289;NM_203500 2 
MAFG NM_002359.2:3529 2 NM_002359;NM_032711 2 
MLX NM_170607.2:565 3 NM_170607;NM_198205;NM_198204 3 
MLXIP NM_014938.3:945 1 NM_014938 1 
MMP1 NM_002421.2:700 2 NM_002421;NM_001145938 2 
MMP13 NM_002427.2:951 1 NM_002427 1 
MMP3 NM_002422.3:25 1 NM_002422 1 
NFE2L2 NM_006164.3:995 3 NM_006164;NM_001145413;NM_001145412 3 
NFKB1 NM_003998.2:1675 2 NM_003998;NM_001165412 2 
NQO1 NM_000903.2:790 3 NM_000903;NM_001025434;NM_001025433 3 
PFKFB2 NM_001018053.1:445 2 NM_001018053;NM_006212 2 
PRDX1 NM_002574.2:632 4 
NM_002574;NM_001202431;NM_181696;NM_1
81697 4 
PSMA1 NM_148976.2:500 3 NM_148976;NM_001143937;NM_002786 3 
PSMB5 NM_001130725.1:716 3 NM_001130725;NM_001144932;NM_002797 3 
RELA NM_021975.2:360 4 
NM_021975;NM_001145138;NM_001243985;N
M_001243984 4 
SERPINB2 NM_002575.1:305 2 NM_002575;NM_001143818 2 
SOD1 NM_000454.4:35 1 NM_000454 1 
SOD2 NM_000636.2:640 3 NM_000636;NM_001024466;NM_001024465 3 
SQSTM1 NM_003900.3:1445 3 NM_003900;NM_001142299;NM_001142298 3 
SREBF1 NM_001005291.1:1392 2 NM_001005291;NM_004176 2 
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TALDO1 NM_006755.1:262 1 NM_006755 1 
TKT NM_001064.2:1235 4 
NM_001064;NR_047580;NM_001135055;NM_0
01258028 4 
TLR4 NM_138554.2:2570 3 NM_138554;NM_138557;NM_003266 3 
TXN NM_003329.2:55 2 NM_003329;NM_001244938 2 
TXNIP NM_006472.1:255 1 NM_006472 1 
TXNRD1 NM_001093771.1:1009 7 
NM_001093771;NM_001261446;NM_00126144
5;NM_003330;NM_182743;NM_182729;NM_18
2742 7 
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Appendix D. Targets Codeset design of genes of interest for Nanostring analysis: early and 
late passage expression analysis in response to sulforaphane and hesperetin 
 
Gene 
Targ 
Regi
on  Target Sequence 
Mrp2/UGT
1A1 
3151
-
3250 
CAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGGGACATGAGAGTTGGAGTCTACGGAGCTCT
GGGATTAGCCCAAGGTATATTT 
ACTB 
1011
-
1110 
TGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGATCAAGATCATTGCTCCTCCTGAGCGCAAGTACTCC
GTGTGGATCGGCGGCTCCATCCT 
AKR1C1 
1211
-
1310 
AGAGGATGGCTCTATGCTGGTGACTGGACACATCGCCTCTGGTTAAATCTCTCCTGCTTGGTGATTTCAGCAAGCTAC
AGCAAAGCCCATTGGCCAGAAA 
CAT 
1131
-
1230 
ATGCTTCAGGGCCGCCTTTTTGCCTATCCTGACACTCACCGCCATCGCCTGGGACCCAATTATCTTCATATACCTGTG
AACTGTCCCTACCGTGCTCGAG 
CCL2 
1-
100 
GAGGAACCGAGAGGCTGAGACTAACCCAGAAACATCCAATTCTCAAACTGAAGCTCGCACTCTCGCCTCCAGCATGA
AAGTCTCTGCCGCCCTTCTGTGC 
CDKN1A 
1976
-
2075 
CATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAGGGACCACACCCTGTACTGTTCTGTG
TCTTTCACAGCTCCTCCCACAA 
CLTC 
291-
390 
GGGTATCAACCCAGCAAACATTGGCTTCAGTACCCTGACTATGGAGTCTGACAAATTCATCTGCATTAGAGAAAAAGT
AGGAGAGCAGGCCCAGGTGGTA 
COL1A1 
5211
-
5310 
CAGAAACATCGGATTTGGGGAACGCGTGTCAATCCCTTGTGCCGCAGGGCTGGGCGGGAGAGACTGTTCTGTTCCTT
GTGTAACTGTGTTGCTGAAAGAC 
ELN 
2667
-
2766 
CCACCGTTGGCTGCCATCCAGTTGGTACCCAAGCACCTGAAGCCTCAAAGCTGGATTCGCTCTAGCATCCCTCCTCT
CCTGGGTCCACTTGGCCGTCTCC 
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FASN 
5388
-
5487 
GAGGTGCTTGGCTACGCACGGTCGCTTCCTGGAAATTGGCAAATTCGACCTTTCTCAGAACCACCCGCTCGGCATGG
CTATCTTCCTGAAGAACGTGACA 
FTH1 
393-
492 
CCAAATACTTTCTTCACCAATCTCATGAGGAGAGGGAACATGCTGAGAAACTGATGAAGCTGCAGAACCAACGAGGTG
GCCGAATCTTCCTTCAGGATAT 
G6PD 
1156
-
1255 
ACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCCTTTGGCACTGAGGGTCGCGGGGGCTATTTCGATGAATTT
GGGATCATCCGGGACGTGATGCA 
GCLC 
521-
620 
CTCAAGTGGGGCGATGAGGTGGAATACATGTTGGTATCTTTTGATCATGAAAATAAAAAAGTCCGGTTGGTCCTGTCT
GGGGAGAAAGTTCTTGAAACTC 
GCLM 
600-
699 
TCATCATCAACTAGAAGTGCAGTTGACATGGCCTGTTCAGTCCTTGGAGTTGCACAGCTGGATTCTGTGATCATTGCT
TCACCTCCTATTGAAGATGGAG 
GLB1 
956-
1055 
CTCACTCCACAATCAAGACCGAAGCAGTGGCTTCCTCCCTCTATGATATACTTGCCCGTGGGGCGAGTGTGAACTTGT
ACATGTTTATAGGTGGGACCAA 
GLO1 
1241
-
1340 
GGAAATGATATGGTACCCAGACACTGGGCTAGGCTGCAACTTTATCTCATTTAATACTCCCAGCTGTCATGTGAGAAA
GAAAGCAGGCTAGGCATGTGAA 
GPX1 
746-
845 
GGTTTTCATCTATGAGGGTGTTTCCTCTAAACCTACGAGGGAGGAACACCTGATCTTACAGAAAATACCACCTCGAGA
TGGGTGCTGGTCCTGTTGATCC 
GSR 
1526
-
1625 
ATGCAGGGACTTGGGTGTGATGAAATGCTGCAGGGTTTTGCTGTTGCAGTGAAGATGGGAGCAACGAAGGCAGACTT
TGACAACACAGTCGCCATTCACC 
GSTP1 
416-
515 
TTTTGAGACCCTGCTGTCCCAGAACCAGGGAGGCAAGACCTTCATTGTGGGAGACCAGATCTCCTTCGCTGACTACA
ACCTGCTGGACTTGCTGCTGATC 
GUSB 
1351
-
1450 
CGGTCGTGATGTGGTCTGTGGCCAACGAGCCTGCGTCCCACCTAGAATCTGCTGGCTACTACTTGAAGATGGTGATC
GCTCACACCAAATCCTTGGACCC 
HIF1A 
1986
-
2085 
ATGGATGATGACTTCCAGTTACGTTCCTTCGATCAGTTGTCACCATTAGAAAGCAGTTCCGCAAGCCCTGAAAGCGCA
AGTCCTCAAAGCACAGTTACAG 
HK1 
3356
-
3455 
CTGTGGCCTGGCATCGCATCGTGGTGTGTCAATGCCACAAAATCGTGTGTCCGTGGAACCAGTCCTAGCCGCGTGTG
ACAGTCTTGCATTCTGTTTGTCT 
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HMOX1 
1431
-
1530 
TGTTGTTTTTATAGCAGGGTTGGGGTGGTTTTTGAGCCATGCGTGGGTGGGGAGGGAGGTGTTTAACGGCACTGTGG
CCTTGGTCTAACTTTTGTGTGAA 
ICAM1 
2254
-
2353 
AAATACTGAAACTTGCTGCCTATTGGGTATGCTGAGGCCCCACAGACTTACAGAAGAAGTGGCCCTCCATAGACATGT
GTAGCATCAAAACACAAAGGCC 
KEAP1 
562-
661 
CTCATTGAATTCGCCTACACGGCCTCCATCTCCATGGGCGAGAAGTGTGTCCTCCACGTCATGAACGGTGCTGTCAT
GTACCAGATCGACAGCGTTGTCC 
MAFG 
3530
-
3629 
CTTCCCCTGGATTTCCTGACATAGATGGTGTGTTCATGTGCAGGTGTGAGTGTGCTGTCCTTCTGATCTCTGTTGATC
CCGCTTTCCTACTGAGAGGGTG 
MLX 
566-
665 
CTCCCAAAAGCTCAGCAAAGCCATCGTTCTACAAAAGACCATTGACTACATTCAGTTTTTGCACAAGGAGAAGAAAAA
GCAGGAGGAGGAGGTGTCCACG 
MLXIP 
946-
1045 
CTGATTCCTTTGCAGCCTAACCTGGACTTCATGGACACCTTTGAGCCTTTCCAGGACCTCTTCTCTTCTAGCCGCTCC
ATTTTTGGCTCCATGCTACCTG 
MMP1 
701-
800 
CAACTTACATCGTGTTGCGGCTCATGAACTCGGCCATTCTCTTGGACTCTCCCATTCTACTGATATCGGGGCTTTGAT
GTACCCTAGCTACACCTTCAGT 
MMP13 
952-
1051 
CTGGCGCCTGCATCCTCAGCAGGTTGATGCGGAGCTGTTTTTAACGAAATCATTTTGGCCAGAACTTCCCAACCGTAT
TGATGCTGCATATGAGCACCCT 
MMP3 
26-
125 
AGGCATAGAGACAACATAGAGCTAAGTAAAGCCAGTGGAAATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGC
AGTTTGCTCAGCCTATCCATTG 
NFE2L2 
996-
1095 
TCCCGGTCACATCGAGAGCCCAGTCTTCATTGCTACTAATCAGGCTCAGTCACCTGAAACTTCTGTTGCTCAGGTAGC
CCCTGTTGATTTAGACGGTATG 
NFKB1 
1676
-
1775 
AGGGTATAGCTTCCCACACTATGGATTTCCTACTTATGGTGGGATTACTTTCCATCCTGGAACTACTAAATCTAATGCT
GGGATGAAGCATGGAACCATG 
NQO1 
791-
890 
CCGAATTCAAATCCTGGAAGGATGGAAGAAACGCCTGGAGAATATTTGGGATGAGACACCACTGTATTTTGCTCCAAG
CAGCCTCTTTGACCTAAACTTC 
PFKFB2 
446-
545 
GTTAAGGCGTATCTCACTGAGGAGAATGGTCAGATTGCGGTGTTTGATGCCACCAATACAACCCGGGAGAGGAGGGA
CATGATTTTGAACTTTGCTGAAC 
PRDX1 
633-
732 
GACCCATGAACATTCCTTTGGTATCAGACCCGAAGCGCACCATTGCTCAGGATTATGGGGTCTTAAAGGCTGATGAAG
GCATCTCGTTCAGGGGCCTTTT 
PSMA1 501- GGTTGCATTGAAAAGGGCGCAATCAGAGCTTGCAGCTCATCAGAAAAAAATTCTCCATGTTGACAACCATATTGGTAT
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600 CTCAATTGCGGGGCTTACTGCT 
PSMB5 
717-
816 
CAGCTGCTTGTGTTTCTTGGGGTGACTGTCATTGGTAATACGGACACAGTGACCCATCCTCCATCCTATTTATAGTGG
AAGGGCCTTCAATTGTATCAGT 
NFKB3 
361-
460 
GATGGCTTCTATGAGGCTGAGCTCTGCCCGGACCGCTGCATCCACAGTTTCCAGAACCTGGGAATCCAGTGTGTGAA
GAAGCGGGACCTGGAGCAGGCTA 
SERPINB2 
306-
405 
CTGTGGGTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCAGATAAAATCCA
TTCATCCTTCCGCTCTCTCAGC 
SOD1 
36-
135 
GCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGCAGCGTCTGGGGTTTCCGTTGCAGT
CCTCGGAACCAGGACCTCGGCGT 
SOD2 
641-
740 
GCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGC
TTACTACCTTCAGTATAAAAATG 
SQSTM1 
1446
-
1545 
GGGCCAGTTTCTCTGCCTTCTTCCAGGATCAGGGGTTAGGGTGCAAGAAGCCATTTAGGGCAGCAAAACAAGTGACA
TGAAGGGAGGGTCCCTGTGTGTG 
SREBF1 
1393
-
1492 
TTCGCTTTCTGCAACACAGCAACCAGAAACTCAAGCAGGAGAACCTAAGTCTGCGCACTGCTGTCCACAAAAGCAAAT
CTCTGAAGGATCTGGTGTCGGC 
TALDO1 
263-
362 
GCTGGGCGGGTCACAAGAGGACCAGATTAAAAATGCTATTGATAAACTTTTTGTGTTGTTTGGAGCAGAAATACTAAA
GAAGATTCCGGGCCGAGTATCC 
TKT 
1236
-
1335 
TGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTCG
CATGGCCGCCATCTCCGAGAGCA 
TLR4 
2571
-
2670 
ACTCAGAAAAGCCCTGCTGGATGGTAAATCATGGAATCCAGAAGGAACAGTGGGTACAGGATGCAATTGGCAGGAAG
CAACATCTATCTGAAGAGGAAAA 
TXN 
56-
155 
CAGCCAAGATGGTGAAGCAGATCGAGAGCAAGACTGCTTTTCAGGAAGCCTTGGACGCTGCAGGTGATAAACTTGTA
GTAGTTGACTTCTCAGCCACGTG 
TXNIP 
256-
355 
TGGTCTTTAACGACCCTGAAAAGGTGTACGGCAGTGGCGAGAGGGTGGCTGGCCGGGTGATAGTGGAGGTGTGTGA
AGTTACTCGTGTCAAAGCCGTTAG 
TXNRD1 
1010
-
1109 
AGTGATGATCTTTTCTCCTTGCCTTACTGCCCGGGTAAGACCCTGGTTGTTGGAGCATCCTATGTCGCTTTGGAGTGC
GCTGGATTTCTTGCTGGTATTG 
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Appendix E. Significant changes in microarray gene 
expression between controls at passage 3 and controls at 
passage 11 after Bonferroni factor of 20773 was applied 
(P<0.05) 
 
Gene ID Significance with BF correction of 20773 Expression 
C11orf70 1.326E-08 3.873 
CXCL2 1.945E-08 -3.042 
LOC644727 1.990E-08 -4.504 
MOB4 2.398E-08 1.810 
COL4A3BP 2.690E-08 0.808 
LOC100499177 3.265E-08 -1.763 
ZMAT2 3.835E-08 1.089 
PDE4DIP 6.129E-08 -1.856 
PRO2852 7.802E-08 -5.223 
SCARNA13 9.806E-08 -2.984 
HLA-E 1.014E-07 1.248 
DNAJC6 1.063E-07 6.408 
ABTB2 1.160E-07 0.989 
BANK1 1.211E-07 3.530 
CPPED1 1.405E-07 3.103 
CCDC144A 1.457E-07 -3.928 
COLEC11 1.556E-07 -1.782 
CCRL1 1.667E-07 5.636 
CCDC144A 1.678E-07 -4.259 
HSD11B1L 1.738E-07 0.754 
LRRC69 2.236E-07 2.971 
HIST2H2AC 3.036E-07 -2.363 
APBB1IP 3.342E-07 5.911 
SNORD12C 3.411E-07 -6.019 
GMFG 3.484E-07 2.075 
UHMK1 3.547E-07 1.499 
DNAJC19 3.887E-07 0.815 
SLC14A1 4.280E-07 2.571 
MTRF1 4.325E-07 -1.240 
OXR1 4.334E-07 -1.473 
SNORD114-3 4.419E-07 -3.536 
MMP3 4.622E-07 3.768 
PPM1N 4.927E-07 -2.089 
LOC400499 5.310E-07 -1.547 
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RGS16 5.439E-07 3.234 
TAX1BP1 5.536E-07 0.763 
TRIM63 5.764E-07 5.257 
LOC400550 5.784E-07 1.039 
PPP1R3G 6.246E-07 2.781 
TMEM165 6.733E-07 0.797 
TRIM45 6.780E-07 -1.942 
BCOR 6.809E-07 -2.952 
COL23A1 6.865E-07 -2.410 
MUC1 7.121E-07 1.060 
SNORD114-26 7.494E-07 -3.226 
FOSB 7.602E-07 -3.919 
KCTD12 7.644E-07 1.575 
NDST2 7.842E-07 1.232 
GPC4 7.866E-07 1.598 
MANBAL 7.913E-07 1.454 
AMPD3 7.975E-07 -2.095 
STYK1 8.146E-07 2.393 
ATCAY 9.127E-07 5.906 
LOC731275 9.143E-07 -2.289 
ABCC3 9.385E-07 -1.803 
LOC401320 9.615E-07 -3.689 
LYPD5 9.626E-07 4.434 
TMEM176A 9.838E-07 4.391 
FBXL17 1.004E-06 -3.316 
PRPF39 1.015E-06 -1.875 
LOC645752 1.017E-06 -3.422 
D4S234E 1.042E-06 2.331 
HIST1H4A 1.051E-06 -3.158 
ADHFE1 1.057E-06 -2.916 
FLJ41170 1.068E-06 -4.372 
XLOC_l2_001134 1.072E-06 -2.417 
NPY 1.074E-06 6.502 
ND1 1.075E-06 -1.857 
LOC440149 1.125E-06 1.861 
LYNX1 1.147E-06 0.850 
NKTR 1.164E-06 -2.329 
ABCC10 1.256E-06 -2.888 
XLOC_003406 1.294E-06 -1.788 
GOLGA6L9 1.330E-06 -2.410 
NAMPT 1.353E-06 -6.265 
DAAM2 1.371E-06 1.946 
FOXL2 1.391E-06 5.013 
LOC400464 1.437E-06 -3.514 
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CASKIN2 1.468E-06 -4.393 
TBC1D3G 1.470E-06 -2.861 
INA 1.477E-06 2.182 
PDP2 1.508E-06 1.343 
ACAD10 1.516E-06 -0.639 
XLOC_012991 1.573E-06 -3.685 
SMA4 1.579E-06 -4.063 
SYPL2 1.637E-06 2.921 
ZNF169 1.666E-06 -1.954 
FBXL19-AS1 1.688E-06 -2.960 
SORT1 1.698E-06 1.685 
SNORD114-17 1.703E-06 -3.510 
SAP25 1.736E-06 -3.412 
MALAT1 1.739E-06 -3.784 
SEPP1 1.771E-06 3.632 
CTBS 1.785E-06 1.041 
LAT 1.789E-06 -1.954 
MATN3 1.792E-06 1.965 
RNU6ATAC 1.810E-06 -5.818 
UFD1L 1.813E-06 1.251 
SLC25A16 1.826E-06 -3.112 
PDK2 1.836E-06 1.730 
Q8RQM5 1.866E-06 -2.145 
FLJ44342 1.866E-06 -3.414 
RCAN3 1.867E-06 1.435 
SHC4 1.922E-06 1.947 
FLJ45248 1.929E-06 -1.719 
PSG1 1.935E-06 1.955 
L2HGDH 2.036E-06 -2.435 
LOC401357 2.039E-06 -2.418 
NR5A2 2.050E-06 6.826 
XLOC_003526 2.070E-06 -4.758 
LOC100130587 2.078E-06 -5.856 
RPL23AP32 2.083E-06 -4.432 
XLOC_003526 2.101E-06 -5.374 
TMEM47 2.118E-06 2.687 
PDE11A 2.128E-06 5.175 
CTSL1 2.136E-06 -3.463 
HSD17B6 2.140E-06 4.681 
TMX2 2.176E-06 0.660 
ZNF525 2.190E-06 0.652 
ANKRD36 2.228E-06 -4.618 
SLC9A7P1 2.243E-06 1.765 
CISH 2.243E-06 -5.363 
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FAM22G 2.263E-06 -2.473 
LOC400550 2.263E-06 -0.890 
XLOC_000390 2.296E-06 -4.266 
PSG9 2.303E-06 1.680 
RAI1 2.311E-06 -0.288 
DAP 2.322E-06 2.487 
MAP7D3 2.375E-06 1.661 
C7orf30 2.382E-06 1.330 
MIAT 2.393E-06 -5.711 
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Appendix F. Significant changes in microarray gene 
expression between SFN treatment at passage 11 and 
control at passage 3 after Bonferroni factor of 20773 was 
applied (P<0.05) 
 
Gene ID Significance with BF correction of 20773 Expression 
FAM46C 4.842E-11 1.645 
FAM63A 3.662E-10 1.669 
DIXDC1 9.153E-10 2.502 
FAM134A 1.159E-09 1.434 
FOSB 4.031E-09 -3.437 
KIAA1826 1.935E-08 1.233 
NR5A2 2.379E-08 6.621 
DUSP11 2.664E-08 2.858 
SNORD99 2.724E-08 -4.627 
MYO15B 2.949E-08 -1.737 
HLA-DMB 3.606E-08 5.228 
SNORD113-3 3.925E-08 -2.784 
MOB4 3.939E-08 1.922 
XLOC_l2_002033 3.959E-08 -3.401 
FNBP4 4.649E-08 -1.462 
USP39 6.608E-08 0.898 
TPD52L2 6.789E-08 1.538 
INPP5F 6.914E-08 1.869 
XLOC_003853 7.365E-08 1.000 
D4S234E 7.372E-08 2.701 
XLOC_l2_012319 7.527E-08 3.512 
SLC46A1 8.204E-08 1.697 
SULF1 8.599E-08 4.352 
MPP2 1.004E-07 4.429 
ERLEC1 1.034E-07 1.654 
KRTAP10-1 1.065E-07 -1.036 
FAM3C 1.072E-07 1.605 
TBC1D10B 1.210E-07 0.989 
DUSP5 1.309E-07 -2.178 
LOC100507319 1.381E-07 1.397 
TCP1 1.421E-07 0.981 
FLJ45445 1.450E-07 -1.452 
PCTP 1.468E-07 1.174 
MRPL37 1.481E-07 1.066 
FRAT1 1.485E-07 2.007 
ANKRD43 1.501E-07 4.586 
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AP1B1 1.571E-07 2.003 
ATCAY 1.577E-07 6.412 
SSX2IP 1.618E-07 1.295 
REXO1L1 1.711E-07 -3.236 
FZD4 1.731E-07 2.420 
ACTG1 1.740E-07 1.101 
LOC100133050 1.758E-07 -2.800 
RCAN1 1.769E-07 1.626 
PLOD1 1.776E-07 1.256 
C6orf97 1.779E-07 2.748 
DACT1 1.825E-07 2.610 
KCNQ1OT1 1.838E-07 -2.595 
ARSJ 1.874E-07 0.819 
SERPINE2 1.892E-07 1.697 
NUP93 1.898E-07 1.231 
DNAJC6 1.961E-07 6.644 
POLR2E 1.972E-07 1.279 
EDIL3 2.007E-07 2.311 
XLOC_012645 2.040E-07 4.841 
ITPR1 2.178E-07 2.091 
LOC440028 2.188E-07 1.817 
SLC35E4 2.204E-07 -2.310 
TPRG1L 2.269E-07 2.770 
MICB 2.298E-07 2.555 
VAMP3 2.318E-07 0.706 
HINT3 2.362E-07 1.536 
TRAPPC4 2.385E-07 1.055 
PCSK6 2.501E-07 6.376 
INO80C 2.556E-07 1.440 
LOC645638 2.570E-07 2.286 
LYPD5 2.638E-07 4.996 
MPP2 2.775E-07 4.099 
NPIP 2.775E-07 -2.451 
MOB1A 2.819E-07 1.966 
THAP10 2.833E-07 1.679 
C19orf18 2.993E-07 -1.018 
ZNF219 3.008E-07 1.591 
YIPF6 3.154E-07 1.143 
ASTN2 3.154E-07 2.175 
LOC100506175 3.199E-07 2.675 
ANGPT2 3.212E-07 3.710 
PRKD3 3.337E-07 1.188 
CAMK2D 3.511E-07 -2.191 
ANKRD29 3.619E-07 4.024 
 259 
 
C11orf70 3.636E-07 3.633 
TOPBP1 3.688E-07 -0.491 
RAD9A 3.698E-07 -1.669 
GK 3.716E-07 -4.544 
MMP3 3.783E-07 4.208 
LOC400499 3.860E-07 -2.174 
SRRT 3.987E-07 -0.561 
MED20 4.006E-07 0.735 
C9orf30 4.165E-07 -0.834 
POTEE 4.224E-07 1.237 
WRB 4.282E-07 2.388 
TGFB2 4.568E-07 2.193 
HIF1A 4.611E-07 1.086 
SRI 4.685E-07 1.423 
FOXL2 4.690E-07 5.220 
IER3IP1 4.728E-07 1.000 
APBB1IP 5.041E-07 6.804 
NDN 5.164E-07 3.398 
TARBP1 5.191E-07 -2.114 
MAP3K8 5.309E-07 -3.990 
PDE11A 5.342E-07 5.742 
RNASET2 5.581E-07 1.276 
SSBP3 5.584E-07 1.069 
XLOC_l2_006399 5.718E-07 -4.501 
ADAMTS5 5.863E-07 4.331 
C5orf62 5.953E-07 2.231 
CMKLR1 6.077E-07 4.518 
TOMM20 6.123E-07 1.267 
ZNF526 6.144E-07 -2.635 
SSX2IP 6.194E-07 3.923 
SYPL2 6.217E-07 2.676 
ARMC4 6.228E-07 0.922 
CCRL1 6.266E-07 5.807 
MCART1 6.301E-07 0.705 
TEK 6.314E-07 1.855 
PTGDS 6.543E-07 -4.817 
ACAA2 6.543E-07 2.498 
LOC729040 6.576E-07 -2.220 
LCE2C 6.655E-07 2.971 
FAM60A 6.703E-07 1.051 
RGS16 6.748E-07 3.644 
TXNIP 6.785E-07 6.814 
PPAPDC3 6.827E-07 4.083 
TMCO7 6.839E-07 1.584 
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STARD13 6.933E-07 -3.174 
SLC35E1 6.974E-07 1.015 
EIF4E2 7.031E-07 1.314 
MR1 7.034E-07 1.610 
MAEA 7.637E-07 1.131 
PSMB9 7.644E-07 1.269 
LOC100507150 7.648E-07 4.448 
MB21D1 7.843E-07 -1.878 
RCAN2 7.900E-07 3.015 
VAMP4 8.004E-07 0.958 
GPRASP1 8.270E-07 -2.094 
GALNT1 8.272E-07 1.445 
ZYG11B 8.296E-07 1.759 
IQCE 8.430E-07 1.858 
TSPYL5 8.472E-07 3.541 
TMEM176B 8.574E-07 3.933 
FKBP1B 8.607E-07 1.734 
CENPBD1 8.640E-07 1.278 
FLJ32255 8.818E-07 1.559 
GLS 9.062E-07 1.413 
SYNGR2 9.071E-07 1.424 
USP22 9.331E-07 1.437 
PDE1C 9.475E-07 2.840 
INHBB 9.668E-07 4.277 
AGAP11 9.843E-07 -3.313 
LIMCH1 9.855E-07 5.947 
C4orf3 9.867E-07 1.836 
TGFBRAP1 1.022E-06 1.228 
C11orf63 1.044E-06 2.624 
LOC729737 1.057E-06 -2.978 
FBXL3 1.066E-06 1.590 
SEMA4F 1.070E-06 1.131 
FBXL8 1.080E-06 0.493 
SHC4 1.080E-06 2.327 
ZNF799 1.081E-06 -2.354 
AASS 1.083E-06 -1.975 
ST8SIA5 1.097E-06 3.506 
MAP3K8 1.104E-06 -4.493 
CYB561D1 1.120E-06 2.178 
NSF 1.124E-06 1.658 
SLC2A3 1.132E-06 -2.833 
LOC440149 1.133E-06 1.740 
LOC145474 1.133E-06 -3.571 
LOC100506528 1.135E-06 -0.927 
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PDCD10 1.138E-06 1.343 
ANKRD1 1.141E-06 3.727 
LOC644727 1.156E-06 -4.274 
ARMCX4 1.169E-06 -3.202 
TMEM45A 1.207E-06 1.978 
RN7SL1 1.209E-06 -2.302 
LRRC57 1.239E-06 1.578 
SEC23B 1.243E-06 1.647 
XLOC_000527 1.264E-06 0.381 
CSNK1G1 1.282E-06 1.579 
KLHL5 1.291E-06 1.677 
HSD17B6 1.299E-06 5.425 
NUDT4 1.304E-06 1.332 
HNRNPU-AS1 1.327E-06 -4.628 
YME1L1 1.330E-06 0.728 
SUN1 1.333E-06 -0.857 
LOC100507904 1.334E-06 -2.385 
FTO 1.354E-06 -5.895 
MSH5 1.363E-06 -3.361 
SNORA70F 1.367E-06 -3.417 
ZNF337 1.396E-06 -2.428 
ITPRIPL2 1.416E-06 1.574 
CPPED1 1.428E-06 3.506 
XLOC_l2_000649 1.434E-06 1.283 
ATP9A 1.434E-06 1.817 
CALCOCO2 1.446E-06 2.083 
PMP22 1.462E-06 -3.304 
SNORA9 1.486E-06 -0.813 
C12orf53 1.517E-06 1.458 
PGM2L1 1.525E-06 3.628 
ARHGEF3 1.535E-06 2.352 
AGMAT 1.553E-06 4.543 
GNPTAB 1.574E-06 -2.516 
C14orf129 1.594E-06 1.975 
ZNF174 1.595E-06 1.482 
NISCH 1.621E-06 -1.617 
LOC645638 1.635E-06 1.853 
SELT 1.636E-06 1.950 
CTNND2 1.637E-06 5.448 
C3orf72 1.641E-06 3.594 
CAPN1 1.656E-06 1.475 
HIGD1A 1.661E-06 1.866 
TMEM167B 1.665E-06 2.186 
MGAT3 1.668E-06 6.218 
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PCDHB2 1.677E-06 2.190 
KPNA3 1.681E-06 1.447 
FGFR1OP2 1.697E-06 -4.162 
LOC100506778 1.698E-06 -1.147 
LPIN1 1.734E-06 -1.424 
GLRX2 1.747E-06 1.137 
LARS 1.752E-06 -1.257 
PCSK6 1.758E-06 4.589 
EIF1AY 1.770E-06 1.434 
MXRA7 1.776E-06 1.965 
MANBAL 1.794E-06 1.497 
STYK1 1.805E-06 2.827 
KCND2 1.808E-06 4.165 
C11orf87 1.836E-06 3.571 
TMEM176A 1.841E-06 4.236 
TSPAN31 1.843E-06 1.474 
LOC100302640 1.860E-06 1.808 
ARRDC4 1.871E-06 3.066 
WFDC1 1.888E-06 3.932 
RGS17 1.903E-06 -3.368 
PSG2 1.922E-06 1.193 
NFASC 1.924E-06 2.372 
XLOC_l2_002767 1.940E-06 2.051 
COPZ2 1.965E-06 1.282 
ABCA11P 1.992E-06 0.462 
C6orf97 2.024E-06 4.086 
IGF2 2.037E-06 3.130 
MED7 2.043E-06 1.003 
PRRX2 2.077E-06 3.357 
RPL7 2.126E-06 0.360 
PMPCA 2.126E-06 0.895 
RAP1A 2.134E-06 1.416 
LOC729603 2.140E-06 -1.814 
DHRS4L1 2.151E-06 -5.252 
KIAA0754 2.151E-06 -3.975 
CCK 2.163E-06 3.064 
TERF2 2.170E-06 1.796 
C11orf58 2.174E-06 1.072 
UBE2G2 2.206E-06 -0.552 
SNORD114-17 2.207E-06 -3.156 
THBS1 2.207E-06 2.211 
XLOC_009474 2.208E-06 -1.177 
RFTN1 2.223E-06 1.299 
SNORA77 2.224E-06 -2.559 
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LOC100506123 2.228E-06 -3.136 
SEPP1 2.237E-06 3.413 
LRRC10 2.243E-06 -4.038 
NRK 2.246E-06 4.933 
FRMD4A 2.292E-06 -5.024 
FAM50B 2.299E-06 1.382 
XAGE-4 2.300E-06 -6.565 
MRAS 2.314E-06 2.357 
XLOC_009895 2.323E-06 -3.088 
FLJ40606 2.324E-06 -3.177 
MCTP2 2.338E-06 6.004 
VAMP3 2.351E-06 0.915 
XLOC_006416 2.369E-06 -2.801 
SLC10A3 2.375E-06 1.985 
POC1B 2.378E-06 1.088 
CXCR7 2.389E-06 6.086 
PMEPA1 2.393E-06 2.752 
KIAA0528 2.396E-06 -1.287 
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